Content Type

What’s new in acne?

Presented By

Dr Julie Claire Harper, Birmingham, AL, USA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 18:01

Nearly all participants respond to deucravacitinib in lichen planopilaris study

Presented By

Dr Alyssa Stockard , Mayo Clinic, AZ, USA

Trial

Phase 2

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 17:55

Dupilumab in bullous pemphigoid

Presented By

Prof. Frédéric Caux, Avicenne Hospital, University of Paris 13, France

Trial

Phase 3, LIBERTY-BP ADEPT

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 17:52

Breaking the cutaneous lupus loop with deucravacitinib

Presented By

Prof. Victoria Werth, University of Pennsylvania, PA, USA

Trial

Phase 2, PAISLEY CLE

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 17:44

Active psoriatic arthritis: POETYK PsA-2 trial results

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

Phase 3, POETYK PsA-2

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 17:31

Upadacitinib efficacious in palmoplantar pustulosis

Presented By

Prof. Yuling Shi, Tongji University School of Medicine, China

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 17:24

Delgocitinib gets the upper hand in chronic hand eczema

Presented By

Prof. April Armstrong, University of California, Los Angeles, CA, USA

Trial

DELTA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 17:00

Excellent long-term data for TYK2 inhibitor ESK-001 in psoriasis

Presented By

Dr Andrew Blauvelt, Blauvelt Consulting LLC, MD, USA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:54

ICONIC-LEAD in plaque psoriasis

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 3, ICONIC-LEAD

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:49

A ‘TYK’ above placebo: ICP-488 in plaque psoriasis

Presented By

Dr Xiaoguang Zhang, Second Hospital of Hebei Medical University, China

Trial

Phase 2

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:44

TYK2 inhibitor D-2570 safe and effective in psoriasis

Presented By

Dr Ling Zhang, InventisBio Co., China

Trial

Phase 2

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:42

Flexing upadacitinib dose adjustment for AD and itch relief

Presented By

Dr Melinda Gooderham, SKiN Health, Canada

Trial

Phase 3, FLEX-UP

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:36

ROCKET ignites interest in rocatinlimab

Presented By

Prof. Emma Guttman, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, ROCKET-Horizon

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:33

Reduced biopsy rate and improved malignancy rate with high-end imaging tool

Presented By

Dr Jordan Phillipps, Washington University School of Medicine, MO, USA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:24

Cutaneous immune-related AEs may predict toxicities in ICI-treated patients

Presented By

Elle Kim, John Hopkins University, MD, USA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:19

Clinical patterns and outcomes in hypopigmented mycosis fungoides

Presented By

Dr Jong Bin Park, Kosin University, South Korea

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:10

Bempikibart shows its potential for hair regrowth in alopecia areata

Presented By

Dr Brett King, Yale Medicine, CT, USA

Trial

Phase 2, SIGNAL-AA

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 16:08

Ivarmacitinib stimulates hair regrowth in severe alopecia areata

Presented By

Prof. Jianzhong Zhang, Peking University People’s Hospital, China

Trial

Phase 3

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 15:51

Baricitinib regrows hair in adolescents with alopecia areata

Presented By

Prof. Thierry Passeron, Nice University Hospital, France

Trial

Phase 3, BRAVE-AA-PEDS

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 15:41

Briquilimab breaks walls in chronic spontaneous urticaria

Presented By

Prof. Martin Metz, Charité Universitätsmedizin, Germany

Trial

Phase 1/2, BEACON

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 15:34

New anti-IL-23p19 inscribes its name on the plaque

Presented By

Dr Furen Zhang, Shandong Academy of Medical Science, China

Trial

Phase 2

Conference

AAD 2025

Type

Peer-reviewed article

17 April 2025 15:20

Antibody responses predict IBD onset 10 years before diagnosis

Presented By

Dr Arno Bourgonje, University Medical Center Groningen, the Netherlands

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 11:48

Therapeutic antibody clearance reliable predictor for endoscopic outcomes in CD

Presented By

Dr Erwin Dreesen, KU Leuven, Belgium

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 11:46

Higher neoplasia detection rate with virtual chromoendoscopy in real-world IBD study

Presented By

Dr Chandni Radia, King’s College London, UK

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 11:44

Reducing the carbon footprint of IBD care

Presented By

Dr Marjolijn Duijvestein, Radboud University Medical Center, the Netherlands

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 11:43

TL1A-LTB axis induces perianal fistulising disease-associated changes in CD

Presented By

Dr Victoria Gudino, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Spain

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 11:31

Emulsifier-restrictive diet effective in alleviating symptoms in CD

Presented By

Dr Aaron Bancil, King’s College London, UK

Trial

ADDapt

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 11:26

Could stem cell transplantation be a fruitful solution for refractory CD?

Presented By

Dr Louis Cohen, Icahn School of Medicine at Mount Sinai, NY, USA

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 11:24

First IL-7 inhibitor for UC shows its potential

Presented By

Dr Arnaud Bourreille, CHU Nantes, France

Trial

Phase 2, CoTikiS

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 11:03

Novel TL1A inhibitor achieves high rates at stringent endpoints in UC

Presented By

Prof. Vipul Jairath, Western University, Canada

Trial

Phase 2, TUSCANY-2

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 10:57

Positive results for TL1A inhibitor duvakitug in CD

Presented By

Prof. Vipul Jairath, Western University, Canada

Trial

Phase 2, RELIEVE UCCD

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 10:52

Improving efficacy with longer mirikizumab treatment in CD

Presented By

Prof. Séverine Vermeire, KU Leuven, Belgium

Trial

Phase 3, VIVID-2

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 10:39

Long-term upadacitinib data reassuring for patients with UC

Presented By

Prof. Remo Panaccione, University of Calgary, Canada

Trial

Phase 3, U-ACTIVATE

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 10:37

EFFICACI: Infliximab or vedolizumab after TNF failure in UC?

Presented By

Prof. Guillaume Bouguen, CHU Rennes, France

Trial

EFFICACI

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 10:34

Latest data for subcutaneous guselkumab in CD and UC

Presented By

Prof. Ailsa Hart, London North-West University, UK; Prof. Laurent Peyrin-Biroulet, University of Lorraine, France

Trial

Phase 3, GRAVITI, ASTRO

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 10:31

Long-term use of etrasimod in UC safe and well-tolerated

Presented By

Prof. Séverine Vermeire, KU Leuven, Belgium

Trial

OASIS, ELEVATE, ES101002

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 10:22

Sustained efficacy and stable safety profile for risankizumab in UC

Presented By

Prof. Raja Atreya, Friedrich-Alexander University, Germany

Trial

Phase 3, COMMAND

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 10:08

VEDOKIDS: Long-term outcomes of vedolizumab in paediatric IBD

Presented By

Dr Ohad Atia, Shaare Zedek Medical Centre, Israel

Trial

VEDOKIDS

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 09:56

PREdiCCT: Role of psychosocial factors in IBD flares unravelled

Presented By

Dr Lauranne Derikx, Erasmus MC, the Netherlands

Trial

PREdiCCT

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 09:49

Kono-S or side-to-side anastomosis for resection in Crohn’s terminal ileitis?

Presented By

Dr Koianka Trencheva, Cornell University, NY, USA

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 09:47

Identifying patients at high risk for chronic pouchitis

Presented By

Dr Edward Barnes, University of North Carolina at Chapel Hill, NC, USA

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 09:34

ECCO consensus on diet and nutrition in IBD

Presented By

Dr Richard Hansen, University of Dundee, UK; Dr Vaios Svolos, University of Thessaly, Greece

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 09:20

ECCO Topical Review: pouch-related disorders

Presented By

Dr Maia Kayal, Icahn School of Medicine at Mount Sinai, NY, USA

Conference

ECCO 2025

Type

Peer-reviewed article

8 April 2025 09:18

PROMPT-AF: Novel ablation strategy improves outcomes for persistent AF

Presented By

Prof. Chenyang Jiang, Sir Run Run Shaw Hospital, China

Trial

PROMPT-AF

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 15:03

ARREST-AF: The true impact of risk factor management on AF recurrence after ablation

Presented By

Prof. Rajeev Pathak, University of Adelaide, Australia

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 15:03

VANISH2: Antiarrhythmic drug therapy or catheter ablation in prior myocardial infarction complicated by ventricular tachycardia?

Presented By

Dr John Sapp, Queen Elizabeth II Health Sciences Centre, Canada

Trial

Phase 4, VANISH2

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 15:03

OPTION: LAAC over OAC after ablation in patients with AF and increased stroke risk

Presented By

Prof. Oussama Wazni, Cleveland Clinic, USA

Trial

OPTION

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 15:02

Head-to-head: Cryoballoon vs radiofrequency ablation in persistent AF

Presented By

Dr Kengo Kusano, National Cerebral and Cardiovascular Center, Japan

Trial

CRRF-PeAF

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 15:02

Will myeloperoxidase inhibition benefit patients with heart failure?

Presented By

Prof. Sanjiv Shah, Northwestern Feinberg School of Medicine, USA

Trial

Phase 2, ENDEAVOR

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 15:02

Is intranasal bumetanide a viable diuretic option in congestive HF?

Presented By

Dr Daniel Bensimhon, Cone Health, USA

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 15:02

REALIZE-K: MRA treatment optimisation in HFrEF plus hyperkalaemia

Presented By

Prof. Mikhail Kosiborod, University of Missouri, USA

Trial

Phase 4, REALIZE-K

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 15:02

SUMMIT: Tirzepatide reduces cardiovascular events in HFpEF plus obesity

Presented By

Prof. Milton Packer, Baylor University Medical Center, USA

Trial

Phase 3, SUMMIT

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 15:01

CLEAR Outcomes: Bempedoic acid reduces MACE and MALE in patients with PAD

Presented By

Prof. Marc Bonaca, University of Colorado, USA

Trial

CLEAR Outcomes

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 15:01

GLORIOUS: Restrictive versus liberal oxygenation during CPB-assisted surgery

Presented By

Dr Sebastian Wiberg, Rigshospitalet Copenhagen University, Denmark

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 15:01

GLORIOUS: GLP-1 agonist did not meet primary endpoint in CABG

Presented By

Dr Sebastian Wiberg, Rigshospitalet Copenhagen University, Denmark

Trial

GLORIOUS

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 15:00

CLEAR SYNERGY: Can routine spironolactone improve post-MI outcomes?

Presented By

Prof. Sanjit Jolly, McMaster University, Canada

Trial

Phase 3, CLEAR SYNERGY

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 15:00

ENBALV: Edoxaban or warfarin as anticoagulant after bioprosthetic valve replacement?

Presented By

Dr Chisato Izumi, National Cerebral and Cardiovascular Center, Japan

Trial

Phase 3, ENBALV

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 15:00

ZODIAC: Can we improve lipid-lowering strategies in ACS?

Presented By

Prof. Ray Kausik, Imperial College London, UK

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 15:00

KRAKEN: Encouraging phase 2 results of Lp(a)-lowering muvalaplin

Presented By

Prof. Stephen Nicholls, Monash University, Australia

Trial

Phase 2, KRAKEN

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 15:00

Reconditioned pacemakers may save lives in low/middle-income countries

Presented By

Dr Thomas Crawford, University of Michigan, USA

Trial

My Heart Your Heart

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 14:59

Comparing dual antihypertensive combination therapies in a South Asian population

Presented By

Prof. Dorairaj Prabhakaran, Centre for Chronic Disease Control, India

Trial

TOPSPIN

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 14:59

BPROAD: Intensive or standard BP treatment strategy in type 2 diabetes?

Presented By

Prof. Guang Ning, Shanghai Jiao Tong University School of Medicine, China

Trial

BPROAD

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 14:59

Promising results for CRISPR-based therapy in ATTR-CM

Presented By

Prof. Marianna Fontana, University College London, UK

Trial

Phase 1

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 14:58

NUDGE-FLU: Effect of science-informed letters on influenza vaccination rates

Presented By

Dr Ankeet Bhatt, Stanford University, USA

Trial

NUDGE-FLU

Conference

AHA 2024

Type

Peer-reviewed article

3 February 2025 14:58

InMIND: Novel standard-of-care for relapsed or refractory follicular lymphoma?

Presented By

Prof. Laurie Sehn, University of British Columbia, Canada

Trial

Phase 3, inMIND

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:34

High CR rates for novel CAR T-cell therapy in follicular lymphoma and DLBCL

Presented By

Dr Jing-Zhou Hou, University of Pittsburgh Medical Center, PA, USA; Dr Sameh Gaballa, Lee Moffitt Cancer Center, FL, USA

Trial

Phase 1

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:31

Excellent CR rates for venetoclax plus pola-R-CHP in BCL2-positive DLBCL

Presented By

Dr Catherine Diefenbach, NYU Langone Health, NY, USA

Trial

Phase 1, BO42203

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:29

ATALANTA-1: Promising data for novel CAR T-cell therapy

Presented By

Prof. Marie José Kersten, Amsterdam University Medical Center, the Netherlands

Trial

Phase 1/2, ATALANTA-1

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:27

ZUMA-5: Curative potential of axi-cel in follicular lymphoma

Presented By

Prof. Sattva Neelapu, MD Anderson Cancer Center, TX, USA

Trial

Phase 2, ZUMA-5

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:25

Can we omit auto-SCT in patients with mantle cell lymphoma with undetectable MRD post-induction?

Presented By

Dr Timothy Fenske, Medical College of Wisconsin, WI, USA

Trial

Phase 3, EA4151

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:23

Quizartinib maintenance therapy crucial for FLT3-ITD-positive AML

Presented By

Prof. Mark Levis, Johns Hopkins University, MD, USA

Trial

Phase 3, QuANTUM-First

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:20

Revumenib combination therapy associated with high response rates in relapsed/refractory AML

Presented By

Dr Ghayas Issa, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2, SAVE

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:17

Venetoclax plus azacitidine in young patients with AML

Presented By

Dr Daniel Pollyea, University of Colorado, CO, USA

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:14

Promising results for ivosidenib-based triplet therapy in IDH1-mutated malignancies

Presented By

Dr Jennifer Marvin-Peek, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:12

CPX-351 outperforms FLAG-Ida in AML/MDS and MDS-related mutations

Presented By

Dr Priyanka Mehta, University Hospitals Bristol NHS Foundation Trust, UK

Trial

Phase 3, AML19

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:09

High MRD-negativity rates for venetoclax plus ‘7+3’ chemotherapy in newly diagnosed AML

Presented By

Dr Ioannis Mantzaris, Montefiore Medical Center, NY, USA

Trial

Phase 1

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:07

Findings from phase 3 uproleselan study in AML not all negative

Presented By

Prof. Daniel DeAngelo, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:05

Menin inhibitors on the rise in KMT2Ar acute leukaemia

Presented By

Dr Ibrahim Aldoss, City of Hope, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:03

New standard-of-care for paediatric B-cell ALL

Presented By

Dr Rachel Rau, University of Washington, WA, USA

Trial

Phase 3, AALL1731

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:57

KCRd offers overall survival benefit over CRd in newly diagnosed MM

Presented By

Dr Charlotte Pawlyn, Institute of Cancer Research, UK

Trial

Phase 3, Myeloma XI/XI+

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:53

AQUILA: Early intervention with daratumumab extends survival in smouldering MM

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, AQUILA

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:49

Emerging mezigdomide-based options for heavily pre-treated MM

Presented By

Prof. Luciano Costa, University of Alabama at Birmingham, AL, USA

Trial

Phase 1/2, CA057-003

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:47

IFM2017-03: Daratumumab therapy fruitful for frail patients with MM

Presented By

Prof. Salomon Manier, University of Lille, France

Trial

Phase 3, IFM2017-03

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:44

CEPHEUS: Further support for daratumumab regimens in untreated MM

Presented By

Prof. Sonja Zweegman, Amsterdam University Medical Centre, the Netherlands

Trial

Phase 3, CEPHEUS

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:42

Positive trends for etavopivat in sickle cell disease

Presented By

Dr Sophia Delicou, Hippocrates General Hospital, Greece

Trial

Phase 2, HIBISCUS

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:40

LUNA 3: Rilzabrutinib meets primary endpoint in ITP

Presented By

Prof. David Kuter, Massachusetts General Hospital, MA, USA

Trial

Phase 3, LUNA 3

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:38

Full-dose or reduced-dose DOACs in high-risk VTE on extended therapy?

Presented By

Prof. Francis Couturaud, Brest University Hospital, France

Trial

Phase 3, RENOVE

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:36

Allo-SCT improves lives of children with sickle cell anaemia and abnormal cerebral artery velocities

Presented By

Dr Françoise Bernaudin, Centre Hospitalier Intercommunal Creteil, France

Trial

DREPAGREFFE-2

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:33

PIVOT: Can hydroxyurea improve outcomes in haemoglobin sickle cell disease?

Presented By

Dr Yvonne Dei-Adomakoh, Korle-bu Teaching Hospital, Ghana

Trial

Phase 2, PIVOT

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:30

ANDROMEDA: Daratumumab-based frontline standard-of-care in AL amyloidosis

Presented By

Dr Efstathios Kastritis, University of Athens, Greece

Trial

Phase 3, ANDROMEDA

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:27

Margetuximab does not improve pCR rate in HER2-positive early breast cancer

Presented By

Dr Adrienne Waks, Dana-Farber Cancer Institute, USA

Trial

Phase 2, MARGOT/TBCRC052

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:37

Obesity is associated with worse prognosis in early-stage breast cancer

Presented By

Dr Hongchao Pan, University of Oxford, UK

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:35

T-DXd outperforms T-DM1 regardless of baseline genomic alterations in HER2-positive metastatic breast cancer

Presented By

Dr Paolo Tarantino, Dana-Farber Cancer Institute, USA

Trial

Phase 3, DESTINY-Breast03

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:33

Immediate surgery can offer long-term benefits for elderly patients with early-stage breast cancer

Presented By

Prof. Robert Hills, University of Oxford, UK

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:33

Long-term benefit of olaparib seen in high-risk early BRCA1/2-mutated breast cancer

Presented By

Prof. Judy Garber, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, OlympiA

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:31

Encouraging results of neoadjuvant SHR-A1811 in the treatment of HER2-positive breast cancer

Presented By

Dr Junjie Li, Fudan University Cancer Hospital, China

Trial

Phase 2, FASCINATE-N

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:30

Active monitoring is a viable option for patients with low-risk DCIS

Presented By

Prof. Eun-sil Hwang, Duke University School of Medicine, NC, USA

Trial

COMET

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:28

Additional CDK4/6 inhibition in HER2-positive patients achieves clinically meaningful outcomes

Presented By

Dr Otto Metzger, Dana-Farber Cancer Institute, USA

Trial

Phase 3, AFT-38 PATINA

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 16:23

NATALEE: Success with adjuvant ribociclib leads to FDA approval in early breast cancer

Presented By

Dr Jennifer Gao, CDER, U.S. Food and Drug Administration, USA

Trial

Phase 3, NATALEE

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 12:00

Inavolisib: The first FDA-approved treatment for use in a triple combination for metastatic breast cancer

Presented By

Dr Suparna Wedam, CDER, U.S. Food and Drug Administration, USA

Trial

Phase 3, INAVO120

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 11:58

Imlunestrant monotherapy improves PFS in ESR1-mutated patients, not in the overall population

Presented By

Dr Komal Jhaveri, Memorial Sloan Kettering Cancer Center, USA

Trial

Phase 3, EMBER-3

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 11:54

Neoadjuvant niraparib plus dostarlimab shows pCR benefit in BRCA-mutated, ER-positive/HER2-negative breast cancer 

Presented By

Dr Erica Mayer, Dana-Farber Cancer Institute, USA

Trial

Phase 2, TBCRC 056

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 11:50

Neoadjuvant HER3-DXd achieves pCR and ORR results similar to multi-agent chemotherapy

Presented By

Dr Mafalda Oliveira, University Hospital Vall d’Hebron, Spain

Trial

Phase 2, SOLTI VALENTINE

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 11:46

SONIA: Potential to defer CDK4/6 inhibitor treatment without impacting HRQoL

Presented By

Prof. Kari Wisinski, University of Wisconsin, USA

Trial

Phase 3, SONIA

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 11:43

Improved TTF and PFS seen with palbociclib plus ET in real-world PADMA study

Presented By

Prof. Sibylle Loibl, University of Frankfurt, Germany

Trial

Phase 4, PADMA

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 11:39

KEYNOTE-522 finds prognostic value of TMB and gene profiles in TNBC

Presented By

Dr Joyce O’Shaughnessy, Baylor University Medical Center, USA

Trial

Phase 3, KEYNOTE-522

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 11:36

The ZEST trial sheds light on the use of ctDNA to predict breast cancer recurrence

Presented By

Prof. Nicholas Turner, Royal Marsden Hospital, UK

Trial

Phase 3, ZEST

Conference

SABCS 2025

Type

Peer-reviewed article

23 January 2025 11:00

No added EFS benefit with neoadjuvant atezolizumab in TNBC

Presented By

Prof. Charles Geyer, University of Pittsburgh, USA

Trial

Phase 3, NSABP B-59/GBG-96-GeparDouze

Conference

SABS 2024

Type

Peer-reviewed article

23 January 2025 10:22

No OS benefit at 10 years with post-mastectomy RT in intermediate-risk breast cancer

Presented By

Prof. Ian Kunkler, University of Edinburgh, Scotland

Trial

Phase 3, SUPREMO

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 10:18

Single-modality radiotherapy may better preserve HRQoL than ET in elderly patients

Presented By

Dr Icro Meattini, University of Florence, Italy

Trial

Phase 3, EUROPA

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 10:11

Tamoxifen reduces ipsilateral breast recurrence in “good risk” DCIS patients without RT

Presented By

Dr Jean Wright, Johns Hopkins Medicine, USA

Trial

NRG/RTOG 9804, ECOG-ACRIN E5194

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 10:09

T2T approach in women with RA associated with increased fertility

Presented By

Prof. Radboud Dolhain, Erasmus University Medical Center, the Netherlands

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 12:06

Positive results for vagus nerve stimulation in RA

Presented By

Dr John Tesser, Arizona Arthritis & Rheumatology Associates, AZ, USA

Trial

Phase 3, RESET-RA

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 12:05

Machine learning to aid evaluation of ANA pattern and titer

Presented By

Dr May Choi, University of Calgary, Canada

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 12:04

ACR presents new 2024 Guideline for lupus nephritis

Presented By

Dr Lisa Sammaritano, Weill Cornell Medicine, NY, USA

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:59

Anifrolumab may delay organ damage in SLE

Presented By

Dr Zahi Touma, University of Toronto, Canada

Trial

LASER

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:58

Dapirolizumab pegol associated with less SLE activity and corticosteroid use

Presented By

Dr Megan Clowse, Duke University, NC, USA

Trial

Phase 3, PHOENYCS GO

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:55

Allogeneic CD19-targeting CAR NK-cell therapy for SLE

Presented By

Dr Max Qian, Rui Therapeutics, China

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:54

XG005 relieves knee osteoarthritis symptoms in phase 2b study

Presented By

Dr Leon Jiang, Xgene Pharmaceutical Lexington, MA, USA

Trial

Phase 2

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:42

NT-3 inhibitor relieves pain caused by osteoarthritis

Presented By

Prof. Philip Conaghan, University of Leeds, UK

Trial

Phase 2

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:39

Therapeutic equivalence between denosumab and biosimilar Bmab-1000

Presented By

Dr Subramanian Loganathan, Biocon Biologic Ltd, India

Trial

Phase 3, DEVOTE

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:37

Post-hoc analysis of 3 large trials maps sex differences in PsA

Presented By

Dr Laura Coates, University of Oxford, UK

Trial

Phase 3, DISCOVER-1, DISCOVER-2, COSMOS

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:36

Global recruitment associated with higher placebo responses in PsA trials

Presented By

Dr Andreas Kerschbaumer, Medical University of Vienna, Austria

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:32

Prolonged plasma urate-lowering with a novel pegylated uricase

Presented By

Dr Orit Cohen Barak, Protalix BioTherapeutics, NJ, USA

Trial

Phase 1

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:31

SGLT2 inhibitor therapy could be beneficial for gout patients

Presented By

Dr Greg Challener, Massachusetts General Hospital, MA, USA

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:29

Fully tapering glucocorticosteroids may be a viable option for GPA

Presented By

Prof. Peter Merkel, University of Pennsylvania, PA, USA

Trial

Phase 3, TAPIR

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:23

Favourable benefit-risk profile of upadacitinib in giant cell arteritis

Presented By

Prof. Peter Merkel, University of Pennsylvania, PA, USA

Trial

Phase 3, SELECT-GCA

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:22

Mycophenolate mofetil plus methotrexate is effective in Takayasu’s arteritis

Presented By

Dr Xiaochuan Sun, Peking Union Medical College Hospital, China

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:20

Emapalumab rapidly controls MAS in patients with Still’s disease

Presented By

Dr Alexei Grom, Cincinnati Children's Hospital, OH, USA

Trial

NI-0501-06, EMERALD

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:17

FcRn blocker nipocalimab improves disease activity in Sjögren’s disease

Presented By

Dr Ghaith Noaiseh, University of Kansas Medical Center, KS, USA

Trial

Phase 2, DAHLIAS

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:15

Inebilizumab associated with reduced flare risk in IgG4-related disease

Presented By

Prof. John Stone, Massachusetts General Hospital, MA, USA

Trial

Phase 3, MITIGATE

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:10

ICI therapy does not increase mortality risk in patients with pre-existing autoimmune disease

Presented By

Dr Greg Challener, Massachusetts General Hospital, MA, USA

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:09

Registry participation can enhance quality of rheumatology care

Presented By

Dr Gabriela Schmajuk, University of California, San Francisco, CA, USA

Conference

ACR 2024

Type

Peer-reviewed article

13 January 2025 11:07

A paradigm shift in CD clinical practice

Presented By

Dr Nuru Noor, University of Cambridge, UK

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:24

LOVE-CD: Vedolizumab yields better outcomes in early than in late CD

Presented By

Prof. Geert D’Haens, Amsterdam UMC, the Netherlands

Trial

LOVE-CD

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:24

Moving towards the prevention of IBD

Presented By

Dr Arno Bourgonje, University Medical Center Groningen, the Netherlands

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:23

New insights into perianal fistulising CD pathogenesis may lead to new therapies

Presented By

Dr Siyan Cao, Washington University, USA

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:23

Risankizumab influences key pathogenic Th17 cells in CD

Presented By

Dr Daniele Noviello, University of Milan, Italy

Trial

SEQUENCE

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:23

Meaningful corticosteroid-sparing effect of mirikizumab in UC

Presented By

Prof. David Laharie, University of Bordeaux, France

Trial

Phase 3, LUCENT-2

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:22

Extending ustekinumab dosing interval does not influence drug survival in IBD

Presented By

Dr Monique Devillers, Erasmus University Medical Center, the Netherlands

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:22

CULTIVATE: Promising signal for etrasimod in Crohn’s disease

Presented By

Prof. Geert D’Haens, Amsterdam UMC, the Netherlands

Trial

Phase 2, CULTIVATE

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:22

Tamuzimod delivers promising long-term data in UC

Presented By

Prof. Silvio Danese, Vito-Salute San Raffaele University, Italy

Trial

Phase 2

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:22

TL1A inhibitor tulisokibart shows potential in UC

Presented By

Dr Christopher Ma, University of Calgary, Canada

Trial

Phase 2, ARTEMIS-UC

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:21

Upadacitinib associated with normalisation of HRQoL in UC

Presented By

Dr Joana Torres, Hospital Beatriz Ângelo, Portugal

Trial

U-ACHIEVE; U-ACCOMPLISH

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:21

Diagnostic accuracy of fluorescence confocal laser microscopy after EUS-TA

Presented By

Dr Serena Stigliano, University of Rome, Italy

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:21

An accelerated treatment approach may save lives in pancreatic walled-off necrosis

Presented By

Dr Gitte Olsen, Copenhagen University Hospital, Denmark

Trial

ACCELERATE

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:21

Guar gum alleviates IBS-related constipation in a randomised controlled trial

Presented By

Dr Silvia Delgado-Aros, Nestle Health Sciences, Switzerland

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:20

How useful is colonoscopy for constipation in young women?

Presented By

Dr Amani Beshara, Hillel Yaffe Medical Center, Israel

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:20

Tradipitant improves symptoms of motion sickness

Presented By

Dr Vasilios Polymeropoulos

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:19

Encouraging results for L-carnitine in metabolic dysfunction-associated steatotic liver disease

Presented By

Dr Pezhman Alavinejad, Ahvaz Jundishapur University of Medical Sciences, Iran

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:19

Exploring zibotentan plus dapagliflozin for cirrhosis

Presented By

Dr Phil Ambery

Trial

Phase 2, ZENITH-CKD

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:19

TACITO: Does faecal microbiota transplantation improve survival in mRCC?

Presented By

Dr Gianluca Ianiro, Agostino Gemelli University Policlinic, Italy

Trial

Phase 2, TACITO

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:19

Is faecal microbiota transplantation a viable option to treat primary C. difficile infections?

Presented By

Dr Frederik Juul, Oslo University Hospital, Norway

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:18

Cendakimab meets primary endpoints in eosinophilic oesophagitis

Presented By

Prof. Alain Schoepfer, University of Lausanne, Switzerland

Trial

Phase 3

Conference

UEGW 2024

Type

Peer-reviewed article

28 November 2024 11:18

Revised McDonald criteria allow earlier and more precise MS diagnosis

Presented By

Prof. Xavier Montalban, Vall d'Hebron University Hospital, Spain

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:52

Approaches to RIS and MS converge

Presented By

Prof. Christine Lebrun-Frénay, Centre Hospitalier Universitaire de Nice, France

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:50

AI versus clinicians: who diagnoses MS faster and better?

Presented By

Ms Mahi Patel, UT Southwestern, TX, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:47

Blood markers predict MS progression

Presented By

Dr Ahmed Abdelhak, University of California San Francisco, CA, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:46

Gut microbiota modulate inflammation and cortical damage

Presented By

Dr Federico Montini, Brigham and Women's Hospital, MA, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:43

Risk factors and importance of persistent PIRA

Presented By

Dr Chao Zhu, Monash University, Australia

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:39

Vitamin D supplementation in progressive MS should be medically supervised

Presented By

Dr Michaela Haindl, Medical University of Graz, Austria

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:38

Encouraging real-world results of AHSCT to treat aggressive MS

Presented By

Prof. Paolo Muraro, London Bridge Hospital, UK

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:35

CAR T-cell therapy in MS: in its infancy but highly anticipated

Presented By

Prof. Frauke Zipp, Johannes Gutenberg University Mainz, Germany

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:33

B cell-tailored dosing of ocrelizumab shows good results

Presented By

Ms Laura Hogenboom, Amsterdam University Medical Center, the Netherlands

Trial

BLOOMS

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:28

Risk associated with discontinuing therapy depends on specific drug

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:26

First-line moderate-efficacy DMTs show similar efficacy

Presented By

Dr Clara López-Caneda, Hospital Alvaro Cunqueiro, Spain

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:23

Tolebrutinib slows disability worsening in relapsing MS

Presented By

Dr Jiwon Oh, St. Michael's Hospital, Canada

Trial

Phase 3, GEMINI 1, GEMINI 2

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:21

Frexalimab shows favourable safety and efficacy in OLE

Presented By

Prof. Gavin Giovannoni, Queen Mary University of London, UK

Trial

Phase 2

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:17

Good safety of ozanimod over up to 8 years of treatment

Presented By

Prof. Krzysztof Selmaj, University of Warmia and Mazury, Poland

Trial

DAYBREAK

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:16

Tolebrutinib slows disability in non-relapsing SPMS

Presented By

Prof. Robert Fox, Cleveland Clinic, OH, USA

Trial

Phase 3, HERCULES

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:13

High-dose simvastatin does not slow disability progression in SPMS

Presented By

Dr Jeremy Chataway, University College London, UK

Trial

Phase 3, MS-STAT2

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:11

High genetic burden for depression associated with MS disease activity

Presented By

Dr Kaarina Kowalec, University of Manitoba, Canada

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:06

More comorbidity is associated with worse clinical outcomes in MS

Presented By

Dr Amber Salter, UT Southwestern, TX, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:05

Transfer of ocrelizumab into breastmilk is negligible

Presented By

Dr Riley Bove, University of California San Francisco, CA, USA

Trial

Phase 4, SOPRANINO

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:03

Ineffective response to EBV in MS not seen in similar diseases

Presented By

Dr Tilman Schneider-Hohendorf, University of Münster, Germany

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:01

Comparative effectiveness and safety of DMTs in NMOSD

Presented By

Dr Philippe-Antoine Bilodeau, Brigham and Women’s Hospital, MA, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 11:59

Age, time, and treatment determine relapse risk in MOGAD

Presented By

Dr Vivien Häußler, University Medical Center Hamburg, Germany

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 11:56

Guidelines for the management of elevated blood pressure and hypertension

Presented By

Prof. John William McEvoy; Prof. Rhian Touyz; Prof. Rosa Maria Bruno

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 14:04

Guidelines for the management of chronic coronary syndromes

Presented By

Prof. Christiaan Vrints; Dr Konstantinos Koskinas

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 13:54

Guidelines for the management of atrial fibrillation

Presented By

Prof. Isabel van Gelder; Prof. Dipak Kotecha

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 13:48

Guidelines for the management of peripheral artery and aortic diseases

Presented By

Prof. Lucia Mazzolai; Prof. José Rodríguez Palomares; Prof. Alessandro Della Corte

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 13:41

EPIC-CAD: What is the best antithrombotic approach in high-risk AF plus stable CAD?

Presented By

Dr Gi-Byoung Nam, Ulsan University Hospital, South Korea

Trial

Phase 4, EPIC-CAD

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 13:23

OCEANIC-AF: Asundexian inferior to apixaban for ischaemic stroke prevention in AF

Presented By

Dr Manesh Patel, Duke Clinical Research Institute, USA

Trial

Phase 3, OCEANIC-AF

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 13:16

MIRACLE-AF: Elegant solution to improve AF care in rural China

Presented By

Prof. Minglong Chen, First Affiliated Hospital of Nanjing Medical University, China

Trial

MIRACLE-AF

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 13:05

SUPPRESS-AF: What is the value of adding LVA ablation to PVI in AF?

Presented By

Dr Masaharu Masuda, Kansai Rosai Hospital, Japan

Trial

SUPPRESS-AF

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 13:03

ABYSS: Can beta-blocker safely be interrupted post-MI?

Presented By

Prof. Johanne Silvain, Pitié-Salpêtrière University Hospital, France

Trial

Phase 3, ABYSS

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 12:58

SWEDEGRAFT: Can a no-touch vein harvesting technique improve outcomes in CABG?

Presented By

Prof. Stefan James, Uppsala University, Sweden

Trial

SWEDEGRAFT

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 12:50

Bioadaptor meets expectations in reducing target lesion failures in coronary artery disease

Presented By

Prof. David Erlinge, Lund University, Sweden

Trial

INFINITY-SWEDEHEART

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 12:48

REC-CAGEFREE I: Can we avoid permanent stenting with drug-coated balloons?

Presented By

Dr Ling Tao, Xijing Hospital, China

Trial

REC-CAGEFREE I

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 12:44

OCCUPI: OCT-guided PCI improves outcomes in complex CAD

Presented By

Prof. Byeong-Keuk Kim, Yonsei University Hospital, South Korea

Trial

OCCUPI

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 12:39

Low-dose 3-drug pill GMRx2 shows promise in lowering BP

Presented By

Prof. Anthony Rodgers, George Institute, Australia

Trial

Phase 3, GMRx2_PCT; GMRx2_ACT

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 12:06

Is administering BP medication in the evening better than in the morning?

Presented By

Dr Ricky Turgeon, University of British Columbia, Canada

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 12:01

VERONICA: Improving BP control in Africa with a simple strategy

Presented By

Dr Dike Ojji, Abuja University, Nigeria

Trial

VERONICA-Nigeria

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 11:56

FINEARTS-HF: Finerenone improves outcomes in heart failure with preserved ejection fraction

Presented By

Prof. Scott Solomon, Brigham and Women's Hospital, MA, USA

Trial

Phase 3, FINEARTS-HF

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 11:45

MRAs show varied efficacy in heart failure across ejection fractions

Presented By

Prof. Pardeep Jhund, University of Glasgow, Scotland

Trial

RALES; EMPHASIS-HF; TOPCAT; FINEARTS-HF

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 11:33

MATTERHORN: Transcatheter repair matches surgery for HF with secondary mitral regurgitation

Presented By

Prof. Volker Rudolph, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany

Trial

MATTERHORN

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 11:19

RESHAPE-HF2: Not a “tie-breaker” for TEER in heart failure

Presented By

Prof. Stefan Anker, Charité Universitätsmedizin, Germany

Trial

RESHAPE-HF2

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 11:15

STEEER-AF: Shockingly low adherence to ESC atrial fibrillation guidelines

Presented By

Prof. Dipak Kotecha, University of Birmingham, UK

Trial

STEEER-AF

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 11:10

SCOFF: To fast or not to fast, that’s the question

Presented By

Dr David Ferreira, John Hunter Hospital, Australia

Trial

SCOFF

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 11:08

WESTCOR-POC: Point-of-care hs-troponin testing increases emergency department efficiency

Presented By

Dr Viola Thulin, Haukeland University Hospital, Norway

Trial

WESTCOR-POC

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 11:05

PROTEUS: Can AI improve decision-making around stress echocardiography?

Presented By

Dr Ross Upton, Ultromics, UK

Trial

PROTEUS

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 11:03

RAPIDxAI: Can AI-augmented chest pain assessment improve cardiovascular outcomes?

Presented By

Dr Derek Chew, Monash University, Australia

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 11:01

HELIOS-B: Vutrisiran candidate for SoC in ATTR cardiomyopathy

Presented By

Prof. Marianna Fontana, University College London, UK

Trial

Phase 3, HELIOS-B

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 10:55

Does RAS inhibitor discontinuation affect outcomes after non-cardiac surgery?

Presented By

Prof. Matthieu Legrand, University of California San Francisco, USA

Trial

STOP-or-NOT

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 10:50

Novel approach to managing severe tricuspid regurgitation proves its value

Presented By

Prof. Erwan Donal, Rennes University Hospital, France

Trial

TRI.Fr

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 10:47

NOTION-3: TAVI plus PCI improves outcomes in CAD plus severe aortic stenosis

Presented By

Dr Jacob Lønborg, Copenhagen University Hospital, Denmark

Trial

Phase 3, NOTION-3

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 10:44

RHEIA: TAVI outperformed surgery in women with aortic stenosis

Presented By

Prof. Hélène Eltchaninoff, University Hospital of Rouen, France

Trial

RHEIA

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 10:36

3-Year results highlight durable effects of IL-13 inhibitor in AD

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

ADjoin

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:59

IL-22RA1 inhibition shows potential in atopic dermatitis

Presented By

Dr Christine Bangert, Medical University Vienna, Austria

Trial

Phase 2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:56

Lifelong psychosocial burden linked to early-onset atopic dermatitis

Editor

George Washington University School of Medicine, USA

Trial

Scars of Life

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:53

Second-generation selective PDE4 inhibitor shows promise in AD

Presented By

Prof. Eric Simpson, Oregon Health and Science University, USA)

Trial

Phase 2, ADESOS

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:50

Prurigo nodularis: long-term treatment decreases relapse events

Presented By

Prof. Franz Legat, Medical University Graz, Austria

Trial

Phase 3

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:47

JAK1 inhibitor shows promising long-term efficacy in PN

Presented By

Dr Shawn Kwatra, Johns Hopkins University School of Medicine, USA

Trial

Phase 2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:44

Deucravacitinib treatment in lichen planopilaris

Presented By

Dr Aaron Mangold, Mayo Clinic, USA

Trial

Phase 2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:41

Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema

Presented By

Prof. Ana Giménez-Arnau, Autonomous University of Barcelona, Spain

Trial

Phase 3, DELTA FORCE

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:33

Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib

Presented By

Prof. April Armstrong, University of California Los Angeles, USA

Trial

DELTA; LIBERTY-AD-HAFT

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:30

Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

Phase 3

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:26

Bimekizumab shows sustained 2-year efficacy in hidradenitis suppurativa

Presented By

Prof. Christos Zouboulis, Dessau Medical Center, Germany

Trial

BE HEARD

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:22

Familial hidradenitis suppurativa tied to metabolic disease

Presented By

Dr Suzan Al-Gburi, University Hospital Cologne, Germany

Trial

EpiCAi; BATMAN

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:19

Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis

Presented By

Prof. Adam Reich, University of Rzeszów, Poland

Trial

Phase 3, GEMINI-1; GEMINI-2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:04

A new era of care: Artificial intelligence in psoriasis

Presented By

Prof. Alexander Navarini, University Hospital of Basel, Switzerland

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 13:00

Deuruxolitinib significantly improves hair satisfaction in AA

Presented By

Dr Paradi Mirmirani, Kaiser Permanente Vallejo Medical Center, USA

Trial

THRIVE-AA

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:56

Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia

Presented By

Prof. Maryanne Senna, Harvard Medical School, USA

Trial

Phase 2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:51

Vitiligo: Prolonged facial re-pigmentation maintained with continued ruxolitinib cream

Presented By

Dr David Rosmarin, Indiana University School of Medicine, USA

Trial

TRuE-V

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:39

Anti-KIT antibody: the next frontier in CSU treatment?

Presented By

Prof. Martin Metz, Charité-University Hospital Berlin, Germany

Trial

Phase 2

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:33

New targets identified for acute and chronic wound healing

Presented By

Dr Marta Bertolini, (QIMA Monasterium GmbH, Germany

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:29

PsoBest registry: Biologics dominate treatment for moderate-to-severe psoriasis

Presented By

Prof. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany

Trial

PsoBest registry

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:23

Semaglutide improves outcomes for patients with obesity and HS

Presented By

Dr Daniel Lyons, St Vincent’s University Hospital, Ireland

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:14

Advanced BCC: histological subtype and time to complete response may predict tumour recurrence

Presented By

Dr Maria Mannino, Catholic University of the Sacred Heart, Italy

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:02

Neoadjuvant chemoradiation does not improve surgical outcomes or survival in pancreatic cancer

Presented By

Dr Aurélien Lambert, Lorraine Cancer Institute, France

Trial

Phase 2, PANDAS/PRODIGE 44

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 13:18

Adding lenvatinib plus pembrolizumab to TACE improves PFS in intermediate-stage HCC

Presented By

Prof. Josep Llovet, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, LEAP-012

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 13:16

Benefit of adjuvant atezolizumab/bevacizumab in HCC not maintained over time

Presented By

Dr Adam Yopp, UT Southwestern Medical Center, TX, USA

Trial

Phase 3, IMbrave050

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 13:13

Pre-operative chemoradiation does not improve survival in resectable gastric cancer

Presented By

Prof. Trevor Leong, Peter MacCallum Cancer Centre, Australia

Trial

Phase 3, TOPGEAR

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 13:10

Final results of the IKF-AIO-Moonlight trial

Presented By

Dr Sylvie Lorenzen, Rechts der Isar Hospital, Germany

Trial

Phase 2, IKF-AIO-Moonlight

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 13:08

Retifanlimab boosts survival in patients with anal cancer

Presented By

Dr Sheela Rao, Royal Marsden, UK

Trial

Phase 3, POD1UM-303/InterAACT 2

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 13:04

NICHE-2 and NICHE-3 show high efficacy of short neoadjuvant immunotherapy in dMMR colon cancer

Presented By

Dr Myriam Chalabi, Netherlands Cancer Institute, the Netherlands; Dr Peter de Gooyer, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, NICHE

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 13:00

Organ-preserving regimens in rectal cancer

Presented By

Dr Alessio Amatu, Niguarda Cancer Center, Italy; Dr Syrine Ben Dhia, Antoine Lacassagne Center, France

Trial

NO-CUT, OPERA

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:57

No benefit of high-dose vitamin D3 supplementation in mCRC

Presented By

Dr Kimmie Ng, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, SOLARIS

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:51

More highlights in Colorectal Cancer

Trial

POCHI, LEANOX

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:48

Trastuzumab deruxtecan also effective in patients with brain metastases

Presented By

Dr Nancy Lin, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, DESTINY-Breast12

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:37

High pCR rates with dual neoadjuvant immunotherapy in TIL-high TNBC

Presented By

Dr Iris Nederlof, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, BELLINI

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:35

Local HER2 IHC0 is often HER2-low or -ultralow

Presented By

Prof. Giuseppe Viale, University of Milan, Italy

Trial

Phase 3, DESTINY-Breast06

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:32

First-line capivasertib improves PFS but not OS in metastatic TNBC

Presented By

Prof. Heather McArthur, UT Southwestern Medical Center, TX, USA

Trial

Phase 3, CAPItello-290

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:27

Breastfeeding does not increase the risk of breast cancer recurrence

Presented By

Dr Fedro Peccatori, European Institute of Oncology, Italy; Dr Eva Blondeaux, University of Genova, Italy

Trial

POSITIVE, BRCA BCY Collaboration

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:23

More highlights in Breast Cancer

Trial

HERA, NATALEE, KEYNOTE-522, HypoG-01

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:20

Adjuvant durvalumab does not improve survival in completely resected NSCLC

Presented By

Prof. Glenwood Goss, Ottawa Hospital, Canada

Trial

Phase 3, BR.31

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:15

NVL-655: a promising new option in pre-treated, drug-resistant ALK-mutated NSCLC

Presented By

Dr Alexander Drilon, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 1/2, ALKOVE-1

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:13

Relatlimab addition benefits only a subgroup of metastatic NSCLC

Presented By

Prof. Nicolas Girard, Institut Curie, France

Trial

Phase 2, RELATIVITY-104

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:11

More highlights in Lung Cancer

Trial

Phase 3, MARIPOSA, MARIPOSA-2

Type

Peer-reviewed article

4 November 2024 12:08

Neoadjuvant nivolumab/ipilimumab improves DMFS in stage III resectable melanoma

Presented By

Dr Minke Lucas, Netherlands Cancer Institute, the Netherlands

Trial

Phase 3, NADINA

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:00

New neoadjuvant combinations in stage III melanoma

Presented By

Dr Alexander Menzies, University of Sydney, Australia

Trial

Phase 1/2, KEYMAKER-U02

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:58

Long-term benefit of nivolumab, ipilimumab, and pembrolizumab: 10-year survival data

Trial

Phase 3, KEYNOTE-006, CheckMate 067

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:53

Rethinking immune rechallenge: Tivozanib monotherapy emerges as a promising post-ICI option in metastatic RCC

Presented By

Prof. Toni Choueiri, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, TiNivo-2

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:52

Perioperative durvalumab combined with neoadjuvant chemotherapy improves survival in bladder cancer

Presented By

Prof. Thomas Powles, University of London; Barts Cancer Center, UK

Trial

Phase 3, NIAGARA

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:49

Watchful waiting is non-inferior to BCG in patients with T0 after second transurethral resection

Presented By

Prof. Hiroshi Kitamura, University of Toyama, Japan

Trial

Phase 3, JCOG1019

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:47

Faecal transplants show promise in enhancing metastatic RCC treatment

Presented By

Dr Chiara Ciccarese, Agostino Gemelli University Policlinic, Italy

Trial

Phase 2, TACITO

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:44

More highlights in Renal Cell Carcinoma

Trial

LITESPARK-005, SUNNIFORECAST

Type

Peer-reviewed article

4 November 2024 11:42

Combination of radium-223 and enzalutamide benefits patients with mCRPC with bone metastases

Presented By

Prof. Silke Gillessen, Oncology Institute of Southern Switzerland

Trial

Phase 3, PEACE-3

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:38

177Lu-PSMA effective both in mCRPC and mHSPC

Presented By

Prof. Oliver Sartor, Tulane University, LA, USA; Dr Arun Azad, Peter MacCallum Cancer Centre, Australia

Trial

SPLASH, UpFrontPSMA

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:35

Decipher score is predictive for docetaxel-benefit in mestastatic prostate cancer

Presented By

Dr Emily Grist, University College London, UK

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:33

Final OS for CONTACT-02 trial in mCRPC

Presented By

Prof. Neeraj Agarwal, Huntsman Cancer Institute; University of Utah, UT, USA

Trial

Phase 3, CONTACT-02

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:30

Increased OS with pembrolizumab in newly diagnosed, high-risk, locally advanced cervical cancer

Presented By

Prof. Domenica Lorusso, Humanitas Hospital San Pio X, Italy

Trial

Phase 3, KEYNOTE-A18

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:27

Doublet maintenance therapy does not outperform monotherapy in ovarian cancer

Presented By

Prof. Bradley Monk, University of Arizona, AZ, USA

Trial

Phase 3, ATHENA-COMBO

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:25

Benefit of pembrolizumab in dMMR, newly diagnosed, high-risk endometrial cancer

Presented By

Dr Toon van Gorp, UZ Leuven, Belgium

Trial

Phase 3, KEYNOTE-B21

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:22

No OS benefit of niraparib maintenance in high-risk ovarian cancer

Presented By

Dr Antonio González-Martin, Clínica Universidad de Navarra, Spain

Trial

Phase 3, PRIMA

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:15

OS benefit in ARMANI, but is it worth it?

Presented By

Dr Giovanni Randon, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

Trial

Phase 3, ARMANI

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 12:08

SPOTLIGHT on new targets in immunotherapy: claudin 18.2

Presented By

Prof. Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, SPOTLIGHT

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 12:03

AI facilitates early detection of hepatocellular carcinoma

Presented By

Dr Kin Nam Kwok, Hong Kong University, Hong Kong

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:59

Encouraging efficacy of anti-claudin 18.2 ADC in G/GEJ cancer

Presented By

Dr Jia Liu, St Vincent’s Hospital Sydney, Australia

Trial

Phase 1

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:58

177Lu-DOTATATE significantly extends PFS in patients with GEP-NETs, regardless of grade or origin

Presented By

Dr Simron Singh, University of Toronto, Canada

Trial

Phase 3, NETTER-2

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:56

Durvalumab plus chemotherapy enhances 3-year survival in advanced biliary tract cancer

Presented By

Prof. Do-Youn Oh, Seoul National University, Korea

Trial

Phase 3, TOPAZ-1

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:53

Promising first results of mitazalimab in metastatic pancreatic ductal adenocarcinoma

Presented By

Dr Teresa Macarulla, Vall d’Hebron University Hospital, Spain

Trial

Phase 1/2, OPTIMIZE-1

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:50

Post-operative MRD status more prognostic than TNM stage

Presented By

Dr Arvind Dasari, MD Anderson Cancer Center, TX, USA

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:48

CAPRI 2 GOIM trial navigates biomarker-driven therapy

Presented By

Dr Giulia Martini, University of Campania Luigi Vanvitelli, Italy

Trial

Phase 2, CAPRI 2 GOIM

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:44

Meta-analysis of triplet therapy in BRAFV600E-mutated mCRC

Presented By

Dr Davi Said G. Celso, Federal University of Viçosa, Brazil

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:41

New analyses validate TAP and CPS scores for PD-L1 expression

Presented By

Prof. Markus Moehler; Prof. Eric Raymond

Trial

Phase 3, RATIONALE-305; RATIONALE-306

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:39

CheckMate 8HW: Nivolumab/ipilimumab in MSI-H/dMMR mCRC

Presented By

Dr Sara Lonardi, Veneto Institute of Oncology, Italy

Trial

Phase 3, CheckMate 8HW

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:39

Sequence effect for third-line treatment of mCRC

Presented By

Prof. Michel Ducreux, Gustave Roussy, France

Trial

Phase 2, SOREGATT

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:36

REGINA meets stage 1 endpoint in rectal cancer and moves to stage 2 with reduced dose regorafenib

Presented By

Dr Francesco Sclafani, Institut Jules Bordet, Belgium

Trial

Phase 2, REGINA

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:34

High efficacy of pembrolizumab combined with standard therapy in patients with MSS/pMMR mCRC and high immune infiltrate

Presented By

Prof. David Tougeron, Poitiers University Hospital, France

Trial

Phase 2, POCHI

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:31

KEYNOTE-585: negative trial, but long-term benefit in PD-L1-high/MSI subgroups?

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, KEYNOTE-585

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:30

Prognostic value of ctDNA in stage III colon cancer

Presented By

Prof. Julien Taieb, Paris Descartes University, France

Trial

Phase 3, IDEA-France, IDEA-Greece

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:28

Neoadjuvant combined immunotherapy also effective in MSS/pMRR CRC

Presented By

Dr Mehraneh Jafari, Weill Cornell Medical Center, NY, USA

Trial

Phase 2, NEST-1

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:25

Neoadjuvant immunotherapy plus radiation effective in advanced MSI-H rectal cancer

Trial

Phase 2, ECOG-ACRIN EA2201

Type

Peer-reviewed article

21 August 2024 11:19

Peri- or post-operative chemotherapy benefits patients with resectable CRCLM

Presented By

Dr Giacomo Bregni, Brussels University Hospital, Belgium

Trial

Phase 3

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:12

MINOTAUR: Promising phase 1 data for lunresertib plus FOLFIRI

Presented By

Dr Elisa Fontana, Sarah Cannon Research Institute, UK

Trial

Phase 1, MINOTAUR

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:09

TRANSMET meets OS endpoint

Presented By

Dr Maximiliano Gelli, Gustave Roussy, France

Trial

TRANSMET

Conference

ESMO GI 2024

Type

Peer-reviewed article

21 August 2024 11:05

The landscape of TP53 mutations and their prognostic impact in CLL

Presented By

Dr Consuelo Bertossi, University Hospital Ulm, Germany

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 15:11

Navitoclax plus ruxolitinib leads to spleen volume reductions in myelofibrosis

Presented By

Prof. Naveen Pemmaraju, MD Anderson Cancer Center, TX, USA

Trial

Phase 3, TRANSFORM-1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:28

Is pelabresib plus ruxolitinib the paradigm-shifting combo therapy for myelofibrosis?

Presented By

Dr Raajit Rampal, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, MANIFEST-2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:28

Can golcadomide plus R-CHOP become the first-line standard of care in high-risk BCL?

Presented By

Dr Marc Hoffman, The University of Kansas Cancer Center, KS, USA

Trial

Phase 1, CC-220-DLBCL-001

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

High survival rates following atezolizumab consolidation in DLBCL

Presented By

Dr Marcel Nijland, University Medical Center Groningen, the Netherlands

Trial

Phase 2, HOVON 151

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL

Presented By

Prof. Paolo Ghia, University Vita-Salute San Raffaele, Italy

Trial

Phase 3, SEQUOIA

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

EPCORE CLL-1: Promising data for epcoritamab in high-risk Richter’s transformation

Presented By

Prof. Arnon Kater, University of Amsterdam, the Netherlands

Trial

Phase 1/2, EPCORE CLL-1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

Updates from the EBMT Lymphoma Working Group: outcomes after allo- and auto-SCT for T-cell lymphoma subtypes

Presented By

Dr Evgenii Shumilov, University of Münster, Germany

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

ECHO: Can we expect a novel standard of care in newly diagnosed MCL?

Presented By

Prof. Michael Wang, University of Texas, TX, USA

Trial

Phase 3, ECHO

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:26

Clinically meaningful outcomes for mosunetuzumab across follicular lymphoma subgroups

Presented By

Dr Sarit Assouline, Jewish General Hospital, Canada

Trial

Phase 1/2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:26

ENERGIZE: Mitapivat meets primary efficacy endpoint in thalassaemia

Presented By

Prof. Ali Taher, American University of Beirut, Lebanon

Trial

Phase 3, ENERGIZE

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:26

Sovleplenib delivers durable responses and QoL improvements in primary ITP

Presented By

Prof. Renchi Yang, Chinese Academy of Medical Sciences, China

Trial

Phase 3, ESLIM-01

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:26

Avatrombopag successful in children with chronic ITP

Presented By

Dr Rachael Grace, Harvard Medical School, MA, USA

Trial

Phase 3, AVA-PED-301

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:26

RUBY: Promising data for first AsCas12a gene-editing therapy in sickle cell disease

Presented By

Dr Rabi Hanna, Cleveland Clinic, OH, USA

Trial

Phase 1/2, RUBY

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

Encouraging data for ELA026 to treat secondary haemophagocytic lymphohistiocytosis

Presented By

Dr Abhishek Maiti, MD Anderson Cancer Center, TX, USA

Trial

Phase 1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

PhALLCON: Third-generation TKI superior to first-generation TKI in Ph+ ALL

Presented By

Prof. Jose Maria Ribera, Josep Carreras Leukaemia Research Institute, Spain

Trial

Phase 3, PhALLCON

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

APOLLO: ATRA plus ATO meets expectations in high-risk APL

Presented By

Prof. Uwe Platzbecker, Leipzig University Hospital, Germany

Trial

Phase 3, TUD-APOLLO-064

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

Excellent phase 3 results for asciminib in chronic myeloid leukaemia

Presented By

Prof. Andreas Hochhaus, Jena University Hospital, Germany

Trial

Phase 3, ASC4FIRST

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

AUGMENT-101: Revumenib trial in KMT2Ar leukaemia stopped early for efficacy

Presented By

Dr Ibrahim Aldoss, City of Hope National Medical Center, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:24

FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML

Presented By

Dr Wei-Ying Jen, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:20

CD40/CD47 inhibitor shows promise in high-risk MDS and AML

Presented By

Prof. Amer Zeidan, Yale University, CT, USA

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

ENHANCE: Magrolimab does not ameliorate health outcomes in high-risk MDS

Presented By

Dr David Sallman, Moffitt Cancer Center, FL, USA

Trial

Phase 3, ENHANCE

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Can MRD-guided azacitidine treatment improve outcomes in AML and MDS?

Presented By

Dr Anne Sophie Kubasch, University of Leipzig, Germany

Trial

Phase 2, RELAZA2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Can WGTS replace standard-of-care diagnostics in AML?

Presented By

Dr Anna Staffas, University of Gothenburg, Sweden

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial

Presented By

Prof. Thierry Facon, University of Lille, France

Trial

Phase 3, IMROZ

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

PERSEUS: High MRD negativity rates with D-VRd and consolidation therapy and D-R maintenance in MM

Presented By

Prof. Pieter Sonneveld, Erasmus University Medical Center, the Netherlands

Trial

Phase 3, PERSEUS

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

Post-intensification data confirm superiority of quadruple therapy in MM

Presented By

Prof. Marc Raab, University Hospital Heidelberg, Germany

Trial

Phase 3, GMMG-HD7

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

Promising phase 1 results for novel CAR T-cell therapy in MM

Presented By

Dr Binod Dhakal, Medical College of Wisconsin, WI, USA

Trial

Phase 1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

DREAMM 8: Belantamab mafodotin offers hope for patients with RRMM

Presented By

Prof. Meletious Dimopoulos, University of Athens, Greece

Trial

Phase 3, DREAMM 8

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:16

Nipocalimab meets primary endpoint in Sjögren’s syndrome

Presented By

Prof. Jacques-Eric Gottenberg, Strasbourg University Hospital, France

Trial

Phase 2, DAHLIAS

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:38

Advanced therapies show promising results in PsA real-world study

Presented By

Prof. Dennis McGonagle, University of Leeds, UK

Trial

PRO-SPIRIT

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:38

Dual IL-17A/F blocker significantly reduces spinal radiographic progression in radiographic axSpA

Presented By

Prof. Xenofon Baraliakos, Ruhr-University Bochum, Germany

Trial

Phase 3, BE MOBILE 2

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:38

Small protein targeting IL-17A effective in PsA management

Presented By

Prof. Philip Mease, University of Washington; Swedish Medical Center, WA, USA

Trial

Phase 2

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:37

New JAK1 inhibitor outperforms placebo in active RA

Presented By

Dr Jinjing Liu, Peking Union Medical College Hospital, China

Trial

Phase 3

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:37

Macrophage profiling in synovial tissue predicts treatment response in RA

Presented By

Dr Simone Perniola, Policlinico Universitario A. Gemelli IRCS, Italy

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:36

Innovative app boosts mental health in patients with RA

Presented By

Prof. Frank Behrens, Goethe-University & Fraunhofer ITMP, Germany

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:35

Daratumumab shows promise in systemic lupus erythematosus

Presented By

Dr Tobias Alexander, Charité-University Medicine Berlin, Germany

Trial

Phase 2

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:35

Severe lung involvement in SSc linked to anti-Ro/SSA antibodies

Presented By

Dr Blaž Burja, University Hospital Zurich, Switzerland

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:35

Early treatment with ambrisentan might prevent PAH development in patients with SSc

Presented By

Dr Panagiota Xanthouli, Heidelberg University Hospital, Germany

Trial

Phase 2, EDITA

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:34

More patients hit their uric acid target with febuxostat and ruzinurad combination

Presented By

Dr Huihua Ding, Shanghai Jiao Tong University, China

Trial

Phase 2

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:34

Tophaceous gout at higher mortality risk than non-tophaceous gout

Presented By

Dr Gregory Challener, Massachusetts General Hospital, MA, USA

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:33

Is JAK inhibition the right choice for patients with relapsing giant cell arteritis?

Presented By

Dr Fernando López Gutiérrez, University Hospital Ramón y Cajal, Spain

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:33

Giant cell arteritis: Upadacitinib may be an upcoming treatment option

Presented By

Prof. Daniel Blockmans, University Hospitals Leuven, Belgium

Trial

Phase 3, SELECT-GCA

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:33

AxSpA: Higher comorbidity burden worsens radiographic progression

Presented By

Dr Sizheng Steven Zhao, University of Manchester, UK

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:32

Hope for a durable effective injection therapy in knee osteoarthritis

Presented By

Prof. Philip Conaghan, University of Leeds, UK

Trial

Phase 2, SPRINGBOARD

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:31

Dermatomyositis: Triple therapy with tacrolimus beats cyclosporin regimen

Presented By

Prof. Yasuhiro Katsumata, Tokyo Women’s Medical University, Japan

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:31

Less fracture risk with denosumab than bisphosphonates in pre-treated osteoporosis

Presented By

Prof. Jeffrey Curtis, University of Alabama at Birmingham, AL, USA

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:29

Low IL-18: a hidden culprit of long COVID in patients with autoimmune disease

Presented By

Dr Jeffrey Sparks, Brigham and Women's Hospital, MA, USA

Trial

RheumCARD

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:29

Stopping DMARDs? These key factors predict RA flares

Presented By

Dr Fiona Rayner, Newcastle University, UK

Trial

BIO-FLARE

Conference

EULAR 2024

Type

Peer-reviewed article

29 July 2024 14:27

No survival benefit of tumour debulking for patients with multi-organ metastatic CRC

Presented By

Dr Elske Gootjes, Radboudumc, the Netherlands

Trial

Phase 3, ORCHESTRA

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:53

Thermal ablation of small-size colorectal liver metastases is non-inferior to resection

Presented By

Prof. Martijn Meijerink, Amsterdam UMC, the Netherlands

Trial

Phase 3, COLLISION

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:48

Benefit of first-line nivolumab/ipilimumab in MSI-H/dMMR metastatic CRC

Presented By

Prof. Heinz-Josef Lenz, University of Southern California Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 3, CheckMate 8HW

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:44

Neoadjuvant checkpoint blockade in MSI-H/dMMR CRC

Trial

Phase 1/2, NICHE-2, NEOPRISM-CRC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:36

CodeBreaK 300: Promising survival trends in KRAS G12C-mutated mCRC

Presented By

Prof. Marwan Fakih, City of Hope Comprehensive Cancer Center, CA, USA

Trial

Phase 3, CodeBreaK 300

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:26

FLOT outperforms CROSS in resectable oesophageal cancer

Presented By

Prof. Jens Höppner, University of Bielefeld, Germany

Trial

Phase 3, ESOPEC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:14

Nivolumab/ipilimumab combination outperforms TKIs in unresectable HCC

Presented By

Dr Peter Galle, Universitätsmedizin Mainz, Germany

Trial

Phase 3, CheckMate 9DW

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:10

No advantage of neoadjuvant radiochemotherapy over neoadjuvant chemotherapy in borderline resectable pancreatic cancer

Presented By

Dr Masafumi Ikeda, National Cancer Center Hospital East, Japan

Trial

Phase 3, GABARNANCE

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:06

Benefit of abemaciclib plus fulvestrant after progression on a CDK4/6 inhibitor

Presented By

Prof. Kevin Kalinsky, Emory School of Medicine, GA, USA

Trial

postMONARCH

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:02

ctDNA is prognostic of worse outcomes for CDK4/6 therapy

Presented By

Prof. Sherene Loi, Peter MacCallum Cancer Centre, Australia

Trial

Phase 3, monarchE

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:56

Adjuvant avelumab significantly improves survival in early TNBC

Presented By

Prof. Pierfranco Conte, University of Padova, Italy

Trial

Phase 3, A-BRAVE

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:53

High pCR rate after neoadjuvant Dato-DXd plus durvalumab therapy

Presented By

Dr Jane Meisel, Emory School of Medicine, GA, USA & Dr Rebecca Shatsky, University of California San Diego, CA, USA

Trial

I-SPY2.2

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:38

Osimertinib significantly improves PFS in patients with unresectable stage III EGFR-mutated NSCLC

Presented By

Prof. Suresh Ramalingam, Emory School of Medicine, GA, USA

Trial

Phase 3, LAURA

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:30

First-line lorlatinib provides unprecedented improvement for patients with advanced ALK-positive NSCLC

Presented By

Prof. Benjamin Solomon, Peter MacCallum Cancer Centre, Australia

Trial

Phase 3, CROWN

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:28

Comparable benefit of video- and in-person-delivered palliative care

Presented By

Dr Joseph Greer, Harvard Medical School, MA, USA

Trial

REACH PC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:25

Consolidation with durvalumab improves survival in LS-SCLC

Presented By

Dr David Spigel, Sarah Cannon Research Institute, TN, USA

Trial

Phase 3, ADRIATIC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:23

Subcutaneous amivantamab non-inferior and more convenient than intravenous amivantamab

Presented By

Dr Natasha Leighl, Princess Margaret Cancer Centre, Canada

Trial

Phase 3, PALOMA-3

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:19

Highly significant event-free survival benefit with neoadjuvant nivolumab/ipilimumab in stage III melanoma

Presented By

Prof. Christian Blank, Antoni van Leeuwenhoek, the Netherlands

Trial

Phase 3, NADINA

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:16

Neoadjuvant intralesional daromun improves relapse-free survival in stage III melanoma

Presented By

Prof. Axel Hauschild, Universitätsklinikum Schleswig-Holstein, Germany

Trial

Phase 3, PIVOTAL

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:13

Intratumoural tilsotolimod shows no benefit for advanced refractory melanoma

Presented By

Prof. Caroline Robert, Gustave Roussy, France

Trial

Phase 3, ILLUMINATE-301

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:09

Immune-enhancing nutrition does not affect complication rate of radical cystectomy

Presented By

Prof. Jill Hamilton-Reeves, University of Kansas Medical Center, KS, USA

Trial

Phase 3, SWOG S1600

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:05

Biomarkers for treatment of renal cell carcinoma

Trial

Phase 3, CLEAR, KEYNOTE-426, IMmotion010

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:00

ctDNA changes as biomarker for pembrolizumab response in advanced urothelial carcinoma

Presented By

Prof. Thomas Powles, Barts Cancer Institute, UK

Trial

Phase 3, KEYNOTE-361

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:51

Highest efficacy of nivolumab/chemotherapy in lymph-node-only metastatic urothelial carcinoma

Presented By

Prof. Matthew Galsky, Tisch Cancer Institute, NY, USA

Trial

Phase 3, CheckMate 901

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:48

Metformin does not prevent progression of low-risk prostate cancer

Presented By

Dr Anthony Joshua, Princess Margaret Cancer Centre, Canada

Trial

Phase 3, MAST

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:46

Baseline ctDNA has both prognostic and predictive value in mCRPC

Presented By

Prof. Johann de Bono, Royal Marsden Hospital, UK

Trial

Phase 3, PSMAfore

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:44

Oxybutynin significantly decreases frequency and severity of hot flashes in men on ADT

Presented By

Dr Brad Stish, Mayo Clinic, MN, USA

Trial

Phase 2, Alliance 222001

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:41

Batiraxcept shows promise in high AXL-expressing, platinum-resistant ovarian cancer

Presented By

Dr Katherine Fuh, University of California San Francisco, CA, USA

Trial

Phase 3, AXLerate-OC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:38

No lymphadenectomy for advanced ovarian cancer without suspicious nodes

Presented By

Prof. Jean-Marc Classe, Nantes Université, France

Trial

Phase 3, CARACO

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:34

SIENDO: Efficacy benefit of selinexor in TP53 wildtype endometrial cancer

Presented By

Dr Vicky Makker, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, SIENDO

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:32

Novel regimen for HR-positive endometrial cancer on the way?

Presented By

Dr Angela Green, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:30

Effects of semaglutide on MACE irrespective of HF status

Presented By

Prof. John Deanfield, University College London, UK

Trial

SELECT

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 17:15

SEQUOIA-HCM: Aficamten demonstrates clinical efficacy in obstructive HCM

Presented By

Dr Martin Maron, Lahey Hospital and Medical Center, USA

Trial

SEQUOIA-HCM

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 17:13

ARIES-HM3 trial: Subgroup analysis in patients with prior need for aspirin

Presented By

Prof. Finn Gustafsson, University of Copenhagen, Denmark

Trial

ARIES HM3

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 17:09

Three diuretic regimens compared in the DEA-HF study

Presented By

Dr Aharon Abbo, Rambam Medical Center, Israel

Trial

DEA-HF

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 17:07

Adding a mineralocorticoid receptor modulator in heart failure with CKD

Presented By

Prof. Carolyn Lam, Duke-National University, Singapore

Trial

Phase 2, MIRACLE

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 17:04

Empagliflozin did not reduce mortality for HF after MI regardless of T2D status

Presented By

Prof. Javed Butler, University of Mississippi, USA

Trial

EMPACT-MI

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 16:49

SGLT2 inhibitors decrease atrial fibrillation risk in patients with HFrEF

Presented By

Dr Joel Manuel Alejandro, University of Maryland, USA

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 16:45

SGLT2 inhibition: Major and early impact on heart failure hospitalisation risk

Presented By

Dr Muthiah Vaduganathan, Brigham and Women's Hospital, USA

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 16:42

Individualised diuretic titration in acute HF without a physician

Presented By

Dr Evelyne Meekers, Hospital Oost-Limburg, Belgium

Trial

EASY-HF

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 16:36

Intravenous iron deficiency treatment improves exercise capacity in patients with HFpEF

Presented By

Prof. Stephan von Haehling, University Medical Centre of Göttingen, Germany

Trial

Phase 2, FAIR-HFpEF

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 16:33

CD34+ stem cells promote reverse cardiac remodelling after acute MI

Presented By

Prof. Faiez Zannad, University of Lorraine, France

Trial

Phase 1/2, EXCELLENT

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 16:30

Sex-specific outcomes and resource utilisation after HF hospitalisation

Presented By

Dr Tauben Averbuch, University of Calgary, Canada

Trial

PACT-HF

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 16:27

Application of guideline-directed medical therapy in patients with HFrEF in the Netherlands

Presented By

Dr Jasper Brugts, Erasmus University Medical Center, the Netherlands

Trial

TITRATE-HF

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 16:17

PAP-guided management system appears safe in patients with HF

Presented By

Dr Michael Kiernan, Tufts University School of Medicine, USA

Trial

PROACTIVE-HF

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 16:12

Delivery of CRT guided by non-invasive anatomy assessment

Presented By

Dr Mikhail Chmelevsky, Cardiocentro Ticino Institute, Switzerland

Trial

CRT-DRIVE

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 16:03

RELIEVE-ing HFrEF with interatrial shunting

Presented By

Prof. Stefan Anker, Charité - University Hospital Berlin, Germany

Trial

RELIEVE-HF

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 15:57

Algorithm-based remote patient monitoring was associated with lower mortality in a retrospective cohort study

Presented By

Prof. Nicolas Girerd, University Hospital of Nancy, France

Trial

TELESAT

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 15:46

High mortality and morbidity in suspected de novo HF in outpatient care

Presented By

Dr Lisa Anderson, St George’s Healthcare NHS Foundation Trust, UK

Trial

REVOLUTION-HF

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 15:44

Bio-ADM as a marker for congestion in patients hospitalised for acute HF

Presented By

Mr Geert Voordes, University Medical Center Groningen, the Netherlands

Trial

STRONG-AF

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 15:39

Hypertonic saline not effective in ambulatory patients with heart failure?

Presented By

Dr Marta Cobo Marcos, Iron Gate Majadahonda University Hospital, Spain

Trial

Phase 3, SALT-HF

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 15:35

No effect of low-dose carperitide on mortality or hospitalisation in acute HF

Presented By

Dr Toshiyuki Nagai, Hokkaido University, Japan

Trial

LASCAR-AHF

Conference

HFA 2024

Type

Peer-reviewed article

16 July 2024 15:32

Mepolizumab improves the histologic severity of eosinophilic oesophagitis

Presented By

Dr Evan Dellon, University of North Carolina School of Medicine, USA

Trial

Phase 2

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 13:43

Budesonide demonstrates efficacy in eosinophilic oesophagitis

Presented By

Prof. Edoardo Savarino, University of Padua, Italy

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 13:41

Dupilumab shows promising results in treating paediatric eosinophilic oesophagitis

Presented By

Dr Puanani Hopson, Mayo Clinic, USA

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 13:38

Quality-of-life assessment in children with eosinophilic oesophagitis

Presented By

Émile L'Heureux-Hubert, University of Montreal, Canada

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 13:36

Gut permeability and neuroinflammation linked in Parkinson’s disease

Presented By

Dr Francesco Rettura, University of Pisa, USA

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 13:26

Promising data for cardiovascular outcomes of bariatric surgery in patients with obesity

Presented By

Dr Soban Maan, West Virginia University, USA

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 13:23

Survodutide meets expectations in MASH

Presented By

Dr Naim Alkhouri, Arizona Liver Health, USA

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 13:07

GALAXI 2 & 3: Guselkumab proves efficacy in Crohn’s disease

Presented By

Dr Remo Panaccione, University of Calgary, Canada

Trial

GALAXI

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 13:01

QUASAR maintenance study: Guselkumab effective and safe for UC

Presented By

Dr David Rubin, University of Chicago, USA

Trial

QUASAR

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 12:58

VEDOKIDS: Vedolizumab maintains remission in patients with paediatric IBD

Presented By

Dr Ronen Stein, Children's Hospital of Philadelphia, USA

Trial

VEDOKIDS

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 12:54

ADMIRE-CD II: Darvadstrocel does not meet primary endpoint in complex Crohn’s perianal fistulas

Presented By

Dr Laura Raffals, Mayo Clinic, USA

Trial

Phase 3, ADMIRE-CD II

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 12:47

PREEMPT CRC: Blood-based screening test for colorectal cancer shows promise

Presented By

Dr Aasma Shaukat, New York University, USA

Trial

PREEMPT CRC

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 12:33

New cable-transmission capsule endoscopy shows high accuracy in detecting upper GI lesions

Presented By

Dr Yuan Tian, Peking University First Hospital, China

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 12:26

Superior OS with atezolizumab plus bevacizumab versus lenvatinib in unresectable HCC

Presented By

Dr Sangdao Boonkaya, King Chulalongkorn Memorial Hospital, Thailand

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 11:46

Nutritional consultation boosts nutritional status in patients with alcohol-associated hepatitis

Presented By

Dr Nariman Hossein-Javaheri, University at Buffalo, USA

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 11:44

REGENERATE study: Obeticholic acid shows antifibrotic benefit in NASH

Presented By

Dr Arun J Sanyal, Virginia Commonwealth University, USA

Trial

Phase 3, REGENERATE

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 11:41

Acalculous cholecystitis as a risk factor for gallbladder perforation: insights from a 10-year retrospective study

Presented By

Dr Se Woo Park, Hallym University Dongtan Sacred Heart Hospital, South Korea

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 11:36

STARS: Apraglutide shows efficacy in short bowel syndrome with intestinal failure

Presented By

Prof. Francisca Joly, Hopital Beaujon, France

Trial

Phase 3, STARS

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 11:30

COX-2 inhibitors show promise in reducing severity of acute pancreatitis

Presented By

Dr Lu-Ming Huang, West China Hospital of Sichuan University, China

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 11:23

Hormone-containing therapies may increase the risk of IBS and functional dyspepsia

Presented By

Dr Michael Jones, Macquarie University, Australia

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 11:15

The management of lymphoedema in 2024

Presented By

Dr Kirsten van Duinen, Nij Smellinghe Hospital, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:53

Diagnosing skin disorders in patients with skin of colour

Presented By

Dr Deepak Balak, Leiden University Medical Center, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:50

What’s new in clinical dermatology?

Presented By

Dr Tamar Nijsten, Erasmus University Medical Centre, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:31

Safety and efficacy of a therapeutic HPV vaccine in high-grade anal intraepithelial neoplasia

Presented By

Dr Karien Gosens, Mauritskliniek, the Netherlands

Trial

Phase 1/2, VACCAIN-T

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:08

Artificial intelligence in dermatology: current applications and future horizons

Presented By

Tobias Sangers, Leiden University Medical Center, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 13:01

Digital dermatology in the Dutch treatment landscape

Presented By

Dr Milan Tjioe, Bravis Hospital, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 12:57

Improving risk classification in cutaneous squamous cell carcinoma

Presented By

Dr Marlies Wakkee, Erasmus MC Rotterdam, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 12:54

Skin cancer in transplant patients: practical challenges

Presented By

Dr Elsemieke Plasmeijer, Leiden University Medical Center, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 12:47

Understanding bullous pemphigoid: a rare skin condition

Presented By

Prof. Barbara Horváth, University Medical Center Groningen, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 12:24

Advancements in gene therapy for epidermolysis bullosa

Presented By

Dr Peter van den Akker, University Medical Center Groningen, the Netherlands

Conference

DDD 2024

Type

Peer-reviewed article

31 May 2024 12:22

Preventive PCI of vulnerable intracoronary plaque leads to favourable outcomes

Presented By

Prof. Seung-Jung Park, University of Ulsan College of Medicine, South Korea

Trial

PREVENT

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 14:52

KARDIA-2: Add-on zilebesiran effectively lowers blood pressure

Presented By

Dr Akshay Desai, Brigham and Women's Hospital, USA

Trial

Phase 2, KARDIA-2

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 14:48

BRIDGE-TIMI 73a: Olezarsen halves triglyceride levels

Presented By

Dr Brian Bergmark, Brigham and Women's Hospital, USA

Trial

Phase 2, BRIDGE-TIMI 73a

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 14:41

High-risk and very high-risk patients meet LDL-cholesterol targets with lerodalcibep

Presented By

Prof. Eric Klug, University of the Witwatersrand, South Africa

Trial

Phase 3, LIBerate-HR

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 14:15

No cardioprotective effect of ACE inhibitors in patients with cancer

Presented By

Dr David Austin, South Tees Hospitals, UK

Trial

Phase 3, PROACT

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 14:06

SGLT2 inhibition in heart failure more advantageous for women than men

Presented By

Dr Mounica Vorla, University of Louisville School of Medicine, USA

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 14:00

Anxiety and depression: Lifestyle influential in MACE prevention

Presented By

Dr Shady Abohashem, Massachusetts General Hospital, USA

Trial

Mass General Brigham Biobank

Conference

ACC 204

Type

Peer-reviewed article

16 May 2024 13:57

Self-expanding versus balloon-expendable TAVR in patients with small aortic annuli

Presented By

Prof. Howard Herrmann, Perelman School of Medicine, PA, USA

Trial

SMART

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 13:52

Safety of TAVI non-inferior to SAVR for patients with lower surgical risk

Presented By

Prof. Moritz Seiffert, BG University Hospital Bergmannsheil, Germany

Trial

DEDICATE-DZHK6

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 13:50

Interatrial shunt for HF: neutral primary endpoint but potential benefit in HFrEF

Presented By

Prof. Gregg Stone, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

RELIEVE-HF

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 13:45

Peripheral artery disease: procedure-guidance by IVUS superior to angiography

Presented By

Prof. Young-Guk Ko, Severance Cardiovascular Hospital; Yonsei University, South Korea

Trial

IVUS-DCB

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 13:43

IVUS-guided PCI beats angiography in patients with acute coronary syndrome

Presented By

Prof. Shao-Liang Chen, Nanjing Medical University, China

Trial

IVUS-ACS

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 13:40

Addressing frailty in patients undergoing TAVR

Presented By

Dr Jonathan Afilalo, McGill University, Canada

Trial

PERFORM-TAVR

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 13:36

ACS: Necessary DAPT after PCI may be shorter than currently advised

Presented By

Prof. Gregg Stone, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

ULTIMATE-DAPT

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 13:29

AEGIS-II: ApoA-1 did not reduce MACE in patients with myocardial infarction but may provide benefit in patients with high LDL levels

Presented By

Prof. Michael Gibson, Harvard Medical School, MA, USA

Trial

Phase 3, AEGIS-II

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 13:26

REDUCE-AMI: Re-evaluating the role of routine beta-blockade in patients with acute myocardial infarction

Presented By

Dr Troels Yndigegn, Lund University, Sweden

Trial

Phase 4, REDUCE-AMI

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 13:23

STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes

Presented By

Prof. Mikhail Kosiborod, Saint Luke's Mid America Heart Institute, MO, USA

Trial

Phase 3, STEP-HFpEF DM

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 13:20

IMPROVE-HCM: Promising results for ninerafaxstat in non-obstructive HCM

Presented By

Prof. Martin Maron, Lahey Hospital & Medical Center, MA, USA

Trial

Phase 2, IMPROVE-HCM

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 13:15

Children with atopic dermatitis may be smaller and heavier than healthy children

Presented By

Prof. Amy Paller, Northwestern University‘s Feinberg School of Medicine, USA

Trial

PEDISTAD

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:54

JAK inhibitors have similar incidence rates of long-term adverse events as traditional immunomodulators

Presented By

Olivia Lamberg, University of Michigan, USA

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:52

Baricitinib maintains regrowth of hair, eyebrows, and eyelashes over 3 years

Presented By

Prof. Maryanne Senna, Harvard Medical School, USA

Trial

BRAVE-AA

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:43

GUIDE demonstrates: Hit hard and early in psoriasis

Presented By

Prof. Knut Schäkel, University Clinic Heidelberg, Germany

Trial

Phase 3, GUIDE

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:36

Hidradenitis suppurativa treatment with secukinumab linked to low immunogenicity

Presented By

Prof. Martina Porter, Beth Israel Deaconess Medical Center, USA

Trial

Phase 3, SUNSHINE; SUNRISE

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:33

HS: Targeting IL-1 pathway potential option after anti-TNF failure

Presented By

Prof. Falk Bechara, Ruhr-University Bochum, Germany

Trial

Phase 2

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:29

BTK signalling as a novel target in hidradenitis suppurativa treatment

Presented By

Prof. Alexandra Kimball, Harvard Medical School, USA

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:20

Topical ruxolitinib shows promise in milder stages of hidradenitis suppurativa

Presented By

Prof. Martina Porter, Beth Israel Deaconess Medical Center, MA, USA

Trial

Phase 2

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:16

Robust long-term efficacy of bimekizumab in psoriasis

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, USA

Trial

BE BRIGHT

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:09

Benefit and safety of TYK2 inhibitor ESK-001 for psoriasis in phase 2

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

Phase 2, STRIDE

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:01

Durable skin clearance by IL-23 blockers due to reduction of resident memory T cells

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Trial

Phase 2, KNOCKOUT

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:41

Amlitelimab leads to a high response 28 weeks after treatment discontinuation

Presented By

Prof. Stephan Weidinger, Christian-Albrechts-University Kiel, Germany

Trial

Phase 2, STREAM-AD

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:35

Delgocitinib cream: A promising treatment option for chronic hand eczema

Presented By

Prof. Melinda Gooderham, Queens University, Canada

Trial

Phase 3, DELTA 3

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:31

Upadacitinib: A novel treatment option for vitiligo

Presented By

Prof. Thierry Passeron, Nice University Hospital, France

Trial

Phase 2

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:21

JAK1 inhibitor meets primary endpoint in prurigo nodularis

Presented By

Prof. Martin Metz, Charité University Hospital, Germany

Trial

Phase 2

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:17

Botanical drug solution leads to sustained hair regrowth in paediatric alopecia

Presented By

Prof. Bianca Piraccini, University of Bologna, Italy

Trial

RAAINBOW

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:14

SGLT2 inhibition: A possible mode-of-action for inflammatory skin diseases?

Presented By

Allison Holt, UMass Chan Medical School, USA

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:06

Promising first results of novel topical treatment for congenital ichthyosis

Presented By

Dr Christopher Bunick, Yale School of Medicine, USA

Trial

Phase 3, ASCEND

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 15:02

Ritlecitinib also effective in patients with total hair loss

Presented By

Dr Melissa Piliang, Cleveland Clinic, USA

Trial

Phase 3, ALLEGRO

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 14:57

VIVID-1: Mirikizumab meets expectations in Crohn’s disease

Presented By

Prof. Marc Ferrante, University Hospitals Leuven, Belgium

Trial

Phase 3, VIVID-1

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:49

COMMAND: Long-term efficacy benefits of risankizumab in ulcerative colitis

Presented By

Prof. Stefan Schreiber, University Hospital Schleswig-Holstein, Germany

Trial

Phase 3, COMMAND

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:47

SEQUENCE: Risankizumab versus ustekinumab across endpoints

Presented By

Prof. Marla Dubinsky, Mount Sinai Hospital, NY, USA

Trial

Phase 3, SEQUENCE

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:45

QUASAR: Guselkumab improves QoL for patients with ulcerative colitis

Presented By

Prof. Julian Panés, Hospital Clinic de Barcelona, Spain

Trial

Phase 3, QUASAR

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:43

Fatigue, urgency, and QoL improvements on mirikizumab in Crohn’s disease

Presented By

Prof. Simon Travis, University of Oxford, UK

Trial

Phase 3, VIVID-1

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:41

Novel agent VTX002 holds promise in ulcerative colitis

Presented By

Prof. Bruce Sands, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 2

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:39

PROFILE: Top-down treatment strategy benefits patients with early Crohn’s disease

Presented By

Dr Nuru Noor, Cambridge University Hospitals, UK

Trial

PROFILE

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:38

Biologicals and JAK inhibitors hold promise in microscopic colitis

Presented By

Dr Bram Verstockt, University Hospitals Leuven, Belgium

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:35

Ustekinumab as alternative for anti-TNFs in HLA-DQA1*05-positive Crohn’s disease

Presented By

Dr Jordi Guardiola, University Hospital Bellvitge, Spain

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:33

How effective is dose escalation of biologicals in IBD?

Presented By

Dr Cristina Rubín de Célix, University Hospital La Princesa, Spain

Trial

RAINBOW-IBD

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:30

Promising data for JAK inhibitors in Crohn’s disease from phase 2 trial

Presented By

Dr Séverine Vermeire, University Hospitals Leuven, Belgium

Trial

Phase 2, PIZZICATO

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:28

U-ENDURE long-term extension: sustained efficacy of upadacitinib in Crohn’s disease

Presented By

Dr Geert D’Haens, Amsterdam University Medical Centers, the Netherlands

Trial

U-ENDURE

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:25

TRIUMPH: Tofacitinib as rescue option for acute severe ulcerative colitis

Presented By

Dr Neeraj Narula, McMaster University, Canada

Trial

Phase 2, TRIUMPH

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:23

Should we screen for metabolic bone disease at IBD diagnosis?

Presented By

Dr Mohamed Attauabi, Copenhagen University Hospital, Denmark

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:20

Predicting relapse in ulcerative colitis with AI-assisted endoscopy

Presented By

Dr Yasuharu Maeda, Showa University Northern Yokohama Hospital, Japan; University College Cork, Ireland

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:19

Clear case for NUDT15 genetic testing in Asian patients with IBD

Presented By

Dr Chris Roberts, University of Exeter, UK

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:14

HELIOS: HD-WLE can yield similar neoplasia detection rates as HD-CE

Presented By

Dr Maarten te Groen, Radboudumc, the Netherlands

Trial

HELIOS

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:12

CURE-CD: Capsule endoscopy-guided proactive treatment leads to fewer relapses in Crohn’s disease

Presented By

Dr Shomron Ben-Horin, Tel-Aviv University, Israel

Trial

CURE-CD

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:10

Extended mesenterectomy or mesenteric-sparing surgery in Crohn’s disease?

Presented By

Dr Eline van der Does de Willebois, Amsterdam University Medical Centers, the Netherlands

Trial

SPICY

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 12:33

Similar outcomes for Kono-S and side-to-side anastomosis in Crohn’s terminal ileitis

Presented By

Dr Koianka Trencheva, Weill Cornell Medicine, NY, USA

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 12:29

Risk factors for re-resection in Crohn’s disease revealed

Presented By

Dr Anja Poulsen, Copenhagen University, Denmark

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 12:26

ADMIRE-CD-II: Darvadstrocel does not meet primary endpoint in complex peri-anal fistula

Presented By

Dr Zuzana Serclova, Hořovice Hospital, Czech Republic

Trial

Phase 3, ADMIRE-CD-II

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 12:23

FLT3-ITD-specific MRD assessment useful for clinical management of AML

Presented By

Prof. Alexander Perl, University of Pennsylvania, PA, USA

Trial

Phase 3, QuANTUM-First

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:05

MRD status rather than FLT3-ITD co-mutation is linked to the benefit of CR1-allo in NPM1-mutated AML

Presented By

Dr Jad Othman, Royal North Shore Hospital, Australia

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

Promising results for quizartinib, venetoclax, and decitabine in FLT3-ITD mutated AML

Presented By

Dr Musa Yilmaz, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

AUGMENT-101: Excellent results for revumenib in R/R KMT2Ar leukaemia

Presented By

Dr Ibrahim Aldoss, City of Hope National Medical Center, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

Blinatumomab reduces toxicity in the consolidation phase in paediatric high-risk B-cell ALL

Presented By

Prof. Martin Schrappe, Hong Kong College of Paediatricians, China

Trial

Phase 3, AIEOP-BFM ALL 2017

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:02

Promising results for olverembatinib in combination with venetoclax for Ph+ ALL

Presented By

Dr Xiaoyuan Gong, Chinese Academy of Medical Sciences, China

Trial

Phase 2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:02

Undetectable MRD on maintenance venetoclax, acalabrutinib, and obinutuzumab in the majority of R/R CLL participants

Presented By

Dr Moritz Fürstenau, University of Cologne, Germany

Trial

Phase 2, CLL2-BAAG

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:01

Is allogeneic stem cell transplantation a solid option in R/R LBCL or R/R T-cell lymphoma?

Presented By

Prof. Bertram Glass, Helios Klinikum Berlin-Buch, Germany

Trial

Phase 2, ASTRAL

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:00

Encouraging results for the addition of acalabrutinib to lenalidomide and rituximab in follicular lymphoma

Presented By

Dr Paolo Strati, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:00

Can ibrutinib ameliorate outcomes in R/R ABC-DLBCL undergoing autoSCT?

Presented By

Dr Charalambos Andreadis, University of California San Francisco, USA

Trial

Phase 3, A051301/BMT-CTN 1201

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

Primary phase 2 efficacy and safety results of M-Pola in relapsed/refractory LBCL

Presented By

Dr Elizabeth Budde, City of Hope National Medical Center, CA, USA

Trial

Phase 1/2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

SYMPATICO: Ibrutinib plus venetoclax boosts PFS in R/R mantle cell lymphoma

Presented By

Prof. Michael Wang, University of Texas, TX, USA

Trial

Phase 3, SYMPATICO

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

KdD outperforms Kd in R/R MM also in participants with poor renal function

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, CANDOR

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:58

IsKia: Novel treatment regimen for MM delivers high MRD-negativity rates

Presented By

Prof. Francesca Gay, University of Torino, Italy

Trial

Phase 3, IsKia

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:57

TRANSFORM-1: High spleen volume reduction rates for navitoclax plus ruxolitinib in myelofibrosis

Presented By

Prof. Naveen Pemmaraju, MD Anderson Cancer Center, TX, USA

Trial

Phase 3, TRANSFORM-1

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:57

Momelotinib beats controls regarding transfusion outcomes in myelofibrosis

Presented By

Prof. Ruben Mesa, Wake Forest Baptist Comprehensive Cancer Center, NC, USA

Trial

Phase 3, Simplify-1, MOMENTUM

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:57

DALIAH: Peginterferon-α head-to-head against hydroxyurea in MPN

Presented By

Dr Trine Knudsen, University Hospital Odense, Denmark

Trial

Phase 3, DALIAH

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:57

Long-term efficacy and safety of iptacopan in PNH with anaemia

Presented By

Prof. Antonio Risitano, University of Naples, Italy

Trial

Phase 3, APPLY-PNH

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:56

ADVANCE IV: Swift responses on efgartigimod in ITP

Presented By

Prof. Catherine Broome, Georgetown University, DC, USA

Trial

Phase 3, ADVANCE IV

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:56

Favourable QoL and bleeding outcomes for rilzabrutinib in ITP

Presented By

Prof. Michael Tarantino, University of Illinois, IL, USA

Trial

Phase 1/2, LUNA 2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:55

Novel risk assessment model acts on increasing hospital-acquired venous thromboembolism rates among children

Presented By

Dr Julie Jaffray, Rady Children’s Hospital-San Diego, CA, USA

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:55

Axatilimab may present a new therapeutic strategy in chronic GvHD

Presented By

Prof. Daniel Wolff, University Hospital Regensburg, Germany

Trial

Phase 2, AGAVE-201

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:54

Pomalidomide may become the first approved therapy for hereditary haemorrhagic telangiectasia

Presented By

Prof. Keith McCrae, Cleveland Clinic, OH, USA

Trial

Phase 2, PATH-HHT

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:54

Ancestry-specific study into CH delivers new leads

Presented By

Dr Sean Wen, University of Cambridge, UK

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:54

Novel standard-of-care in newly diagnosed MM

Presented By

Prof. Pieter Sonneveld, Erasmus MC, the Netherlands

Trial

Phase 3, Perseus

Conference

ASH 2023

Type

Peer-reviewed article

6 February 2024 16:34

Successful results for semaglutide in the highly anticipated SELECT trial 

Presented By

Dr Michael Lincoff, Cleveland Clinic, USA

Trial

Phase 3, SELECT

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 15:37

Can a walking intervention improve functional status and quality of life in HFrEF?

Presented By

Dr Tomas Vetrovsky, Charles University, Czechia

Trial

WATCHFUL

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 15:30

Head-to-head: Surgical embolectomy versus ultrasound-assisted thrombolysis in high-risk pulmonary embolism

Presented By

Dr Stefan Stortecky, University of Bern, Switzerland

Trial

Phase 2, SPECIAL

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 15:26

Abelacimab substantially lowers bleeding risk compared with rivaroxaban 

Presented By

Dr Christian Ruff, Brigham and Women’s Hospital, USA

Trial

Phase 2, AZALEA-TIMI 71

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 15:22

Liraglutide may improve post-ablation outcomes in obese patients with AF

Presented By

Dr Jeffrey Goldberger, University of Miami, USA

Trial

Phase 4, LEAF

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 15:19

Single or dual cardioversion in patients with obesity and AF?

Presented By

Dr Joshua Aymond, Ochsner Health, USA

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 15:16

NOAH-AFNET 6: Does the duration of AHRE influence response to edoxaban?

Presented By

Dr Nina Becher, University of Hamburg, Germany

Trial

Phase 3, NOAH-AFNET 6

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 15:13

ARTESIA: How useful is anticoagulation in subclinical AF? 

Presented By

Prof. Jeff Healey, McMaster University, Canada

Trial

Phase 4, ARTESIA

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 15:08

Jewel IDE: High compliance rates for novel patch wearable cardioverter defibrillator

Presented By

Dr John Hummel, Ohio State University, USA

Trial

Jewel IDE

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 15:04

Sudden cardiac death in athletes: incidence, causes, and trends over 20 years

Presented By

Dr Bradley Petek, Oregon Health and Science University, USA

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 15:01

Encouraging data for lepodisiran as Lp(a) lowering therapy 

Presented By

Dr Steven Nissen, Cleveland Clinic, USA

Trial

Phase 1

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 14:38

Gene editing may change the treatment landscape of hypercholesterolaemia 

Presented By

Dr Andrew Bellinger, Verve Therapeutics, USA

Trial

Phase 1, heart-1

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 14:35

REPRIEVE: Mechanisms behind MACE reduction in HIV population on pitavastatin

Presented By

Dr Michael Lu, Massachusetts General Hospital, USA

Trial

Phase 3, REPRIEVE

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 14:31

Recaticimab may offer a solution for uncontrolled hypercholesterolaemia

Presented By

Dr Xin Du, Beijing Anzhen Hospital, China

Trial

Phase 3, REMAIN-2

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 14:27

Edoxaban versus warfarin in chronic thromboembolic pulmonary hypertension

Presented By

Dr Kazuya Hosokawa, Kyushu University, Japan

Trial

Phase 3, KABUKI

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 14:09

Sodium intake and blood pressure: new insights

Presented By

Dr Deepak Gupta, Vanderbilt University Medical Centre, USA

Trial

CARDIA-SSBP

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 14:04

Intensive BP intervention reduces risk of dementia 

Presented By

Dr Jiang He, Tulane University, USA

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 14:01

Post-partum intervention lowers BP after hypertensive pregnancy 

Presented By

Dr Jamie Kitt, University of Oxford, UK

Trial

POP-HT

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 13:58

Biannual zilebesiran associated with substantial BP reductions 

Presented By

Prof. George Bakris, University of Chicago, USA

Trial

Phase 2, KARDIA-1

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 13:56

MINT: Liberal or restrictive transfusion strategy in MI with anaemia? 

Presented By

Dr Jeffrey Carson, Rutgers University, NJ, USA

Trial

Phase 3, MINT

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 13:52

ORBITA-2 confirms PCI effective for symptom relief in patients with stable angina 

Presented By

Dr Christopher Rajkumar, Imperial College London, UK

Trial

ORBITA-2

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 13:48

Nicotinamide riboside shows promising trend for walking function in PAD 

Presented By

Prof. Mary McDermott, Northwestern University, USA

Trial

Phase 2, NICE

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 13:43

Pemafibrate reduces microvascular complications of PAD and T2D 

Presented By

Dr Aruna Pradhan, Brigham and Women’s Hospital, USA

Trial

Phase 3, PROMINENT

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 13:39

Dapagliflozin improves cardiometabolic outcomes in myocardial infarction  

Presented By

Prof. Stefan James, Uppsala University, Sweden

Trial

Phase 3, DAPA-MI

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 13:33

Addition of atezolizumab to chemotherapy and maintenance PARP inhibitor has no benefit in ovarian cancer

Presented By

Prof. Antonio Gonzalez Martin, Cancer Centre Clinica Universidad de Navarre, Spain

Trial

Phase 3, ANITA

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 12:43

Short-induction chemotherapy improves survival in advanced cervical cancer

Presented By

Dr Mary McCormack, University College London, UK

Trial

Phase 3, INTERLACE

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 12:37

Neoadjuvant immune checkpoint blockade safe and effective in MMRd endometrial cancer

Presented By

Dr Marco de Bruyn , University Medical Center Groningen, the Netherlands

Trial

Phase 1, PAM

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 12:34

Two potential new first-line standards of care in metastatic urothelial cancer

Presented By

Prof. Thomas Powles, Queen Mary University of London, UK

Trial

Phase 3, EV-302/KEYNOTE-A39; CheckMate 901

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 12:19

LuPSMA and enzalutamide: a promising combination

Presented By

Prof. Louise Emmet, St Vincent’s Hospital Sydney, Australia

Trial

Phase 2, ENZA-p

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 12:15

No benefit of erdafitinib over pembrolizumab in urothelial cancer second-line therapy

Presented By

Prof. Arlene Siefker-Radtke, MD Anderson Cancer Centre, USA

Trial

Phase 3, THOR

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 11:20

Lifileucel induces a durable response in heavily pretreated mucosal melanoma

Presented By

Dr Evidio Domingo-Musibay, Masonic Cancer Center, USA

Trial

Phase 2, C-144-01

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 11:15

Darovasertib/crizotinib combination: a potential first-line therapy in metastatic uveal melanoma

Presented By

Dr Meridith McKean, Tennessee Oncology, USA

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 11:06

Perioperative durvalumab/FLOT improves pCR in gastric cancer

Presented By

Prof. Salah-Eddin Al-Batran, Northwest Hospital Frankfurt, Germany

Trial

Phase 3, MATTERHORN

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 10:58

Active surveillance after neoadjuvant chemoradiotherapy in oesophageal cancer

Presented By

Dr Berend van der Wilk, Erasmus Medical Centre, the Netherlands

Trial

Phase 3, SANO

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 10:48

FOLFIRINOX equals gemcitabine-based chemoradiotherapy in neoadjuvant setting for pancreatic cancer

Presented By

Prof. Bas Groot Koerkamp, Erasmus Medical Centre, the Netherlands

Trial

Phase 3, PREOPANC-2

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 10:35

Modified FLOT regime outperforms FOLFOX in advanced/metastatic gastric/gastroesophageal junction adenocarcinoma

Presented By

Prof. Aziz Zaanan, Université Paris Cité, France

Trial

Phase 3, GASTROFOX

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 10:30

Perioperative nivolumab boosts event-free survival in NSCLC

Presented By

Dr Tina Cascone, MD Anderson Cancer Center, USA

Trial

Phase 3, CheckMate 77T

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 09:56

Selective RET inhibitor selpercatinib doubles progression-free survival in RET-mutated NSCLC

Presented By

Prof. Herbert Ho Fung Loong, Chinese University of Hong Kong, China

Trial

Phase 3, LIBRETTO-431

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 09:54

Dato-DXd outperforms docetaxel in previously treated patients with metastatic NSCLC  

Presented By

Dr Aaron Lisberg, University of California Los Angeles, USA

Trial

Phase 3, TROPION-LUNG01

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 09:51

First-line and second-line benefit of amivantamab in advanced, EGFR-mutated NSCLC

Presented By

Prof. Nicolas Girard, Institut du Thorax Curie-Montsouris, France

Trial

Phase 3, PAPILLON

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 09:47

Neoadjuvant nivolumab/relatlimab demonstrates 100% pathological response in MMRd colon cancer

Presented By

Dr Yara Verschoor, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, NICHE-3

Conference

ESMO 2023

Type

Peer-reviewed article

18 December 2023 16:04

Selective KRASG12C inhibitor sotorasib leads to superior PFS in colorectal cancer

Presented By

Dr Filippo Pietrantonio, Istituto Nazionale dei Tumori, Italy

Trial

Phase 3, CodeBreak300

Conference

ESMO 2023

Type

Peer-reviewed article

18 December 2023 16:01

Postoperative ctDNA predicts survival in colorectal cancer

Presented By

Dr Yoshiaki Nakamura, National Cancer Centre Hospital East, Japan

Trial

GALAXY

Conference

ESMO 2023

Type

Peer-reviewed article

18 December 2023 15:55

Overall survival in patients with initially unresectable colorectal liver metastases does not depend on choice of induction regimen 

Presented By

Prof. Cornelis J. Punt, University Medical Center Utrecht, the Netherlands

Trial

Phase 3, CAIRO5

Conference

ESMO 2023

Type

Peer-reviewed article

18 December 2023 15:53

Benefit of pembrolizumab in TNBC remains after 5 years of follow-up  

Presented By

Prof. Peter Schmid, Barts Cancer Institute, UK

Trial

Phase 3, KEYNOTE-522

Conference

ESMO 2023

Type

Peer-reviewed article

18 December 2023 15:50

Addition of pembrolizumab promising in early-stage high-risk ER+/HER2- breast cancer

Presented By

Dr Fatima Cardoso, Champalimaud Clinical Centre, Portugal

Trial

Phase 3, KEYNOTE-756 trial

Conference

ESMO 2023

Type

Peer-reviewed article

18 December 2023 15:48

Long-term air pollution exposure at both residential and workplace locations increases breast cancer risk

Presented By

Prof. Béatrice Fervers, Centre Léon Bérard, France

Conference

ESMO 2023

Type

Peer-reviewed article

18 December 2023 15:45

Third-line datopotamab deruxtecan improves progression-free survival in previously treated metastatic HR+/HER2- breast cancer compared with chemotherapy

Presented By

Dr Aditya Bardia, Massachusetts General Hospital, USA

Trial

Phase 3, TROPION-Breast01

Conference

ESMO 2023

Type

Peer-reviewed article

18 December 2023 15:41

DIVERSITY1: Filgotinib results in Crohn’s disease leave investigators puzzled

Presented By

Prof. Séverine Vermeire, UZ Leuven, Belgium

Trial

Phase 3, DESTINY1

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:48

SEQUENCE: Risankizumab doubles endoscopic remission rates compared with ustekinumab in CD

Presented By

Prof. Laurent Peyrin-Biroulet, University Hospital of Nancy, France

Trial

Phase 3, SEQUENCE

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:44

Guselkumab provides benefits in UC regardless of advanced therapy history

Presented By

Prof. Axel Dignass, Goethe University, Germany

Trial

Phase 3, QUASAR

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:42

INSPIRE: Risankizumab meets all efficacy endpoints in UC

Presented By

Prof. Edouard Louis, Liège University Hospital, Belgium

Trial

Phase 3, INSPIRE

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:39

Risankizumab resolves extraintestinal manifestations in CD

Presented By

Prof. Subrata Ghosh, Cork University College, Ireland

Trial

Phase 3, ADVANCE; MOTIVATE; FORTIFY

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:36

Obefazimod takes the spotlight as promising UC treatment

Presented By

Prof. Séverine Vermeire, UZ Leuven, Belgium

Trial

Phase 2

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:32

Rapid response to upadacitinib boosts outcomes in severe Crohn’s disease

Presented By

Prof. Jean-Frederic Colombel, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, U-EXCEED; U-EXCEL

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:27

LUCENT trials: Mirikizumab works in UC, regardless of targeted therapy history

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 3, LUCENT-2

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:23

ARTEMIS-UC: New kid in town for UC

Presented By

Prof. Bruce Sands, Icahn School of Medicine at Mount Sinai, USA

Trial

Phase 2, ARTEMIS-UC

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:20

Subcutaneous infliximab shows promise in UK IBD study

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:16

Safer removal of large polyps with cold snare technique

Presented By

Dr Ingo Steinbrück, Evangelisches Diakoniekrankenhaus Freiburg, Germany

Trial

CHRONICLE

Conference

UEGW 2-23

Type

Peer-reviewed article

7 December 2023 15:12

Higher recurrence rates with cold snare EMR than with conventional EMR

Presented By

Dr Óscar Nogales, Hospital General Universitario Gregorio Marañón, Spain

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:10

How to deal with at-risk patients above the CRC screening age limit?

Presented By

Dr Esther Toes-Zoutendijk, Erasmus University Medical Center, the Netherlands

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:05

European CRC screening needs to be revised

Presented By

Dr Julian Prosenz, Karl Landsteiner University of Health Sciences, Austria

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:02

Epinephrine boosts efficiency in gastric ESD

Presented By

Dr Hon Chi Yip, The Chinese University of Hong Kong, China

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 14:38

Artificial intelligence-aided colonoscopy did not improve outcomes in Lynch syndrome

Presented By

Mr Oswaldo Ortiz, Hospital Clinic Barcelona, Spain

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 14:34

Can computer technology improve our everyday colonoscopy results?

Presented By

Dr Michiel Maas, Radboudumc, the Netherlands

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 14:31

Is AI-assisted colonoscopy ready for clinical practice?

Presented By

Dr Alexander Seager, Newcastle University, UK

Trial

Colo-detect

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 14:26

Should we use E-SEMS or EVT for traumatic oesophageal perforations?

Presented By

Dr Alessandrino Terceiro de Oliveira, Federal University of Ceará, Brazil

Trial

FORTAL

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 14:22

Digital intervention relieves symptoms and improves QoL in IBS

Presented By

Ms Linda Weißer, HiDoc Technologies GmbH, Germany

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 14:18

GastroGPT: Successful proof-of-concept study of gastroenterology-specific large language model

Presented By

Dr Cem Şimşek, Hacettepe University, Turkey

Trial

GastroGPT

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 14:14

Primary results from MAESTRO-NASH trial: resmetirom efficacious for NASH

Presented By

Prof. Jörn Schattenberg, University Medical Center Mainz, Germany

Trial

Phase 3, MAESTRO-NASH

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 14:03

Apraglutide: Advancing the treatment of short bowel syndrome

Presented By

Ms Astrid Verbiest, University of Leuven, Belgium

Trial

Phase 2

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 13:58

Endobiliary radiofrequency ablation in pCCA: a pilot study

Presented By

Dr Jeska Fritzsche, Amsterdam UMC, the Netherlands

Trial

RACCOON-P

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 13:55

Raising awareness for microscopic colitis: disease course and predictors

Presented By

Dr Bas Verhaegh, Laurentius Hospital Roermond, the Netherlands

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 13:51

Retinal OCT markers hold promise for early MS diagnosis

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:13

Early intensive treatment enhances long-term clinical outcomes

Presented By

Dr Pietro Iaffaldano, University of Bari, Italy

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:12

χ-separation can assess the effects of tissue destruction in early MS lesions

Presented By

Dr Jannis Müller, University of Basel, Switzerland

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:12

Anti-CD40L antibody safe and effective in a phase 2 study

Trial

Phase 2

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:11

High sGFAP levels are associated with disease progression, independent of NfL or relapse activity

Presented By

Dr Pascal Benkert, University Hospital Basel, Switzerland

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:11

Oral glycolipid shows promise in the treatment of MS, especially SPMS

Presented By

Dr Tomoko Okamoto, National Center Hospital, Tokyo, Japan

Trial

Phase 2

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

Prioritising high efficacy therapies in children with MS

Presented By

Dr Nail Benallegue, Nantes University, France

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

New insights into the contribution of EBV to MS pathogenesis

Presented By

Prof. Thomas Berger, Medical University of Vienna, Austria

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

Early initiation of highly active treatment associated with a lower risk of SPMS

Presented By

Dr Christine Lebrun-Frenay, CHU de Nice, France

Trial

SPAM

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

Broad rim lesions correlate with a rapidly progressive MS phenotype

Presented By

Dr Jussi Lehto, University of Turku, Finland

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

Progressive brain tissue loss precedes the onset of clinical MS by years

Presented By

Dr Christina Azevedo, University of Southern California, CA, USA

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

COVID-19 infection associated with higher MS relapse rate

Presented By

Mr David Levitz, Monash University, Australia

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

An update on evolving treatment algorithms for NMOSD and MOGAD

Presented By

Prof. Jeffrey Bennett, University of Colorado, CO, USA

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Rate of grey matter brain atrophy accelerates after menopause

Presented By

Dr Alyssa Nylander, University of California, CA, USA

Trial

EPIC

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Omega-3 polyunsaturated fatty acids associated with lower risk of MS activity

Presented By

Dr Vinicius Schoeps, University of California, CA, USA

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Ocrelizumab more effective than interferon/glatiramer acetate in older MS patients

Presented By

Dr Yi Chao Foong, Monash University, Australia

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Smouldering inflammation detectable even in the earliest stages of MS

Presented By

Dr Markus Matilainen, University of Turku, Finland

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Fenebrutinib shows rapid reduction of new Gd+ T1 lesions

Presented By

Prof. Amit Bar-Or, University of Pennsylvania, PA, USA

Trial

Phase 2, FENopta

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Sickness absence rate increases years before clinical onset of MS

Presented By

Dr Ali Manouchehrinia, Karolinska University, Sweden

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Understanding what an MS cure means and what it takes

Presented By

Prof. Stephen Hauser, University of California, CA, USA

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Switching from rituximab to C5 complement inhibitors is safe in AQP4+ NMOSD

Trial

Phase 3, PREVENT, CHAMPION-NMOSD

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Telerehabilitation effective in improving MS symptoms in patients with moderate disability

Presented By

Dr Maria Petracca, Sapienza University of Rome, Italy

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Challenges of de-escalation versus discontinuation of highly effective DMTs in older MS patients

Presented By

Prof. Vincent Van Pesch, UCLouvain, Belgium

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Real-world data supports ocrelizumab prior to conception

Presented By

Dr Wei Yeh, Alfred Health and Monash University, Australia

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:07

Tapinarof on course to become a new topical treatment in AD

Presented By

Dr Jonathan Silverberg, George Washington University, USA

Trial

Phase 3, ADORING

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:43

Upadacitinib provides sustained skin clearance in adolescents and adults with AD

Presented By

Dr Jonathan Silverberg, George Washington University, USA

Trial

Phase 3, Measure Up; AD UP

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:39

Sustained deep clinical and itch responses with novel IL-13 inhibitor

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Trial

Phase 3, ADvocate; ADvantage

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:13

IL-13 inhibitor shows potential in atopic dermatitis

Presented By

Prof. Eric Simpson, Oregon Health and Science University, USA

Trial

Phase 2, TREK-AD

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:08

Encouraging results for amlitelimab in atopic dermatitis

Presented By

Prof. Stephan Weidinger, University Hospital Schleswig-Holstein, Germany

Trial

Phase 2, STREAM-AD

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 13:03

Chronic hand eczema: patients share similar molecular signatures regardless of AD status

Presented By

Dr Jonathan Bar, Icahn School of Medicine at Mount Sinai, USA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:58

Severe hand eczema: dupilumab could be a future treatment

Presented By

Dr Laura Loman, University Medical Center Groningen, the Netherlands

Trial

Phase 2

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:55

Dual IL-17 blockade yields efficacy on joints and skin

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

Phase 3, BE OPTIMAL; BE COMPLETE

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:27

High-dose subcutaneous spesolimab prevents GPP flares up to week 48

Presented By

Prof. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany

Trial

Phase 2, Effisayil 2

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:23

Drug survival of guselkumab and risankizumab seems superior to other biologics

Presented By

Dr Zenas Yiu, University of Manchester, UK

Trial

BADBIR

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:04

IL-23 blockers may lower the risk of developing inflammatory and psoriatic arthritis

Presented By

Prof. Bruce Strober, Yale University School of Medicine, USA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:01

First-in-class oral IL-23 inhibitor safe and effective for moderate-to-severe plaque psoriasis

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 2, FRONTIER 1

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:57

Skin tape stripping allows a novel precision medicine approach in HS

Presented By

Dr Kristina Navrazhina, Icahn School of Medicine at Mount Sinai, USA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:51

Nanobodies: A novel way to treat HS

Presented By

Prof. Brian Kirby, St. Vincent´s University Hospital, Ireland

Trial

Phase 2, MIRA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:48

Anti-IL17 blockade leads to maintained pain reduction in patients with HS

Presented By

Dr John Ingram, Cardiff University, UK

Trial

Phase 3, SUNSHINE; SUNRISE

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:44

JAK1 inhibition: a promising forthcoming treatment option in vitiligo

Presented By

Prof. Khaled Ezzedine, University Paris-Est Créteil, France

Trial

Phase 2

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:17

Vitiligo: Continuation of topical ruxolitinib successful in many initial non-responders

Presented By

Dr Albert Wolkerstorfer, Amsterdam University Medical Centers, the Netherlands

Trial

Phase 3, TRuE-V1; TRuE-V1

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 11:10

JAK3/TEC inhibition achieves clinically meaningful responses in AA

Presented By

Dr Athanasios Tsianakas, Fachklinik Bad Bentheim, Germany

Trial

Phase 3, ALLEGRO-LT

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:31

Alopecia areata: remarkable regrowth rates with deuruxolitinib

Presented By

Prof. Brett King, Yale University School of Medicine, USA

Trial

Phase 3, THRIVE-AA

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:28

Botanical drug solution improves hair regrowth in children and adolescents with AA

Presented By

Prof. Ulrike Blume-Peytavi, Charité – Berlin University Medicine, Germany

Trial

RAAINBOW

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:23

Nemolizumab shows high success rates in prurigo nodularis

Presented By

Prof. Sonja Ständer, Münster University Hospital, Germany

Trial

Phase 3, OLYMPIA 1

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:19

Remibrutinib reduces itch, sleep problems, and activity impairment in patients with CSU

Presented By

Dr Ana Giménez-Arnau, Autonomous University and Pompeu Fabra University, Spain

Trial

Phase 2

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:13

Innovative wound gel reduces frequency of painful dressing changes in epidermolysis bullosa

Presented By

Prof. Dimitra Kiritsi, University of Freiburg, Germany

Trial

Phase 3, EASE

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 10:08

Women with psoriasis face increased adverse effects with systemic therapy

Presented By

Dr Fabio Verardi, University Hospital Zurich, Switzerland

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 09:50

Improved AI tool shows high sensitivity rates in skin cancer detection

Presented By

Dr Kashini Andrew, University Hospitals Birmingham NHS Foundation Trust, UK

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 09:46

Dermoscopy training combined with AI significantly improves skin cancer detection

Presented By

Dr Christian Dorado Cortez, University Hospital of Saint-Etienne, France

Conference

EADV 2024

Type

Peer-reviewed article

28 November 2023 09:43

Traditional Chinese medicine successful in HFrEF

Presented By

Dr Xinli Li, First Affiliated Hospital of Nanjing Medical University, China

Trial

Phase 4, QUEST

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:09

CRT upgrade benefits patients with HFrEF and an ICD

Presented By

Dr Béla Merkely, Semmelweis University, Hungary

Trial

BUDAPEST CRT Upgrade

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:08

Catheter ablation saves lives in end-stage HF with AF

Presented By

Prof. Christian Sohns, Heart and Diabetes Center NRW, Germany

Trial

CASTLE-HTx

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:07

Immediate or staged revascularisation in STEMI plus multivessel disease?

Presented By

Prof. Barbara Stähli, University of Zürich, Switzerland

Trial

MULTISTARS AMI

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:07

Lp(a) and cardiovascular events: which test is the best?

Presented By

Prof. Michael Szarek, University of Colorado, USA

Trial

Phase 3, ODYSSEY OUTCOMES

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:06

Meta-analysis: Does FCM improve clinical outcomes in HF?

Presented By

Prof. Piotr Ponikowski, Medical University Wroclaw, Poland

Trial

CONFIRM-HF; AFFIRM-AHF; HEART-FID

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:06

No benefit of extracorporeal life support in MI plus cardiogenic shock

Presented By

Prof. Holger Thiele, University of Leipzig, Germany

Trial

ECLS-SHOCK

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:05

HEART-FID: Is intravenous ferric carboxymaltose helpful in HFrEF with iron deficiency?

Presented By

Dr Robert Mentz, Duke University, USA

Trial

Phase 3, HEART-FID

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:05

Heart failure: the 2023 update

Presented By

Prof. Theresa McDonagh; Prof. Roy Stuart Gardner; Prof. Alexandre Mebazaa; Prof. Ewa Jankowska; Prof. Marianna Adamo

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:05

Should we use anticoagulation in AHRE to prevent stroke?

Presented By

Prof. Paulus Kirchhof, University Heart & Vascular Center Hamburg, Germany

Trial

Phase 3, NOAH-AFNET 6

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:05

Minimising atrial pacing does not reduce the risk for AF in sinus node disease

Presented By

Dr Mads Brix Kronborg, Aarhus University, Denmark

Trial

DANPACE II

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:04

Functional revascularisation outperforms culprit-only strategy in older MI patients

Presented By

Dr Simone Biscaglia, Ferrara University Hospital, Italy

Trial

FIRE

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:04

Natriuresis-guided diuretic therapy to facilitate decongestion in acute HF

Presented By

Dr Jozine ter Maaten, University of Groningen, the Netherlands

Trial

PUSH-AHF

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:04

ARAMIS: Can anakinra alleviate acute myocarditis?

Presented By

Prof. Mathieu Kerneis, Sorbonne University, France

Trial

ARAMIS

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:03

Can aspirin be omitted after PCI in patients with high bleeding risk?

Presented By

Dr Masahiro Natsuaki, Saga University, Japan

Trial

Phase 4, STOPDAPT-3

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:03

Guidelines for the management of cardiomyopathies

Presented By

Prof. Elena Arbelo; Dr Juan Pablo Kaski

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:03

DICTATE-AHF: Early dapagliflozin to manage acute HF

Presented By

Prof. Zachary Cox, Lipscomb University College of Pharmacy, USA

Trial

Phase 3, DICTATE-AHF

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:03

The optimal duration of anticoagulation therapy in cancer patients with DVT

Presented By

Dr Yugo Yamashita, Kyoto University, Japan

Trial

ONCO DVT

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:03

Expedited transfer to a specialised centre does not improve cardiac arrest outcomes

Presented By

Dr Tiffany Patterson, King’s College London, UK

Trial

ARREST

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:02

Angiography vs OCT vs IVUS guidance for PCI: a network meta-analysis

Presented By

Prof. Gregg Stone, Icahn School of Medicine at Mount Sinai, USA

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:02

Cardiovascular disease and diabetes: new guidelines

Presented By

Prof. Emanuele Di Angelantonio; Prof. Nikolaus Marx; Dr Katharina Schuett; Prof. Dirk Müller-Wieland; Prof. Bianca Rocca

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:02

Does colchicine prevent perioperative AF and MINS?

Presented By

Dr David Conen, McMaster University, Canada

Trial

Phase 3, COP-AF

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:02

DAPT or clopidogrel monotherapy after stenting in high-risk East-Asian patients?

Presented By

Prof. Yaling Han, General Hospital of Northern Theater Command, China

Trial

OPT-BIRISK

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:02

OCTOBER trial: OCT-guided PCI improves clinical outcomes in bifurcation lesions

Presented By

Dr Lene Nyhus Andreasen, Aarhus University, Denmark

Trial

OCTOBER

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:01

Acoramidis improves survival and functional status in ATTR-CM

Presented By

Prof. Julian Gillmore, University College London, UK

Trial

Phase 3, ATTRIbute-CM

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:01

Diagnostic tool doubles cardiovascular diagnoses in patients with COPD or diabetes

Presented By

Dr Amy Groenewegen, University Medical Center Utrecht, the Netherlands

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:01

STEP-HFpEF: Semaglutide safe and efficacious in HFpEF plus obesity

Presented By

Dr Mikhail Kosiborod, University of Missouri, USA

Trial

Phase 3, STEP-HFpEF

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:01

Inorganic nitrate strongly reduces CIN in high-risk patients undergoing angiography

Presented By

Dr Dan Jones, Queen Mary University of London, UK

Trial

Phase 2, NITRATE-CIN

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:01

Guidelines for the management of endocarditis

Presented By

Dr Stefano Caselli; Prof. Nina Ajmone Marsan; Dr Emil Fosbøl

Conference

ESC 2023

Type

Peer-reviewed article

30 October 2023 16:01

sRAGE: A novel potential biomarker to assess the risk of acute respiratory events

Presented By

Dr Jinying Chen, Sichuan University, China

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 16:12

Most severe asthma patients are candidates for biologic therapy on a global scale

Presented By

Dr Freda Yang, Imperial College London, UK

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 16:10

Aspergillus infections: resistance to azole treatment increased in the presence of diesel particles

Presented By

Valentina Huang, Imperial College London, UK

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 16:08

Tacrolimus versus cyclosporin: Less lung graft dysfunction

Presented By

Prof. Göran Dellgren, Sahlgrenska University Hospital, Sweden

Trial

ScanCLAD

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 16:06

CPAP effective in reducing cardiovascular mortality in a practice study

Presented By

Dr Jordi De Batlle Garcia, Institut de Recerca Biomèdica de Lleida, Spain

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 16:05

Gefapixant curbs chronic cough independent of its duration

Presented By

Prof. Imran Satia, McMaster University, Canada

Trial

Phase 3, COUGH

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 16:02

Primary ciliary dyskinesia: Idrevloride shows promising results in phase 2 trial

Presented By

Prof. Thomas Ferkol Jr, University of North Carolina, NC, USA

Trial

Phase 2, CLEAN-PCD

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 15:59

Promising new agent as treatment for pulmonary fibrosis

Presented By

Prof. Tamara Corte, University of Sydney, Australia

Trial

Phase 2

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 15:57

Novel immunomodulator offers hope to reduce steroid dependency in sarcoidosis

Presented By

A Chandrasekaran

Trial

Phase 1/2

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 15:55

Encouraging long-term outcomes observed in the treatment of PAH with sotatercept

Presented By

Prof. Ioanna Preston , Tufts University School of Medicine, MA, USA

Trial

SOTERIA

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 15:48

Chronic thromboembolic pulmonary hypertension: surgery entails encouraging long-term results

Presented By

Dr Paula Appenzeller, University of Zürich, Switzerland

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 15:46

Women with pulmonary hypertension have better survival chances than men

Presented By

Dr Anna Titz, University Hospital Zürich, Switzerland

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 15:45

Women at higher risk of functional respiratory complaints following a COVID-19 infection

Presented By

Prof. Thomas Gille, Université Sorbonne Paris Nord, France

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 15:39

Elevated myeloid inflammation and complement activation present in various phenotypes of long COVID

Presented By

Dr Felicity Liew, Imperial College London, UK

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 15:32

Gabapentinoids increase risk of exacerbations in COPD

Presented By

Mr Alvi Rahman, McGill University, Canada

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 15:29

Future treatment of fatigue in COPD: 4 possible targets identified

Presented By

Dr Maarten Van Herck, Ciro, the Netherlands

Trial

FAntasTIGUE

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 15:27

Large infant study demonstrates the importance of a mature microbiome

Presented By

Dr Yuan Gao, Deakin University, Australia

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 15:25

Healthy maternal lifestyle during pregnancy reduces wheezing and rhinitis in infants

Presented By

Dr Alicia Guillien, University of Grenoble Alpes, France

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 15:21

Mechanism of autophagy in a newborn responsible for deleterious effect of air pollutants

Presented By

Dr Olga Gorlanova, University of Basel, Switzerland

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 15:18

Tapering from high-dose inhaled corticosteroids possible in most asthma patients treated with benralizumab

Presented By

Prof. David J. Jackson, King's College London, UK

Trial

SHAMAL

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 15:15

Tezepelumab therapy: hints toward a disease-modifying effect?

Presented By

Prof. Christopher Brightling, University of Leicester, UK

Trial

NAVIGATOR, SOURCE, DESTINATION

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 15:10

Digital inhaler programme improves asthma control also in the long term, but not long-term adherence

Presented By

Susanne J van de Hei, University Medal Center Groningen, the Netherlands

Trial

ACQ-5

Conference

ERS 2023

Type

Peer-reviewed article

29 October 2023 14:59

EAN guidelines on the management of ALS

Presented By

Prof. Philip van Damme, University Hospital Gasthuisberg, Belgium

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 12:12

What neurologists should know about bladder and sexual problems

Presented By

Prof. Jalesh Panicker, University College London, UK

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 12:08

Laughing gas abuse often leads to polyneuropathy, myelopathy, and encephalopathy

Presented By

Ms Anne Bruijnes, Maastricht University, the Netherlands

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 12:05

Nightmares during childhood linked to cognitive decline later in life

Presented By

Dr Abidemi Otaiku, University of Birmingham, UK

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:55

Sleep changes contribute to the pathogenesis of neurodegenerative diseases

Presented By

Dr Abubaker Ibrahim, Medical University of Innsbruck, Austria

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:51

Which patients can initially be treated with platform DMT?

Presented By

Dr Ilaria Addazio, University of Florence, Italy

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:44

Retinal layer thickness predicts disability accumulation in early RMS

Presented By

Prof. Gabriel Bsteh, Medical University of Vienna, Austria

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:38

Withdrawing DMF in early pregnancy does not increase relapse risk in pregnant patients with MS

Presented By

Prof. Doriana Landi, University of Rome Tor Vergata, Italy

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:12

Immunosenescence and MS: relevance to immunopathogenesis and treatment

Presented By

Prof. Monika Adamczyk-Sowa, Medical University of Silesia, Poland

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:04

GLP-1 agonists induce weight loss and alleviate headache in idiopathic intracranial hypertension

Presented By

Dr Nik Krajnc, Medical University of Vienna, Austria

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:00

Cannabis-based medicine does not beat placebo in central neuropathic pain

Presented By

Dr Julie Hansen, Aarhus University, Denmark

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:56

80% of patients reverse from chronic to episodic migraine on anti-CGRP antibodies

Presented By

Dr Gabriella Egeo, IRCCS San Raffaele, Italy

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:52

Minimising co-medication optimises cenobamate efficacy in drug-resistant epilepsy

Presented By

Dr Juan Sanchez-Caro, Advanced Neurology Center, Spain

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:42

Towards cell biology of Alzheimer’s disease

Presented By

Prof. Thomas C. Südhof, Stanford Medicine, CA, USA

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:35

New study characterises brain fog

Presented By

Dr Mohammad Mahmud, Imperial College London, UK

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:32

Intensive BP reduction associated with smaller haematoma

Presented By

Prof. Qi Li, Chongqing Medical University, China

Trial

Phase 3, ATACH-2

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:26

Amantadine in early COVID-19 enhances recovery

Presented By

Prof. Konrad Rejdak, Medical University of Lublin, Poland

Trial

Phase 3, COV-PREVENT

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:13

SARS-CoV-2 vaccination in CIDP and MMN: more benefit than harm

Presented By

Dr. Pietro Doneddu, IRCCS-Humanitas Reserach Institute, Italy

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:09

Contribution of genomics and genetics to personalised medicine

Presented By

Prof. Nicholas Wood, University College London, UK

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 09:56

How big data can boost care for neurodegenerative disorders

Presented By

Prof. Gunhild Waldemar, University of Copenhagen, Denmark

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 09:46

Rocatinlimab delivers efficacy and safety in atopic dermatitis

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, NY, USA

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 18:08

Head-to-head: paraffin- versus ceramide-based moisturiser for paediatric AD

Presented By

Prof. Sachin Gupta, All India Institute of Medical Sciences, India

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 18:06

JAK inhibitors for AD in the real world

Presented By

Dr Yik Weng, National Skin Centre, Singapore

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 18:02

Novel JAK1 inhibitor for patients with atopic dermatitis

Presented By

Jianzhong Zhang, Peking University People’s Hospital, China

Trial

Phase 3, QUARTZ3

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 18:00

Can lebrikizumab maintain response rates in atopic dermatitis?

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, ADvocate 1 and ADvocate 2

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 17:58

Most patients with AD on dupilumab stick with this drug long-term

Presented By

Dr Elena Pezzolo, San Bortolo Hospital, Italy

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 17:56

Botulinum toxin A might provide efficacious treatment option for nail psoriasis

Presented By

Dr Premjit Juntongjin, Thammasat University, Thailand

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 17:53

POETYK PSO-1 and 2: Long-term efficacy results of deucravacitinib in plaque psoriasis

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

POETYK PSO-LTE

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 17:52

Encouraging results for first oral IL-23 receptor antagonist in plaque psoriasis

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 2, FRONTIER 1

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:35

Subcutaneous spesolimab for GPP flare prevention

Presented By

Prof. Bruce Strober, Yale University School of Medicine, CT, USA

Trial

Effisayil 2

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:32

Knocking out psoriasis with high-dose risankizumab?

Presented By

Dr Andrew Blauvelt, Oregon Medical Research Center, OR, USA

Trial

Phase 2, KNOCKOUT

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:30

Deucravacitinib versus other systemic therapies in Asian patients with psoriasis

Presented By

Prof. Tsen-Fang Tsai, (National Taiwan University Hospital, Taiwan

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:26

Patients with AA report high long-term regrowth rates with baricitinib

Presented By

Dr Maryanne Senna, Harvard Medical School, MA, USA

Trial

BRAVE-AA1 and BRAVE-AA2

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:22

Can ritlecitinib deliver long-term efficacy in alopecia areata?

Presented By

Prof. Melissa Piliang, Cleveland Clinic, OH, USA

Trial

Phase 3, ALLEGRO

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:18

TikTok videos on hair disorders lack reliability

Presented By

Dr Betty Nguyen, University of Miami, FL, USA

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:14

Spesolimab appears successful in hidradenitis suppurativa

Presented By

Prof. Afsaneh Alavi, Mayo Clinic, MN, USA

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:12

Promising results for paroxetine in rosacea

Presented By

Dr Yingxue Huang, Central South University, China

Trial

PRRERCT

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:10

Novel PPARγ modulator reduces acne manifestations

Presented By

Prof. Mauro Picardo, International Medical University, Italy

Trial

Phase 3, GEDACNE

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:07

Microencapsulated benzoyl peroxide shifts skin microbiome in rosacea

Presented By

Prof. Raja Sivamani, Pacific Skin Institute, CA, USA

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 15:04

OLYMPIA 2: Positive results for nemolizumab in prurigo nodularis

Presented By

Prof. Sonja Ständer, University Hospital Münster, Germany

Trial

Phase 3, OLYMPIA 2

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 14:59

PRFM or PRP therapy for trophic ulcers due to leprosy?

Presented By

Prof. Amrita Sil, Rampurhat Government Medical College & Hospital, India

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 13:19

Large teledermatology project in a remote island in Eastern Indonesia

Presented By

Dr Marlous Grijsen, University of Oxford, UK

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 12:56

Can AI-driven teledermatology increase access to healthcare in rural African settings?

Presented By

Mr Philippe Gottfrois, Basel University, Switzerland

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 12:54

Oleogel-S10 shows long-term efficacy and safety in dystrophic epidermolysis bullosa

Presented By

Prof. Dedee Murrell, University of New South Wales, Australia

Trial

Phase 3, EASE

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 11:50

Picosecond alexandrite laser safe and effective in benign pigmentary disorders

Presented By

Dr Kentaro Oku, Hills Grace Clinic, Japan

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 11:46

Gentamicin improves symptoms in paediatric Nagashima-type palmoplantar keratosis

Presented By

Dr Shan Wang, National Center for Children’s Health, China

Conference

WCD 2023

Type

Peer-reviewed article

31 August 2023 11:41

Frequent co-existence of atrial fibrillation and obstructive sleep apnoea in stroke patients

Presented By

Dr Maria Rita Lo Monaco, Catholic University of the Sacred Heart, Italy

Conference

HFA 2023

Type

Peer-reviewed article

8 August 2023 16:27

VOICE-COVID-II : Alexa successful in SARS-CoV-2 symptoms screening

Presented By

Prof. Abhinav Sharma, McGill University Health CentreMontreal, Canada

Trial

VOICE-COVID-II

Type

Peer-reviewed article

8 August 2023 16:10

HF patients with metabolic dysfunction at high risk to develop depressive symptoms

Presented By

Dr Adesegun Kuye, Kharkiv National Medical University, Ukraine

Conference

HFA 2023

Type

Peer-reviewed article

8 August 2023 16:08

Standardised diuretic protocol significantly increases natriuresis in acute HF

Presented By

Dr Jeroen Dauw, AZ Sint-Lucas, Belgium

Trial

Phase 2, ENACT-HF

Conference

HFA 2023

Type

Peer-reviewed article

8 August 2023 16:04

Low concentrations of VEGF-C: a negative prognostic factor

Presented By

Dr Gracjan Iwanek, Wroclaw Medical University,  Poland

Conference

HFA 2023

Type

Peer-reviewed article

8 August 2023 16:00

Patisiran benefits maintained over 18 months in patients with transthyretin amyloidosis

Presented By

Prof. Marianna Fontana, University College London, Royal Free Hospital, UK

Trial

Phase 3, APOLLO-B

Conference

HFA 2023

Type

Peer-reviewed article

8 August 2023 15:57

Aficamten may lower symptom burden in non-obstructive hypertrophic cardiomyopathy

Presented By

Prof. Ahmad Masri, Oregon Health & Science University, OR, USA

Trial

REDWOOD-HCM

Conference

HFA 2023

Type

Peer-reviewed article

8 August 2023 15:52

Sacubitril/valsartan reduces natriuretic peptides in HF patients with ejection fraction >40%

Presented By

Prof. Robert Mentz, Duke University Medical Center, NC, USA

Conference

HFA 2023

Type

Peer-reviewed article

8 August 2023 15:39

Clinically relevant reduction in HF hospitalisation due to haemodynamic monitoring

Presented By

Prof. Jasper Brugts, Erasmus University Medical Centre, the Netherlands

Trial

MONITOR-HF

Type

Peer-reviewed article

8 August 2023 15:34

TRACER-HF: Trientine reduced biomarkers up to 8 weeks

Presented By

Prof. James Januzzi, Harvard Medical School, MA, USA

Trial

Phase 2, TRACER-HF

Conference

HFA 2023

Type

Peer-reviewed article

8 August 2023 15:16

Dapagliflozin improves LAVI, LV mass, and concentration of natriuretic peptides after 6 months

Presented By

Prof. Domingo Pascual-Figal, University of Murcia, Spain

Trial

DAPA MODA

Conference

HFA 2023

Type

Peer-reviewed article

8 August 2023 15:12

NUDGE-FLU: Repeated electronic nudges improve flu vaccination rates in patients with HF

Presented By

Dr Niklas Dyrby Johansen, Herlev and Gentofte Hospital, University of Copenhagen, Denmark

Trial

NUDGE-FLU

Conference

HFA 2023

Type

Peer-reviewed article

8 August 2023 15:08

COMMANDS trial: A paradigm shift in LR-MDS-associated anaemia

Presented By

Dr Matteo Della Porta, Humanitas Cancer Centre Milan, Italy

Trial

Phase 3, COMMANDS

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 17:39

REVIVE: Rusfertide meets the primary endpoint in PV

Presented By

Dr Marina Kremyanskaya, Mount Sinai, New York, USA

Trial

Phase 2, REVIVE

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 17:34

Mapping healthy HPSC variations to diagnose haematopoietic abnormalities

Presented By

Dr Nili Furer, Weizmann Institute of Science, Israel

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 17:28

High risk of death for individuals with C282Y/C282Y hereditary haemochromatosis and diabetes

Presented By

Dr Mathis Mottelson, Copenhagen University Hospital, Denmark

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 17:05

QuANTUM-First: Updated results on quizartinib in AML with FLT3-ITD

Presented By

Dr Richard Schlenk, University of Heidelberg, Germany

Trial

Phase 3, QuANTUM-First

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:54

Promising data for ziftomenib in relapsed/refractory NPM1-mutated AML

Presented By

Dr Amir Fathi, Massachusetts General Hospital, Massachusetts, USA

Trial

Phase 1/2, KOMET-001

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:51

MRD-positive patients with FLT3-ITD AML may benefit from post-transplant gilteritinib

Presented By

Dr Mark Levis, Johns Hopkins Hospital, Maryland, USA

Trial

MORPHO

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:45

Deep responses with asciminib in CML-CP  

Presented By

Prof. Timothy Hughes, University of Adelaide, Australia

Trial

Phase 3, ASCEMBL

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:41

QUIWI: First results suggest a clinical benefit of quizartinib in AML

Presented By

Dr Pau Montesinos, University of Valencia, Spain

Trial

Phase 2, QUIWI

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:38

Investigational agent OMS906 performs well in PNH

Presented By

Dr Jens Panse, University of Aachen, Germany

Trial

Phase 1

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:32

Robust platelet responses with cevidoplenib in ITP

Presented By

Dr Jun-Ho Jang, Samung Medical Center, South Korea

Trial

Phase 2

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:23

Radiotherapy or not in patients with PMBCL after immunochemotherapy?

Presented By

Dr Maurizio Martelli, University Sapienza Roma, Italy

Trial

IELSG37

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:16

Durable responses for loncastuximab tesirine in relapsed/refractory DLBCL

Presented By

Dr Paolo Caimi, Cleveland Clinic, Ohio, USA

Trial

Phase 2, LOTIS-2

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:12

Zandelisib promising in relapsed/refractory indolent B-cell NHL

Presented By

Dr Takahiro Kumode, Kindai University, Japan

Trial

Phase 2, MIRAGE

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:05

Promising data for epcoritamab plus R-CHOP in untreated DLBCL

Presented By

Dr Michael Clausen, Lillebaelt Hospital, Denmark

Trial

Phase 1/2, EPCORETM NHL-2

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:43

Can we combine teclistamab and nirogacestat for the treatment of RRMM?

Presented By

Dr Jeffrey Matous, Colorado Blood Cancer Institute, Colorado, USA

Trial

Phase 1, MajesTEC-2

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:21

Encouraging results for low-dose belantamab mafodotin plus nirogacestat in patients with RRMM

Presented By

Prof. Sebastian Grosicki, Medical University of Silesia, Poland

Trial

Phase 1/2, DREAMM 5

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:15

CARTITUDE-4: Cilta-cel meets expectations in lenalidomide-refractory MM

Presented By

Dr Hermann Einsele, University of Würzburg, Germany

Trial

Phase 3, CARTITUDE-4

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:08

7-year outcomes of PRODIGE 23 trial

Presented By

Prof. Thierry Conroy, Institut de Cancérologie de Lorraine, France

Trial

Phase 3, PRODIGE 23

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 10:04

Neoadjuvant chemotherapy may be viable option in locally advanced colon cancer

Presented By

Dr Lars Hendrik Jensen, University of Southern Denmark, Denmark

Trial

Phase 3, NeoCol

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 10:00

De-escalation of neoadjuvant treatment of locally advanced rectal cancer is non-inferior

Presented By

Dr Deborah Schrag, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, PROSPECT

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:58

SONIA: No survival benefit with first-line versus second-line CDK4/6 inhibition in metastatic breast cancer

Presented By

Prof. Gabe Sonke, Netherlands Cancer Institute, the Netherlands

Trial

Phase 3, SONIA

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:55

Adjuvant ribociclib improves invasive DFS in early breast cancer

Presented By

Prof. Dennis Slamon, David Geffen School of Medicine, CA, USA

Trial

Phase 3, NATALEE

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:52

Gene expression profiles predict benefit of neoadjuvant immune checkpoint therapy in triple-negative breast cancer

Presented By

Dr Hanna Huebner, Erlangen University Hospital, Germany

Trial

Phase 2, GeparNuevo

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:49

Adding pembrolizumab to perioperative chemotherapy improves EFS in early-stage NSCLC

Presented By

Prof. Heather Wakelee, Stanford University, CA, USA

Trial

Phase 3, KEYNOTE-671

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:44

TTFields therapy: a new treatment modality for metastatic NSCLC

Presented By

Prof. Ticiana Leal, Emory University, GA, USA

Trial

Phase 3, LUNAR

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:42

Adding chemotherapy to EGFR TKI does not improve OS in advanced EGFR-mutated NSCLC

Presented By

Dr Shintaro Kanda, Shinshu University, Japan

Trial

Phase 3, AGAIN

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:39

No improved OS in pancreatic cancer after neoadjuvant mFOLFIRINOX

Presented By

Prof. Knut Labori, Oslo University Hospital, Norway

Trial

Phase 2, NorPACT-1

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:35

AI detects gastric cancer with high accuracy in common blood tests

Presented By

Mr Tsz Chun Bryan Wong, Hong Kong University of Science and Technology, Hong Kong

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:34

Response-directed treatment personalisation in stage III melanoma

Presented By

Dr Irene Reijers, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, OpACIN-neo, PRADO

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:30

Prognostic and predictive biomarkers in patients with resected stage IIB/C melanoma

Presented By

Prof. Georgina Long, University of Sydney, Australia

Trial

Phase 3, CheckMate76K

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:27

Combining PARP inhibition and androgen receptor-signalling inhibition improves radiographic progression-free survival in HRR-deficient mCRPC

Presented By

Prof. Karim Fizazi, Institute Gustave Roussy, France

Trial

Phase 3, TALAPRO-2

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:24

Erdafitinib outperforms chemotherapy in FGFR-altered advanced urothelial cancer

Presented By

Dr Yohann Loriot, Gustave Roussy Cancer Institute, France

Trial

Phase 3, THOR

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:20

Probiotic CBM588 seems to improve clinical effect cabozantinib/nivolumab in mRCC

Presented By

Dr Hedyeh Ebrahimi, Tehran University of Medical Sciences, Iran

Trial

Phase 1

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:11

Exploratory analysis of IMvigor130 trial finds no OS benefit from atezolizumab in subgroups

Presented By

Dr Enrico Grande, MD Anderson Cancer Center, Spain

Trial

Phase 3, IMvigor130

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:08

Immune checkpoint inhibition improves PFS in non-BRCA-mutated ovarian cancer

Presented By

Dr Philipp Harter, Kliniken Essen-Mitte, Germany

Trial

Phase 3, DUO-O

Conference

ASCO 2023

Type

Peer-reviewed article

1 August 2023 12:44

First-line nivolumab-AVD improves PFS both in adult and paediatric patients with advanced Hodgkin lymphoma

Presented By

Prof. Alex Herrera, City of Hope Medical Center, CA, USA

Trial

Phase 3, SWOG S1826

Conference

ASCO 2023

Type

Peer-reviewed article

1 August 2023 12:38

Vorasidenib successfully targets IDH1/2-mutated glioma

Presented By

Dr Ingo Mellinghoff, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, INDIGO

Conference

ASCO 2023

Type

Peer-reviewed article

1 August 2023 12:33

In vitro and in vivo studies confirm the role of regulatory volume decrease

Presented By

Dr Twinu Wilson Chirayath, Paris Cité University, France

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:54

Therapy with biological DMARDs shows no correlation with fracture risk in RA

Presented By

Ms Ingebjorg Tronstad, Norwegian University of Science and Technology, Norway

Trial

HUNT

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:50

Bimekizumab: high rates of sustained response in PsA

Trial

Phase 3, BE OPTIMAL

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:46

Drugs for osteoporosis: time to reach fracture risk reduction varies

Presented By

Dr Giovanni Adami, University of Verona, Italy

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:41

Romosozumab: the new option for glucocorticoid-induced osteoporosis with high fracture risk?

Presented By

Dr Chi Chiu Mok, Tuen Muk Hospital, China

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:38

Targeted DMARDs advantageous in SSc patients with pre-capillary pulmonary hypertension

Presented By

Dr Cosimo Bruni, University Hospital Zurich, Switzerland

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:33

Methotrexate lowers pain in inflammatory hand OA

Presented By

Prof. Flavia Cicuttini, Monash University, Australia

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:25

AxSpA: Adalimumab biosimilar equally effective as IL-17 inhibitor in hindering radiographic progression

Presented By

Prof. Xenofon Baraliakos, Rheumazentrum Ruhrgebiet, Germany

Trial

Phase 3, SURPASS

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:22

Vascular inflammation may be characteristic of PsA

Presented By

Dr Nienke Kleinrensink, UMC Utrecht, the Netherlands

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:18

Obesity in PsA is increasingly affecting male patients

Presented By

Dr Marlene Stirnimann-Agustoni, University Hospital of Zürich, Switzerland

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:13

PsA patients: highest risk of developing NAFLD

Presented By

Mr Anthony Harrison, Leeds Teaching Hospitals NHS Trust, UK

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:09

Poly-refractory RA: not common, but still present

Presented By

Dr Paula David, University of Leeds, UK

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:04

COBRA-Slim bio-induction: no benefit compared with the standard regimen

Trial

CareRA2020

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 05:59

AI almost as successful as experts in predicting early RA

Presented By

Dr Yanli Li, Leiden University Center, the Netherlands

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 05:54

Worse self-management in patients with inflammatory arthritis in the presence of comorbid anxiety or depression

Presented By

Ms Sofie Bech Vestergaard, Aarhus University Hospital, Denmark

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 05:51

Disease activity-guided dose reduction may be a long-term option for stable RA

Presented By

Dr Noortje van Herwaarden, Sint Maartenskliniek, the Netherlands

Trial

DRESS

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 05:40

Cardiovascular safety of JAK inhibitors: reassuring results from a real-world study

Presented By

Mr Romain Aymon, Geneva University Hospital, Switzerland

Trial

ORAL Surveillance

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 00:00

Selective JAK1/TYK 2 inhibitor effective in patients with difficult-to-treat RA

Presented By

Prof. Xiaofeng Zeng, Peking Union Medical College Hospital, China

Conference

EULAR 2023

Type

Peer-reviewed article

30 July 2023 23:53

Novel 2-drug combo improves treatment possibilities for patients with refractory gout

Presented By

Prof. Herbert SB Baraf, Center for Rheumatology and Bone Research, IL, USA

Trial

Phase 3, DISSOLVE I, II

Conference

EULAR 2023

Type

Peer-reviewed article

30 July 2023 23:34

Dazodalibep improves dryness, fatigue, and pain in patients with Sjögren’s syndrome with a high symptom burden

Presented By

Dr Chiara Baldini, University of Pisa, Italy

Trial

ALISS

Conference

EULAR 2023

Type

Peer-reviewed article

30 July 2023 23:25

COVID-19: Young adults with auto-immune diseases have different risks than their healthy counterparts

Presented By

Dr Alessia Alunno, University of L’Aquila, Italy

Conference

EULAR 2023

Type

Peer-reviewed article

30 July 2023 23:20

IMbrave050: Adjuvant atezolizumab plus bevacizumab provides landmark recurrence-free survival for HCC

Expert

Prof. Masatoshi Kudo, Kindai University, Japan

Conference

ASCO 2023

Type

Peer-reviewed article

17 July 2023 14:51

What can real-world evidence teach us about atezolizumab plus bevacizumab in HCC?

Expert

Dr Cha Len Lee, University of Toronto, Canada

Conference

ASCO 2023

Type

Peer-reviewed article

17 July 2023 14:47

Artificial intelligence applications in neurology: seize the moment

Presented By

Prof. Kathryn Davis, Penn Medicine, PA, USA

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 21:10

Spinal cord stimulation eases painful diabetic neuropathy

Presented By

Dr Erika Petersen, University of Arkansas, AR, USA

Trial

SENZA-PDN

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 21:08

EVT improves functional outcomes in Chinese patients with BAO

Presented By

Prof. Raul Nogueira, Grady Memorial Hospital, GA, USA

Trial

ATTENTION

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 21:05

Severe sleep apnoea associated with white matter hyperintensities

Presented By

Dr Diego Carvalho, Mayo Clinic, MN, USA

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 21:03

Harnessing the microbiome as a possible stroke treatment

Presented By

Prof. Louise McCullough, University of Texas Health Science Center, TX, USA

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 21:00

Patients with a large core infarct benefit from thrombectomy

Presented By

Dr Amrou Sarraj, UH Cleveland Medical Center, OH, USA

Trial

Phase 3, SELECT2

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:57

Continuous levodopa/carbidopa infusion shows favourable safety and efficacy

Presented By

Dr Aaron Ellenbogen, Michigan Institute for Neurological Disorders, MI, USA

Trial

Phase 2, BeyoND

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:54

Unilateral right STN-DBS improves verbal fluency

Presented By

Dr Victor del Bene, University of Alabama, AL, USA

Trial

SUNDIAL

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:52

First-ever ALS platform trial reports on outcomes of 4 treatments

Presented By

Prof. Sabrina Paganoni, Massachusetts General Hospital, MA, USA

Trial

HEALEY ALS Platform Trial

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:49

Pridopidine for Huntington’s disease fails to meet the primary endpoint

Presented By

Prof. Andrew Feigin, NYU Grossman School of Medicine, NY, USA

Trial

Phase 3, PROOF-HD

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:46

Transcriptome data predicts long-term outcomes in untreated PPMS patients

Trial

ORATORIO

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:42

Teriflunomide prevents conversion to MS in patients with RIS

Presented By

Prof. Christine Lebrun-Frenay, Centre Hospitalier Universitaire de Nice, France

Trial

Phase 3, TERIS

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:39

Positive 4-year efficacy and safety data of ocrelizumab in early MS

Trial

Phase 3, ENSEMBLE

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:36

Gold nanocrystals may be effective as adjunctive MS therapy

Presented By

Prof. Michael Barnett, University of Sydney, Australia

Trial

Phase 2, VISIONARY-MS

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:33

Stem cell therapy fails primary endpoint but improves walking in more advanced progressive MS

Trial

Phase 2

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:30

Ravulizumab effective in AQP4+ NMOSD

Presented By

Dr Sean Pittock, Mayo Clinic, NY, USA

Trial

Phase 3, CHAMPION-NMOSD

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:28

Lecture on migraine: from the prodromal phase to future paradigm shifts

Presented By

Prof. Peter Goadsby, King's College London, UK

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:24

Zavegepant nasal spray exhibits good efficacy and safety in acute migraine

Presented By

Prof. Richard Lipton, Albert Einstein College of Medicine, NY, USA

Trial

Phase 3

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:18

Atogepant helps prevent treatment-resistant episodic migraine

Trial

ELEVATE

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:13

Simultaneous head-to-head comparison of 25 migraine medications

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:10

A vaccine as a potentially safe and effective immunotherapy against CGRP

Presented By

Dr Jean-Cosme Dodart, Vaxxinity Inc, FL, USA

Trial

Phase 1, UB-313

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:04

Seizure forecasting and detection with wearable devices are feasible

Presented By

Dr Benjamin Brinkmann, Mayo Clinic, MI, USA

Trial

My Seizure Gauge

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 19:56

Encouraging first results of GABAergic interneurons implants for focal epilepsy

Presented By

Prof. David Spencer, Oregon Health & Science University, OR, USA

Trial

Phase 1/2, NTRX-1001 GABAergic interneuron cell therapy

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 19:50

Lecanemab may slow decline of cognition and function in Alzheimer’s Disease

Presented By

Prof. Christopher van Dyck, Yale School of Medicine, CT, USA

Trial

Phase 3, CLARITY AD

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 19:44

Donanemab shows rapid and deep plaque clearance in early Alzheimer’s Disease

Presented By

Prof. Stephen Salloway, Warren Alpert Medical School of Brown University, RI, USA

Trial

Phase 3, TRAILBLAZER-ALZ 4

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 19:38

Original antigenic sin influences humoral immune response to SARS-CoV-2

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 19:36

Allogenic T-cell-based immunotherapy for PML in development

Presented By

Dr George Ambalathingal, QIMR Berghofer Medical Research Institute, Australia

Trial

Phase 2, CE-VST01-JC

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 19:32

Long-term success for CD19 CAR T-cell therapy in CLL

Presented By

Dr Emily Liang, University of Washington, WA, USA

Trial

Phase 2

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 17:31

Can molecular data improve prognostication in MDS patients undergoing HSCT?

Presented By

Dr Carmelo Gurnari, Cleveland Clinic, OH, USA & Tor Vergata University, Italy

Conference

EMBT 2023

Type

Peer-reviewed article

15 June 2023 17:27

Next-generation cell therapies for cancer: CAR-NK cells

Presented By

Dr Katy Rezvani, MD Anderson Cancer Center, TX, USA

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 17:20

Novel drugs and strategies around ASCT for Hodgkin lymphoma

Presented By

Dr Anna Sureda, Catalan Institute of Oncology, Spain

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 17:15

Thalassaemia: Advances in conventional transplantation and gene therapy

Presented By

Prof. Josu de la Fuente, Imperial College London, UK

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 17:06

New options to treat steroid-refractory chronic GvHD

Presented By

Prof. Mohamad Mohty, Sorbonne University, France

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 16:59

New developments in steroid-refractory acute GvHD

Presented By

Prof. Ronjon Chakraverty, University of Oxford, UK

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 16:54

Ide-cel superior to standard therapies in triple-class exposed RRMM

Presented By

Dr Paula Rodríguez-Otero, Clinica Universidad de Navarra, Spain

Trial

Phase 3, KarMMa-3

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 16:48

ASCT or CAR T cell as first-line therapy for MM?

Presented By

Prof. Salomon Manier, Lille University Hospital, France

Trial

Phase 3, CARTITUDE-6

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 20:23

DETERMINATION: Does one size fit all in multiple myeloma?

Presented By

Dr Hani Hassoun, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, DETERMINATION

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 20:14

Quizartinib plus chemotherapy improves OS in patients with AML undergoing ASCT

Presented By

Prof. Radovan Vrhovac, University Hospital Centre Zagreb, Croatia

Trial

Phase 3, QuANTUM-First

Conference

EMBT 2023

Type

Peer-reviewed article

14 June 2023 20:07

Blinatumomab may improve outcomes in patients with B-cell ALL undergoing ASCT

Presented By

Dr Ayman Sayyed, University of Toronto, Canada

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 20:02

Is ASCT a reasonable option in patients with invasive aspergillosis?

Presented By

Prof. Olaf Penack, Charité University Hospital of Berlin, Germany

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 19:55

Tacrolimus versus cyclosporin A in AML

Presented By

Dr Gesine Bug, Goethe University Frankfurt, Germany

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 19:48

Promising novel target identified for AML

Presented By

Prof. Edmund Waller, Emory University, GA, USA

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 19:42

Sotatercept improves exercise capacity in patients with PAH

Presented By

Prof. Marius Hoeper, Hannover Medical School, Germany

Trial

Phase 3, STELLAR

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 17:10

Fixed-dose macitentan plus tadalafil superior to either agent alone in PAH

Presented By

Prof. Kelly Chin, UT Southwestern Medical Center, TX, USA

Trial

Phase 3, A DUE

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 17:08

Immediate complete revascularisation non-inferior to staged complete revascularisation

Presented By

Dr Roberto Diletti, Erasmus MC, the Netherlands

Trial

BIOVASC

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 17:02

RENOVATE-COMPLEX-PCI results support intravascular-guided PCI for complex lesions

Presented By

Prof. Joo-Yong Hahn, Sungkyunkwan University School of Medicine, South Korea

Trial

RENOVATE-COMPLEX-PCI

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 16:59

No need to restrict vigorous exercise in selected HCM patients?

Presented By

Prof. Rachel Lampert, Yale School of Medicine, CT, USA

Trial

LIVE-HCM

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 10:26

No difference in CV outcomes between PET or CMR and SPECT

Presented By

Prof. Lisa Mielniczuk, University of Ottawa, Canada

Trial

AIMY-HF

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 10:24

Benefits of MitraClip sustained to 5 years in COAPT trial

Presented By

Prof. Gregg Stone, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

COAPT

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 10:18

Transcatheter repair for patients with tricuspid regurgitation

Presented By

Dr Paul Sorajja, Minneapolis Heart Institute, MI, USA

Trial

TRILUMINATE

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 10:16

Minimally invasive versus conventional sternotomy for mitral valve repair

Presented By

Dr Enoch Akowuah, James Cook University Hospital, UK

Trial

UK Mini Mitral

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 10:11

Durable benefits of TAVR versus surgical aortic valve replacement in aortic stenosis patients

Presented By

Prof. John Forrest, Yale Medicine, CT, USA

Trial

Evolut Low Risk

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 10:07

PCI not better than GDMT in severe ischaemic cardiomyopathy

Presented By

Prof. Divaka Perera, King's College London, UK

Trial

REVIVED-BCIS2

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 10:05

Anticoagulation in non-critically ill hospitalised COVID patients

Presented By

Prof. Valentín Fuster, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 4, FREEDOM COVID Anticoagulation

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 10:02

Statins associated with reduced heart dysfunction from anthracyclines

Presented By

Prof. Tomas Neilan, Massachusetts General Hospital, MA, USA

Trial

Phase 2, STOP-CA

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 09:58

Multifaceted strategy improves prescription of therapies for diabetes and ASCVD

Presented By

Prof. Neha Pagidipati, Duke University Hospital, NC, USA

Trial

COORDINATE-Diabetes

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 09:55

Bempedoic acid benefits statin-intolerant patients at high cardiovascular risk

Presented By

Prof. Steven Nissen, Cleveland Clinic, OH, USA

Trial

Phase 3, CLEAR Outcomes

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 09:49

Evolocumab improves coronary plaque morphology in stable CAD

Presented By

Prof. Annapoorna Kini, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 4, YELLOW III

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 09:40

Inflammation stronger predictor of MACE than cholesterol levels

Presented By

Prof. Paul Ridker, Brigham and Women's Hospital, MA, USA

Trial

Phase 3, PROMINENT, REDUCE-IT, STRENGTH

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 09:36

Oral PCSK9 inhibitor significantly lowers LDL-C

Presented By

Prof. Christie Ballantyne, Baylor College of Medicine, TX, USA

Trial

Phase 2

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 09:30

Baxdrostat in patients with uncontrolled hypertension

Presented By

Dr Deepak Bhatt, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 2, HALO

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 09:27

Hormone therapy for gender dysphoria associated with increased CV risk

Presented By

Dr Ibrahim Ahmed, Mercy Catholic Medical Center, PA, USA

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 09:24

Pulsed-field ablation appears safe and effective for atrial fibrillation

Presented By

Prof. Atul Verma, McGill University Health Centre, Canada

Trial

PULSED AF

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 09:19

Half-dose tenecteplase safe and effective for STEMI without timely PCI

Trial

Phase 4, STREAM-2

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 09:15

Key correlates of incident dementia identified in the MESA study

Presented By

Dr Mohammad Ostovaneh, Johns Hopkins Hospital, MD, USA

Trial

MESA

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 09:03

Biologics in psoriasis: can they prevent joint involvement?

Presented By

Ms Kathleen Miao, Keck School of Medicine of USC, CA, USA

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 12:46

JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata

Presented By

Dr Maryanne Senna, Lahey Hospital and Medical Center, MA, USA

Trial

Phase 3, THRIVE-AA1

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 12:41

Biomarkers predicting response of different CSU treatments in children

Presented By

Mr Alex Nguyen, McGill University, Canada

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 12:35

Izokibep shows remarkably high grades of clinical response in HS

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

Phase 3

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 12:31

Bimekizumab could be the new up-and-comer for HS treatment

Presented By

Prof. Alexa Kimball, Harvard Medical School, MA, USA

Trial

Phase 3, BE HEARD I and BE HEARD II

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 12:26

Switching to risankizumab successful in IL-17 inhibitor non-responders

Presented By

Prof. Richard Warren, University of Manchester, UK

Trial

Phase 3, aIMM study

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:56

Novel, selective TYK2 inhibitor shows promise for psoriasis

Presented By

Prof. April Armstrong, Keck School of Medicine of University of California, LA, USA

Trial

Phase 2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:51

As-needed ruxolitinib shows successful long-term symptom control in AD

Presented By

Dr Andrew Blauvelt, Oregon Medical Research Center, OR, USA

Trial

Phase 3, TRuE-AD1 and TRuE-AD2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:43

Dupilumab: a viable option for atopic hand and foot eczema

Presented By

Prof. Eric Simpson, Oregon Health & Science University, OR, USA

Trial

Phase 3, LIBERTY-AD-HAFT

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:33

Topical roflumilast beneficial in atopic dermatitis

Presented By

Prof. Lawrence Eichenfield, University of California San Diego, CA, USA

Trial

Phase 3, INTEGUMENT-1 and INTEGUMENT-2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:27

IL-22 receptor blocker reduces itch and skin lesions in AD

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

Phase 2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 11:17

Delgocitinib shows promise as topical therapy for chronic hand eczema

Presented By

Dr Robert Bissonnette, Innovaderm Research, Canada

Trial

Phase 3, DELTA 1

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 10:58

Vitiligo patients maintain re-pigmentation after ruxolitinib cream withdrawal

Presented By

Prof. John Harris, UMass Chan Medical School, MA, USA

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 10:51

Nemolizumab decreases lesions and itch in prurigo nodularis

Presented By

Prof. Shawn Kwatra , Johns Hopkins University School of Medicine, MD, USA

Trial

Phase 3, OLYMPIA 2

Conference

AAD 2023

Type

Peer-reviewed article

15 May 2023 10:40

Lichen planus: a future indication for baricitinib?

Presented By

Ms Angelina Hwang , Mayo Clinic College of Medicine, AZ, USA

Trial

Phase 2

Conference

AAD

Type

Peer-reviewed article

15 May 2023 09:58

Eligibility and selection of JAK inhibitors for constitutional eczema

Presented By

Dr Dirk Jan Hijnen, Erasmus MC, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:57

The rise of JAK inhibitors for alopecia areata

Presented By

Dr Brett King, Yale University, CT, USA

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:47

Obesity and the skin: state of affairs

Presented By

Dr Mariëtte Boon , Leiden University Medical Center, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:30

The role of surgeons in stage I–II melanoma

Presented By

Dr Dirk Grünhagen, Erasmus MC, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:26

Skin diseases and nutrition

Presented By

Prof. Reinhart Speeckaert, UZ Gent, Belgium

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:21

Melanoma: Surveillance and follow-up

Presented By

Dr Remco van Doorn, Leiden University Medical Center, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:19

When to screen for anal intraepithelial neoplasia?

Presented By

Prof. Henry de Vries, Amsterdam UMC, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:12

The importance of anti-microbial proteins in the skin

Presented By

Dr Hanna Niehues, Radboud University Medical Center, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:08

Scabies: Therapy failure and tips for the clinic

Presented By

Dr Robert Vodegel, Medical Center Leeuwarden, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 13:03

Life-threatening skin infections

Presented By

Dr Sandra Arend , Leiden UMC, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 12:58

OCT non-inferior to biopsy in basal cell carcinoma

Presented By

Dr Tom Wolswijk , Maastricht UMC, the Netherlands

Conference

DDD 2023

Type

Peer-reviewed article

10 May 2023 12:42

Checking kidney function is important during the course of IBD

Presented By

Dr Yuanhang Yang, Karolinska Institutet, Sweden

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 17:05

Diabetes therapy with GLP-1-based drugs does not elevate the risk of IBD

Presented By

Dr Heidi Søgaard Christensen , Aalborg University Hospital, Denmark

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:59

Long-term resection potentially better than anti-TNF treatment in CD

Presented By

Prof. Manasi Agrawal, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

LIR!C

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:58

Early, post-operative complications in CD reduced by pre-operative enteral nutrition, irrespective of biologic exposure

Presented By

Prof. Mathurin Fumery, Amiens University Hospital, France

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:55

Perinatal period is crucial for the risk of developing CD

Presented By

Prof. Sun-Ho Lee, Mount Sinai Hospital, Canada

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:53

Drop in overall IBD procedures during the pandemic

Presented By

Dr M Derks Eduarda Wilhelmina, Radboud University Medical Centre, the Netherlands

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:46

Early-life antibiotic exposure: a risk factor for paediatric-onset IBD

Presented By

Dr Mikkel Malham, Copenhagen University Hospital, Denmark

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:46

Proton pump inhibitors associated with worse outcomes in CD

Presented By

Dr Stéphanie Barrau, Saint Etienne University Hospital, France

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:42

Paediatric patients with immune-mediated inflammatory disease harbour a heightened cancer risk

Presented By

Ms Andrea Ehrström , Hvidovre Hospital, Denmark

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:40

Poor sleep in CD linked to low levels of vitamin D

Presented By

Dr Caroline Walker, Tallaght University Hospital, Ireland

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:38

Novel AI tool assessing mucosal inflammation achieves high correlation with histopathologists

Presented By

Prof. Laurent Peyrin-Biroulet, Nancy University Hospital, France

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:33

Beneficial effect of early, post-operative vedolizumab on endoscopic recurrence in CD

Presented By

Prof. Geert D’Haens , Academic Medical Center University of Amsterdam, the Netherlands

Trial

REPREVIO

Conference

ECCO

Type

Peer-reviewed article

4 May 2023 16:28

Long-term data supports the established efficacy and safety of ustekinumab in UC

Presented By

Prof. Silvio Danese , Vita-Salute San Raffaele University, Italy

Trial

UNIFI LTE UNIFI LTE

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:21

Anti-TNF withdrawal may be a safe option in stable IBD

Presented By

Prof. María Chaparro Sánchez , Hospital Universitario de La Princesa, Spain

Trial

Phase 4, EXIT

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:12

Intensified drug therapy leads to better stricture morphology in CD

Presented By

Dr Julien Schulberg , St Vincent’s Hospital Melbourne, Australia

Trial

STRIDENT

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:03

Continued efficacy of long-term ozanimod as UC treatment

Presented By

Prof. Silvio Danese , Vita-Salute San Raffaele University, Italy

Trial

True North OLE

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 15:51

Upadacitinib successful in the management of both CD and UC

Presented By

Dr Brian Feagan , University of Western Ontario, Canada

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 15:40

Solid results for long-term therapy of UC with filgotinib

Presented By

Dr Brian Feagan, University of Western Ontario, Canada

Trial

Phase 3, SELECTION

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 15:01

First-line NALIRIFOX superior to standard treatment in mPDAC

Presented By

Prof. Zev Wainberg, University of California Los Angeles, CA, USA

Trial

Phase 3, NAPOLI-3

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:37

Novel approach delivers quality-of-life benefits for patients with pancreatic cancer

Presented By

Dr Yaacov Lawrence, Sheba Medical Center, Israel

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:34

Palliative radiation therapy improves hepatic pain in HCC and liver metastasis

Presented By

Prof. Laura Dawson, Princess Margaret Cancer Centre, Canada

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:30

Improved survival following postoperative sorafenib plus TACE in HCC

Presented By

Prof. Ming Kuang, The First Affiliated Hospital, China

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:28

Quality-of-life benefits for tislelizumab in uHCC

Presented By

Prof. Richard Finn, University of California Los Angeles, CA, USA

Trial

Phase 3, RATIONALE-301

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:26

Stereotactic body radiation therapy beneficial for patients with locally advanced HCC

Presented By

Prof. Laura Dawson, Princess Margaret Cancer Centre, Canada

Trial

Phase 3, NRG/RTOG1112

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:23

SWOG 1815, first-ever phase 3 trial in BTC, fails

Presented By

Prof. Rachna Shroff, University of Arizona Cancer Center, AZ, USA

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:20

IMbrave 151 missed primary endpoint in advanced BTC

Presented By

Prof. Anthony El-Khoueiry, USC Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 2, IMbrave151

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:15

Acceptable safety profile and encouraging efficacy of nanvuranlat in BTC

Presented By

Dr Junji Furuse, Kanagawa Cancer Center, Japan

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:11

Combination botensilimab plus balstilimab demonstrates promising activity in heavily pre-treated MSS CRC

Presented By

Prof. Anthony El-Khoueiry, Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 1, C-800

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:06

Mutation-based selection to identify patients suitable for panitumumab treatment

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, PARADIGM

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:01

Fucoidan associated with quality-of-life benefits in patients with rectal cancer receiving CCRT

Presented By

Prof. Jaw-Yuan Wang, Pingtung Hospital, Taiwan

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:58

ctDNA appears useful in monitoring patients with anal cancer undergoing CRT

Presented By

Dr Janet Alvarez, Memorial Sloan Kettering Cancer Center, NY, USA

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:55

SUNLIGHT trial meets primary endpoint in refractory metastatic CRC

Presented By

Prof. Josep Tabernero, Val d’Hebron University Hospital and Institute of Oncology, Spain

Trial

Phase 3, SUNLIGHT

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:45

Does cell-free DNA influence MRD testing in post-operative colon cancer?

Presented By

Dr Stacey Cohen, University of Washington, WA, USA

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:41

OPERA: surgery may be avoided with adequate therapy in rectal cancer

Presented By

Prof. Arthur Sun Myint, Clatterbridge Cancer Centre, UK

Trial

Phase 3, OPERA

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:39

Can we improve total neoadjuvant therapy for rectal cancer?

Presented By

Dr Thomas George, University of Florida, FL, USA

Trial

Phase 2, NRG-GI002

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:36

Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, SPOTLIGHT

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:31

Regorafenib offers survival benefit for patients with pre-treated gastric cancer

Presented By

Prof. Nick Pavlakis, University of Sydney, Australia

Trial

Phase 3, INTEGRATE IIa

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:24

Radiotherapy or not in locally advanced oesophageal or junctional cancer?

Presented By

Prof. Maeve Lowery, St James’s Hospital, Ireland

Trial

Phase 3, Neo-AEGIS

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:20

Neoadjuvant immunotherapy is safe and efficacious in a phase 2 gastric cancer trial

Presented By

Dr Filippo Pietrantonio, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

Trial

Phase 2, INFINITY

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:19

S-1 adjuvant chemotherapy: 4 or 8 courses in stage 2 gastric cancer?

Presented By

Dr Souya Nunobe, Cancer Institute Hospital, Japan

Trial

Phase 3, OPAS-1

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:18

LATG/LAPG demonstrates excellent long-term efficacy in stage 1 gastric cancer

Presented By

Dr Shinichi Sakuramoto, Saitama Medical University International Medical Center, Japan

Trial

JCOG1401

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:15

3-year follow-up data confirms benefits of nivolumab plus chemotherapy

Presented By

Dr Yelena Janjigian, Memorial Sloan Kettering Cancer, NY, USA

Trial

Phase 3, CheckMate 649

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:10

Long-term results for nivolumab plus chemotherapy and nivolumab plus ipilimumab in oesophageal cancer

Presented By

Dr Ken Kato, National Cancer Center Hospital, Japan

Trial

Phase 3, CheckMate 648

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:02

Promising phase 2 results for HER-Vaxx in gastric cancer

Presented By

Dr Tanuj Chawla, Tata Medical Center, India

Trial

Phase 2, HERIZON

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:00

C1 inhibitor deficiency linked to thrombosis

Presented By

Dr Steven Grover, University of North Carolina, NC, USA

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:18

Durable responses to gene therapy in haemophilia A

Presented By

Prof. Stacy Croteau, Harvard Medical School, MA, USA

Trial

Phase 1/2, SPK-8011

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:16

Long-term benefits from beti-cel in transfusion-dependent β-thalassaemia

Presented By

Prof. Mark Walters; Prof. Franco Locatelli

Trial

LTF-303

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:14

Neutrodiet: non-restricted diet is the preferred option after SCT

Presented By

Prof. Federico Stella, Università degli Studi di Milano, Italy

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:11

Iptacopan offers solution for patients with PNH and residual anaemia after standard-of-care 

Presented By

Prof. Régis de Latour, Saint-Louis Hospital, France

Trial

Phase 3, Apply-PNH

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:09

Novel therapy may replace standard-of-care prophylaxis for GVHD

Presented By

Prof. Shernan Holtan, University of Minnesota, MN, USA

Trial

Phase 3, BMT CTN 1703

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:05

LMWH does not result in higher live birth rates in women with inherited thrombophilia 

Presented By

Prof. Saskia Middeldorp, Radboud UMC, the Netherlands

Trial

ALIFE2

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:01

Efgartigimod successful in immune thrombocytopenia 

Presented By

Prof. Catherine Broome, Georgetown University, Washington DC, USA

Trial

Phase 3, ADVANCE

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:57

Long-term risk for haematologic disease in persistent, isolated mild thrombocytopenia

Presented By

Dr Nardeen Ayad, Massachusetts General Hospital, MA, USA

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:50

INCA033989: novel investigational agent for CALR-mutated MPN

Presented By

Dr Edimara Reis, Incyte Corporation, DE, USA

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:47

Ruxolitinib mediates clonal evolution of RAS pathway mutations in MPN

Presented By

Dr Nabih Maslah, Université Paris Cité, France

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:43

Ibrutinib added to ASCT improves clinical outcomes in mantle cell lymphoma 

Presented By

Prof. Martin Dreyling, University Hospital Munich, Germany

Trial

Phase 3, Triangle

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:39

High-dose chemotherapy plus ASCT superior to standard immuno-chemotherapy in primary CNS lymphoma 

Presented By

Prof. Gerald Illerhaus, Klinikum Stuttgart, Germany

Trial

Phase 3, MATRix/IELSG43

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:37

Odronextamab has considerable anti-tumour effects in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Presented By

Prof. Won-Seog Kim, Samsung Medical Center, South Korea

Trial

Phase 2, ELM-2 trial

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:30

Excellent results for AFM13-complexed NK cells in CD30-positive lymphoma

Presented By

Dr Yago Nieto, University of Texas, TX, USA

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:27

CAR-Hematotox score predicts toxicity, infections, and clinical outcomes in MCL 

Presented By

Dr Kai Rejeski, LMU Munich, Germany

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:23

Talquetamab further investigated in heavily pre-treated MM after promising phase 2 data 

Presented By

Prof. Ajai Chari, Mount Sinai School of Medicine, NY, USA

Trial

Phase 1/2, MonumenTAL-1

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:19

Promising results of elranatamab for MM in phase 2 MagnetisMM-3 trial 

Presented By

Prof. Nizar Bahlis, University of Calgary, Canada

Trial

Phase 2, MagnetisMM-3

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:09

Deep and durable responses for quadruple therapy in smouldering MM 

Presented By

Prof. Shaji Kumar, Mayo Clinic, MN, USA

Trial

Phase 2, ASCENT

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:04

Ultra-sensitive MRD assessment in MM with BloodFlow

Presented By

Dr Laura Notarfranchi, University of Parma, Italy

Trial

Phase 3, GEM2014MAIN

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:55

CAR-Hematotox score proves useful in relapsed/refractory MM

Presented By

Dr Kai Rejeski, LMU Munich, Germany

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:52

Head-to-head: VMP versus Rd in transplant-ineligible MM

Presented By

Dr Sara Bringhen, Università degli Studi di Torino, Italy

Trial

Phase 4, REAL-MM

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:47

Zanubrutinib wins battle of BTK inhibitors in relapsed or refractory CLL/SLL

Presented By

Prof. Jennifer Brown, Dana Farber Cancer Institute, MA, USA

Trial

Phase 3, ALPINE

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:40

Ibrutinib plus venetoclax displays long-term benefits in CLL 

Presented By

Prof. John Allan, Weill Cornell Medicine, NY, USA

Trial

Phase 2, CAPTIVATE

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:28

Excellent results for triplet regimen in FLT3-mutated AML 

Presented By

Prof. Nicholas Short, University of Texas, TX, USA

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:25

MRD by qPCR prognostic of outcomes in venetoclax-treated NPM1-mutated AML 

Presented By

Mr Jad Othman, Guy’s and St Thomas’ NHS Foundation Trust, UK

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:20

Promising results for triplet therapy with magrolimab in AML

Presented By

Prof. Naval Daver, Anderson Cancer Center, TX, USA

Trial

Phase 3, ENHANCE-3

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:17

Should we use intensive chemotherapy prior to allo-HCT in relapsed/refractory AML? 

Presented By

Prof. Matthias Stelljes, University of Muenster, Germany

Trial

Phase 3, EATL3-ASAP

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:13

Blinatumomab candidate for standard-of-care in newly diagnosed B-ALL 

Presented By

Prof. Mark Litzow, Mayo Clinic, MN, USA

Trial

Phase 3, ECOG-ACRIN-E1910 NCTN

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:07

High-dose methotrexate or standard interim maintenance in young patients with ALL? 

Presented By

Ms Amy Kirkwood, University College London, UK

Trial

UKALL 2011

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:01

Racial disparity in the tumour microenvironment

Presented By

Dr Burcu Karadal-Ferrena, Albert Einstein College of Medicine, NY, USA

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:42

Chemo-endocrine therapy worse for cognition than endocrine therapy alone

Presented By

Dr Irene Kang, City of Hope Orange County, CA, United States

Trial

RxPONDER PRO

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:36

Resistance to CDK4/6 inhibitors is likely due to expansion of pre-existing resistant clones

Presented By

Dr Cristina Guarducci, Dana-Farber Cancer Institute, MA, USA

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:32

Baseline CTC count can guide first-line treatment in HR-positive/HER-negative metastatic breast cancer

Presented By

Prof. François-Clément Bidard, Institut Curie, France

Trial

Phase 3, STIC CTC

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:30

Germline pathogenic variants for breast cancer also increase contralateral breast cancer risk

Presented By

Prof. Siddhartha Yadav, Mayo Clinic, MN, USA

Trial

CARRIERS

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:27

Low-dose tamoxifen still prevents recurrence from non-invasive breast cancer

Presented By

Dr Andrea De Censi, Ospedali Galliera, Italy

Trial

Phase 3, TAM-01

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:24

Endocrine interruption to pursue pregnancy does not impact short-term disease in breast cancer

Presented By

Dr Ann Partridge, Dana-Farber Cancer Institute, MA, USA

Trial

POSITIVE

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:22

ZNF689 deficiency promotes intratumour heterogeneity and resistance to immune checkpoint blockade in TNBC

Presented By

Dr Li-Peng Ge, Fudan University Shanghai Cancer Center, China

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:17

Oestradiol represses anti-tumoural immune response to promote progression of brain metastases

Presented By

Dr Maria Contreras-Zarate, University of Colorado, CO, USA

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:14

Benefit of adjuvant abemaciclib continues to deepen at longer follow-up

Presented By

Prof. Stephen Johnston, The Royal Marsden NHS Foundation Trust, UK

Trial

Phase 3, monarchE

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:10

First-line ribociclib plus endocrine therapy outperforms combination chemotherapy

Presented By

Dr Yen-Shen Lu, National Taiwan University Hospital, Taiwan

Trial

Phase 2, RIGHT Choice

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:07

Treatment options beyond CDK4/6 inhibition

Presented By

Dr Erica Mayer (Dana-Farber Cancer Institute, MA, USA); Prof. Virginia Kaklamani (University of Texas Health Sciences Center, TX, USA);

Trial

PACE; EMERALD; SERENA-2; CAPItello-291; VERITAC

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:03

Trastuzumab deruxtecan effective in both second-line and neoadjuvant setting

Presented By

Dr Ian Krop (Yale Cancer Center, CT, USA); Prof. Sara Hurvitz (David Geffen School of Medicine, CA, USA); Prof. Aditya Bardia (Harvard Medical School, MA, USA)

Trial

Phase 3, DESTINY-Breast02; DESTINY-Breast03; TRIO-US B-12 TALENT

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 17:51

Anti-PD-1/anti-LAG-3 combination highly effective in HER2-negative breast cancer

Presented By

Prof. Claudine Isaacs, Georgetown University Medical Center, DC, USA

Trial

Phase 2, I-SPY 2

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 17:42

MammaPrint test predictive for benefit of extended endocrine therapy

Presented By

Dr Laura van ‘t Veer, UCLA, CA, USA

Trial

Phase 3, IDEAL

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 17:32

IRONMAN failed primary endpoint but shows potential long-term benefits of iron repletion in HF patients

Presented By

Prof. Paul Kalra, University of Glasgow, UK

Trial

Phase 4, IRONMAN

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 18:05

Up-titration of HF therapies following HF discharge saves lives

Presented By

Prof. Alexandre Mebazaa, Université Paris Cité, France

Trial

STRONG-HF

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 17:57

The endothelin system: a new target for resistant high blood pressure

Presented By

Prof. Markus P Schlaich, University of Western Australia, Perth

Trial

Phase 3, PRECISION

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 17:20

Can renal denervation lower BP on top of antihypertensive drugs?

Presented By

Dr David Kandzari, Piedmont Heart Institute, GA, USA

Trial

SPYRAL HTN-ON MED

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 16:33

Quadruple, ultra-low-dose treatment did not meet primary endpoint in hypertension

Presented By

Dr Mark Huffman, Washington University School of Medicine, USA

Trial

QUARTET USA

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 14:33

Mindfulness programme contributes to office blood pressure lowering

Presented By

Prof. Eric Loucks , Brown University, RI, USA

Trial

Phase 2, MB-BP

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 14:28

Grafting with the radial vein: an underrated option in CABG surgery?

Presented By

Prof. David Hare , Austin Health, Australia

Trial

RAPCO

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 14:25

Methylprednisolone does not reduce risk of adverse outcomes in infants undergoing heart surgery

Presented By

Dr Kevin Hill, Duke Children’s Hospital & Health Center, NC, USA

Trial

STRESS

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 14:21

Extracorporeal membrane oxygenation not superior to conservative therapy in cardiogenic shock

Presented By

Prof. Petr Ostadal, Charles University, Czech Republic

Trial

ECMO-CS

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 14:17

Surgery with adequate saphenous vein partly better than endovascular treatment in CLTI

Presented By

Dr Matthew Menard, Brigham and Women’s Hospital, MA, USA

Trial

BEST-CLI

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 14:14

Doubling the dose of self-administered etripamil terminates PSVT

Presented By

Dr James Ip, Weill Cornell Medicine, NY, USA

Trial

Phase 3, RAPID

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 14:05

Digitally delivered cognitive behavioural therapy successful in type 2 diabetes

Presented By

Prof. Marc Bonaca, University of Colorado, CO, USA

Trial

Phase 3, BT-001

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 14:00

Empagliflozin reduces risk of kidney disease progression and CV events in patients with CKD

Presented By

Prof. David Preiss, University of Oxford, UK

Trial

Phase 3, EMPA-KIDNEY

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 13:56

RESPECT-EPA misses primary endpoint but hints towards improvements in CV outcomes by EPA

Presented By

Dr Hiroyuki Daida, Juntendo University, Japan

Trial

RESPECT-EPA

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 13:50

Pemafibrate fails to reduce cardiovascular events in diabetes but may benefit the liver

Presented By

Dr Aruna Pradhan, Brigham and Women’s Hospital, MA, USA

Trial

Phase 3, PROMINENT

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 13:46

Olpasiran leads to dramatic reductions in Lp(a) concentrations

Presented By

Prof. Michelle O´Donoghue, Brigham and Women's Hospital, MA, USA

Trial

Phase 2, OCEAN(a)-DOSE

Conference

AHA 2023

Type

Peer-reviewed article

11 January 2023 12:50

Dietary supplements not effective in lowering LDL-C, use of low-dose statins encouraged

Presented By

Dr Luke Laffin, Cleveland Clinic, OH, USA

Trial

SPORT

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 12:45

No sex differences in lipid-lowering effect and treatment benefit of PCSK9 inhibitors

Presented By

Dr Frederick Rivera, Lincoln Medical Center, NY, USA

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 12:40

‘No’ to routine use of rivaroxaban in outpatients with COVID-19

Presented By

Dr Gregory Piazza, Brigham and Women’s Hospital, MA, USA

Trial

PREVENT-HD

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 12:21

COVID-19 pandemic: Older adults and those affected by the delta variant experienced increased cardiovascular morbidity and mortality

Presented By

Dr Pratyaksh Srivastava, Cedars-Sinai Medical Center, CA

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 10:01

COVID-19 mRNA vaccination does not amplify risk of cardiovascular hospitalisation

Presented By

Dr Anthony Simone, Kaiser Permanente Los Angeles Medical Center, USA

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 09:57

Higher LDL-cholesterol levels linked to higher CVD mortality risk in the elderly

Presented By

Dr Zhen Zhou, University of Tasmania, Australia

Trial

ASPREE

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 09:53

AF: Moderate alcohol intake possibly associated with a reduced mortality risk

Presented By

Dr Alireza Oraii, Population Health Research Institute, Canada

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 09:50

Periodontitis: An independent risk factor for AF

Presented By

Prof. Shunsuke Miyauchi, Hiroshima University, Japan

Conference

AHA 2022

Type

Peer-reviewed article

11 January 2023 09:46

Re-myelination strategies in MS still pose many unanswered questions

Presented By

Prof. Catherine Lubetzki, Sorbonne University, France

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 12:01

MS associated with a broader Epstein-Barr virus specific T-cell receptor repertoire

Presented By

Dr Tilman Schneider-Hohendorf, University of Muenster, Germany

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:58

Cognitive rehab and mindfulness reduce cognitive complaints in MS

Presented By

Dr Ilse Nauta, Vrije Universiteit Amsterdam, the Netherlands

Trial

REMIND-MS

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:56

COVID-19 and MS: lessons learned thus far

Presented By

Prof. Céline Louapre, Sorbonne University, France

Trial

COVISEP

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:52

Ocrelizumab and fingolimod increase the risk of COVID-19 and of worse outcomes

Presented By

Dr Nikos Evangelou, Nottingham University Hospital, UK

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:46

Humoral and cellular immune responses after SARS-CoV-2 vaccination

Presented By

Dr Monika Rabenstein, Karolinska Institute, Sweden

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:42

Ravulizumab significantly reduced relapses in AQP4+ NMOSD

Presented By

Dr Sean Pittock, Mayo Clinic, MN, USA

Trial

Phase 3, CHAMPION-NMOSD

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:36

NMOSD patients are cognitively impaired regardless of serostatus

Presented By

Dr Martin Hümmert, Hannover Medical School, Germany

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:25

Evidence-based consensus on pregnancy in NMOSD

Presented By

Prof. Sandra Vukusic, University Hospital Lyon, France

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 10:34

Pregnancy and infant outcomes in women receiving ocrelizumab

Presented By

Prof. Celia Oreja-Guevara, University Hospital San Carlos, Spain

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 10:29

New safety data of anti-CD20 mAbs around pregnancy

Presented By

Dr Carolin Schwake, Ruhr-University Bochum, Germany

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 10:24

MS activity and pregnancy outcomes after long-term use of natalizumab

Presented By

Prof. Sandra Thiel, Ruhr University Bochum, Germany

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 10:19

Early treatment with DMT effective in paediatric-onset MS

Presented By

Dr Emilio Portaccio, University of Florence, Italy

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:55

Fingolimod in paediatric MS: results of up to 6 years

Presented By

Dr Kumaran Deiva, Paris South University Hospitals, France

Trial

Phase 3, PARADIGMS

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:50

Switching treatment after initial platform injectable DMT: real-world data

Presented By

Dr Aaron Abrams, Cleveland clinic, OH, USA

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:43

Stem cell transplantation not superior to natalizumab in progressive MS

Presented By

Prof. Tomas Kalincik, Royal Melbourne Hospital, Australia

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:37

Efficacy of DMTs fades away in secondary progressive MS

Presented By

Dr Luigi Pontieri, The Danish Multiple Sclerosis Registry, Denmark

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:32

Smartphone tapping can help detect progressive MS

Presented By

Dr Juan Luis Chico-Garcia, Hospital Ramon y Cajal, Spain

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:19

Dimethyl fumarate reduces the risk of a first clinical event in RIS

Presented By

Prof. Darin Okuda, University of Texas Southwestern Medical Center, TX, USA

Trial

Phase 4, ARISE

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:14

How and when to make a timely switch to high-efficacy DMT

Presented By

Dr Dalia Rotstein, University of Toronto, Canada

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:08

Comparing real-world effectiveness of DMTs

Presented By

Prof. Marcello Moccia, University College London, UK

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 09:05

Study fails to show non-inferiority of rituximab to ocrelizumab

Presented By

Dr Izanne Roos, University of Melbourne, Australia

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 08:55

Autologous haematopoietic stem cell transplantation versus DMTs

Presented By

Prof. Tomas Kalincik, University of Melbourne, Australia

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 08:52

A case for including optic nerve lesions in the McDonald criteria

Presented By

Prof. Frederik Barkhof, Vrije Universiteit Amsterdam, the Netherlands

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 08:49

Cerebrospinal fluid kappa-free light chains for MS diagnosis

Presented By

Dr Harald Hegen, Medical University of Innsbruck, Austria

Conference

ECTRIMS 2022

Type

Peer-reviewed article

19 December 2022 19:19

Early, non-disabling relapses increase disability accumulation

Presented By

Dr Cyrus Daruwalla, Cambridge University Hospitals, UK

Conference

ECTRIMS 2022

Type

Peer-reviewed article

19 December 2022 19:13

Physical impairment is present before perceived MS onset

Presented By

Ms Annalaura Lerede, Imperial College London, UK

Conference

ECTRIMS 2022

Type

Peer-reviewed article

19 December 2022 19:09

Chronic active MS lesions respond poorly to anti-CD20 antibodies

Presented By

Dr Pietro Maggi, Saint-Luc University Hospital, Belgium

Conference

ECTRIMS 2022

Type

Peer-reviewed article

19 December 2022 19:06

Isuzinaxib effective in patients with CKD and T2D

Trial

Phase 2

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:56

VALOR-CKD trial did not show any benefits for veverimer

Presented By

Dr Navdeep Tangri, Seven Oaks General Hospital, Winnipeg, Canada

Trial

Phase 3, VALOR-CKD

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:54

EMPA-KIDNEY: empagliflozin slashes kidney disease progression or CV death

Presented By

Dr William Herrington, University of Oxford, UK

Trial

Phase 3, EMPA-KIDNEY

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:53

Combining UACR and GFR improves prediction of drug effect in CKD phase 2 trials

Presented By

Dr Tom Greene, University of Utah, USA

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:49

Dapagliflozin reduces number of hospitalisations in patients with CKD

Presented By

Dr Meir Schechter, Universitair Medisch Centrum Groningen, Netherlands

Trial

Phase 3, DAPA-CKD

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:47

Novel MSC therapy appears safe and effective in preventing decline in eGFR

Presented By

Dr Matthew Griffin, University of Galway, Ireland

Trial

Phase 1/2, NEPHSTROM

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:43

Dapagliflozin improves anaemia in patients with CKD with or without T2D

Presented By

Prof. Hiddo Heerspink, University of Groningen, Netherlands

Trial

Phase 3, DAPA-CKD

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:39

Balanced crystalloid solution better for deceased donor kidney transplantations

Presented By

Dr Michel G. Collins, Royal Adelaide Hospital, Australia

Trial

BEST-Fluids

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:36

Modified donor blood cells seem a promising option in kidney transplant recipients

Presented By

Dr Matthias Schaier, Heidelberg University, Germany

Trial

Phase 1

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:34

Wearable serum potassium-monitoring device serves haemodialysis patients well

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:22

Cooler dialysate does not offer any clinical benefits

Presented By

Prof. Amit Garg, London Health Sciences Centre and Western University, Ontario, Canada

Trial

MyTEMP

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:20

Sodium zirconium cyclosilicate maintains pre-dialysis serum potassium

Trial

Phase 3, DIALIZE China

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:18

Antiviral effect of MAU868 against BK virus prompts further research

Presented By

Dr Stanley Jordan, Cedars-Sinai Medical Center/Comprehensive Transplant Center, CA, USA

Trial

Phase 2

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:16

Medication-targeted alerts for the risk of AKI

Presented By

Dr F. Perry Wilson, Yale School of Medicine, CT, USA

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:13

Coaching with a DASH diet improves albuminuria

Presented By

Prof. Diedre C. Crews, Johns Hopkins University School of Medicine Equity, MD, USA

Trial

Five, Plus Nuts and Beans for Kidneys

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 15:09

Cemdisiran shows promise in IgA nephropathy

Presented By

Prof. Jonathan Barratt, University of Leicester, UK

Trial

Phase 2

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 14:58

Long-term nephroprotective effects of sparsentan in FSGS

Presented By

Dr Tarak Srivastava, Children’s Mercy Hospital, USA

Trial

Phase 2, DUET

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 14:55

Encaleret normalises mineral homeostasis in patients with ADH1

Presented By

Dr Kelly Roszko, National Institutes of Health, USA

Trial

Phase 2

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 14:52

Adding voclosporin to MMF and steroids results in long-term higher CRR in severe lupus nephritis

Presented By

Dr Hanni Menn-Josephy, Boston University School of Medicine, USA

Trial

AURORA 1, AURORA 2

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 14:49

Selonsertib poses risk of AKI in patients with DKD

Presented By

Prof. Vlado Perkovic, University of New South Wales, Australia

Trial

Phase 2, MOSAIC

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 14:34

Significantly higher risk of overcorrection in hyponatraemic patients with standard bolus infusion

Presented By

Dr Anissa Pelouto, Erasmus Medical Center, Rotterdam, the Netherlands

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 14:29

Lowering blood pressure intervention favourable for CV outcomes

Presented By

Dr Amara Sarwal, University of Utah Health, UT, USA

Conference

ASN 2022

Type

Peer-reviewed article

8 December 2022 14:27

Immunotherapy response may be modulated by microbiome

Presented By

Dr Johannes Björk, University Medical Center Groningen, the Netherlands

Trial

PRIMM

Conference

UEGW 2022

Type

Peer-reviewed article

2 December 2022 09:48

Computer-aided colonoscopies improved adenoma detection rates

Presented By

Dr Michiel Maas, Raboud UMC, the Netherlands

Conference

UEGW 2022

Type

Peer-reviewed article

2 December 2022 09:44

Benefit of colon cancer screening with colonoscopy lower than anticipated

Presented By

Prof. Michael Bretthauer, Oslo University, Norway

Trial

Phase 3, NordICC

Conference

UEGW 2022

Type

Peer-reviewed article

2 December 2022 09:41

Screening-detected colorectal cancers may have superior surgical outcomes

Presented By

Dr Jannie Dressler, Bispebjerg Hospital, Denmark

Conference

UEGW 2022

Type

Peer-reviewed article

2 December 2022 09:37

Favourable pancreatitis outcomes with procalcitonin-based algorithm to guide antibiotic use

Presented By

Prof. Ajith Siriwardena, Manchester Royal Infirmary, UK

Trial

PROCAP

Conference

UEGW 2022

Type

Peer-reviewed article

2 December 2022 09:35

Fewer long-term interventions after delayed drainage in necrotising pancreatitis

Presented By

Noor Sissingh, Leiden University Medical Centre, the Netherlands

Trial

POINTER

Conference

UEGW 2022

Type

Peer-reviewed article

2 December 2022 09:24

Detection of Europe´s deadliest cancer: much room for improvement

Presented By

Dr Nosheen Umar, University of Birmingham, UK

Conference

UEGW 2022

Type

Peer-reviewed article

2 December 2022 09:21

Portal hypertension is associated with poor prognosis in cirrhotic patients

Presented By

Mr Phil Ambery, AstraZeneca, Sweden

Conference

UEGW 2022

Type

Peer-reviewed article

2 December 2022 09:18

Chances of transplant-free survival in PSC enhanced by colectomy with ileostomy

Presented By

Dr Bregje Mol, Amsterdam UMC, the Netherlands

Conference

UEGW 2022

Type

Peer-reviewed article

2 December 2022 09:13

SARS-CoV-2: Booster doses of key importance for cirrhotic patients

Presented By

Dr Samer Al-Dury, Sahlgrenska University Hospital, Sweden

Conference

UEGW 2022

Type

Peer-reviewed article

2 December 2022 09:11

Less ulcer bleeds early after H. pylori eradication in aspirin users

Presented By

Prof. Christopher Hawkey, Nottingham Digestive Diseases Centre, UK

Trial

Phase 4, HEAT

Conference

UEGW 2022

Type

Peer-reviewed article

2 December 2022 09:08

Dupilumab effective in paediatric patients with eosinophilic oesophagitis

Presented By

Prof. Evan S. Dellon, University of North Carolina School of Medicine in Chapel Hill, NC, USA

Trial

Phase 3, EoE KIDS

Conference

UEGW 2022

Type

Peer-reviewed article

2 December 2022 09:04

Neoplasia in Barrett’s oesophagus: the earlier the intervention, the better the long-term outcome

Presented By

Dr Fadi Younis, University Hospital Hamburg-Eppendorf, Germany

Conference

UEGW 2022

Type

Peer-reviewed article

2 December 2022 09:00

Fast recapture of response with ozanimod after withdrawal in UC

Presented By

Dr Anita Afzali, University of Cincinnati College of Medicine, OH, USA

Trial

Phase 3, True North

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 22:08

Ozanimod treatment prompted substantial response after failure of response to induction

Presented By

Prof. Remo Panaccione, University of Calgary, Canada

Trial

Phase 3, True North

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 22:06

Etrasimod shows advantage over placebo in UC

Presented By

Prof. Séverine Vermeire, University Hospital Leuven, Belgium

Trial

Phase 3, ELEVATE UC

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 22:03

Etrasimod reduces adaptive immune cells in the periphery in UC

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 3, ELEVATE UC

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 22:00

Favourable maintenance rates for risankizumab also in delayed responders with CD

Presented By

rof. Geert D’Haens, Amsterdam UMC, the Netherlands

Trial

Phase 3, FORTIFY

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 21:56

IL-23 inhibition reduces inflammatory biomarkers in pre-treated UC

Presented By

Prof. Julian Panés, Hospital Clínic Barcelona, Spain

Trial

Phase 2, QUASAR

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 21:53

Maintained symptom control with mirikizumab in UC

Presented By

Prof. Axel Dignass, Agaplesion Markus Hospital, Germany

Trial

Phase 3, LUCENT 2

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 21:49

Mirikizumab successfully resolves active histologic inflammation in UC

Presented By

Prof. Fernando Magro, CHU de São João, Portugal

Trial

Phase 2, LUCENT 2

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 21:44

Upadacitinib for CD: remarkable efficacy in induction therapy

Presented By

Prof. Julian Panés, Hospital Clínic Barcelona, Spain

Trial

Phase 3, U-EXCEL

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 21:42

Sustained maintenance results with upadacitinib in UC

Presented By

Prof. Séverine Vermeire, University Hospital Leuven, Belgium

Trial

U-ACHIEVE Maintenance

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 21:37

Start low with brepocitinib and ritlecitinib in UC

Presented By

Dr Kenneth Hung, Pfizer, MA, USA

Trial

Phase 2, VIBRATO

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 21:34

Another chance for TYK2 inhibition in UC

Presented By

Prof. Stephan Schreiber, University Hospital Schleswig-Holstein, Germany

Trial

Phase 2, LATTICE-UC

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 21:29

Small molecule obefazimod shows promise in UC

Presented By

Prof. Séverine Vermeire, University Hospital Leuven, Belgium

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 21:26

Pivotal results of etrolizumab for CD partly disappointing

Presented By

Prof. Séverine Vermeire, University Hospital Leuven, Belgium

Trial

Phase 3, BERGAMOT

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 17:27

Better results for vedolizumab in early CD

Presented By

Prof. Geert D’Haens, Amsterdam UMC, the Netherlands

Trial

Phase 4, LOVE-CD

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 17:19

Some patients with limited CD may benefit from an early surgical intervention

Presented By

Dr Melek Zahra Sarikaya, Sjællands Universitetshospital, Denmark

Trial

LIR!C

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 17:11

Dose-interval of adalimumab might be prolonged in CD patients in stable remission

Presented By

Dr Reinier van Linschoten , Franciscus Gasthuis en Vlietland, the Netherlands

Trial

Phase 4, LADI

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 17:01

Zuranolone shows rapid-acting efficacy in postpartum depression

Presented By

Dr Kristina Deligiannidis, Zucker Hillside Hospital, NY, USA

Trial

Phase 3, SKYLARK

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 11:35

Probiotics could reduce perceived stress

Presented By

Dr Julie Hudry, Nestlé Institute of Health Science, Switzerland

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 11:33

KarXT is effective in schizophrenic patients experiencing acute psychosis

Presented By

Dr Stephen Brannan, Karuna Therapeutics, MA, USA

Trial

Phase 3, EMERGENT-2

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 11:30

Low-dose ulipristal acetate is an effective treatment for PMDD

Presented By

Dr Erika Comasco, Uppsala University, Sweden

Trial

Phase 2

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 11:28

Endogenous oxytocin release helps the mind to deal with pain

Presented By

Stephanie Küppers, Central Institute of Mental Health Mannheim, Germany

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 11:24

Nitric oxide synthase genetic variant is a risk factor for suicidal behaviour

Presented By

Dr Aiste Lengvenyte, CHU Montpellier, France

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 11:23

Early-life gut microbiota depletion changes brain morphology and behaviour

Presented By

Caoimhe Lynch, University College Cork, Ireland

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 11:21

Treating intrusive memories after trauma in healthcare workers using Tetris

Presented By

Prof. Emily Holmes, Uppsala University, Sweden

Trial

GAINS

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 11:19

VR exposure as effective as in vivo exposure for phobia

Presented By

Prof. Peter Zwanzger, kbo-Inn-Salzach-Klinikum, Germany

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 11:16

Efficacy of smartphone-based treatment of bipolar disorders not (yet) validated

Presented By

Dr Maria Faurholt-Jepsen, Rigshospitalet, Denmark

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 11:13

Mode of action of psilocybin

Presented By

Prof. Scott Thompson, University of Colorado School of Medicine, CO, USA

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 11:11

Fast and sustained effect of 2 administrations of psilocybin on depression

Presented By

Dr David Erritzoe, Imperial College London, UK

Trial

Phase 2, Psilodep-RCT

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 11:09

Antidepressant properties of psilocybin might be related to changes in sleep

Presented By

Dr Tomas Palenicek, National Institute of Mental Health, Czech Republic

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 11:06

Both sex hormones and serotonin play a role in peripartum mental health

Presented By

Dr Vibe Frokjaer, Copenhagen University Hospital, Denmark

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 11:04

Child loss induces short- and long-term neurobiological changes

Presented By

Prof. Oliver Bosch, University of Regensburg, Germany

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 11:01

Reproductive state matters when looking at the female brain and drug treatment effects

Presented By

Dr Jodi Pawluski, University of Rennes, France

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 10:59

Different brain responses to fat and/or sugar

Presented By

Prof. Susanne la Fleur, University of Amsterdam, the Netherlands

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 10:55

Diabetes not related to abnormal biomarkers of Alzheimer’s disease

Presented By

Veerle van Gils, Maastricht University, the Netherlands

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 10:53

Oxytocin treatment induces long-lasting neurobiological adaptations in autism

Presented By

Dr Kaat Alaerts, KU Leuven, Belgium

Conference

ECNP 2022

Type

Peer-reviewed article

28 November 2022 10:50

Adding first-line pembrolizumab to CRT in locally advanced HNSCC does not significantly prolong survival or event-free survival

Presented By

Prof. Jean-Pascal Machiels, Cliniques Universitaires Saint-Luc, Belgium

Trial

Phase 3, KEYNOTE-412

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 01:12

5-FU-free chemotherapy combination as an alternative for first-line treatment of recurrent or metastatic HNSCC

Presented By

Dr Marcin Dzienis, Gold Coast University Hospital, Australia

Trial

Phase 4, KEYNOTE-B10

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 01:06

Epstein Barr virus-specific autologous cytotoxic T lymphocytes do not improve survival in nasopharyngeal carcinoma

Presented By

Dr Han Chong Toh, National Cancer Centre, Singapore

Trial

Phase 3, VANCE

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 01:02

OS benefit for advanced ovarian cancer patients treated with maintenance olaparib

Presented By

Prof. Isabelle Ray-Coquard, Centre Léon Bérard, France

Trial

Phase 3, PAOLA-1/ENGOT-ov25

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:57

Maintenance tegafur-uracil does not improve survival in locally advanced cervical cancer

Presented By

Prof. Keiichi Fujiwara, Saitama Medical University, Japan

Trial

GOTIC-002 LUFT

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:52

Adjuvant nivolumab plus ipilimumab does not improve survival in patients with localised RCC at high risk of relapse after nephrectomy

Presented By

Prof. Robert Motzer, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, CheckMate 914

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:46

Triple therapy improves progression-free survival in patients with advanced RCC versus dual therapy

Presented By

Prof Toni Choueiri, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, COSMIC-313

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:41

Adjuvant atezolizumab does not improve outcomes for patients with RCC and increased risk of recurrence

Presented By

Dr Axel Bex, The Royal Free London NHS Foundation Trust, UK

Trial

Phase 3, IMmotion-010

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:28

Overall survival benefit of abiraterone in mHSPC is maintained for 7 years

Presented By

Prof. Gerhardt Attard, UCL Cancer Institute London, UK

Trial

Phase 3, STAMPEDE

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:23

Limited benefit of adding long-term ADT to post-operative radiotherapy in prostate cancer

Presented By

Prof. Chris Parker, The Royal Marsden Hospital, UK

Trial

RADICALS-HD

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:17

Intensified ADT benefits biochemical progression-free survival in biochemically relapsed prostate cancer

Presented By

Dr Rahul Aggarwal, University of California San Francisco, CA, USA

Trial

Phase 3, PRESTO

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:13

Treatment with tumour-infiltrating lymphocytes for advanced melanoma outperforms ipilimumab

Presented By

Prof. John Haanen, Netherlands Cancer Institute, the Netherlands

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:29

Neoadjuvant pembrolizumab outperforms adjuvant pembrolizumab in resectable stage III–IV melanomas

Presented By

Dr Sapna Patel, MD Anderson Cancer Center, TX, USA

Trial

Phase 2, SWOG S1808

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:26

Survival-benefit of neoadjuvant T-VEC maintained over 5 years of follow-up

Presented By

Prof. Reinhard Dummer, University of Zürich, Switzerland

Trial

T-VEC

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:24

Baseline ctDNA predicts survival in resected stage III–IV melanoma

Presented By

Prof. Georgina Long, University of Sydney, Australia

Trial

Phase 3, CheckMate 915

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:21

A pathway from air pollution to lung cancer in non-smokers identified

Presented By

Prof. Charles Swanton, University College London, UK

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:17

Selective KRASG12C inhibitor sotorasib demonstrates superior PFS and ORR compared to docetaxel in previously treated patients with NSCLC

Presented By

Dr Melissa Johnson, Sarah Cannon Research Institute, TN, USA

Trial

Phase 3, CodeBreaK 200

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:14

Promising clinical activity of tepotinib plus osimertinib in NSCLC with MET amplification after progression on first-line osimertinib

Presented By

Prof. Julien Mazières, CHU de Toulouse, France

Trial

Phase 2, INSIGHT-2

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:10

High pathological responses in borderline resectable NSCLC patients after induction with dual immunotherapy and concurrent chemoradiotherapy

Presented By

Dr Idris Bahce, Amsterdam UMC, the Netherlands

Trial

Phase 2, INCREASE

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:05

Tumour infiltrating lymphocytes identify patients with immunogenic triple-negative breast cancer

Presented By

Prof. Marleen Kok, Netherlands Cancer Institute, the Netherlands)

Trial

Phase 2, BELLINI

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 18:01

OS benefit of abemaciclib in HR-positive/HER2-negative advanced breast cancer not (yet) statistically significant

Presented By

Prof. Matthew Goetz, Mayo Clinic Rochester, MN, USA

Trial

Phase 3, MONARCH 3

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:48

OS benefit of sacituzumab govitecan in pre-treated HR-positive/HER2-negative metastatic breast cancer

Presented By

Prof. Hope Rugo, Helen Diller Family Comprehensive Cancer Centre, CA, USA

Trial

Phase 3, TROPiCS-02

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:43

Deep learning models predict the risk of relapse and the mutational profile in GIST

Presented By

Dr Raul Perret, Institute Bergonié, France

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:40

Addition of pembrolizumab to lenvatinib does not improve OS in advanced HCC

Presented By

Prof. Richard Finn, David Geffen School of Medicine, CA, USA

Trial

Phase 3, LEAP-002

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:37

New, highly selective inhibitor of FGFR2 driver alterations and resistance mutations

Presented By

Prof. Antoine Hollebecque, Institut Gustave Roussy, France

Trial

Phase 1/2, REFOCUS

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:35

Chemo-immunotherapy in gastric cancer is more effective when administered in parallel

Presented By

Prof.  Sylvie Lorenzen, Klinikum rechts der Isar, TU München, Germany

Trial

Phase 2, Moonlight

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:31

High pathological responses to neoadjuvant immune checkpoint inhibition in locally advanced dMMR colon cancer

Presented By

Dr Miriam Chalabi, Netherlands Cancer Institute, the Netherlands

Trial

NICHE-2

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:28

Fruquintinib: a potential new treatment for patients with refractory mCRC

Presented By

Prof. Nageshwara Arvind Dasari, MD Anderson Cancer Centre, TX, USA

Trial

Phase 3, FRESCO-2

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:21

Second-line avelumab is effective in patients with MSI-H/dMMR mCRC

Presented By

Prof. Julien Taieb, Hopital European George Pompidou, France

Trial

Phase 2, SAMCO-PRODIGE 54

Conference

ESMO 2022

Type

Peer-reviewed article

16 November 2022 17:13

High rate of non- or partial responders jeopardises therapeutic success in HS

Presented By

Dr Hayley Wallinger, Adelphi Real World, UK

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 11:15

Genital psoriasis: high prevalence, often underdiagnosed

Presented By

Dr Toni Klein, University Medical Center Hamburg-Eppendorf, Germany

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 11:12

Decreased overall survival in melanoma patients with low vitamin D

Presented By

Dr Inés Gracia-Darder, Son Espases University Hospital, Spain

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 11:09

High potential for secukinumab as next biologic treatment for HS

Presented By

Prof. Alexandra Kimball, Harvard Medical School, MA, USA

Trial

Phase 3, SUNSHINE; SUNRISE

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 11:06

Hidradenitis suppurativa: TYK2/JAK1 inhibitor shows promise

Presented By

Prof. Alexandra Kimball, Harvard Medical School, MA, USA

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 11:03

Dupilumab leads to clinically relevant improvements in signs and symptoms of prurigo nodularis

Presented By

Prof. Gil Yosipovitch, University of Miami, FL, USA

Trial

Phase 2, LIBERTY-PN PRIME

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:59

Nalbuphine: aspiring to become another treatment for prurigo nodularis?

Presented By

Prof. Sonja Ständer, University Medical Centre of Münster, Germany

Trial

Phase 3, PRISM

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:57

Notalgia paresthetica: may κ-opioid receptor agonists be a long-awaited effective therapy?

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 2, KOMFORT

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:55

Enhancing re-pigmentation rates with topical ruxolitinib in all body areas

Presented By

Prof. Thierry Passeron, University Côte d’Azur, France

Trial

Phase 3, TRuE-V1; TRuE-V2

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:50

Markedly lower skin cancer risk in vitiligo patients

Presented By

Dr John Ferguson, St John’s Institute of Dermatology, UK

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:47

Myths regarding “health benefit” of suntan prevail in majority of population

Presented By

Prof. Thierry Passeron, Université Côte d’Azur, France

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:43

Fern extract reverses severe actinic keratosis lesions

Presented By

Dr Stefania Guida, Sapienza University of Rome, Italy

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:41

Novel oral psoriasis drug maintains efficacy over 2 years

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, POETYK-PSO-1

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:36

A3 adenosine receptor agonist showed modest efficacy but excellent tolerability

Presented By

Dr Kim A. Papp, Probity Medical Research, Canada

Trial

Phase 3, COMFORT

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:32

Selective IL-23 inhibitor achieves long-term disease control in many patients with active PsA

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

KEEPsAKE 1; KEEPsAKE 2

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:28

AI machine learning algorithm useful in early detection of PsA

Presented By

Dr Jonathan Shapiro, Maccabi Healthcare Services, Israel

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 10:24

Long-term improvement in alopecia areata with ritlecitinib therapy

Presented By

Dr Athanasios Tsianakas, Fachklinik Bad Bentheim, Germany

Trial

Phase 3, ALLEGRO-LT

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:30

Topical gel plus finasteride beneficial for patients with androgenetic alopecia

Presented By

Dr Michela Starace, University of Bologna, Italy

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:20

Deuruxolitinib achieves hair regrowth, even in patients with severe alopecia areata

Presented By

Prof. Brett King, Yale University School of Medicine, CT, USA

Trial

Phase 3, THRIVE-AA1

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:18

Baricitinib possible therapeutic option for children with AD

Presented By

Dr Antonio Torrelo Fernández, Hospital Infantil Universitario Niño Jesús, Spain

Trial

Phase 3, BREEZE-AD-PEDS

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:15

Amlitelimab therapy leads to sustained decrease of IL-22 in AD patients

Presented By

Dr Stephan Weidinger, University Hospital Schleswig-Holstein, Germany

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:10

IL-13 inhibition with lebrikizumab shows high maintenance rates in AD

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, OR, USA

Trial

Phase 3, ADvocate

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:05

Does 8 weeks of emollients use prevent AD in high-risk infants?

Presented By

Prof. Alan Irvine, Trinity College Dublin, Ireland

Trial

STOP AD

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:02

Roflumilast foam led to high response rates in seborrheic dermatitis

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, OR, USA

Trial

Phase 3, STRATUM

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 09:00

Study fails to show non-inferiority of rituximab with ocrelizumab

Presented By

Dr Izanne Roos, University of Melbourne, Australia

Conference

ECTRIMS 2022

Type

Peer-reviewed article

31 October 2022 11:16

Excellent results for high-flow nasal cannula oxygen therapy in acute respiratory failure

Presented By

Prof. Gamal Agmy, Assiut University, Egypt

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 22:14

Antifibrotic therapy may slow down FVC decline in RAILD 

Presented By

Prof. Ivan Rosas, Baylor College of Medicine, TX, USA

Trial

Phase 2, TRAIL1

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 22:11

Intravenous N-acetylcysteine performs well in hospitalised patients 

Presented By

Prof. Alberto Papi, University of Ferrara, Italy

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 22:09

Men and women respond differently to diesel exhaust

Presented By

Dr Mahadevappa Hemshekhar, University of Manitoba, Canada

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 22:06

New trends in cystic lung diseases

Presented By

Prof. Cormac McCarthy, University College Dublin, Ireland

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 22:04

In the spotlight: Cancer trends in obstructive sleep apnoea

Presented By

Dr Andreas Palm, Uppsala University, Sweden

Trial

DISCOVER

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 21:56

Impact of CPAP on cardiac endpoints in OSA

Presented By

Prof. Anita Simonds, National Heart & Lung Institute, UK

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 21:54

Sustained hypoxaemia predicts unprovoked VTE in OSA

Presented By

Prof. Wojciech Trzepizur, University of Angers, France

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 21:50

CPAP therapy in the prevention of cardiovascular risk in patients with OSA

Presented By

Prof. Raphael Heinzer, Lausanne University Hospital, Switzerland

Trial

SAVE

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 21:48

Head-to-head: lung volume reduction surgery vs endobronchial valves 

Presented By

Ms Sara Buttery, Royal Brompton and Harefield NHS Foundation Trust, UK

Trial

CELEB

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 21:42

Durable effect of endobronchial valves in severe emphysema 

Presented By

Prof. Gerard Criner, Temple University, PA, USA

Trial

EMPROVE

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 21:40

Cone beam CT-guided ENB improves detection of pulmonary nodules

Presented By

Prof. Benjamin Bondue, Université Libre de Bruxelles, Belgium

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 21:37

Confirmatory mediastinoscopy not needed in resectable NSCLC

Presented By

Prof. Jouke Annema, Amsterdam UMC, the Netherlands

Trial

MEDIASTrial

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 21:30

Antibiotics cause increased risk of wheezing in severe RSV bronchiolitis 

Presented By

Prof. Avraham Beigelman, Schneider Children's Medical Center of Israel, Israel

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 21:23

Inhaled corticosteroids useful in preterms with decreased lung function 

Presented By

Prof. Shannon Simpson, Curtin University, Australia

Trial

PICSI

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 21:19

Fish oil or vitamin D during pregnancy can prevent croup

Presented By

Dr Nicklas Brustad, University of Copenhagen, Denmark

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 21:16

Encouraging results of nintedanib in children with fibrosing ILD 

Presented By

Dr Robin Deterding, Children’s Hospital Colorado, CO, USA

Trial

Phase 3, InPedILD

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 21:10

Tezepelumab in asthma: mucus plugging down, lung function up

Presented By

Prof. Christopher Brightling, University of Leicester, UK

Trial

Phase 2, CASCADE

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 21:06

Digital asthma intervention improves health and reduces costs 

Presented By

Mr Luca Ponti, Amiko Digital Health, Italy

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 21:03

Digitally enhanced therapy lowers treatment burden and costs in severe asthma 

Presented By

Prof. Richard Costello, Bon Secours Hospital Dublin, Ireland

Trial

INCA-SUN

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 21:01

Mepolizumab beneficial for patients with severe eosinophilic asthma 

Presented By

Dr Rupert Jakes, GSK, UK

Trial

REALITI-A

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 20:59

Icenticaftor achieves results on top of triple inhalation therapy in COPD 

Presented By

Prof. Frits Franssen, Maastricht University, the Netherlands

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 20:50

STARR2: A new approach for treating COPD exacerbations 

Presented By

Prof. Mona Bafadhel, King’s College London, UK

Trial

Phase 4, STARR2

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 20:48

COPD medication not effective in symptomatic smokers with preserved spirometry 

Presented By

Prof. MeiLan Han, University of Michigan, MI, USA

Trial

Phase 3, RETHINC

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 20:46

Do digital tools improve physical activity in COPD?

Presented By

Prof. Andre Nyberg, University of Umeå, Sweden

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 20:43

Hyperpolarised gas MRI ready for clinical use

Presented By

Dr Sarah Svenningsen, McMaster University, Canada

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 20:41

Does vilobelimab reduce mortality in severe COVID-19? 

Presented By

Prof. Alexander Vlaar, Amsterdam UMC, the Netherlands

Trial

Phase 3, PANAMO

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 20:35

Awake proning not positive in COVID-19

Presented By

Prof. Jason Weatherald, University of Alberta, Canada

Trial

COVI-PRONE

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 20:30

Favipiravir may help patients over 60 years with COVID-19 to recover 

Presented By

Dr Christopher Orton, Royal Brompton Hospital, UK

Trial

Phase 3, PIONEER

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 20:28

Brensocatib fails in severe COVID-19 

Presented By

Ms Holly Keir, University of Dundee, UK

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 20:25

Inhaled agent under investigation for COVID-19 

Presented By

Prof. Tom Wilkinson, University of Southampton, UK

Trial

Phase 3, SPRINTER

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 20:22

Accurate voice-based COVID-19 diagnostic test in development

Presented By

Ms Wafaa Aljbawi, Maastricht University, the Netherlands

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 20:19

Novel scoring tool for post-COVID syndrome aids clinicians and researchers

Presented By

Prof. Thomas Bahmer, University of Kiel, Germany

Conference

ERS 2022

Type

Peer-reviewed article

30 October 2022 20:16

Old dogs, new tricks: Acetazolamide plus loop diuretics improves decongestion

Presented By

Prof. Wilfried Mullens, Hospital Oost-Limburg, Belgium

Trial

Phase 4, ADVOR

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 14:43

No effect of neprilysin inhibition on cognition

Presented By

Prof. John McMurray, University of Glasgow, UK

Trial

Phase 3, PERSPECTIVE

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 14:41

Dapagliflozin DELIVERs for HFmrEF/HFpEF

Presented By

Prof. Scott Solomon, Brigham and Women's Hospital, Harvard Medical School, MA, USA

Trial

Phase 3, DELIVER

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 14:35

Pooled analysis of DAPA-HF and DELIVER

Presented By

Prof. Pardeep Jhund, University of Glasgow, UK

Trial

Phase 3, DAPA-HF, DELIVER

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 14:33

Meta-analysis of DELIVER and EMPEROR-Preserved

Presented By

Dr Muthiah Vaduganathan, Brigham and Women's Hospital, Harvard Medical School, MA, USA

Trial

Phase 3, DELIVER, EMPEROR-Preserved

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 14:27

Rheumatic heart disease-associated AF: standard-of-care holds ground

Presented By

Prof. Ganesan Karthikeyan, All India Institute of Medical Sciences, India

Trial

Phase 3, INVICTUS

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 14:14

New anticoagulant safe and maybe effective: PACIFIC-AMI and PACIFIC-Stroke outcomes

Presented By

Prof. John Alexander, Duke University, NC, USA & Prof. Ashkan Shoamanesh, McMaster University, Canada

Trial

Phase 2, PACIFIC-AMI, PACIFIC-Stroke

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 14:02

AXIOMATIC-SSP: Reducing risk of ischaemic stroke with factor XIa inhibition?

Presented By

Dr Mukul Sharma, McMaster University, Canada

Trial

Phase 2, AXIOMATIC-SSP

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 13:59

Evolving evidence for P2Y12 inhibition in chronic coronary syndromes: PANTHER

Presented By

Prof. Marco Valgimigli, Cardiocentro Ticino Foundation, Switzerland

Trial

PANTHER

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 13:55

Danish study suggests starting CVD screening before age 70

Presented By

Prof. Axel Cosmus Pyndt Diederichsen, Odense University Hospital, Denmark

Trial

DANCAVAS

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 12:59

Polypill SECUREs win in secondary prevention in elderly

Presented By

Dr Valentin Fuster, Mount Sinai Health System, NY, USA

Trial

Phase 3, SECURE

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 12:56

Long-term therapy with evolocumab associated with lower CV mortality

Presented By

Prof. Michelle O'Donoghue, Brigham and Women's Hospital, MA, USA

Trial

FOURIER

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 12:54

ARBs + beta-blockers may delay Marfan syndrome aortic root replacement

Presented By

Dr Alex Pitcher, Oxford University Hospitals NHS Foundation Trust, UK

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 12:52

ENTRIGUE: Subcutaneous pegozafermin in severe hypertriglyceridaemia

Presented By

Prof. Deepak Bhatt, Harvard Medical School, MA, USA

Trial

Phase 2, ENTRIGUE

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 12:49

First RCT evidence for use of AI in daily practice

Presented By

Dr David Ouyang, Cedars-Sinai Smidt Heart Institute, CA, USA

Trial

EchoNet-RCT

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 12:40

AI-enhanced echography supports aortic stenosis patients

Presented By

Prof. Geoffrey Strange, University of Notre Dame, Australia

Trial

AI-ENHANCED AS

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 12:38

Smartphones for AF detection

Presented By

Prof. Axel Bauer, Innsbruck Medical University, Austria

Trial

eBRAVE-AF

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 12:25

Medical therapy versus PCI for ischaemic cardiomyopathy

Presented By

Prof. Divaka Perera, Guy's & St Thomas' NHS Foundation Trust, London, UK

Trial

REVIVED-BCIS2

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 12:16

Allopurinol disappoints in ALL-HEART

Presented By

Prof. Isla Shelagh Mackenzie, University of Dundee, UK

Trial

ALL-HEART

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 12:13

Conservative or invasive management for high-risk kidney disease patients with ischaemia?

Presented By

Prof. Sripal Bangalore, New York University School of Medicine, NY, USA

Trial

Phase 4, ISCHEMIA-CKD EXTEND

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 12:10

Genotype-guided antiplatelet therapy in patients receiving PCI

Presented By

Dr Brenden Ingraham, Mayo Clinic, MN, USA

Trial

Phase 4, TAILOR-PCI

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 12:06

Prevention of VT and sudden cardiac death: the new recommendations

Presented By

Prof. Katja Zeppenfeld, Leiden University Medical Center, the Netherlands & Prof. Jacob Tfelt-Hansen, Copenhagen University Hospital, Denmark

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 11:56

New and first ESC cardio-oncology guideline

Presented By

Dr Teresa López-Fernández, La Paz University Hospital, Spain & Dr Alexander Lyon, Royal Brompton Hospital, London, UK

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 11:54

The 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension

Presented By

Prof. Stephan Rosenkranz, Heart Center at the University Cologne, Germany & Prof. Marion Delcroix, University Hospitals Leuven, Belgium

Type

Peer-reviewed article

27 October 2022 11:47

Cardiovascular assessment and management of patients undergoing non-cardiac surgery

Presented By

Prof. Sigrun Halvorsen, Oslo University Hospital Ulleval, Norway & Prof. Julinda Mehilli, Landshut-Achdorf Hospital, Germany

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 11:45

Take hypertension medication anyTIME

Presented By

Prof. Thomas MacDonald, University of Dundee, UK

Trial

TIME

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 10:44

BOXing out oxygen and blood pressure targets

Presented By

Prof. Jacob Eifer Møller & Dr Jesper Kjaergaard, Copenhagen University Rigshospitalet, Denmark

Trial

BOX

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 10:40

Coronary CT angiography diagnostics compared head-to-head

Presented By

Prof. Morten Bøttcher, Aarhus University, Denmark

Trial

DanNICAD-2

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 10:38

High-dose influenza vaccine: mortality benefit?

Presented By

Dr Niklas Dyrby Johansen, Herlev and Gentofte Hospital, Denmark

Trial

Phase 2, DANFLU-1

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 10:30

FFR-guided decision-making in patients with AMI and multivessel disease

Presented By

Dr Joo-Yong Hahn, Samsung Medical Center, Seoul, South Korea

Trial

FRAME-AMI

Conference

ESC 2022

Type

Peer-reviewed article

27 October 2022 10:29

Therapies for atopic dermatitis: still moving forward

Presented By

Prof. Christian Vestergaard, Aarhus University Hospital, Denmark

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:58

Children with AD: high risk of bacterial infections in carriers of a filaggrin gene variant

Presented By

Prof. Alina Suru , Carol Davila University of Medicine and Pharmacy, Romania

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:53

Men on biologics report fewer adverse events than women

Presented By

Ms Jette van Lint , Pharmacovigilance Centre Lareb, the Netherlands

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:51

Conceptual framework of adverse drug reactions may improve treatment of patients with IMIDs

Presented By

Ms Jette van Lint , Pharmacovigilance Centre Lareb, the Netherlands

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:49

No adverse pregnancy outcomes in patients exposed to baricitinib

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:47

Systemic treatment for psoriasis: what is on the horizon?

Presented By

Prof. Diamant Thaci , University of Lübeck, Germany

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:45

Topical therapy in psoriasis: an important partner in combination therapy

Presented By

Prof. Peter van de Kerkhof, Radboud University Medical Centre, the Netherlands

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:40

GPP flares: pronounced undertreatment is common

Presented By

Dr Wendell Valdecantos , Boehringer Ingelheim Pharmaceuticals, CT, USA

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:38

All patients with GPP benefit from IL-36 inhibitor therapy

Trial

Phase 2, Effisayil 1

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:37

IL-17A/F inhibitor bimekizumab shows higher response and maintenance rates compared with secukinumab

Trial

Phase 3, BE RADIANT

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:35

Greater PASI reductions lead to less impairment in social and sexual life

Trial

Phase 3, VOYAGE 1, VOYAGE 2

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:32

Paediatric psoriasis: ixekizumab beneficial in difficult-to-treat areas

Presented By

Dr Marieke Seyger , Radboud University Medical Centre, the Netherlands

Trial

Phase 3, IXORA-PEDS

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:30

Psoriasis patients see great benefit in achieving complete skin clearance

Presented By

Prof. Matthias Augustin , University Medical Centre Hamburg, Germany

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:25

Predilection sites for skin signs of vitiligo disease activity determined

Presented By

Dr Liesbeth Delbaere , Ghent University Hospital, Belgium

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:24

Vitiligo-childhood onset commonly under 10 years

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:21

IHS4 better suited as an outcome measure in HS trials?

Presented By

Prof. Thrasyvoulos Tzellos, Nordland Hospital Trust, Norway

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:18

New treatments for HS: IL-17 inhibitors next in practice?

Presented By

Dr Axel Villani, University of Lyon, France & Prof. Thrasyvoulos Tzellos, Nordland Hospital Trust, Norway

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:05

Alopecia areata: light at the end of the tunnel

Presented By

Prof. Maryanne Senna , Harvard Medical School, MA, USA

Trial

Phase 3, BRAVE-AA1, BRAVE-AA2

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:01

Alopecia areata pathogenesis: known genetic background, unknown environmental triggers

Presented By

Prof. Rodney Sinclair , University of Melbourne, Australia

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 09:56

Psoriasis treatment: no elevation of MACE and VTE on deucravacitinib

Presented By

Prof. Mark Lebwohl , Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, POETYK PSO-1, POETYK PSO-2

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 09:50

Comorbid anxiety and depression may benefit from psoriasis treatment with certolizumab

Presented By

Prof. April Armstrong, Keck School of Medicine of USC, CA, USA

Trial

Phase 3, CIMPASI-1, CIMPASI-2

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 09:47

Dose tapering in psoriasis is associated with a low relapse rate

Presented By

Dr Juan Raul Castro Ayarza , Medicarte, Colombia

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 09:43

Tau autoimmunity associated with systemic disease

Presented By

Dr Andreia Magalhães, University of Zurich, Switzerland

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 17:15

Long-term effects of avalglucosidase alfa in late-onset Pompe disease

Presented By

Prof. Benedikt Schoser, Friedrich Baur Institute, Germany

Trial

Phase 3, COMET

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 17:12

European survey of patient satisfaction in the treatment of cancer-related neuropathic pain

Presented By

‪Prof. Martin Rakusa, ‬University Medical Centre Maribor, Slovenia

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 17:09

COVID-19 elevates risk of neurodegenerative disorders

Presented By

Dr Pardis Zarifkar, Rigshospitalet, Denmark

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 17:03

More headaches in adolescents during COVID-19 pandemic

Presented By

Dr Ayşe Nur Özdag Acarli, Ermenek State Hospital, Turkey

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:59

AstraZeneca vaccination and risk of cerebral venous sinus thrombosis

Presented By

Dr Jonathan Coutinho, Amsterdam University Medical Centre, the Netherlands

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:55

Large impact of COVID-19 on dementia diagnosis and care

Presented By

Prof. Bengt Winblad, Karolinska Institutet, Sweden

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:49

Seizure forecasting with non- and minimally-invasive devices

Presented By

Dr Pedro Faro Viana, King's College London, UK

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:44

Real-world efficacy of cenobamate in focal-onset seizures

Presented By

Dr Giovanni Falcicchio & Dr Ariadna Gifreu

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:38

Possible new biomarker for early neuronal death in mesial temporal lobe epilepsy

Presented By

Mr Ricardo Martins-Ferreira, University of Porto, Spain

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:33

Most acute stroke patients have undiagnosed risk factors

Presented By

Dr André Rêgo, Lausanne University Hospital and University of Lausanne, Switzerland

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:27

Absence of Susceptibility Vessel Sign points to malignancy in stroke patients

Presented By

Dr Morin Beyeler, Bern University Hospital, Switzerland

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:24

Acute stroke management: from time window to tissue window?

Presented By

Dr Davide Strambo, University of Lausanne, Switzerland

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:20

Intestinal alterations in patients with Parkinson’s disease

Presented By

Dr Gabriele Bellini, University of Pisa, Italy

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:12

Gene variants impact survival in monogenic Parkinson’s disease

Presented By

Dr Aymeric Lanore, Paris Brain Institute, France

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 16:08

When to start, switch, and stop MS therapy: Real-world evidence counts

Presented By

Prof. Melinda Magyari, Rigshospitalet, Denmark

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:36

Updated EAN-ECTRIMS guideline on pharmacological MS treatment

Presented By

Prof. Maria Pia Amato, University of Florence, Italy

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:31

Gut microbiota composition associated with disability worsening

Presented By

Dr Ayla Pauwels, Vrije Universiteit Brussel, Belgium

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:26

Teriflunomide in children with MS: final results of TERIKIDS

Presented By

Prof. Tanuja Chitnis, Brigham and Women’s Hospital, MA, USA

Trial

Phase 3, TERIKIDS

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:22

Estimating brain age in MS: machine learning versus deep learning

Presented By

Dr Lars Skattebøl, Oslo University Hospital, Norway

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:17

Ofatumumab improves cognitive processing speed

Presented By

Prof. Ralph H.B. Benedict, University at Buffalo, NY, USA

Trial

Phase 3, ASCLEPIOS I/II

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:13

Targeting cortical activation by transcranial magnetic stimulation

Presented By

Dr Anna Andreou, King's College London, United Kingdom

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:07

Erenumab more than doubles plasma CGRP levels

Presented By

Dr Nina Vashchenko, Sechenov First Moscow State Medical University, Russia

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:03

Over a third of patients responds late to CGRP antibodies

Presented By

Dr Cinzia Aurilia, University of Florence, Italy

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 14:59

Getting evidence into practice

Presented By

Prof. Carl Clarke & Prof. Barbara Tettenborn

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 14:50

Physical activity improves asthma control

Presented By

Morten Hostrup, University of Copenhagen, Denmark

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 16:30

Tailored exercise needed for COPD patients

Presented By

Prof. Andre Nyberg, Umea University, Sweden

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 16:28

Exercise training for IPF patients is feasible but access needs to be improved

Presented By

Dr Jana de Brandt, Umeå University, Sweden

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 16:24

Asthma increases risks around delivery

Presented By

Dr Paula Kauppi, University of Helsinki, Finland

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 16:13

PRO-ART study: unravelling the link between asthma and subfertility

Presented By

Dr Anne Hansen, Copenhagen University Hospital, Denmark

Trial

Phase 2, PRO-ART

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 16:10

Early-onset and uncontrolled asthma: strong association with recurrent pregnancy loss

Presented By

Dr Casper Tidemandsen, Copenhagen University Hospital, Denmark

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 16:08

Round-up of respiratory disease and reproduction topics

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 16:06

Advance care planning

Presented By

Prof. Mette Asbjørn Neergaard, Aarhus University, Denmark & Dr Reeta Piili, Tampere University, Finland

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 16:01

Severe asthma in the spotlights

Presented By

Prof. Lena Uller, Lund University, Sweden

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 15:58

Common comorbidities in severe asthma

Presented By

Dr Asger Sverrild, Bispebjerg Hospital, Denmark

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 15:56

Switching biologicals in severe asthma

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 15:53

Targeting treatable traits allows a personalised approach to management of (severe) asthma

Presented By

Dr Florence Schleich, University of Liège, Belgium

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 15:44

Social distancing led to a reduced number of exacerbations in bronchiectasis patients

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 15:42

Exercise-induced laryngeal obstruction (EILO) is often misdiagnosed

Presented By

Dr Emil Walsted, Bispebjerg Hospital, Denmark

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 15:40

CRSwNP outlined

Presented By

Dr Sanna Toppila-Salmi, University of Helsinki, Finland

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 15:36

The role of biologics in CRSwNP

Presented By

Prof. Lars-Olaf Cardell, Karolinska Institute, Sweden

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 15:31

The ULANC Group: working together in CRSwNP/asthma

Presented By

Prof. Vibeke Backer, Rigshospitalet/Copenhagen University, Denmark

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 15:29

No oral corticosteroids before a confirmed diagnosis of ILD

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 15:27

Rheumatoid arthritis-associated ILD

Presented By

Dr Phuong Phuong Diep, Oslo University Hospital, Norway

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 15:22

Thoracic ultrasound: a new diagnostic imaging tool in RA-ILD?

Presented By

Dr Bjørk Sofíudóttir, University of South Denmark, Denmark

Trial

AURORA

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 15:19

Update on treatment of fibrotic ILD

Presented By

Dr Elisabeth Bendstrup, Aarhus University Hospital, Denmark

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 15:14

The role of CPAP and HFNC in COVID-19

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 15:12

Hypoxemia and dyspnoea

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 15:09

Lung cancer screening in Denmark

Presented By

Dr Zaigham Saghir, University of Copenhagen, Denmark

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 14:43

Points of interest for radiologists screening for lung cancer

Presented By

Dr Michael Brun Andersen, Copenhagen University Hospital, Denmark

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 14:41

E-cigarettes impose detrimental effects on health

Presented By

Dr Linnea Hedman, Umeå University, Sweden

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 14:34

Effects of passive vaping in COPD patients

Presented By

Prof. Torben Sigsgaard, Aarhus University, Denmark

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 14:32

Vaping amongst adolescents: an alarming trend

Presented By

Dr Anu Linnansaari, University of Tampere, Finland

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 13:54

Sarcoidosis guidelines update

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 13:52

New antigens in sarcoidosis

Presented By

Prof. Johan Grünewald, Karolinska Institute, Sweden

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 13:50

Fatigue syndrome in sarcoidosis

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 13:44

Detection of latent TB infection key to preventing the spread of the disease

Presented By

Prof. Tuula Vasankari, University of Turku, Finland

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 13:41

TB management update

Conference

NLC 2022

Type

Peer-reviewed article

17 August 2022 13:37

Bacterial decolonisation effective against radiation dermatitis

Presented By

Ms Yana Kost, Albert Einstein College of Medicine, NY, USA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:38

New standard-of-care for cisplatin-ineligible locally advanced head and neck squamous cell carcinoma

Presented By

Prof. Vanita Noronha, Tata Memorial Hospital, India

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:35

Ifosfamide is likely to be the go-to therapy in recurrent Ewing sarcoma 

Presented By

Dr Martin McCabe, University of Manchester, UK

Trial

Phase 3, rEECur

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:32

Dabrafenib plus trametinib candidates for standard-of-care in BRAF V600-mutated paediatric low-grade glioma 

Presented By

Prof. Eric Bouffet, University of Toronto, Canada

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:30

Primary results of rucaparib in ovarian cancer 

Presented By

Prof. Bradley Monk, University of Arizona, AZ, USA

Trial

Phase 3, ATHENA-MONO

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:28

Trabectedin not superior to chemotherapy in recurrent epithelial ovarian cancer 

Presented By

Dr Domenica Lorusso, San Raffaele Scientific Institute, Italy

Trial

Phase 3, MIT023

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:25

Encouraging results of relacorilant in ovarian cancer

Presented By

Prof. Nicoletta Colombo, University of Milan, Italy

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:23

Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer  

Presented By

Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan

Trial

Phase 3, PARADIGM

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:19

Spectacular results for dostarlimab in mismatch repair deficient rectal cancer 

Presented By

Dr Andrea Cercek, Memorial Sloan Kettering Cancer Center, NY, USA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:14

Triplet chemotherapy beats doublet chemotherapy in colorectal cancer liver metastases

Presented By

Prof. Cornelis Punt, University Medical Center Utrecht, the Netherlands

Trial

Phase 3, CAIRO5

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:11

To resect or not to resect primary tumours in stage IV colon cancer?

Presented By

Prof. Jürgen Weitz, Technische Universität Dresden, Germany

Trial

SYNCHRONOUS

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:08

Novel treatment option for KRAS wildtype pancreatic cancer 

Presented By

Prof. Shukui Qin, Cancer Center of Jinling Hospital, China

Trial

Phase 3, NOTABLE

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:03

Autologous stem cell transplantation plus RVd improves PFS in multiple myeloma  

Presented By

Prof. Paul Richardson, Harvard Medical School, MA, USA

Trial

Phase 3, DETERMINATION

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:33

Novel first-line treatment option for mantle cell lymphoma 

Presented By

Prof. Michael Wang, Anderson Cancer Center, TX, USA

Trial

Phase 3, SHINE

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:30

Promising results for novel CAR-T therapy in relapsed/refractory multiple myeloma

Presented By

Prof. Juan Du, Shanghai Chang Zheng Hospital, China

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:24

Exploratory treatment options fail in ccRCC 

Presented By

Prof. Thomas Powles, University of London, UK

Trial

Phase 2, CALYPSO

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:18

Adjuvant everolimus did not benefit high-risk renal cell carcinoma 

Presented By

Dr Christopher W. Ryan, Oregon Health & Science University, OR, USA

Trial

Phase 3, EVEREST

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:14

Cabozantinib fails as first-line maintenance therapy in urothelial cancer

Presented By

Prof. Robert Jones, University of Glasgow, UK

Trial

Phase 2, ATLANTIS

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:11

177Lu-PSMA-617 is a valid treatment option for PSMA-positive mCRPC

Presented By

Prof. Michael Hofman, Peter McCallum Cancer Centre, Australia

Trial

Phase 2, TheraP

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:08

Enzalutamide performs well in metastatic hormone-sensitive prostate cancer

Presented By

Prof. Ian Davis, Monash University, Australia

Trial

Phase 3, ENZAMET

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:04

First results on distant metastasis-free survival in stage II melanoma 

Presented By

Prof. Georgina Long, The University of Sydney, Australia

Trial

Phase 3, KEYNOTE-716

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 13:54

Higher response rates for concurrent triple therapy versus sequential therapy in melanoma

Presented By

Prof. Georgina Long, The University of Sydney, Australia

Trial

Phase 2, NeoTrio

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 13:50

Additional tiragolumab does not help patients with untreated small cell lung cancer 

Presented By

Dr Charles Rudin, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, SKYSCRAPER-02

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:42

Success for serplulimab plus chemotherapy in small cell lung cancer

Presented By

Prof. Ying Cheng, Jilin Cancer Hospital, China

Trial

Phase 3, ASTRUM-005

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:38

Adagrasib safe and clinically active in non-small cell lung cancer

Presented By

Dr Alexander Spira, Virginia Cancer Specialists Research Institute, VA, USA

Trial

Phase 2, KRYSTAL-1

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:33

Long-term benefits of combined immunotherapy over chemotherapy in non-small cell lung cancer

Presented By

Prof. Julie Brahmer, Sidney Kimmel Comprehensive Cancer Center, Australia

Trial

Phase 3, CheckMate 227

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:29

Effect of KRAS mutations and PD-L1 expression on therapy response in non-small cell lung cancer

Presented By

Dr Oladimeji Akinboro, US Food and Drug Administration, MD, USA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:26

Sacituzumab govitecan meets primary endpoint 

Presented By

Prof. Hope Rugo, University of California San Francisco, CA, USA

Trial

Phase 3, TROPiCS-02

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:11

Shaky OS results of palbociclib in ER-positive/HER2-negative breast cancer 

Presented By

Prof. Richard Finn, David Geffen School of Medicine at UCLA, CA, USA

Trial

Phase 3, PALOMA-2

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:09

Practice-changing results of T-DXd in HER2-low breast cancer 

Presented By

Prof. Shanu Modi, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, DESTINY-Breast04

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:04

SET2,3 to inform on chemotherapy decisions in ER-positive breast cancer

Presented By

Dr Otto Metzger, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, CALGB9741

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 11:59

Metastasis-directed therapy fails in oligometastatic breast cancer

Presented By

Dr Steven Chmura, University of Chicago, IL, USA

Trial

Phase 2, NRG-BR002

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 11:34

Analysis by residual cancer burden further clarifies effect of pembrolizumab

Presented By

Prof. Lajos Pusztai, Yale School of Medicine, CT, USA

Trial

Phase 3, KEYNOTE-522

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 11:26

Contribution of metastatic therapies on mortality reduction in breast cancer

Presented By

Prof. Jennifer Caswell-Jin, Stanford University, CA, USA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 11:19

Radiotherapy may be omitted in breast cancer patients 

Presented By

Prof. Timothy Whelan, McMaster University, Canada

Trial

LUMINA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 10:59

Promising data for ribociclib after progression on ET plus CDK4/6 inhibitors in HR-positive/HER2-negative metastatic breast cancer

Presented By

Prof. Kevin Kalinsky, Winship Cancer Institute of Emory University, GA, USA

Trial

Phase 2, MAINTAIN

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 10:53

7-gene biosignature: Benefits of endocrine therapy and radiotherapy in breast cancer risk groups

Presented By

Dr Pat Whitworth, Nashville Breast Cancer Center, TN, USA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 10:44

GALACTIC-HF: Omecamtiv mecarbil as option for HFrEF patients with low SBP

Presented By

Prof. Marco Metra, University of Brescia, Italy

Trial

Phase 3, GALACTIC-HF

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 12:19

HELIOS-A: Vutrisiran meets exploratory endpoints

Presented By

Dr Pablo García-Pavía , Hospital Universitario Puerta de Hierro Majadahonda, Spain

Trial

Phase 4, HELIOS-A

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 12:16

Patiromer helps HFrEF patients to optimise RAAS inhibitors without hyperkalaemia

Presented By

Prof. Stefan Anker, Charité Campus Virchow Clinic Berlin, Germany & Dr Javed Butler, Baylor University Medical Center, TX, USA

Trial

Phase 3, DIAMOND

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 12:13

FIDELITY: Cardiorenal benefits of finerenone, regardless of LVH status

Presented By

Prof. Gerasimos Filippatos , Attikon University Hospital, Greece

Trial

Phase 3, FIDELIO-DKD, FIGARO-DKD

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 12:09

DAPA-VO2: Rapid effect of dapagliflozin on peak VO2 in stable HFrEF

Presented By

Prof. Julio Núñez Villota , University of Valencia, Spain

Trial

Phase 4, DAPA-VO2

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 12:04

Significant improvement in BP from istaroxime, a novel non-adrenergic agent

Presented By

Prof. Marco Metra , University of Brescia, Italy

Trial

Phase 2, SEISMiC

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 11:55

SERENADE: Macitentan fails in HFpEF plus PAH

Presented By

Prof. Adriaan Voors , University of Groningen, the Netherlands

Trial

Phase 2, SERENADE

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 11:49

Ghrelin improves cardiac output in HFrEF

Presented By

Prof. Lars Lund, Karolinska Institutet, Sweden

Trial

Phase 2, MetaAnEnd-HF

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 11:47

Combination of filgrastim and dutogliptin appears safe in STEMI

Presented By

Prof. Markus Wallner , Medical University of Graz, Austria

Trial

Phase 2

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 11:44

Cardiac contractility modulation therapy promising for patients with HFpEF

Presented By

Prof. Cecilia Linde , Karolinska University Hospital, Sweden

Trial

CCM-HFpEF

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 11:37

REBALANCE-HF: Encouraging observations for splanchnic nerve ablation in HFpEF

Presented By

Prof. Marat Fudim , Duke Cardiology Clinic, NC, USA

Trial

REBALANCE-HF

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 11:34

DAPA-HF: Dapagliflozin is safe and efficacious in frail patients

Presented By

Dr Jawad Haider Butt , Copenhagen University Hospital, Denmark

Trial

Phase 3, DAPA-HF

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 11:29

EMPEROR-Preserved: Empagliflozin stable across age groups

Presented By

Prof. Michael Böhm , University of the Saarland, Germany

Trial

Phase 3, EMPEROR-Preserved

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 11:26

EMPULSE: Empagliflozin delivers rapid and clinically meaningful decongestion

Presented By

Prof. Piotr Ponikowski , Medical University of Wroclaw, Poland

Trial

Phase 3, EMPULSE

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 11:23

Dapagliflozin performs consistently across LVEF in HF

Presented By

Dr Mikhail Kosiborod , St. Luke’s Hospital, MO, USA

Trial

Phase 4, DEFINE-HF, PRESERVED-HF

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 11:21

Cardiac wasting relevant for clinical outcomes in cancer

Presented By

Dr Alessia Lena , Charité Universitätsmedizin Berlin, Germany

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 10:45

Urocortin-2 a potential treatment target for HFpEF

Presented By

Ms Inês Vasconcelos, Medicine University of Porto, Portugal

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 10:43

Should ATTR-CM be added to the differential diagnosis of patients with HF?

Presented By

Dr Rocío Ruiz Hueso , University Hospital of Virgen Macarena, Spain

Trial

PREVAMIC

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 10:38

Delayed initiation of novel GDMTs associated with adverse outcomes in HF patients

Presented By

Prof. Gianluigi Savarese , Karolinska University Hospital, Sweden

Trial

EVOLUTION-HF

Conference

HFA 2022

Type

Peer-reviewed article

28 July 2022 10:36

Alarmingly low activity in patients with non-inflammatory and inflammatory rheumatic disease

Presented By

Prof. Luca Quartuccio, University of Udine, Italy

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 19:31

High prevalence of fibromyalgia in patients with inflammatory bowel disease

Presented By

Dr Laura Guida , Luigi Sacco University Hospital, Italy

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 19:27

Inhibition of Bruton’s tyrosine kinase: a new way of approaching SLE?

Presented By

Prof. Zangou Li , Peking University People’s Hospital, China

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 19:21

Pregnancies in SLE: many complications for mothers and their unborn children

Presented By

Prof. Bella Mehta , Weill Cornell Medical College, NY, USA

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 19:16

Lupus nephritis: Efficient treatment may reduce the risk of kidney disease advancement

Presented By

Prof. Konstantinos Tselios , McMaster University, Canada

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 18:10

Antifibrotic therapy with nintedanib is beneficial for patients with negative prognostic factors

Presented By

Prof. Christopher Denton , University College London, United Kingdom

Trial

Phase 3, SENSCIS

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 18:07

New treatments in osteoarthritis

Presented By

Prof. Tonia Vincent , University of Oxford, United Kingdom

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 18:01

OA associated with alcohol and drug abuse

Presented By

Dr Anne Kamps, Erasmus University Medical Center, the Netherlands

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 17:55

Body mass index increase associated with structural changes in knee OA

Presented By

Dr Zubeyir Salis, University of New South Wales, Australia

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 17:52

How to treat enthesitis in 2022

Presented By

Prof. Dennis McGonagle, University of Leeds, United Kingdom

Trial

Phase 3, SEAM-PsA, EXCEED, SPIRIT-H2H

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 17:42

Baseline cardiovascular risk linked to higher rates of MACE in PsA and PsO patients receiving tofacitinib

Presented By

Prof. Lars Erik Kristensen , Copenhagen University Hospital, Denmark

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 17:30

Treat-to-target dose reduction effective in spondyloarthritis

Presented By

Dr Celia Michielsens , Sint Maartenskliniek, the Netherlands

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 17:21

A novel oral treatment possibility for non-radiographic axSpA on the horizon

Presented By

Prof. Filip van den Bosch , Ghent University, Belgium

Trial

Phase 3, SELECT-AXIS 2

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 17:17

Many RA and PsA patients have problems with their sex life

Presented By

Dr Carlos Valera-Ribera , Doctor Peset University Hospital, Spain

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 17:12

Comorbid depression comes with a profoundly higher mortality risk in RA

Presented By

Dr Jens Kristian Pedersen, Odense University Hospital, Denmark

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 15:10

Preventive treatment with methotrexate benefits pre-RA patients with arthralgia

Presented By

Dr Doortje Krijbolder, Leiden University Medical Center, the Netherlands

Trial

TREAT EARLIER

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 15:07

Risk factors for dementia in RA patients discovered

Presented By

Prof. Elena Myasoedova , Mayo Clinic, MN, USA

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 15:02

VTE in global registry data more common in JAK inhibitor-treated RA patients

Presented By

Prof. Adeline Ruyssen-Witrand, Toulouse University Hospital, France

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 14:52

TYK2 inhibition: the future of treating lupus erythematosus?

Presented By

Prof. Eric Morand , Monash University, Australia

Trial

Phase 2, PAISLEY

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 14:45

Psoriatic arthritis: significant improvement with bimekizumab

Presented By

Prof. Iain McInnes , Glasgow University, United Kingdom

Trial

Phase 3, BE OPTIMAL

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 14:36

Baricitinib could open the door to oral treatment for juvenile idiopathic arthritis

Presented By

Prof. Athimalaipet Ramanan , Bristol Medical School, United Kingdom

Trial

Phase 3, JUVE-BASIS

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 14:22

SPRINTER: SNG001 still in the running?

Presented By

Dr Philip Monk , Synairgen Research LtD, UK

Trial

Phase 3, SPRINTER

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 14:04

Nebulised aviptadil “futile” in I-SPY COVID-19 trial

Presented By

Prof. Carolyn Calfee, University of California at San Francisco, CA, USA

Trial

Phase 2, I-SPY COVID-19

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 14:01

Lung transplantation after COVID-19-associated ARDS

Presented By

Prof. G.R. Scott Budinger, Northwestern University, IL, USA

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 13:59

COVI-PRONE trial on its back

Presented By

Prof. Waleed Alhazzani, McMaster University, Canada

Trial

COVI-PRONE

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 13:57

Mesenchymal stem cells offer no benefit in COVID-19

Presented By

Dr Ellen Gorman, Queen’s University Belfast, UK

Trial

Phase 2, REALIST-COVID

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 13:55

Alpha-1 antitrypsin for ARDS secondary to severe COVID-19

Presented By

Dr Oliver McElvaney, Royal College of Surgeons, Ireland

Trial

Phase 2

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 13:53

Frailty prevalent 5 months following hospitalisation for COVID-19

Presented By

Dr Hamish McAuley, University of Leicester, UK

Trial

PHOSP-COVID

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 13:51

Paediatric long COVID lacks definitions

Presented By

Ms Nadia Baalbaki, Emma Children’s Hospital, the Netherlands

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 13:49

MANDALA and DENALI pattern success for albuterol-budesonide in asthma

Presented By

Prof. Alberto Papi, University of Ferrara, Italy & Dr Bradley Chipps, Capital Allergy & Respiratory Disease Center, CA, USA

Trial

Phase 3, MANDALA, DENALI

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 13:05

ACOUSTICS data sounds good for adolescent asthma exacerbations

Presented By

Prof. Stanley Szefler, Children’s Hospital Colorado, CO, USA

Trial

Phase 3, ACOUSTICS

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 13:02

Type 2 asthma in children managed by dupilumab, despite atopic comorbidities

Presented By

Prof. Theresa Guilbert, University of Cincinnati, OH, USA

Trial

Phase 3, Liberty Asthma VOYAGE

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 13:00

NAVIGATOR steers asthma patients to tezepelumab

Presented By

Prof. Njira Lugogo, University of Michigan, MI, USA

Trial

Phase 3, NAVIGATOR

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 12:57

High-intensity interval training slashes daily corticosteroids in asthma

Presented By

Dr Anders Pitzner-Fabricius, Rigshospitalet Copenhagen, Denmark

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 12:55

Three’s a crowd for triple therapy in COPD

Presented By

Prof. Claus Vogelmeier, Philipps-University Marburg, Germany

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 12:40

Higher 1-year COPD mortality after hospitalisation for White patients

Presented By

Dr Snigdha Jain, Yale School of Medicine, CT, USA

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 12:39

Reducing dyspnoea in chronic lung disease through weight loss

Presented By

Dr Maria Benzo, Mayo Clinic Rochester, MN, USA

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 12:37

CT-evident mucus plugs in COPD associated with death

Presented By

Dr Alejandro Diaz, Brigham and Women’s Hospital, MA, USA

Trial

COPDGene

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 12:35

Home-based rehabilitation improves COPD: a randomised study

Presented By

Dr Roberto Benzo, Mayo Clinic Rochester, MN, USA

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 12:33

Novel P2X3 antagonist can SOOTHE chronic cough

Presented By

Prof. Jaclyn Smith, University of Manchester, UK

Trial

Phase 2, SOOTHE

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 12:01

Colistimethate sodium PROMISing for non-cystic fibrosis bronchiectasis

Presented By

Dr Charles Haworth, Royal Papworth Hospital, UK

Trial

Phase 3, PROMIS

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 11:59

Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?

Presented By

Prof. Ulrich Specks, Mayo Clinic, MN, USA

Trial

Phase 3, ADVOCATE

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 11:56

PAGANINI phase 2b data promising for eliapixant

Presented By

Prof. Peter Dicpinigaitis, Albert Einstein College of Medicine, NY, USA

Trial

Phase 2, PAGANINI

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 11:54

New guidelines for IPF and PPF

Presented By

Dr Elizabeth Renzoni, Royal Brompton Hospital, UK

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 11:52

POISE-3: Tranexamic acid for non-cardiac surgery

Presented By

Prof. Philip Devereaux, McMaster University, Canada

Trial

Phase 3, POISE-3

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 11:48

Obstructive sleep apnoea in most children with pulmonary hypertension

Presented By

Dr Daniel Ignatiuk, Cincinnati Children’s Hospital, OH, USA

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 11:45

No screening evidence for COPD

Presented By

Prof. Carol Mangione, University of California at Los Angeles, CA, USA

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 11:44

Novel PDE4B inhibitor offers breakthrough for IPF

Presented By

Prof. Luca Richeldi, Università Cattolica del Sacro Cuore, Italy

Trial

Phase 2

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 11:42

Hydrocortisone does not help preterm infants

Presented By

Prof. Namasivayam Ambalavanan, University of Alabama, AL, USA

Trial

Phase 3, Hydrocortisone and Extubation

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 11:38

CPAP temporarily supports pulmonary oxygenation in morbidly obese patients

Presented By

Dr Felix Girrbach, University Hospital of Leipzig, Germany

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 11:36

ISAACC trial: CPAP controls blood pressure in ACS patients with severe OSA

Presented By

Dr Manuel Sánchez De La Torre, Lleida Biomedical Research Institute, Spain

Trial

ISAACC

Conference

ATS 2022

Type

Peer-reviewed article

18 July 2022 11:34

POISE-3: Tranexamic acid for non-cardiac surgery

Presented By

Prof. Philip Devereaux; Dr Maura Marcucci, McMaster University, Canada

Trial

Phase 3, POISE-3

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 15:34

Treating chronic mild hypertension during pregnancy leads to better outcomes

Presented By

Prof. Alan Tita, University of Alabama, USA

Trial

CHAP

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 15:28

New VOYAGER PAD data: Should patients with both PAD and CKD get rivaroxaban?

Presented By

Dr Mark Svet, University of Colorado, USA

Trial

VOYAGER-PAD

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 15:24

Alirocumab significantly reduces high-risk coronary plaques

Presented By

Prof. Lorenz Räber, Bern University Hospital, Switzerland

Trial

Phase 3, PACMAN-AMI

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 15:20

Aggressive warming during non-cardiac surgery does not improve outcomes

Presented By

Prof. Daniel Sessler, Cleveland Clinic, USA

Trial

PROTECT

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 15:15

DIAMOND trial: Patiromer lowers risk of severe hyperkalaemia

Presented By

Prof. Javed Butler, University of Mississippi, MS, USA

Trial

Phase 3, DIAMOND

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 15:12

Replacing septal reduction therapy with mavacamten for HCM

Presented By

Prof. Milind Desai, Cleveland Clinic, USA

Trial

Phase 3, VALOR-HCM

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 15:08

Surprise outcome for SODIUM-HF

Presented By

Prof. Justin Ezekowitz, University of Alberta, Canada

Trial

Phase 3, SODIUM-HF

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 15:03

Sotagliflozin SCORED MACE benefit

Presented By

Prof. Deepak Bhatt, Brigham and Women's Hospital, USA

Trial

Phase 3, SCORED

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 14:57

Omecamtiv mecarbil does not impact exercise capacity of patients with HFrEF

Presented By

Prof. Michael Felker, Duke Clinical Research Institute, USA

Trial

Phase 3, METEORIC-HF

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 14:50

Symptomatic obstructive hypertrophic cardiomyopathy: long-term mavacamten control

Presented By

Prof. Florian Rader, Cedars-Sinai Medical Center, CA, USA

Trial

MALVA-LTE

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 14:47

COMPLETE revascularisation improves angina-related QoL

Presented By

Prof. Shamir Mehta, McMaster University, Canada

Trial

COMPLETE

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 14:24

Plot twist for negative FAME 3 results: early QoL benefits of PCI

Presented By

Dr Frederik Zimmermann, Catharina Hospital, the Netherlands

Trial

FAME 3

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 14:19

1-year CLASP TR results support tricuspid regurgitation repair

Presented By

Prof. Adam Greenbaum, Emory University School of Medicine, USA

Trial

CLASP TR

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 14:14

Head-to-head: post-TAVR edoxaban not better than DAPT

Presented By

Prof. Duk-Woo Park, Asan Medical Center, Korea

Trial

Phase 4, ADAPT-TAVR

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 14:09

Chocolate Touch vs Lutonix catheters

Presented By

Prof. Mehdi Shishehbor, Harrington Heart & Vascular Institute, USA

Trial

Chocolate Touch

Conference

ACC 2021

Type

Peer-reviewed article

15 June 2022 13:53

No FLAVOUR difference between FFR and IVUS for PCI guidance

Presented By

Prof. Bon-Kwon Koo, Seoul National University College of Medicine, Korea

Trial

FLAVOUR

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 13:49

Low-resource countries benefit from global STEMI initiative

Presented By

Prof. Cesar Herrera, Montefiore-Einstein Center for Heart and Vascular Care, USA

Trial

GHATI

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 13:44

Sodium thiosulfate ineffective at cardiac protection

Presented By

Dr Marie-Sophie de Koning, University Medical Center Groningen, the Netherlands

Trial

Phase 2, GIPS-IV

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 13:40

ICM-guided management did not improve MACE after MI

Presented By

Prof. Christian Jøns, Rigshospitalet, Denmark

Trial

BIO|GUARD-MI

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 13:36

PACIFIC-AF: Low bleeding rates for asundexian in atrial fibrillation

Presented By

Prof. Manesh Patel, Duke University School of Medicine, USA

Trial

Phase 2, PACIFIC-AF

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 13:31

RCT-IVVE trial: Do HF patients benefit from annual flu shots?

Presented By

Prof. Mark Loeb, McMaster University, Canada

Trial

Phase 4, RCT-IVVE

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 13:26

TRANSLATE-TIMI 70: Primary endpoint met but safety concerns for vupanorsen

Presented By

Dr Brian Bergmark, Brigham and Women’s Hospital, USA

Trial

Phase 2, TRANSLATE-TIMI 70

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 13:21

Lipoprotein(a) slashed by 98% in APOLLO trial

Presented By

Prof. Steven Nissen, Cleveland Clinic, USA

Trial

Phase 1, APOLLO

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 13:16

Dietary intervention from your supermarket

Presented By

Prof. Dylan Steen, University of Cincinnati, OH, USA

Trial

SuperWIN

Conference

ACC 2022

Type

Peer-reviewed article

15 June 2022 13:05

Cognitive, EEG, and MRI features in COVID-19 survivors

Presented By

Dr Giordano Cecchetti, Vita-Salute San Raffaele University, Italy

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 17:41

Neurological manifestations of COVID-19 worsen prognosis

Presented By

Dr Anna Cervantes-Arslanian, Boston University School of Medicine, MA, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 17:35

New evidence for biological basis of “COVID-19 brain fog”

Presented By

Dr Joanna Hellmuth, University of California, CA, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 17:26

Prasinezumab in Parkinson’s disease: delayed-start analysis of PASADENA trial

Presented By

Dr Gennaro Pagano, King’s College London, UK

Trial

Phase 2, PASADENA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 17:18

IPX203 versus immediate release carbidopa-levodopa

Presented By

Prof. Robert Hauser, USF Parkinson's Disease and Movement Disorders Center, FL, USA

Trial

Phase 3, RISE-PD

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 17:12

Impact of COVID-19 public health interventions

Presented By

Mr Ari Vandersluis, Heritage College of Osteopathic Medicine, OH, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 17:07

Intravenous thrombolysis after ischaemic stroke: When in doubt, leave it out?

Presented By

Dr Natalie LeCouffe, Amsterdam University Medical Centre, the Netherlands

Trial

Phase 3, MR CLEAN-NO IV

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 17:03

Better outcomes with mechanical thrombectomy in elderly stroke patients

Presented By

Dr Aisha Ali, University of Illinois, IL, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 16:59

Plasma NfL levels associated with cardiovascular risk

Presented By

Dr Hugo Aparicio, Boston University School of Medicine, MA, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 16:47

Non-invasive vagus nerve stimulation for acute stroke

Presented By

Prof. Ethem Murat Arsava, Hacettepe University, Turkey

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 16:42

Ravulizumab in patients with generalised myasthenia gravis

Presented By

Dr Tuan Hoang Vu, University of South Florida Physicians Group, FL, USA

Trial

Phase 3, CHAMPION MG

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 16:33

Gene therapy effective in older patients with spinal muscular atrophy

Presented By

Prof. Laurent Servais, MDUK Oxford Neuromuscular Centre, UK

Trial

RESTORE

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 16:27

Losmapimod for facioscapulohumeral muscular dystrophy

Presented By

Prof. Al-Rabi N. Tawil, University of Rochester, NY, USA

Trial

ReDUX4

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 16:22

SRP-9001 for treating patients with Duchenne muscular dystrophy

Presented By

Dr Jerry Mendell, Nationwide Children's Hospital, OH, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 16:17

Ublituximab versus teriflunomide in relapsing MS patients

Presented By

Prof. Lawrence Steinman, Stanford University, CA, USA

Trial

Phase 3, ULTIMATE I; ULTIMATE II

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 16:07

Ketogenic diet may improve disability and quality of life

Presented By

Dr James Nicholas Brenton, University of Virginia Medical Center, VA, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 15:53

Favourable additional safety data for ofatumumab

Presented By

Prof. Stephen Hauser, University of California, CA, USA

Trial

Phase 3, ALITHIOS

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 15:45

Predicting new T2 lesions using a machine learning algorithm

Presented By

Mr Bastien Caba, Biogen Digital Health, MA, USA

Trial

Phase 3, ADVANCE; ASCEND

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 15:38

Evobrutinib reduces volume of slowly expanding lesions

Presented By

Prof. Douglas Arnold, McGill University, Canada

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 15:34

Sustained long-term efficacy and safety of satralizumab in NMOSD

Presented By

Prof. Jeffrey Bennett, University of Colorado Hospital, CO, USA

Trial

Phase 3, SAkuraSky; SAkuraStar

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 15:29

Migraine may be an important obstetric risk factor

Presented By

Dr Alexandra Purdue-Smithe, Harvard Medical School, MA, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 14:57

Intranasal zavegepant safe and well tolerated in healthy adults

Presented By

Prof. Richard Bertz, University of Pittsburgh, PA, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 14:52

Telemedicine during COVID-19 pandemic highly appreciated

Presented By

Dr Chia-Chun Chiang, Mayo Clinic, MN, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 14:38

“Women with epilepsy should be encouraged to breastfeed”

Presented By

Prof. Kimford Meador, Stanford Comprehensive Epilepsy Center, CA, USA

Trial

MONEAD

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 13:52

Fenfluramine: possible new treatment for Lennox-Gastaut syndrome

Presented By

Dr Kelly Knupp, Children's Hospital Colorado, CO, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 13:42

Laser interstitial thermal therapy for refractory epilepsy

Presented By

Prof. Varun Kumar, Icahn School of Medicine at Mount Sinai, NY, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 13:17

Targeting senescent cells to treat age-related diseases

Presented By

Dr Miranda Orr, Wake Forest School of Medicine, NC, USA

Trial

Phase 2, StoMP-AD

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 12:29

Cardiorespiratory fitness protects against dementia

Presented By

Dr Edward Zamrini, Washington DC VA Medical Center, DC, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 12:12

Safety and effects of bosutinib in Lewy body dementia

Presented By

Dr Fernando Pagán, Georgetown University Hospital, DC, USA

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 12:06

Benefits of SGLT2 inhibitors may extend beyond HF-associated outcomes

Presented By

Dr Ameenathul Fawzy, Liverpool Heart and Chest Hospital, UK

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 11:03

Updates on anti-arrhythmic agents

Presented By

Prof. John Camm, St George’s University of London, UK

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 10:59

Sex differences revealed in AF determinants and AF progression

Presented By

Prof. Michiel Rienstra, University Medical Center Groningen, Netherlands

Trial

RACE V

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 10:50

Early rhythm-control therapy efficacious in men and women with AF

Presented By

Prof. Isabelle van Gelder, University Medical Center Groningen, Netherlands

Trial

EAST-AFNET 4

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 10:47

Progression in remote app-based monitoring of atrial fibrillation

Presented By

Prof. Dominik Linz, Maastricht University Medical Center, the Netherlands

Trial

Telecheck-AF

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 10:41

First results of the POWER FAST III trial

Presented By

Prof. José Luis Merino, La Paz University Hospital, Spain

Trial

POWER FAST III

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 10:35

Real-world safety results on pulsed-field ablation with pentaspline catheter

Presented By

Dr Vivek Reddy, Mount Sinai Hospital, NY, USA

Trial

MANIFEST-PF

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 10:30

VANISH: Ablation reduces shock burden compared with anti-arrhythmic drug in ventricular tachycardia

Presented By

Prof. Michelle Samuel, University of Montreal, Canada

Trial

VANISH

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 10:26

Low AF recurrence rates after PVI using pulsed-field ablation

Presented By

Mr Thomas Kueffer, University of Bern, Switzerland

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 10:19

Pulsed-field ablation reduces neurocardiac damage versus cryoballoon ablation

Presented By

Dr Marc Lemoine, University Heart & Vascular Center Hamburg, Germany

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 10:15

Ultrasound-guided femoral venipuncture reduces complications in catheter ablation

Presented By

Dr Jana Haskova, Institute for Clinical and Experimental Medicine, Czechia

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 10:10

Conduction system pacing potential alternative for biventricular pacing in heart failure

Presented By

Dr Margarida Pujol-López, Institut Clínic Cardiovascular, Spain

Trial

LEVEL-AT

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 10:04

Left bundle branch area pacing is a feasible technique for HF and bradyarrhythmia

Presented By

Prof. Marek Jastrzębski, Jagiellonian University, Poland

Trial

MELOS

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 09:58

Focus on the efficacy of cardiac resynchronisation therapy in HF plus concomitant AF

Presented By

Dr Frederik Dalgaard, Herlev and Gentofte Hospital, Denmark

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 09:52

RESET: No survival benefit of CRT-defibrillator over CRT-pacemaker in heart failure

Presented By

Prof. Nikolaos Dagres, Heart Center Leipzig, Germany

Trial

RESET-CRT

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 09:46

Insertable cardiac monitors effective for AF detection in cryptogenic stroke

Presented By

Dr Barbara Ratajczak-Tretel, University of Oslo, Norway

Trial

NOR-FIB

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 09:30

Cardiac magnetic resonance imaging improves prediction of post-MI sudden cardiac death

Presented By

Dr Nikolaos Dagres, Heart Center Leipzig, Germany

Trial

PROFID

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 09:18

AI model accurately predicts sudden cardiac death in overall population

Presented By

Prof. Xavier Jouven, Georges-Pompidou European Hospital, France

Conference

EHRA 2022

Type

Peer-reviewed article

1 June 2022 09:12

Developments in imaging tools for AF

Presented By

Prof. Lluis Mont , University of Barcelona, Spain

Conference

EHRA 2022

Type

Peer-reviewed article

31 May 2022 22:17

Large impact of remote screening tool on sleep apnoea diagnoses in AF

Presented By

Dr Dominique Verhaert, Maastricht University Medical Center, Netherlands

Conference

EHRA 2022

Type

Peer-reviewed article

31 May 2022 22:08

AI model accurately discriminates between arrhythmias

Presented By

Dr Arunashis Sau, Imperial College London, UK

Conference

EHRA 2022

Type

Peer-reviewed article

31 May 2022 22:01

Impact of AF screening on stroke prevention influenced by systolic blood pressure

Presented By

Dr Lucas Yixi Xing, Copenhagen University Hospital, Denmark

Conference

EHRA 2022

Type

Peer-reviewed article

31 May 2022 21:53

Real-world treatment and survival in early-stage NSCLC

Presented By

Dr Howard West, City of Hope Comprehensive Cancer Center, CA, USA

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:44

Consistent efficacy of osimertinib in Chinese and global population

Presented By

Dr Jie Wang, Beijing Cancer Hospital, China

Trial

Phase 3, ADAURA

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:43

Promising efficacy of neoadjuvant osimertinib in EGFR-mutated NSCLC

Presented By

Dr Chao Lyu, Beijing Cancer Hospital, China

Trial

Phase 2, NEOS

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:43

Peri-operative survival in bilobectomy is comparable with that of left pneumonectomy

Presented By

Dr Andrew Li, Yale School of Medicine, CT, USA

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:42

Pro-inflammatory tumour profile predicts complete pathological response to neoadjuvant chemoimmunotherapy

Presented By

Dr Marta Casarrubios, Hospital Puerta de Hierro-Majadahonda, Spain

Trial

Phase 2, NADIM

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:41

Furmonertinib outperforms gefitinib as first-line therapy in patients with EGFR-mutated NSCLC

Presented By

Dr Yuankai Shi, National Cancer Center, China

Trial

Phase 3, FURLONG

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:41

Second-line oritinib demonstrated potential clinical benefit in advanced EGFR-mutated NSCLC

Presented By

Prof. Caicun Zhou, Shanghai Pulmonary Hospital, China

Trial

Phase 2

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:40

Updated results confirm efficacy and safety of entrectinib in patients with NTRK fusion-positive NSCLC

Presented By

Prof. Byoung Chul Cho, Yonsei Cancer Center Seoul, South Korea

Trial

Phase 1/2, ALKA-372-001, STARTRK-1, STARTRK-2

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:40

ROS1 rearrangement-targeting unecritinib is a potential new first-line strategy

Presented By

Dr Shun Lu, Shanghai Chest Hospital, China

Trial

Phase 2

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:40

Savolitinib is effective in patients with MET-mutated NSCLC

Presented By

Dr Shun Lu, Shanghai Chest Hospital, China

Trial

Phase 2

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:39

Sintilimab plus chemotherapy improves OS in treatment-naïve, stage III–IV non-squamous NSCLC

Presented By

Dr Yunpeng Yang, Sun Yat-sen University Cancer Center, China

Trial

Phase 3, ORIENT-11

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:39

Updated results of CameL-sq trial confirm benefit of camrelizumab

Presented By

Prof. Caicun Zhou, Shanghai Pulmonary Hospital, China

Trial

Phase 3, CameL-sq

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:38

No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC

Presented By

Dr Delvys Rodriguez-Abreu, Universidad de Las Palmas de Gran Canaria, Spain

Trial

Phase 3, KEYNOTE-598

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:38

In concurrent CRT for stage III, unresectable NSCLC, performance status is better with proton therapy than photon therapy

Presented By

Dr Francesco Cortiula, Maastricht University Medical Center, the Netherlands

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

No improved prognosis for concurrent versus sequential immune checkpoint inhibition and CRT in unresectable NSCLC

Presented By

Dr Lukas Käsmann, University Hospital Munich, Germany

Trial

Phase 3

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

Durvalumab after sequential CRT safe in stage III, unresectable NSCLC

Presented By

Dr Marina Garassino, University of Chicago, IL, USA

Trial

Phase 2, PACIFIC-6

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

No impact of grade ≥2 pneumonitis on patient-reported outcomes in PACIFIC

Presented By

Prof. Rina Hui, University of Sydney, Australia

Trial

Phase 3, PACIFIC

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC

Presented By

Dr Edward Garon, David Geffen School of Medicine at UCLA, CA, USA

Trial

Phase 3, POSEIDON

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:36

Total metabolic tumour volume: a new potential prognostic factor in SCLC

Presented By

Dr Elisa Andrini, Sant'Orsola-Malpighi University Hospital, Italy

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:34

Radiation dose on oesophagus predicts OS in SCLC patients treated with chemoradiotherapy

Presented By

Dr Bilal Tahir, University of Sheffield, United Kingdom

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:34

Characteristics of long-term survivors in the CASPIAN trial

Presented By

Dr Niels Reinmuth, Asklepios Lung Clinic, Germany

Trial

Phase 3, CASPIAN

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:34

Outcomes of real-world CANTABRICO trial match results from CASPIAN

Presented By

Dr Dolores Isla, Hospital Clinico Universitario Lozano Blesa, Spain

Trial

CANTABRICO

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:33

Lung cancer diagnosis with liquid biopsy of peripheral blood cells

Presented By

Dr Andreas Thomsen, University of Freiburg, Germany

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:32

Rare EGFR mutations as oncogenic drivers

Presented By

Dr Alfredo Addeo (University Hospital of Geneva, Switzerland) and Dr Giulia Pasello (Veneto Institute of Oncology, Italy)

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:32

Decline in lung cancer mortality is almost exclusive to men

Presented By

Dr Philip Baum, Thoraxklinik Heidelberg, Germany

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:32

Inpatient dermatologic therapy is linked to lower mortality and readmission rates

Presented By

Dr Pranav Puri

Conference

AAD 2022

Type

Peer-reviewed article

18 May 2022 12:31

AD treatment during the pandemic: dupilumab does not raise COVID-19 infection risk

Presented By

Dr Brian Rankin, University of Calgary, Canada

Trial

Cohort study

Conference

AAD 2022

Type

Peer-reviewed article

18 May 2022 12:27

Upadacitinib: Fast and more pronounced skin improvement in AD patients

Presented By

Prof. Jonathan Silverberg, George Washington University School of Medicine, USA

Trial

Phase 3, Heads Up

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:35

Dermatology diseases need the highest doses of biologics

Presented By

Dr Charlotte Greif, Beth Israel Deaconess Medical Center, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:24

JAK inhibitors in AD: Setting the efficacy bar even higher

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Trial

Measure Up 1; JADE Mono-1; JADE Compare; Heads Up

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:21

Lebrikizumab treatment leads to encouraging outcomes in multiple traits of AD

Presented By

Prof. Jonathan Silverberg, George Washington University School of Medicine, USA

Trial

Phase 3, ADvocate 1; ADvocate 2

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:18

Novel IL-4/IL-13 blocker shows high efficacy with only modest conjunctivitis signal

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:15

New insights into psoriasis comorbidity

Presented By

Prof. Joel Gelfand, University of Pennsylvania, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:12

Long-term psoriasis treatment with bimekizumab results in maintained efficacy

Presented By

Prof. Kenneth Gordon, Medical College of Wisconsin, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:09

Novel developments in topical psoriasis therapy

Presented By

Prof. April Armstrong, University of Southern California Keck School of Medicine, USA

Trial

Phase 3, PSOARING; PSO-LONG

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:06

Add-on apremilast may improve recalcitrant dermatomyositis

Presented By

Prof. Carole Bitar, Tulane University School of Medicine, USA

Trial

Phase 2

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:03

Fungal skin infections in children: A diagnosis to keep in mind

Presented By

Prof. A. Yasmine Kirkorian, George Washington University School of Medicine, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 11:54

Innovative gel speeds up clearance of molluscum contagiosum lesions

Presented By

Prof. John Browning, University of Texas, USA

Trial

Phase 3, B-SIMPLE4

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 11:51

JAK inhibition offers promising treatment prospects for uncommon dermatoses

Presented By

Prof. Matthew Vesely, Yale School of Medicine, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 11:48

JAK inhibitors may offer a new horizon in the treatment of sarcoidosis

Presented By

Prof. William Damsky, Yale School of Medicine, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 11:12

Light at the end of the tunnel for vitiligo therapy

Presented By

Dr David Rosmarin, Tufts Medical Center, USA

Trial

Phase 3, TRuE-V1; TRuE-V2

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 11:05

JAK inhibitors: A risk assessment

Presented By

Prof. Brett King, Yale School of Medicine, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 10:59

Monitoring is key during JAK inhibitor therapy

Presented By

Prof. Jonathan Silverberg

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 10:47

Intestinal microbe-preparation: Modest activity but safe for mild psoriasis

Presented By

Dr Douglas Maslin

Trial

Phase 2

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 10:40

Alopecia areata: 1-year baricitinib treatment increases success

Presented By

Prof. Brett King, Yale School of Medicine, USA

Trial

Phase 3, BRAVE-AA1; BRAVE-AA2

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 10:35

New anticholinergic preparation is effective and tolerable in hyperhidrosis

Presented By

Prof. David Pariser, Eastern Virginia Medical School, USA

Trial

Phase 3, Cardigan I and II

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 10:23

Lessons from the COVID-19 pandemic for IBD management

Presented By

Prof. Siew Ng, Chinese University of Hong Kong, Hong Kong

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:32

AI model distinguishes between histologic activity and remission in ulcerative colitis

Presented By

Dr Tommaso Parigi, Humanitas University, Italy

Trial

PICaSSO

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:29

Multi-Omic and dietary analysis of Crohn’s disease identifies pathogenetic factors

Presented By

Dr Yael Haberman, Sheba Medical Center, Israel

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:27

Novel classification system for perianal fistulising Crohn’s disease

Presented By

Dr Philip Tozer, St Mark’s Hospital and Academic Institute, UK

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:26

Vaccination tool associated with improved vaccination coverage in IBD

Presented By

Ms Liselotte Fierens, KU Leuven, Belgium

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:24

Comparable safety profiles of biological therapies in elderly patients with IBD

Presented By

Dr Gustavo Drügg Hahn, McGill University Health Center, Canada

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:22

Early biologic therapy induces larger effect than delayed treatment in Crohn’s disease

Presented By

Prof. Shomron Ben-Horin, Tel-Aviv University, Israel

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:21

RESTORE-UC: No better outcomes with FMT superdonors than with autologous stools

Presented By

Dr Clara Caenepeel, KU Leuven, Belgium

Trial

RESTORE-UC

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:17

Positive outcomes with therapeutic drug monitoring during infliximab maintenance therapy

Presented By

Dr Kristin Jørgensen, Akershus University Hospital, Norway

Trial

NOR-DRUM B

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:14

Segmental colectomy beneficial over total colectomy in Chrohn’s disease

Presented By

Dr Gianluca Pellino, University of Campania Luigi Vanvitelli, Italy

Trial

SCOTCH

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:11

Modified 2-stage ileal pouch-anal anastomosis versus 3-stage alternative

Presented By

Dr Stefan Holubar, Cleveland Clinic Foundation, OH, USA

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:06

Similar results for different corticosteroid tapering protocols in UC

Presented By

Ms Pernille Ovesen, Herlev University Hospital, Denmark

Trial

SCOTCH

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:04

Ozanimod treatment shows maintained response in ulcerative colitis

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 3, True North

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:57

Stopping infliximab but not antimetabolites leads to more relapses in Crohn’s disease

Presented By

Prof. Edouard Louis, University Hospital Liège, Belgium

Trial

Phase 4, SPARE

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:55

Vedolizumab first approved therapy for chronic pouchitis

Presented By

Prof. Simon Travis, University of Oxford, UK

Trial

Phase 4, EARNEST

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:53

VEDOKIDS: Vedolizumab seems effective in paediatric IBD

Presented By

Dr Dan Turner, Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Israel

Trial

VEDOKIDS

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:51

Primary endpoint of 5-hydroxytryptophan for fatigue in IBD not met

Presented By

Dr Marie Truyens, Ghent University Hospital, Belgium

Trial

Phase 2, Trp-IBD

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:48

Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease

Presented By

Dr Neeraj Narula, McMaster University, Canada

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:46

Upadacitinib appears to be an efficacious therapy for moderately-to-severely ulcerative colitis

Presented By

Prof. Remo Panaccione , University of Calgary, Canada

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:44

Subcutaneous infliximab versus subcutaneous vedolizumab in IBD

Presented By

Prof. Laurent Peyrin-Biroulet, Nancy University Hospital, France

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:41

Vedolizumab outperforms anti-TNF in biologic-naïve ulcerative colitis

Presented By

Dr Bernd Bokemeyer, University Hospital Schleswig-Holstein, Germany

Trial

VEDO-IBD

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:37

Guselkumab shows encouraging safety and efficacy in ulcerative colitis

Presented By

Prof. Axel Dignass, Agaplesion Markus Hospital, Germany

Trial

Phase 2, QUASAR Induction

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:23

Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 2, GALAXI-1

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:21

Mirikizumab efficacious for active ulcerative colitis

Presented By

Prof. Geert D’Haens, Amsterdam University Medical Center, the Netherlands

Trial

Phase 3, LUCENT-1

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:18

Risankizumab more efficacious in colonic than in ileal Crohn’s disease

Presented By

Dr Peter Bossuyt, Imelda General Hospital, Belgium

Trial

Phase 3, ADVANCE, MOTIVATE, FORTIFY

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:15

Guselkumab plus golimumab promising combination for ulcerative colitis

Presented By

Prof. Bruce Sands, Mount Sinai School of Medicine, NY, USA

Trial

Phase 2, VEGA

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:10

Combined endpoint may support personalised medicine in ulcerative colitis

Presented By

Prof. Stefan Schreiber, Christian-Albrecht University, Germany

Trial

Phase 3, SELECTION

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:06

Filgotinib seems promising for perianal fistulising Crohn’s disease

Presented By

Dr Walter Reinisch, Medical University of Vienna, Austria

Trial

Phase 2, DIVERGENCE 2

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:04

Upadacitinib maintenance therapy delivers sustained improvements in active ulcerative colitis

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 3, U-ACHIEVE

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 15:57

Upadacitinib counters extraintestinal manifestations in ulcerative colitis

Presented By

Prof. Jean-Frédéric Colombel, Icahn School of Medicine at Mount Sinai, NY, USA

Trial

Phase 3, U-ACHIEVE; U-ACCOMPLISH

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 15:53

Upadacitinib effector pathways unravelled

Presented By

Dr Bram Verstockt, KU Leuven, Belgium

Trial

Phase 2, U-ACHIEVE

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 15:49

Deucravacitinib does not meet primary endpoint for ulcerative colitis

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 2, LATTICE-UC

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 15:43

First-line treatment with olaparib significantly improves PFS in mCRPC

Presented By

Dr Fred Saad, Centre Hospitalier de l’Université de Montréal, Canada

Trial

Phase 3, PROpel

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:25

First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC

Presented By

Dr Kim Chi, University of British Columbia, Canada

Trial

Phase 3, MAGNITUDE

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:25

Darolutamide improves OS in mHSPC

Presented By

Dr Matthew Smith, Massachusetts General Hospital Cancer Center, MA, USA

Trial

Phase 3, ARASENS

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:24

Continued enzalutamide plus docetaxel offers clinical benefit for mCRPC patients who progress on enzalutamide

Presented By

Dr Axel Merseburger, Universitätsklinikum Schleswig-Holstein, Germany

Trial

Phase 3, PRESIDE

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:24

Radiohybrid PSMA PET imaging has favourable detection rate for prostate cancer recurrence

Presented By

Dr David Schuster, Emory University School of Medicine, GA, USA

Trial

Phase 3, SPOTLIGHT

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:24

PSMA PET is a predictive biomarker in mCRPC progressing after docetaxel

Presented By

Prof. Michael Hofman, Peter MacCallum Cancer Centre, Australia

Trial

Phase 2, TheraP

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:23

Artificial intelligence improves prediction of long-term outcomes

Presented By

Dr Osama Mohamad, University of California San Francisco, CA, USA

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:22

Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer

Presented By

Prof. Neil Fleshner, Princess Margaret Cancer Centre, Canada

Trial

Phase 2, ACDC-RP

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:22

Addition of abiraterone to ADT/docetaxel does not increase bone loss

Presented By

Dr Guilhem Roubaud, Institut Bergonié, France

Trial

Phase 3, PEACE-1

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:21

Bavdegalutamide, a novel androgen receptor degrader, demonstrates clinical activity

Presented By

Dr Xin Gao, Massachusetts General Hospital, MA, USA

Trial

Phase 2, ARDENT

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:21

No benefit of olaparib in previously untreated, platinum-ineligible, metastatic urothelial carcinoma

Presented By

Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2, BAYOU

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:19

Rucaparib maintenance therapy extends PFS in platinum-responsive metastatic urothelial carcinoma

Presented By

Dr Simon Crabb, University of Southampton, UK

Trial

Phase 2, ATLANTIS

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:18

Positive efficacy and safety of N-803 plus BCG infusion in BCG-unresponsive NMIBC

Presented By

Dr Sam Chang, Vanderbilt University Medical Center, TN, USA

Trial

Phase 3, QUILT-3.032

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:18

Adding lenvatinib to pembrolizumab does not improve survival in advanced urothelial carcinoma

Presented By

Dr Yohann Loriot, Institut Gustave Roussy, France

Trial

Phase 3, LEAP-011

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:18

Maintenance niraparib fails to improve PFS in advanced urothelial cancer

Presented By

Dr Francesca Vignani, Ordine Mauriziano Hospital, Italy

Trial

Phase 2, Meet-URO12

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

First-line avelumab shows clinical activity in advanced urothelial carcinoma

Presented By

Dr Roberto Iacovelli, Catholic University of Rome, Italy

Trial

Phase 2, ARIES

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

Favourable pathologic response rate with neoadjuvant chemotherapy in high-risk upper tract urothelial carcinoma

Presented By

Dr Wesley Yip, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

Second-line nivolumab/ipilimumab boost improves ORR in metastatic urothelial carcinoma

Presented By

Prof. Marc-Oliver Grimm, University Hospital Jena, Germany

Trial

Phase 2, TITAN-TCC

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

Sacituzumab govitecan effective in platinum-refractory metastatic urothelial cancer

Presented By

Dr Petros Grivas, University of Washington, WA, USA

Trial

Phase 2, TROPHY-U-01

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:16

Neoadjuvant enfortumab vedotin promising in MIBC ineligible for cisplatin

Presented By

Prof. Daniel Petrylak, Yale School of Medicine, CT, USA

Trial

Phase 1/2, EV-103

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:16

High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib

Presented By

Dr Axel Bex, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, NeoAvAx

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:14

DFS benefits with adjuvant pembrolizumab in RCC persist with longer follow-up

Presented By

Dr Toni Choueiri, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, KEYNOTE-564

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:14

Biomarkers predict response to immune nivolumab (± ipilimumab) in advanced RCC

Presented By

Dr Marc-Oliver Grimm, University Hospital Jena, Germany

Trial

Phase 2, TITAN-RCC

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:13

Combined nivolumab/axitinib treatment elicits good response in metastatic RCC

Presented By

Dr Matthew Zibelman, Fox Chase Cancer Center, PA, USA

Trial

Phase 1/2

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:13

Folliculin mutations not associated with sporadic chromophobe RCC

Presented By

Dr Joseph Jacob, Upstate University Hospital, NY, USA

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:13

Differential patterns of molecular alterations among sites of metastasis in RCC

Presented By

Dr Rana McKay, University of California San Diego, CA, USA

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:12

Nivolumab monotherapy represents an alternative first-line treatment option for treatment-naïve mRCC

Presented By

Dr Michael Atkins, Georgetown Lombardi Comprehensive Cancer Center, DC, USA

Trial

Phase 2, HCRN GU16-260

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:12

HPV-positive and HPV-negative penile squamous cell carcinoma are molecularly distinct tumours

Presented By

Dr Bassel Nazha, Emory University, GA, USA

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:11

Atezolizumab does not improve survival in advanced penile cancer

Presented By

Dr Hielke-Martijn de Vries, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, PERICLES

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:11

Biomarkers to distinguish necrosis from teratoma before pcRPLND in testicular cancer

Presented By

Dr Tim Nestler, University of Cologne, Germany

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:10

Sintilimab plus FOLFIRINOX may provide benefits in metastatic pancreatic cancer

Presented By

Dr Qihan Fu, Zhejiang University School of Medicine, China

Trial

Phase 3, CISPD3

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 12:43

TRYbeCA-1: Eryaspase + chemotherapy does not meet primary endpoint in pancreatic cancer

Presented By

Prof. Pascal Hammel, Université Paris VII, France

Trial

Phase 3, TRYbeCA-1

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 12:40

Persisting disparities in pancreatic cancer care

Presented By

Prof. Susan Tsai, Medical College of Wisconsin, WI, USA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 12:38

ctDNA promising biomarker for recurrence of pancreatic cancer

Presented By

Dr Gregory Botta, UCSD Moores Cancer Center, CA, USA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 12:32

Head-to-head: Etoposide and irinotecan equally effective in neuroendocrine carcinoma

Presented By

Dr Chigusa Morizane, National Cancer Center Hospital, Japan

Trial

Phase 3, JCOG1213, TOPIC-NEC

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 12:26

EMR versus ESD in oesophageal cancer

Presented By

Dr Vani Konda, Baylor University Medical Center, TX, USA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:23

Pre-operative chemoradiation versus peri-operative chemotherapy for oesophageal cancer

Presented By

Prof. Karyn Goodman, Icahn School of Medicine at Mount Sinai, NY, USA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:22

AK104 plus chemotherapy promising first-line option for gastric cancer

Presented By

Dr Jiafu Ji, Beijing Cancer Hospital, China

Trial

Phase 1/2, AK104-201

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:19

DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer

Presented By

Dr Kensei Yamaguchi, Cancer Institute Hospital of JFCR, Japan

Trial

Phase 2, DESTINY-Gastric01

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:17

The emerging role of AI in gastroesophageal cancer

Presented By

Dr Wai Leung, University of Hong Kong, China

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:15

DCF outperforms standard-of-care for locally advanced oesophageal cancer

Presented By

Dr Ken Kato, National Cancer Center Hospital, Japan

Trial

Phase 3, JCOG1109, NExT

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:13

Nivolumab in gastric cancer: Efficacy update and the role of gut microbiome

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan; Dr Yu Sunakawa, St. Marianna University School of Medicine, Japan

Trial

Phase 3, CheckMate 649, DELIVER

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:11

Updates on pembrolizumab for oesophageal and gastric cancer

Presented By

Dr Jean-Philippe Metges, CHU Brest, France; Dr Zev Wainberg, University College Los Angeles, CA, USA

Trial

Phase 3, KEYNOTE-590, KEYNOTE-062

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:08

NIPICOL: New data on optimal ICI treatment duration in MSI/dMMR mCRC

Presented By

Dr Romain Cohen, Sorbonne University, France

Trial

Phase 2, NIPICOL

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:30

Dostarlimab may offer an alternative for dMMR rectal cancer

Presented By

Dr Melissa Lumish, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:28

DESTINY-CRC01: Maintained efficacy of T-DXd in mCRC

Presented By

Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan

Trial

Phase 2, DESTINY-CRC01

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:26

Key updates in colorectal cancer screening

Presented By

Dr Robin Mendelsohn, Memorial Sloan Kettering Cancer Center, NY, USA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:25

Impact of COVID-19 on screening for colorectal cancer

Presented By

Dr John Carethers, University of Michigan, MI, USA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:23

Nivolumab plus standard-of-care does not meet primary endpoint for mCRC

Presented By

Dr Heinz-Josef Lenz, USC Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 3, CheckMate 9X8

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:21

No benefit of additional oxaliplatin in elderly patients with mCRC

Presented By

Dr Tetsuya Hamaguchi, National Cancer Center, Japan

Trial

Phase 3, JCOG1018, RESPECT

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:19

Prognostic impact of early oxaliplatin discontinuation in colon cancer unravelled

Presented By

Dr Claire Gallois, Université de Paris, France

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:17

Long-course chemoradiation versus short-course radiotherapy in rectal cancer

Presented By

Dr Emma Holliday, MD Anderson Cancer Center, University of Texas, TX, USA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:15

Adjuvant S-1 therapy superior to observation in resected biliary tract cancer

Presented By

Dr Masafumi Ikeda, Japan Clinical Oncology Group, Japan

Trial

Phase 3, JCOG1202, ASCOT

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:13

Analysis of metastasectomy in CRC reveals benefits and disparities

Presented By

Dr Jude Khatib (University of Texas, TX, USA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:12

Pembrolizumab safe and efficacious in advanced hepatocellular carcinoma

Presented By

Prof. Shukui Qin, Nanjing University of Chinese Medicine, China

Trial

Phase 3, KEYNOTE-394

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:11

EPOCH trial: Subgroup analyses and additional endpoints for TARE plus chemo

Presented By

Dr William Harris, Seattle Cancer Care Alliance, WA, USA

Trial

Phase 3, EPOCH

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:09

TOPAZ-1: Adding durvalumab to chemotherapy effective in advanced biliary tract cancer

Presented By

Dr Do-Youn Oh, Seoul National University College of Medicine, South Korea

Trial

Phase 3, TOPAZ-1

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:09

HIMALAYA: Durvalumab ± tremelimumab new first-line option for unresectable HCC

Presented By

Prof. Ghassan Abou-Alfa, Memorial Sloan Kettering Center, NY, USA

Trial

Phase 3, HIMALAYA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:05

LAUNCH: TACE plus lenvatinib efficacious in advanced HCC

Presented By

Prof. Ming Kuang, Sun Yat-sen University, China

Trial

Phase 3, LAUNCH

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:03

Modest activity of atezolizumab plus bevacizumab in Child-Pugh B HCC

Presented By

Dr Hyeyeong Kim, Ulsan University Hospital, South Korea

Trial

Phase 3, IMbrave150

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:00

New Interfant protocol includes blinatumomab for KMT2A-r ALL

Presented By

Dr Inge van der Sluis, Princess Máxima Center for Pediatric Oncology, the Netherlands

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 12:00

Persistent disparities in ALL health outcomes

Presented By

Dr Sumit Gupta, University of Toronto, Canada

Trial

COG ALL

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:59

EWALL-INO: Inotuzumab ozogamicin promising as first-line therapy for BCP-ALL

Presented By

Prof. Patrice Chevallier, Nantes University Hospital, France

Trial

Phase 2, EWALL-INO

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:57

UKALL 2003: Therapy de-escalation safe in low-risk MRD patients with ALL

Presented By

Dr Sujith Samarasinghe, Great Ormond Street Hospital, UK

Trial

UKALL 2003

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:55

AMLSG 16-10: Long-term benefits of midostaurin for FLT3-ITD-mutated AML

Presented By

Dr Hartmut Döhner, Universitätsklinikum Ulm, Germany

Trial

Phase 2, AMLSG 16-10

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:53

Comparable effectiveness of CPX-351 and venetoclax plus HMA in older AML patients

Presented By

Dr Justin Grenet, Weill Cornell Medical Center, NY, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:51

Promising frontline triplet regimen for TP53-mutated AML

Presented By

Dr Naval Daver, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:49

Encouraging results of novel triplet combination for AML

Presented By

Dr Patrick Reville, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:48

Heavily pre-treated FLT3-mutated AML population may benefit from novel triplet regimen

Presented By

Dr Musa Yilmaz, MD Anderson Cancer Center, TX, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:46

Benefits of eprenetapopt plus azacitidine for TP53-mutant MDS and oligoblastic AML

Presented By

Dr David Sallman, H. Lee Moffitt Cancer Center, FL, USA

Trial

Phase 2

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:44

Improved risk stratification in MDS via gene-based scoring system

Presented By

Dr Elsa Bernard, Memorial Sloan Kettering Cancer Center, NY, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:43

CAPTIVATE: Ibrutinib plus venetoclax shows ongoing efficacy in CLL

Presented By

Dr Paolo Ghia, Università Vita-Salute San Raffaele, Italy

Trial

Phase 2, CAPTIVATE

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:41

SEQUOIA: Zanubrutinib meets primary endpoint for treatment-naïve CLL/SLL

Presented By

Prof. Constantine Tam, Peter MacCallum Cancer Centre, Australia

Trial

Phase 3, SEQUOIA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:39

Investigational therapies superior to standard-of-care in double-exposed CLL

Presented By

Dr Meghan Thompson, Memorial Sloan Cancer Center, NY, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:36

GRIFFIN: Sustained responses of daratumumab plus RVd in MM

Presented By

Dr Jacob Laubach, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 2, GRIFFIN

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:30

MajesTEC-1: Teclistamab efficacious in heavily pre-treated MM

Presented By

Prof. Philippe Moreau, University Hospital of Nantes, France

Trial

Phase 1/2, MajesTEC-1

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:26

iStopMM: Smouldering MM highly prevalent in general population

Presented By

Dr Sigrún Thorsteinsdóttir, University of Iceland, Iceland

Trial

iStopMM

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:25

Mechanisms of D-KRd treatment failure in MM identified

Presented By

Dr Eileen Boyle, NYU Langone Health, NY, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:22

TRIMM-2: Favourable results of talquetamab plus daratumumab for MM

Presented By

Dr Ajai Chari, Mount Sinai School of Medicine, NY, USA

Trial

Phase 1, TRIMM-2

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:16

Second-line tisa-cel similar to standard-of-care for R/R aggressive non-Hodgkin lymphoma

Presented By

Dr Michael Bishop, University of Chicago, IL, USA

Trial

Phase 3, BELINDA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:11

Axi-cel improved event-free survival in R/R DLBCL

Presented By

Dr Frederick Locke, Moffitt Cancer Cancer, FL, USA

Trial

Phase 3, ZUMA-7

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:09

Axi-cel more effective but tisa-cel less toxic in DLBCL

Presented By

Dr Emmanuel Bachy, Hospices Civils de Lyon, France

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:01

POLARIX: Novel regimen superior to R-CHOP in DLBCL

Presented By

Prof. Hervé Tilly, University of Rouen, France

Trial

Phase 3, POLARIX

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:56

Novel non-invasive biomarker ctDNA shows value in CNS lymphoma

Presented By

Dr Jurik Mutter, University Medical Center Freiburg, Germany

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:53

Mechanisms behind TP53 mutations revealed in myeloproliferative neoplasms

Presented By

Dr Alba Rodriguez-Meira, University of Oxford, UK

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:51

JAK2V617F variant allele frequency prognostic of venous events in polycythaemia vera

Presented By

Dr Giuseppe Loscocco, University of Florence, Italy

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:51

Promising results of tacrolimus plus dexamethasone for ITP

Presented By

Dr Zhuo-Yu An, Peking University People’s Hospital, China

Trial

Phase 2, TARGET 020

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:50

Sustained remission after TPO-RA discontinuation in chronic ITP

Presented By

Prof. Matthieu Mahevas, Hôpital Henri-Mondor, France

Trial

STOPAGO

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:50

Fitusiran meets primary endpoint in ATLAS-A/B trial

Presented By

Dr Alok Srivastava, Christian Medical College Vellore, India

Trial

Phase 3, ATLAS-A/B

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:50

ATLAS-INH: Impressive results of fitusiran for haemophilia with inhibitors

Presented By

Dr Guy Young, University of Southern California, CA, USA

Trial

Phase 3, ATLAS-INH

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:50

rFVIIIFc establishes rapid tolerisation in haemophilia A with inhibitors

Presented By

Dr Lynn Malec, Versiti Blood Research Institute, WI, USA

Trial

verITI-8

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:50

Reduced risk of Alzheimer’s disease in CHIP carriers

Presented By

Dr Hind Bouzid, Stanford University, CA, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:49

Lifelong patterns of clonal haematopoiesis revealed

Presented By

Dr Margarete Fabre, University of Cambridge, UK

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:49

Potential biomarker discovered for treatment response to ustekinumab

Presented By

Mr Shane Solanky, King’s College London, UK

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 15:46

TNF inhibitor for immune-mediated inflammatory disease doubles the risk of paradoxical psoriasis

Presented By

Dr Nikolai Loft, Copenhagen University Hospital, Denmark

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 15:08

Secukinumab also tolerable in paediatric psoriasis patients

Presented By

Prof. Michael Sticherling, University Erlangen–Nürnberg, Germany

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 11:22

High treatment success with ixekizumab in patients with psoriasis and diabetes

Presented By

Dr Alexander Egeberg, Copenhagen University Hospital Gentofte, Denmark

Trial

Phase 3, UNCOVER

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 11:15

The Yin and Yang of opposing vectors: an explanation for side effects of biologics

Presented By

Prof. Curdin Conrad, Lausanne University Hospital, Switzerland

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 11:07

Explaining arthropathy development through IL-4 and IL-13 blockade

Presented By

Dr Charlie Bridgewood, University of Leeds, UK

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 10:51

DLQI scores underestimated during lockdowns?

Presented By

Dr Ali Alsharqi, St. Vincent’s University Hospital, Ireland

Conference

PFGC 2021

Type

Peer-reviewed article

3 February 2022 10:34

TNF blockers likely beneficial for psoriatic patients with COVID-19

Presented By

Prof. Catherine Smith, King’s College London, UK

Trial

PsoProtect

Conference

PFG 2021

Type

Peer-reviewed article

2 February 2022 15:42

Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion

Presented By

Dr Ali Al-Janabi, University of Manchester, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 15:22

IL-36 gene expression in GPP lesions reduced by spesolimab

Presented By

Dr Ahmed Farag

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 15:09

Inhibition of heat shock protein: A novel way to treat psoriasis?

Presented By

Dr Anne Bregnhøj, Aarhus University Hospital, Denmark

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 15:02

Guselkumab shows highest drug survival among systemic treatments

Presented By

Dr Zenas Yiu, University of Manchester, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:55

Risankizumab superior to ustekinumab in skin histopathology scores

Presented By

Dr Kathleen Smith

Trial

Phase 3, UltiMMa-1 trial

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:49

Tapering biologics: No alarming signs of increased anti-drug antibodies

Presented By

Dr Juul van den Reek , Radboudumc, the Netherlands

Trial

Phase 4, CONDOR

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:43

Intermediate monocytes are possible predictors of response to secukinumab

Presented By

Dr Jonathan Hardman-Smart, King’s College London, UK

Trial

Phase 3, SIGNATURE

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:34

Gut microbiota of psoriasis patients: less diverse and reduced functionality

Presented By

Dr Tanja Todberg, University of Copenhagen, Denmark

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:29

Psoriasis associated with a higher cancer risk

Presented By

Mr Alex Trafford, University of Manchester, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:23

Comorbidity and clinical features of psoriasis vary according to HLA-C*06:02 status

Presented By

Dr Ravi Ramessur, King’s College London, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:20

Psoriasis patients with cardiovascular comorbidity characterised by high systemic inflammation

Presented By

Dr Niamh Kearney, St. Vincent’s University Hospital, Ireland

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:16

HLA-C*06:02-positive patients on ustekinumab show higher drug survival in a real-world scenario

Presented By

Dr Oras Alabas, University of Manchester, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:05

Selective IL-23 inhibition normalises gene expression in active PsA

Presented By

Ms Michelle Miron

Trial

Phase 3, DISCOVER-1&-2

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 13:48

Protective factors identified against anti-drug antibody formation to adalimumab in psoriasis

Presented By

Dr Teresa Tsakok, King’s College London, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 13:37

Olaparib is well tolerated as an additional treatment

Presented By

Dr Patricia Ganz, UCLA School of Medicine, CA, USA

Trial

Phase 3, OlympiA

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 22:26

Race effects the likelihood to develop lymphoedema following breast cancer treatment

Presented By

Dr Andrea Barrio, Memorial Sloan-Kettering Cancer Center, NY, USA

Trial

Phase 2, I-SPY

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 22:25

Sentinel lymph node staging is non-inferior to complete axillary lymph node dissection

Presented By

Dr Damiano Gentile, Humanitas Research Hospital, Italy

Trial

SINODAR ONE

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 22:23

One in 7 breast cancers detected during screening are overdiagnosed

Presented By

Dr Marc Ryers , Duke University Medical Center, NC, USA

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 22:21

Using genomics to match treatments improves outcomes

Presented By

Prof. Fabrice André, Institut Gustave Roussy, France

Trial

Phase 2, SAFIR02-BREAST; SAFIR-PI3K

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 22:19

How tamoxifen can induce uterine cancer

Presented By

Dr Kirsten Kübler, Broad Institute, MA, USA

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 22:15

Loss of ASXL1 tumour suppressor promotes resistance to CDK4/6 inhibitors

Presented By

Dr Dhivya Sudhan, UT Southwestern Medical Center, TX, USA

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 22:12

Inducers of ferroptosis are potential drugs to target p53-mutated TNBC cells

Presented By

Dr William Tahaney, MD Anderson Cancer Center, TX, USA

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 22:10

MAPK-pathway alterations are associated with resistance to anti-HER2 therapy

Presented By

Dr Emanuela Ferraro, Memorial Sloan-Kettering Cancer Center, NY, USA

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 22:08

Genomic signatures of DCIS define biology and correlate with clinical outcomes

Presented By

Dr Siri Strand, Stanford University, CA, USA

Trial

TBCRC 038;RAHBT

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 18:11

BRCA2 linked to inferior outcomes with CDK4/6 inhibitors plus endocrine therapy

Presented By

Dr Anton Safonov, Memorial Sloan-Kettering Cancer Center, NY, USA

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 18:08

Datopotamab deruxtecan shows promising anti-tumour activity

Presented By

Dr Ian Krop, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 1, TROPION-PanTumor01

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 18:05

Trastuzumab deruxtecan outperforms trastuzumab emtansine

Presented By

Dr Sara Hurvitz, University of California, CA, USA

Trial

Phase 3, DESTINY-Breast03

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 18:02

Nivolumab plus ipilimumab serve promising dual checkpoint inhibition

Presented By

Dr Romualdo Barroso-Sousa , Hospital Sírio-Libanês, Brazil

Trial

Phase 2, NIMBUS

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 17:59

Entinostat plus exemestane improves progression-free survival in Chinese patients

Presented By

Prof. Binghe Xu, Chinese Academy of Medical Sciences, China

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 17:57

Efficacy of pyrotinib plus capecitabine confirmed in previously treated patients

Presented By

Prof. Binghe Xu, Chinese Academy of Medical Sciences, China

Trial

Phase 3, PHOEBE

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 17:54

Single-cell spatial analysis can predict response to neoadjuvant immunotherapy

Presented By

Dr Giampaolo Bianchini, Ospedale San Raffaele, Italy

Trial

Phase 3, NeoTRIPaPDL1

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 17:48

Neoadjuvant pembrolizumab plus chemotherapy benefits event-free survival in TNBC

Presented By

Prof. Peter Schmid, Barts Cancer Institute, UK

Trial

Phase 3, KEYNOTE-522

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 17:45

Early use of ctDNA testing can identify likelihood of relapse in TNBC

Presented By

Prof. Nicholas Turner, The Institute of Cancer Research, UK

Trial

Phase 2, c-TRAK-TN

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 17:42

Pembrolizumab plus chemotherapy benefits patients with combined positive score ≥10

Presented By

Dr Javier Cortés, Vall d'Hebron Institute of Oncology, Spain

Trial

Phase 3, KEYNOTE-355

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 17:40

Neratinib plus trastuzumab plus fulvestrant shows encouraging clinical activity

Presented By

Dr Komal Jhaveri, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2, SUMMIT

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 17:37

Addition of palbociclib to standard endocrine therapy does not improve outcome in adjuvant treatment

Presented By

Prof. Michael Gnant, Medical University of Vienna, Austria

Trial

Phase 3, PALLAS

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 17:31

The SERD elacestrant improves outcomes for patients unresponsive to endocrine therapy

Presented By

Dr Aditya Bardia, Massachusetts General Hospital, MA, USA

Trial

Phase 3, EMERALD

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 17:29

Consistent overall survival benefit of ribociclib in advanced breast cancer

Presented By

Prof. Lisa Carey & Dr Joyce O’Shaughnessy

Trial

Phase 3, MONALEESA

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 17:24

Premenopausal women benefit from adjuvant chemotherapy next to endocrine therapy

Presented By

Dr Kevin Kalinsky, Emory University Winship Cancer Institute, GA, USA

Trial

Phase 3, RxPONDER

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 17:19

Promising anti-tumour activity of the CDK7-inhibitor samuraciclib plus fulvestrant

Presented By

Prof. Charles Coombes, Imperial College London, UK

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 17:16

ctDNA is prognostic and predictive for response to ribociclib plus letrozole

Presented By

Dr Giampaolo Bianchini, San Raffaele Scientific Institute, Italy

Trial

Phase 3, BioItaLEE

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 17:13

Early switch to fulvestrant plus palbociclib beneficial for patients with ESR1 mutation

Presented By

Prof. François-Clément Bidard, Institut Curie, France

Trial

Phase 3, PADA-1

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 17:09

Aromatase inhibitors outperform tamoxifen in premenopausal women

Presented By

Ms Rosie Bradley, University of Oxford, UK

Trial

Phase 3, ABCGS12; TEXT; SOFT; HOBOE

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 16:49

Concurrent taxane plus anthracycline most beneficial in reducing risk of breast cancer

Presented By

Dr Jeremy Braybrooke, University Hospitals Bristol NHS Foundation Trust, UK

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 16:44

Reduced risk of recurrence with ovarian suppression plus tamoxifen/exemestane

Presented By

Dr Meredith Regan, Dana-Farber Cancer Institute, USA

Trial

Phase 3, TEXT; SOFT

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 16:36

Metformin does not improve outcomes in patients with early-stage breast cancer

Presented By

Dr Pamela Goodwin, Lunenfeld-Tanenbaum Research Institute, Canada

Trial

Phase 3, CCTGMA.32

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 16:32

Omitting sentinel lymph node biopsy improves arm symptoms

Presented By

Prof. Bernd Gerber, University of Rostock, Germany

Trial

INSEMA

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 16:29

2021 Guideline for Chest Pain: Top 10 takeaways

Presented By

Prof. Martha Gulati, University of Arizona, USA

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 16:55

Accurate ejection fraction assessment in paediatric patients via artificial intelligence

Presented By

Dr Charitha Reddy, Stanford Children’s Health, USA

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 16:49

Concomitant tricuspid annuloplasty reduces treatment failure in moderate tricuspid regurgitation

Presented By

Prof. James Gammie, University of Maryland, USA

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 16:46

Blood pressure control disrupted during the pandemic

Presented By

Dr Alanna Chamberlain, Mayo Clinic, USA

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 16:43

Icosapent ethyl did not reduce the risk of hospitalisation in COVID-19

Presented By

Dr Rafael Díaz, Estudios Clínicos Latinoamérica, Argentina

Trial

PREPARE IT-2

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 16:37

Neutral effect of P2Y12 inhibitors in non-critical COVID-19 hospitalisations

Presented By

Prof. Jeffrey Berger, New York University Langone, USA

Trial

ACTIV-4A

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 16:30

COVID-19 mRNA vaccination benefits outweigh the risk for myocarditis

Presented By

Prof. Biykem Bozkurt, Baylor College of Medicine Houston, USA

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 16:24

Long-term reduced risk of CV events with ticagrelor plus aspirin after CABG

Presented By

Dr Qiang Zhao, Shanghai Jiao Tong University, China

Trial

DACAB-FE

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 16:17

Early surgery outperforms conservative management in asymptomatic severe aortic stenosis

Presented By

Prof. Marko Banovic, University Clinical Centre of Serbia, Serbia

Trial

AVATAR

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 16:11

External support device for SVG grafts in CABG surgery shows promise

Presented By

Prof. John Puskas, Mount Sinai Hospital, Israel

Trial

VEST Pivotal

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 16:04

Rivaroxaban regimen beneficial after revascularisation for claudication

Presented By

Prof. Marc Bonaca, University of Colorado, USA

Trial

VOYAGER PAD

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 15:57

LIBERTY 360 shows quality-of-life improvements after peripheral vascular intervention

Presented By

Dr Mohsin Chowdhury, Harvard Medical School, USA

Trial

LIBERTY 360

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 15:46

Deficient treatment outcomes after PVI in Black and low-income adults with PAD

Presented By

Dr Anna Krawisz, Beth Israel Deaconess Medical Center, MA, USA

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 15:39

REDUCE-IT: Cardiovascular risk reduction with icosapent ethyl in PAD

Presented By

Dr Deepak Bhatt, Brigham and Women’s Hospital, Boston, USA

Trial

Phase 3, REDUCE-IT

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 15:36

Ticagrelor cessation: early CABG non-inferior to delayed surgery

Presented By

Dr Derek So, University of Ottowa Heart Institute, Canada

Trial

RAPID CABG

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 15:30

Distinguishing patients before AMI based on plaque morphology

Presented By

Dr Alfredo Ricchiuto, Università Cattolica del Sacro Cuore, Italy

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 15:26

Empagliflozin efficacious in HF patients with preserved ejection fractions ≥50%

Presented By

Dr Stefan Anker, Charité University Berlin, Germany

Trial

EMPEROR-Preserved

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 15:15

EMPULSE: Empagliflozin improves outcomes of acute heart failure

Presented By

Prof. Adriaan Voors, University of Groningen, the Netherlands

Trial

Phase 3, EMPULSE

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 15:03

CHIEF-HF: Canagliflozin improves health status in heart failure

Presented By

Prof. John Spertus, University of Missouri-Kansas City, USA

Trial

Phase 3, CHIEF-HF

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 14:59

DREAM-HF: MPC therapy for HFrEF did not meet primary endpoint

Presented By

Dr Emerson Perin, Texas Heart Institute, US

Trial

Phase 3, DREAM-HF

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 14:52

Therapeutic approaches in heart failure with diabetes

Presented By

Prof. Lynne Stevenson, Vanderbilt University Medical Center, USA

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 14:48

Remote healthcare programme improves hypertension and lipid control

Presented By

Dr Alexander Blood, Brigham and Women’s Hospital, USA

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 14:19

Novel oral PCSK9 inhibitor shows promising results for hypercholesterolaemia

Presented By

Dr Douglas Johns

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 14:16

REVERSE-IT: Interim analysis shows promising effect of bentracimab on ticagrelor reversal

Presented By

Dr Deepak Bhatt, Brigham and Women’s Hospital, USA

Trial

Phase 3, REVERSE-IT

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 14:12

No significant effect of aspirin on reducing cognitive impairment

Presented By

Prof. Jane Armitage, Oxford University, UK

Trial

ASCEND

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 14:05

Milvexian phase 2 data supports safety and efficacy for VTE prevention after total knee replacement

Presented By

Prof. Jeffrey Weitz, McMaster University, Canada

Trial

Phase 2, AXIOMATIC-TKR

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 13:54

Network meta-analysis observes no clear effect of eicosapentaenoic acid on CV outcomes

Presented By

Dr Yujiro Yokoyama, St. Luke’s University Health Network, USA

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 13:31

New developments in remote diagnostics and monitoring of AF

Presented By

Dr Steven Lubitz, Massachusetts General Hospital, USA

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 13:23

Head-to-head: Efficacy of dabigatran versus warfarin on cognitive impairment

Presented By

Prof. Bruno Caramelli, University of São Paulo, Brazil

Trial

Phase 4, GIRAF

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 13:11

Posterior left pericardiotomy safe and effective in reducing atrial fibrillation

Presented By

Dr Mario Gaudino, Weill Cornell Medical Center, USA

Trial

PALACS

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 13:05

LAA ligation did not reduce recurrent atrial arrhythmias in persistent AF

Presented By

Dr David Wilber, Loyola University Chicago, USA

Trial

aMAZE

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 12:59

Equal benefits of early rhythm control in AF subtypes

Presented By

Dr Andreas Goette, St. Vincenz Hospital Paderborn, Germany

Trial

EAST-AFNET 4

Conference

AHA 2021

Type

Peer-reviewed article

14 January 2022 12:52

Vaccine booster improves immune response in patients treated with rituximab

Presented By

Prof. Michael Bonelli, Medical University of Vienna, Austria

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 11:07

IL-17 inhibition showing efficacy in GCA in phase 2 trials

Presented By

Prof. Jens Thiel, Medical University Graz, Austria

Trial

Phase 2, TitAIN

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 11:05

Cycling JAK inhibitors shows similar effectiveness to switching to a bDMARD in difficult-to-treat RA

Presented By

Dr Manuel Pombo-Suarez, Hospital Clinico Universitario de Santiago De Compostela, Spain

Trial

JAK-pot

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 11:03

Pre-existing heart failure affects safety of hydroxychloroquine in RA patients

Presented By

Dr Elvira D’Andrea, Brigham and Women’s Hospital, MA, USA

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 11:01

Patients with RA-associated interstitial lung disease benefit from antifibrotic agent

Presented By

Prof. Joshua J. Solomon, National Jewish Health, CO, USA

Trial

Phase 2, TRAIL1

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 10:59

Ultra-low dosing of rituximab in RA is a viable treatment option

Presented By

Mr Nathan den Broeder, Sint Maartenskliniek, the Netherlands

Trial

REDO

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 10:58

Kidney disease and hydroxychloroquine dose are risk factors for developing retinopathy

Presented By

Dr April Jorge, Massachusetts General Hospital, MA, USA

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 10:55

More pros than cons for the use of statins in RA

Presented By

Dr Gulsen Ozen, University of Nebraska Medical Center, NE, USA

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 10:54

Selective IL-23 inhibition: a new option in active PsA

Presented By

Prof. Andrew Östör, Monash University, Australia

Trial

Phase 3, KEEPsAKE 1, KEEPsAKE 2

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 10:52

Ustekinumab: highly efficacious in PSA independent of methotrexate

Presented By

Dr Michaela Köhm, Goethe-University Frankfurt, Germany

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 10:48

Vaccinated rheumatic patients carry increased risk for COVID-19 breakthrough infections

Presented By

Prof. Jasvinder Singh, University of Alabama at Birmingham, AL, USA

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 10:47

B-cell depleting medication increases COVID-19 breakthrough infection outcome risk

Presented By

Prof. Jean Liew, Boston University, MA, USA

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 10:45

COVID-19 mRNA vaccine safe and tolerable in adults with autoimmune disease

Presented By

Dr Inés Colmegna, McGill University Health Centre, Canada

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 10:06

Iberdomide: an upcoming new treatment possibility in lupus erythematosus

Presented By

Prof. Joan Merrill, Oklahoma Medical Research Foundation, OK, USA

Trial

Phase 2

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 10:04

Sequential rituximab after belimumab does not improve disease control in SLE

Presented By

Prof. Cynthia Aranow, Feinstein Institutes for Medical Research, NY, USA

Trial

Phase 3, BLISS-BELIEVE

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 10:02

Lupus patients less protected by COVID-19 vaccine

Presented By

Dr Peter Izmirly, New York University Grossman School of Medicine, NY, USA

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 10:00

Promising results in uric acid-lowering in gout patients with a new xanthine oxidase inhibitor

Presented By

Prof. Robert Terkeltaub, University of California San Diego, CA, USA

Trial

Phase 2

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 09:58

Laboratory and clinical signs 24h after hospitalisation predict MIS-C in children

Presented By

Dr Matthew Clark, Vanderbilt University Medical Center, TN, USA

Conference

ACR 2021

Type

Peer-reviewed article

14 January 2022 09:55

WNT9B-gene variant associated with doubled relapse risk in MS

Presented By

Ms Marijne Vandebergh, KU Leuven, Belgium

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:57

Melatonin associated with improved sleep quality in MS patients

Presented By

Dr Wan-Yu Hsu, University of California San Francisco, CA, USA

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:55

“Expanded Disability Status Scale 0 is not normal”

Presented By

Dr Stephen Krieger, Mount Sinai Hospital, NY, USA

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:51

Personality trait alterations in MS patients

Presented By

Dr Laura Chu, Memorial University of Newfoundland, Canada

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:49

Charcot Award 2021: Progressive MS, a personal perspective

Presented By

Prof. Alan J. Thompson, University College London, UK

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:48

Top score poster: Meta-analysis on the effect of DMTs

Presented By

Dr Mirko Capanna, University of Genoa, Italy

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:45

Cortical lesions predict disease progression and disability accumulation

Presented By

Dr Gian Marco Schiavi, University of Verona, Italy

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:40

Ocrelizumab shows long-term benefits in primary progressive MS

Presented By

Prof. Jerry S. Wolinsky, University of Texas Health Science Center at Houston, TX, USA

Trial

Phase 3, ORATORIO

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:39

Eculizumab, satralizumab, or inebilizumab for NMOSD?

Presented By

Prof. Dean Wingerchuk, Mayo Clinic Phoenix/Scottsdale, AZ, USA

Trial

Phase 3, N-MOmentum, PREVENT, SAkuraStar, SAkuraSky

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:37

Long-term efficacy of satralizumab for NMOSD

Presented By

Dr Ingo Kleiter, Ruhr-Universität Bochum, Germany

Trial

Phase 3, SAkuraStar, SAkuraSky

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:34

Long-term efficacy data: inebilizumab for NMOSD

Presented By

Prof. Bruce Cree, UCSF Multiple Sclerosis Center, CA, USA

Trial

Phase 3, N-MOmentum

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:31

Changes in GABA-receptor binding among cognitively impaired MS patients

Presented By

Prof. Hanneke Hulst, Amsterdam UMC, the Netherlands

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:28

T2 lesions independently predict early conversion to SPMS

Presented By

Dr Laura Lacruz-Ballester, Health Research Institute La Fe, Spain

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:26

Natural killer-like CD8+ T cells as a reservoir of clonal cells related to MS activity

Presented By

Dr Emilie Dugast, Centre de Recherche en Transplantation et Immunologie, France

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:23

The importance of MS progression independent of relapses

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:21

Early predictors of disability progression in paediatric-onset MS

Presented By

Dr Sifat Sharmin, University of Melbourne, Australia

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:15

High-sensitive biomarker detection in MS via novel ELISA assay

Presented By

Prof. Maria Cruz Sádaba, Private University San Pablo CEU, Spain

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:13

Cortical lesions predict cognitive impairment 20 years after MS diagnosis

Presented By

Mr Stefano Ziccardi, University of Verona, Italy

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:06

Applicability of sNfL measurement in clinical practice

Presented By

Prof. Elias Sotirchos, Johns Hopkins University, MD, USA

Trial

MS PATHS

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:04

MRI more sensitive for disease activity than relapses in SPMS

Presented By

Prof. Gavin Giovannoni, Queen Mary University of London, UK

Trial

Phase 3, EXPAND

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:58

ECTRIMS/EAN Clinical Guidelines on MS treatment: an update

Presented By

Prof. Xavier Montalban, Vall d’Hebron University Hospital, Spain

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:37

Rituximab most effective initial MS therapy in Swedish real-world study

Presented By

Mr Peter Alping, Karolinska Institutet, Sweden

Trial

Phase 4, COMBAT-MS

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:36

Ublituximab meets primary endpoint for relapsing MS

Presented By

Prof. Lawrence Steinman, Stanford University, CA, USA

Trial

Phase 3, ULTIMATE I, ULTIMATE II

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:33

Dynamic scoring system aids decision to switch MS therapies early

Presented By

Dr Camille Sabathé, French Institute of Health and Medical Research, France

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:31

Long-term suppression of MRI disease activity with ocrelizumab

Presented By

Dr Douglas Arnold, McGill University, Canada

Trial

Phase 3, OPERA I/II, ORATORIO

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:30

Stopping DMT: when or if at all?

Presented By

Prof. Ilya Kister (NYU Grossman School of Medicine, NY, USA); Prof. Gavin Giovannoni (Queen Mary University of London, UK)

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:25

The role of astrocyte phenotypes in acute MS lesions

Presented By

Dr Veit Rothhammer, University of Erlangen-Nürnberg, Germany

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:22

Promising results of intrathecal MSC-NTF cells in progressive MS

Presented By

Dr Jeffrey A. Cohen, Cleveland Clinic, OH, USA

Trial

Phase 2, BCT-101, SPRINT-MS

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:18

Preliminary data shows positive results of ATA188 for progressive MS

Presented By

Prof. Douglas Arnold, McGill University, Canada

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:16

Evobrutinib reduces relapses and MRI lesion activity

Presented By

Prof. Jens Kuhle (University Hospital Basel, Switzerland); Prof. Douglas Arnold (McGill University, Canada)

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:15

Primary endpoint of opicinumab for relapsing MS not met in AFFINITY trial

Presented By

Prof. Peter Calabresi, Johns Hopkins University, MD, USA

Trial

Phase 2, AFFINITY

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:12

Elezanumab did not outperform placebo in progressive and relapsing MS

Presented By

Prof. Bruce Cree, University of California, CA, USA

Trial

Phase 2, RADIUS-R, RADIUS-P

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:10

Ibudilast reduced retinal atrophy in primary progressive MS

Presented By

Dr Henrik Ehrhardt, Johns Hopkins University, MD, USA

Trial

Phase 2, SPRINT-MS

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 14:07

MS patients at risk of hampered immune response after vaccination

Presented By

Prof. Maria Pia Sormani, University of Genoa, Italy

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 10:49

Immunotherapy in MS does not influence COVID-19 severity and mortality

Presented By

Dr Gabriel Bsteh, Medical University of Vienna, Austria

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 10:45

Anti-CD20 antibodies associated with worse COVID-19 outcomes

Presented By

Dr Steve Simpson-Yap, University of Melbourne, Australia

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 10:41

ECTRIMS-EAN consensus on vaccination in MS patients

Presented By

Dr Mauricio Farez, Fundacion FLENI, Argentina

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 10:35

Depression and brain structures associations across a lifespan

Presented By

Ms Julia Binnewies , University of Groningen, the Netherlands

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:54

BDNF/TrkB pathway promising alternative for new antidepressants

Presented By

Dr Johan Sandin, AlzeCure Pharma, Sweden

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:52

Zuranolone reduces symptoms of major depression

Presented By

Dr Anita Clayton , University of Virginia, VA, USA

Trial

Phase 3, WATERFALL

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:48

Vortioxetine effectively reduces symptoms of depression and anxiety

Presented By

Dr Michael Christensen , H. Lundbeck A/S, Denmark

Trial

Phase 4, RECONNECT

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:45

Esketamine outperforms real-world management for treatment-resistant depression: preliminary results

Presented By

Mr Joachim Morrens , Janssen EMEA, Belgium

Trial

Phase 3, SUSTAIN-2; EOTC

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:42

Evaluating vafidemstat for the treatment of borderline personality disorder

Presented By

Ms Sonia Gutiérrez , Oryzon, Spain

Trial

Phase 2, PORTICO

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:41

Smartphone interventions in bipolar disorder: a position paper

Presented By

Dr Gerard Anmella, University of Barcelona, Spain

Type

Peer-reviewed article

26 November 2021 11:39

Deep brain stimulation effective in the treatment of refractory OCD

Presented By

Ms Ilse Graat, Amsterdam University Medical Center, the Netherlands

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:38

Connecting, challenging, and empowering youth through their smartphone

Presented By

Prof. Manon Hillegers , Erasmus MC Sophia, the Netherlands

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:36

Alcohol consumption during lockdown

Presented By

Ms Agnese Merlo & Ms Pauline A. Hendriksen, Utrecht Institute for Pharmaceutical Sciences

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:19

Why antipsychotics cause weight gain

Presented By

Prof. Louise Gallagher, University of Dublin, Ireland

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:18

Post-COVID-19 depression responds well to SSRIs

Presented By

Dr Mario Mazza , San Raffaele University, Italy

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:17

Roluperidone improves negative symptoms in schizophrenia

Presented By

Prof. Michael Davidson , Nicosia Medical School, Cyprus

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:15

Impact of COVID-19 on patients with psychotic disorders

Presented By

Dr Amir Krivoy, Tel-Aviv University, Israel

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:14

Sex similarities and differences in the neurobiology of aggression

Presented By

Dr Graeme Fairchild, University of Bath, UK

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:10

Risky driving and lifestyle may have a common psychobiological basis

Presented By

Dr Tõnis Tokko, University of Tartu, Estonia

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:08

Cannabidiol for cannabis cessation shows positive results

Presented By

Dr Tom Freeman , University of Bath, UK

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:05

Brain Prize Lecture: Prof. Jes Olesen on migraine

Presented By

Prof. Jes Olesen, University of Copenhagen, Denmark

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:02

Somatic comorbidities of ADHD: epidemiological and genetic data

Presented By

Dr Isabell Brikell , Karolinska Institutet, Sweden

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:02

Laxative may improve cognitive performance

Presented By

Ms Angharad de Cates , University of Oxford, UK

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 11:01

Novel approaches to understanding the social brain

Presented By

Dr David Slattery, Goethe University, Germany ; Dr Joana Vieira, Karolinska Institute, Sweden

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 10:59

Finding biomarkers for improved patient stratification

Presented By

Dr Hanna Hörnberg; Dr Emily Jones; Dr Clara Moreau; Prof. Louise Gallagher

Trial

AIMS-2-TRIALS

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 10:55

Anxiolytic activity of a novel orexin-1 receptor antagonist

Presented By

Dr Mark Schmidt, Janssen, Belgium

Conference

ECNP 2021

Type

Peer-reviewed article

26 November 2021 10:51

A pragmatic guide to the updated IBS guidelines

Expert

Nottingham University Hospital, UK

Conference

ECNP2021

Type

Peer-reviewed article

26 November 2021 10:47

Trastuzumab deruxtecan triples PFS

Presented By

Dr Javier Cortés, International Breast Cancer Center Barcelona, Spain

Trial

Phase 3, DESTINY-Breast03

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:51

Novel conjugate meets primary endpoint

Presented By

Dr Cristina Saura, Vall d’Hebron Institute of Oncology, Spain

Trial

Phase 3, TULIP

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:50

Longest survival benefit from first-line CDK4/6 inhibitor

Presented By

Prof. Gabriel Hortobagyi, University of Texas MD Anderson Cancer Center, USA

Trial

Phase 3, MONALEESA-2

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:50

Meta-analysis shows 6-months adjuvant trastuzumab is optimal

Presented By

Prof. Helena Earl, Addenbrooke's Hospital, UK

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:50

BrighTNess data may change guidelines

Presented By

Prof. Sibylle Loibl, German Breast Group, Germany

Trial

Phase 3, BrighTNess

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:49

Double-positive results for triple-negative metastatic breast cancer

Presented By

Prof. Hope Rugo, University of California, San Francisco, USA

Trial

Phase 3, KEYNOTE-355

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:48

Survival after neoadjuvant therapy with trastuzumab-lapatinib plus chemotherapy

Presented By

Prof. Valentina Guarneri, University of Padua, Italy

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:48

Postmenopausal breast cancer: extended letrozole reduces recurrence

Presented By

Prof. Lucia Del Mastro, University of Genoa, Italy

Trial

Phase 3

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:47

Asian women also benefit from palbociclib plus letrozole

Presented By

Prof. Binghe Xu, Peking Union Medical College, Beijing, China

Trial

Phase 3, PALOMA-4

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:47

No PEARLs of survival with palbociclib plus endocrine therapy compared with capecitabine, but QoL better

Presented By

Prof. Miguel Martín Jiménez, Complutense University of Madrid, Spain

Trial

Phase 3, PEARL

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:45

Neoadjuvant chemotherapy potential alternative to neoadjuvant chemoradiotherapy in LARC

Presented By

Dr Pei-Rong Ding, Sun Yat-sen University Cancer Center, China

Trial

Phase 3, CONVERT

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:43

Immune chemo-sensitisation looks promising in microsatellite-stable mCRC

Presented By

Dr Filippo Pietrantonio, Istituto Nazionale dei Tumori di Milano, Italy & Dr Chiara Cremolini, Azienda Ospedaliero-Universitaria Pisana, Italy

Trial

Phase 2, MAYA & AtezoTRIBE

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:42

Adagrasib shows promising clinical activity in heavily pretreated KRAS-mutated CRC

Presented By

Dr Jared Weiss, University of North Carolina at Chapel Hill, NC, USA

Trial

Phase 1/2, KRYSTAL-1

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:42

Automated detection of microsatellite status on unstained samples in early colon cancer

Presented By

Dr Frederik Großerüschkamp, Ruhr-Universität Bochum, Germany

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:41

Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer

Presented By

Dr Yelena Janjigian, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, CheckMate649

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:41

HIPEC in gastric cancer with peritoneal metastases

Presented By

Prof. Beate Rau, Charité University Hospital Berlin, Germany

Trial

Phase 3, GASTRIPEC I

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:41

ctDNA highly predictive in HER2-positive, advanced gastric or gastro-oesophageal junction cancer

Presented By

Dr Alexander Stein, University Cancer Center Hamburg, Germany

Trial

Phase 2, INTEGA

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:39

Robust anticancer activity of trastuzumab deruxtecan in HER2-mutated NSCLC

Presented By

Dr Bob Li, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2, DESTINY-Lung01

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:36

Nivolumab/ipilimumab continues to provide survival benefit in unresectable MPM

Presented By

Prof. Solange Peters, Lausanne University Hospital, Switzerland

Trial

Phase 3, CheckMate743

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:36

Adjuvant atezolizumab lowers relapse rate in resected NSCLC

Presented By

Dr Enriqueta Felip, Vall d’Hebron Institute of Oncology, Spain

Trial

Phase 3, Impower010

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:35

Three-year OS follow-up from CASPIAN trial

Presented By

Dr Luis Paz-Ares, Hospital Universitario 12 de Octubre, Spain

Trial

Phase 3, CASPIAN

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:32

TCR clonality predicts pembrolizumab response in NSCLC

Presented By

Dr Afef Abed, Edith Cowan University, Australia

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:31

Adjuvant immunotherapy reduces risk of disease recurrence in stage II melanoma

Presented By

Dr Jason Luke, UPMC Hillman Cancer Center, PA, USA

Trial

Phase 3, KEYNOTE-716

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:30

IFN-γ signature predicts response to immunotherapy

Presented By

Prof. Christian Blank, Netherlands Cancer Institute, the Netherlands

Trial

Phase 1, DONIMI

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:30

Updated results of SECOMBIT trial

Presented By

Prof. Paolo Ascierto, Istituto Nazionale Tumori "Fondazione Pascale", Italy

Trial

Phase 2, SECOMBIT

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:30

Combining T-VEC and pembrolizumab does not significantly improve survival in advanced, unresectable melanoma

Presented By

Dr Helen Gogas, National and Kapodistrian University of Athens, Greece

Trial

Phase 3, MASTERKEY-265

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:30

Durable intracranial responses with nivolumab/ipilimumab

Presented By

Dr Kim Margolin, City of Hope, CA, USA

Trial

Phase 2, CheckMate204

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:29

Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment

Trial

Phase 3, PEACE-1, STAMPEDE, ARCHES

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:27

TKI drug-free interval strategy not detrimental to conventional continuation strategy in RCC

Presented By

Prof. Janet Brown, University of Sheffield, UK

Trial

Phase 2, STAR

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:26

Modified ipilimumab schedule reduces risk of grade 3/4 adverse events

Presented By

Dr Naveen Vasudev, St James University Hospital, UK

Trial

Phase 2, PRISM

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:26

Optimal neoadjuvant dose ipilimumab/nivolumab in stage III urothelial cancer

Presented By

Dr Jeroen van Dorp, Netherlands Cancer Institute, the Netherlands

Trial

Phase 1, NABUCCO

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:26

Better survival with neoadjuvant dose-dense MVAC regimen in MIBC

Presented By

Dr Christian Pfister, Rouen University Hospital, France

Trial

Phase 3, VESPER

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:25

PARP inhibitor rechallenge improves PFS in ovarian cancer

Presented By

Dr Eric Pujade-Lauraine, Université Paris Descartes, France

Trial

Phase 3, OReO/ENGOT Ov-38

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:24

Pembrolizumab prolongs survival in persistent, recurrent, or metastatic cervical cancer

Presented By

Prof. Nicoletta Colombo, Istituto Europeo di Oncologia, Italy

Trial

Phase 3, KEYNOTE-826

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:23

Pembrolizumab has durable effect in previously treated MSI-H/dMMR advanced endometrial cancer

Presented By

Prof. David O’Malley, Ohio State University, USA

Trial

Phase 2, KEYNOTE-158

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:23

HRR mutational status is prognostic and predictive biomarker olaparib activity

Presented By

Dr Joyce Liu, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, NRG-GY004

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:20

Mutational analyses are predictive in malignant lymphomas

Presented By

Dr Ismael Fernández-Miranda, Institute of Sanitary Investigation Puerta de Hierro, Spain & Dr Shan-Shan Li, Hospital of Sun Yat-sen University, China

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:19

Low numbers of M2 macrophages in tumour microenvironment associated with superior response to immunotherapy in Hodgkin lymphoma

Presented By

Dr Liudmila Fedorova, Pavlov University, Russia

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:18

Adequate response to SARS-CoV-2 vaccine in cancer patients

Presented By

Dr Sjoukje Oosting, University Medical Center Groningen, the Netherlands & Dr Scott Shepherd, Royal Marsden NHS Foundation Trust, UK

Trial

VOICE & CAPTURE

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:15

Cancer patients more likely to die from COVID-19 when hospital admittance is required

Presented By

Dr Tom Drake, University of Edinburgh, UK

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:15

Third global survey of the ESMO Resilience Task Force

Presented By

Dr Jonathan Lim, Imperial College London, UK

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:15

High COVID-19 mortality in Swiss cancer patients

Presented By

Dr Markus Joerger, Cantonal Hospital St Gallen, Switzerland

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:14

Neutrophils negatively correlate with response to anti-PD-1 monotherapy in dMMR tumours

Presented By

Dr Laetitia Nebot-Bral, Institute Gustave Roussy, France

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:09

Tetraspecific ANKETs harnesses innate immunity in cancer therapies

Presented By

Prof. Eric Vivier, University Hospital Marseille, France

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:09

Early ctDNA reduction in metastatic uveal melanoma correlates better with OS than RECIST response

Presented By

Dr Alexander Shoushtari, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 1/2, IMCgp100-202

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:09

Gut microbiota as a potential predictive biomarker

Presented By

Dr Kentaro Sawada, Kushiro Rosai Hospital, Japan

Trial

MONSTAR-SCREEN

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:08

Targeting OX40 in the treatment of atopic dermatitis meets expectations

Presented By

Prof. Stephan Weidinger, University Hospital Schleswig-Holstein, Germany

Trial

Phase 2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:35

Superior EASI scores after switch from dupilumab to upadacitinib

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Trial

Heads Up

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:34

CSU: Novel agent targeting Bruton’s tyrosine kinase leads to disease control

Presented By

Prof. Marcus Maurer, Charité University Hospital, Germany

Trial

Phase 2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:33

Novel JAK3/TEC blocker leads to maintained re-pigmentation in vitiligo

Presented By

Prof. Khaled Ezzedine, University Hospital Henri Mondor, France

Trial

Phase 2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:32

TYK2 inhibitor deucravacitinib shows impressive long-term response in psoriasis

Presented By

Prof. Richard Warren, University of Manchester, UK

Trial

Phase 3, POETYK PSO

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:31

Tapinarof cream for psoriasis leads to high clearance rates and remittive effect

Presented By

Dr Linda Stein Gold, Henry Ford Health System, USA

Trial

PSOARING 3

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:30

CSU: Ligelizumab likely safe and effective for adolescents

Presented By

Prof. Bülent Şekerel, Hacettepe University, Turkey

Trial

Phase 2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:29

Long-term disease control in AD could be in reach with anti-OX40 antibody KHK4083

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA

Trial

Phase 2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:28

Topical JAK1/JAK2 inhibitor effective in vitiligo

Presented By

Dr David Rosmarin, Tufts Medical Center Boston, USA

Trial

Phase 3, TRuE-V1; TruE-V2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:27

Abrocitinib demonstrates fast itch control and skin clearance in atopic dermatitis

Presented By

Prof. Kristian Reich, University Medical Center Hamburg-Eppendorf, Germany

Trial

Phase 3, JADE DARE

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:26

AD patients with stable response fare well with a monthly dose of tralokinumab

Presented By

Prof. Stephan Weidinger, University of Kiel, Germany

Trial

ECZTRA1 and 2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:25

Damaged skin as a possible transmission route for SARS-CoV-2

Presented By

Dr Hanan Osman-Ponchet

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:24

Upadacitinib beats dupilumab in different body regions

Presented By

Prof. Jacob Thyssen, Bispebjerg Hospital, Denmark

Trial

Phase 3, Heads Up

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:23

Efficacious 2-year AD control with IL-13 inhibitor tralokinumab

Presented By

Prof. Andrew Blauvelt, Oregon Medical Research Center, USA

Trial

ECZTEND

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:22

Ruxolitinib cream: a safe treatment for elderly AD patients

Presented By

Prof. Jacek Szepietowksi, Wroclaw Medical University, Poland

Trial

Phase 3, TRuE-AD1; TRuE-AD2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:21

Novel and upcoming targeted AD treatment

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA

Trial

ECZTRA 3; Measure Up; ADVISE

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:20

Existing and upcoming small molecules in psoriasis

Presented By

Dr Enikö Sonkoly , Karolinska University Hospital, Sweden

Trial

POETYK PSO; PSOARING

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:19

Treating psoriasis during pregnancies

Presented By

Prof. Mahira Hamdy El Sayed, Ain Shams University, Egypt

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:18

A patient-related approach to freedom of disease

Presented By

Elfie Deprez , Ghent University Hospital, Belgium

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:17

Ixekizumab superior to secukinumab in real-world psoriasis study

Presented By

Dr Caterina Cariti, University of Turin, Italy

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:16

Nail psoriasis: An important target to be treated

Presented By

Prof. Peter van de Kerkhof , Radboudumc, the Netherlands

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:15

Grand debate: Is psoriasis a systemic or skin-only disease?

Presented By

Prof. Brian Kirby & Prof. Stefano Piaserico

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:14

JAK1/2: A promising novel treatment target in alopecia areata

Presented By

Prof. Brett King, Yale University School of Medicine, USA

Trial

Phase 3, BRAVE-AA1; BRAVE-AA2

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:12

Alopecia areata: encouraging response rates with JAK3/TEC inhibition

Presented By

Prof. Brett King, Yale University School of Medicine, USA

Trial

ALLEGRO

Conference

EADV 2021

Type

Peer-reviewed article

18 November 2021 13:11

Opioid receptor agonist difelikefalin disappoints in AD

Presented By

Prof. Brian Kim, Washington University School of Medicine, USA

Trial

Phase 2, KARE

Conference

EADV 2021

Type

Peer-reviewed article

17 November 2021 14:28

Higher inflammation markers in COVID-19 patients with a first negative PCR test

Presented By

Dr Thomas Gille, Université Paris 13, France

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:31

Breathing techniques contributed to COVID-19 recovery

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:30

Persistent fatigue following COVID-19

Presented By

Ms Zjala Ebadi, Radboud University Medical Center, the Netherlands

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:30

Risk of COVID-19-related morbidity and mortality in young and middle-aged adults

Presented By

Dr Eva Tabernero Huguet, Hospital Universitario Cruces, Spain

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:30

Fear of COVID-19 related to dyspnoea in COPD patients

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:29

Impact of COVID-19 on the dynamics of respiratory viruses

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:29

Cost-effectiveness of extending palivizumab duration

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:28

Rhinovirus bronchiolitis increased risk of recurrent wheezing and asthma

Presented By

Dr Heidi Makrinioti, Imperial College London, UK

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:28

No prognostic value of clinical scores for RSV mortality in stem cell transplant recipients

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:28

Livestock farming affected the airway microbiome of COPD patients

Presented By

Mr Warner van Kersen, Utrecht University, the Netherlands

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:27

Adherence to singing training similar to standard physical therapy in COPD patients

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:27

COPD symptoms and lung function related to sleep quality

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:26

Reduction of COPD severe acute exacerbations by candidate vaccine

Presented By

Prof. Stefan Andreas, Gastarzt Abteilung Pneumologie der Medizinischen Klinik II Gießen, Germany

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:26

The effect of the pandemic on the discharge diagnosis of older COPD patients

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:25

Lower influenza vaccination coverage in children with chronic conditions

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:24

Better lung function in children with a healthy diet

Presented By

Dr Mohammad Talaei Pashiri, Queen Mary University of London, UK

Trial

ALSPAC

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:24

Impaired response to pneumococcal vaccine in children with recurrent respiratory infections

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:22

Need for validated severity score in the assessment of bronchiolitis

Presented By

Mr William Bedson, University of Liverpool, UK

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:22

No immunological parameters identified for Down syndrome children

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:22

Increased impact of air pollution on lung function in preterm infants

Presented By

Ms Fabienne Decrue, University of Basel, Switzerland

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:22

Biomarkers do not discriminate severe from severe uncontrolled asthma

Presented By

Dr Bo Ding, AstraZeneca, Sweden

Trial

NOVELTY

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:21

Increased blood neutrophiles in patients with obesity and asthma

Presented By

Dr Helena Backman, Umea University, Sweden

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:20

Dynamics of environmental pollution during and after COVID-19 lockdown

Trial

POLCOV

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:20

Magnesium supplements improved lung function in asthma patients

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:19

Blood inflammatory phenotypes associated with clinical symptoms of asthma

Presented By

Dr Tajidine Tsiavia, University of Paris-Saclay, France

Conference

ERS 2021

Type

Peer-reviewed article

9 November 2021 10:19

Occipital nerve stimulation effective and safe in chronic cluster headache

Presented By

Dr Poldi Wilbrink, Zuyderland Medical Centre, the Netherlands

Trial

Phase 3, ICON

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 16:30

Insights in drug-drug interactions facilitate rational polypharmacy

Presented By

Dr Victor Kaytser, Robert Wood Johnson Medical School, TX, USA

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 16:26

Rimegepant confers long-term improvements in MMDs

Presented By

Evan Popoff, Broadstreet Health Economics & Outcomes Research, Canada

Trial

Phase 2, BHV3000-201

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 16:19

First real-world effectiveness data of erenumab is promising

Presented By

Prof. Andreas R. Gantenbein, Zurzach Care, Switzerland

Trial

SQUARE

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 16:11

Galcanezumab effective in patients with episodic or chronic cluster headache

Presented By

Dr Charly Gaul, Headache Clinic Königstein, Germany

Trial

Phase 3

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 16:04

Central effects and affected somatosensory processing with galcanezumab in migraine

Presented By

Dr Hauke Basedau, Dr Kuan-Po Peng, University Medical Centre Hamburg-Eppendorf, Germany

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 16:00

Long-term safety and tolerability of atogepant in migraine

Presented By

Prof. Laszlo Mechtler, DENT Neurologic Institute, NY, USA

Trial

Phase 3, ADVANCE trial

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 15:53

Largest genome-wide association study of migraine to date

Presented By

Heidi M. Hautakangas, Institute for Molecular Medicine, Finland

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 15:39

Robust evidence that cluster headache has a genetic basis

Presented By

Dr Bendik S. Winsvold, Oslo University Hospital, Norway

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 15:35

Functional brainstem somatotopy of the trigeminal nerve during nociception

Presented By

Dr Lisa-Marie Sturm, University Clinic Hamburg Eppendorf, Germany

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 15:25

Morphological changes in cluster headache between attacks

Presented By

Dr Kuan-Lin Lai, Taipei Veterans General Hospital, Taiwan

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 15:21

Interictal pontine metabolism in migraine patients without aura

Presented By

Dr Samaira Younis, Danish Headache Centre, Denmark

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 14:55

AI-enabled ECG algorithm predicts atrial fibrillation risk in migraine

Presented By

Dr Nikita Chhabra, Mayo Clinic, NY, USA

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 14:45

Migraine may not be a risk factor for stroke

Presented By

Cevdet Acarsoy, Erasmus Medical Centre, the Netherlands

Trial

The Rotterdam study

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 14:38

Predictors of health-related quality of life in cluster headache

Presented By

Dr Soo-Kyoung Kim, Gyeongsang National University, South Korea

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 14:29

Dry eye disease is more prevalent in migraine

Presented By

Dr Bithi Chowdhury, Hindu Rao Hospital and MDMC Medical College, India

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 14:25

Voice change and throat swelling are cranial autonomic symptoms in primary headache

Presented By

Dr Nazia Karsan, King’s College London, UK

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 14:20

Association between physical inactivity and headache disorders

Presented By

Dr Arão Oliveira, University of São Paulo, Brazil

Trial

ELSA-Brasil cohort

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 14:13

Increased suicidal attempts and risks of ideation in medication-overuse headache

Presented By

Dr Yen-Feng Wang, Taipei Veterans General Hospital, Taiwan

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 14:08

Telemedicine beneficial for headache care during the pandemic

Presented By

Dr Chia-Chun Chiang , Mayo Clinic, NY, USA

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 13:58

Comparison of headaches after SARS-CoV-2 vaccination

Presented By

Dr Carl Göbel, Universitätsklinikum Schleswig-Holstein, Germany

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 13:55

Grey matter cortical changes in patients with persistent headache after COVID-19

Presented By

Dr Álvaro Planchuelo-Gómez, Universidad de Valladolid, Spain

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 13:43

Increased risk of cerebral venous thrombosis in COVID-19

Presented By

Dr Sajid Hameed , Aga Khan University, Pakistan

Conference

IHC 2021

Type

Peer-reviewed article

8 November 2021 13:26

Breathing problems: the most frequently reported symptom before cardiac arrest

Presented By

Mr Filip Gnesin, Nordsjaellands Hospital, Denmark

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 16:54

Lay responders can improve survival in out-of-hospital cardiac arrest

Presented By

Dr Martin Jonsson, Karolinska Institute, Sweden

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 16:44

Rivaroxaban improves clinical outcomes in discharged COVID-19 patients

Presented By

Prof. Eduardo Ramacciotti, Santa Casa School of Medicine, Brasil

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 16:40

COVID-19: Thromboembolic risk reduction with therapeutic heparin dosing

Presented By

Prof. Alex Spyropoulos, Northwell Health, USA

Trial

Phase 3, HEP-COVID

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 16:34

Long COVID symptoms – Is ongoing cardiac damage the culprit?

Presented By

Dr Betty Raman, University of Oxford, UK

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 16:27

VOYAGER PAD: Fragile or diabetic patients also benefit from rivaroxaban

Presented By

Prof. Cecilia Low Wang, University of Colorado, USA

Trial

VOYAGER PAD

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 16:24

NATURE-PCSK9: Vaccine-like strategy successful in lowering CV events

Presented By

Prof. Brian Ference, University of Cambridge, UK

Trial

NATURE-PCSK9

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 16:19

Polypill: A successful tool in primary prevention

Presented By

Prof. Philip Joseph, McMaster University, Canada

Trial

TIPS-3; HOPE-3; Polylran

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 15:58

Smartphone app improves BP control independent of age, sex, and BMI

Presented By

Prof. Kazuomi Kario, Jichi Medical University, Japan

Trial

HERB-DH1

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 15:51

QUARTET demonstrates that simplicity is key in BP control

Presented By

Prof. Clara Chow, University of Sydney, Australia

Trial

QUARTET

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 15:06

Salt substitutes: a successful strategy to improve blood pressure

Presented By

Prof. Yangfeng Wu, Peking University Clinical Research Institute, China

Trial

Phase 4, DECIDE-Salt

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 14:51

Valsartan seems to attenuate hypertrophic cardiomyopathy progression

Presented By

Prof. Carolyn Ho, Brigham and Women’s Hospital, USA

Trial

Phase 2, VANISH

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 14:41

Dapagliflozin reduces incidence of sudden death in HFrEF patients

Presented By

Dr James Curtain, University of Glasgow, Scotland

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 14:19

Empagliflozin: First drug with clear benefit in HFpEF patients

Presented By

Prof. Stefan Anker, Charité University Hospital, Germany

Trial

Phase 3, EMPEROR-Preserved

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 13:45

CardioMEMS: neutral outcome but possible benefit prior to COVID-19

Presented By

Prof. JoAnn Lindenfeld, Vanderbilt University Medical Center, USA

Trial

GUIDE-HF

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 13:36

Cardiac arrest without ST-elevation: instant angiogram does not improve mortality

Presented By

Prof. Steffen Desch, University Heart Center Lübeck, Germany

Trial

TOMAHAWK

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 13:32

Older hypertensive patients benefit from intensive blood pressure control

Presented By

Prof. Jun Cai, FuWai Hospital, China

Trial

STEP

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 12:45

Antagonising the mineralocorticoid receptor beneficial for patients with diabetes and CKD

Presented By

Prof. Bertram Pitt, University of Michigan School of Medicine, USA

Trial

Phase 3, FIGARO-DKD

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 12:40

2021 ESC Guidelines on Heart Failure

Presented By

Prof. Carolyn Lam, Duke-NUS Medical School, Singapore

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 12:34

2021 ESC/EACTS Guidelines on Valvular Heart Disease

Presented By

Dr Victoria Delgado, Leiden University Medical Center, the Netherlands

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 12:18

2021 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronisation Therapy

Presented By

Prof. Jean-Claude Deharo, Hospital La Timone of Marseille, France

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 12:05

2021 ESC Guidelines on Cardiovascular Disease Prevention

Presented By

Prof. Frank Visseren, Guidelines Task Force Chair

Conference

ESC 2021

Type

Peer-reviewed article

26 October 2021 11:52

Unresolved needs for patients with PsA despite growing therapeutic options

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 13:46

PsoBarrier EU: Large survey evaluating quality of care in Europe

Presented By

Dr Anna Langenbruch, Universitätsklinikum Hamburg-Eppendorf, Germany

Trial

PsoBarrier EU

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 13:43

Bridging the gap between patients and access to psoriasis specialists

Presented By

Dr Silvia Fernandez Barrio, AEPSO, Argentina

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 13:42

Psoriasis and PsA in transgender adults on hormone therapy

Presented By

Ms Julia Gao, Fenway Health, MA, USA

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 13:41

Psoriasis: New disease severity classification

Presented By

Prof. Lone Skov, University of Copenhagen, Denmark

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 13:39

Active PsA: Biomarkers distinguish radiographic progressors from non-progressors

Trial

Phase 3, SPIRIT-P1

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 13:37

Immune checkpoint inhibitors in patients with pre-existing psoriasis

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 13:35

Axial involvement is critical in psoriatic arthritis

Presented By

Dr Elena Gubar, Nasonova Research Institute of Rheumatology, Russia

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 13:34

Psoriasis registries yield important data about COVID-19

Presented By

Dr Satveer Mahil, St John’s Institute of Dermatology, UK

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 12:35

COVID-19 affects patients and care

Presented By

Prof. Peter van de Kerkhof, Radboudumc, the Netherlands

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 12:33

Vaccination feasible in people with psoriatic disease

Presented By

Prof. Ulrich Mrowietz, University Medical Centre Schleswig-Holstein, Germany

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 12:30

Low COVID-19 risk for patients with psoriasis on biologic treatment

Presented By

Dr Jorge Georgakopoulos, University of Toronto, Canada

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 12:28

Psoriasis: Disrupted gut-skin axis

Presented By

Dr Mariusz Sikora, Medical University of Warsaw, Poland

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 12:22

Psoriasis associated with increased duodenum inflammation

Presented By

Prof. Maria Lampinen, Uppsala University, Sweden

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 12:20

Whole-exome sequencing to study the underlying pathogenesis of psoriasis

Presented By

Mr Sigurgeir Olafsson, University of Cambridge, UK

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 12:19

Pan-European guidelines for the treatment of psoriasis and comorbid conditions

Presented By

Prof. Alexander Nast, Charité Universitätsmedizin Berlin, Germany

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 12:09

Psoriatic arthritis: Guidelines and best practice

Trial

Phase 3, BE ACTIVE, PATERA

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 11:19

Patients with PsA have a higher cardiovascular risk

Presented By

Dr Natalia Guajardo-Jauregui, Autonomous University of Nuevo León, Mexico

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 11:16

Potential role of inflammation in cardiovascular comorbidity

Presented By

Dr Alexander Egeberg, Herlev and Gentofte Hospital, Denmark

Trial

Phase 3, CANTOS, CIRT

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 11:13

Psoriasis: New treatments and current pipeline

Presented By

Prof. Kristian Reich, Dermatologikum Hamburg, Germany

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 11:08

Rapid pustule and skin clearance with IL-36 receptor inhibitor spesolimab

Presented By

Prof. Hervé Bachelez, Hôpital Saint-Louis, France

Trial

Phase 2, Effisayil 1

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 11:04

Selective TYK2 inhibitor effective in moderate-to-severe plaque psoriasis

Trial

Phase 3, POETYK PSO-1, POETYK PSO-2

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 10:59

Best of EAU: Immune cell populations have prognostic value in RCC

Presented By

Dr Alberto Breda, Autonomous University of Barcelona, Spain

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:28

KEYNOTE-564: First positive phase 3 results with adjuvant checkpoint inhibition in RCC

Presented By

Prof. Thomas Powles, Barts Cancer Centre, London, UK

Trial

Phase 3, KEYNOTE-564

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:28

PSMA PET-CT more accurate than standard-of-care imaging in RCC

Presented By

Dr Arsalan Tariq , Royal Brisbane and Women's Hospital, Australia

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:28

Worse renal function after radical versus partial nephrectomy

Presented By

Prof. Francesco Trevisani, IRCCS Ospedale San Raffaele, Milan, Italy

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:28

Best of EAU: Highlights on bladder cancer

Presented By

Prof. Morgan Rouprêt, Pitié-Salpêtrière Hospital, Paris, France

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:26

ctDNA can guide adjuvant immunotherapy in muscle-invasive bladder cancer

Presented By

Prof. Jürgen Gschwend, Technical University Munich, Germany

Trial

Phase 3, IMvigor010, IMvigor011

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:26

Durvalumab ± tremelimumab by cisplatin eligibility in metastatic urothelial carcinoma

Presented By

Prof. Thomas Powles, Barts Cancer Centre, London, UK

Trial

Phase 3, DANUBE

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:26

Circulating tumour cells could aid in the decision to give neoadjuvant chemotherapy

Presented By

Dr Nick Beije, Erasmus Medical Center, Rotterdam, the Netherlands

Trial

CirGuidance

Type

Peer-reviewed article

31 August 2021 12:26

Best of EAU: New advances in testicular and penile cancer

Presented By

Prof. Maarten Albersen, UZ Leuven, Belgium

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:23

Recommendations for the management of indeterminate small testis masses

Presented By

Mr Shafi Wardak, University College London Hospitals, UK

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:23

Residual tumour resection in case of elevated markers

Presented By

Dr Yue Che, University of Düsseldorf, Germany

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:23

Best of EAU: Updates on imaging and treatment of prostate cancer

Presented By

Prof. Alberto Briganti, IRCCS Ospedale San Raffaele, Milan, Italy

Trial

STHLM3MRI, TITAN

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:15

Radiographic PFS benefit of adding abiraterone to ADT and docetaxel in mCSPC

Presented By

Prof. Karim Fizazi, University of Paris-Saclay, Villejuif, France

Trial

Phase 3, PEACE-1

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:15

177Lu-PSMA-617: A new class of effective therapy

Presented By

Prof. Johann de Bono; Prof. Michael Hofman

Trial

VISION, TheraP

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:15

Prophylactic treatments for recurrent urinary tract infections

Presented By

Prof. María Fernanda Lorenzo Gómez, University of Salamanca, Spain

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:13

Failure of conservative management in emphysematous pyelonephritis

Presented By

Dr Ahmed Saadi, University of Tunis, Tunesia

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:13

Antibiotic treatment of healthcare-associated infections

Presented By

Dr José Medina-Polo, Hospital Universitario 12 de Octubre, Madrid, Spain

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:13

Best of EAU: The surgical armamentarium is evolving

Presented By

Prof. Jean-Nicolas Cornu, CHU Charles Nicolle, Rouen, France

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:11

IPSS: Visual alternatives to aid comprehension and new risk prediction models

Presented By

Dr Florine Schlatmann; Prof. Stavros Gravas

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:11

Iron substitution improves LVEF in intensively treated CRT patients with iron deficiency

Presented By

Dr Pieter Martens, Hospital Oost-Limburg, Belgium

Trial

Phase 4, IRON-CRT

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 16:10

Novel mineralocorticoid receptor antagonist effective irrespective of HF history

Presented By

Prof. Gerasimos Filippatos, Attikon University Hospital, Greece

Trial

FIDELIO-DKD

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 16:05

Iron substitution in iron-deficient HF patients is highly cost-effective

Presented By

Prof. Phil McEwan, Swansea University, UK

Trial

AFFIRM-AHF

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 15:59

Omecamtiv mecarbil might be less effective in patients with atrial fibrillation or flutter

Presented By

Prof. Scott Solomon, Brigham and Women’s Hospital, MA, USA

Trial

GALACTIC-HF

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 15:52

Vericiguat effective irrespective of atrial fibrillation status

Presented By

Prof. Piotr Ponikowski, Wrocław Medical University, Poland

Trial

VICTORIA

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 15:45

Baroreflex activation: a novel option to improve heart failure symptoms

Presented By

Prof. Andrew Coats, University of Warwick, UK

Trial

BEAT-HF; HOPE4HF

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 15:35

Beta-blocker withdrawal to enhance exercise capacity in heart failure?

Presented By

Prof. Julio Nuñez Villota, University Clinical Hospital of Valencia, Spain

Trial

Phase 4, PRESERVE-HR

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 15:29

Inconclusive results for dapagliflozin treatment in heart failure

Presented By

Prof. John McMurray, University of Glasgow, UK

Trial

DETERMINE-Reduced; DETERMINE-Preserved

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 15:23

Computerised cognitive training improves cognitive function in HF patients

Presented By

Sonja Wedegärtner, Saarland University Hospital, Germany

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 15:15

Real-world study suggests sacubitril/valsartan benefits elderly patients with HF

Presented By

Dr Andrea Herbst, Azienda Ospedaliero-Universitaria Careggi, Italy

Trial

PARADIGM-HF

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 12:59

Proenkephalin: A useful biomarker for new-onset heart failure?

Presented By

Dr Lisa Emmens, University Medical Center Groningen, the Netherlands

Trial

PREVEND

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 12:56

Weight loss associated with increased mortality risk in heart failure patients

Presented By

Dr Nuno Melo, Centro Hospitalar e Universitário de São João, Portugal

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 12:53

Echocardiographic parameters linked to dementia diagnosis

Presented By

Dr Karol Nowak, Jagiellonian University Medical College, Poland

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 12:49

Telemedicine: Every light has its shadow

Presented By

Dr Arvind Singhal, Royal Brompton Hospital, UK

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 12:46

COVID-19-related HF: from systemic infection to cardiac inflammation

Presented By

Prof. Marco Metra, University of Brescia, Italy

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 10:19

Increased COVID-19 mortality in patients with cardiorenal comorbidity

Presented By

Dr Johan Bodegård

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 10:07

Myocardial infarction outcomes were significantly affected by the pandemic

Presented By

Dr Ayman Haq, Baylor University Medical Center, USA

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 10:03

Empagliflozin linked to lower cardiovascular risk and renal events in real-world study

Presented By

Prof. Leo Niskanen, University of Eastern Finland, Finland

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 09:43

Efficacy of dapagliflozin and empagliflozin not influenced by diabetes status

Presented By

Prof. Faiez Zannad, University of Lorraine, France

Trial

EMPEROR-Reduced; DAPA=HF; DAPA-CKD; EMPA-Kideney

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 09:39

TAPSE effective biomarker associated with high-risk of severe COVID-19

Presented By

Dr Neil Bodagh, King´s College Hospital NHS Foundation Trust, UK

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 09:38

COVID-19 in AF patients with HF: no higher mortality but longer hospital stay

Presented By

Prof. Bektaş Murat, Eskisehir Osmangazi University, Turkey

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 09:38

Biomarker panel predicts SGLT2 inhibitor response

Presented By

Dr Muthiah Vaduganathan, Brigham and Women´s Hospital, MA, USA

Trial

CANVAS

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 09:33

Psychoactive substances put young people at risk of cardiovascular disease

Presented By

Dr Vijay Chopra, Max Super Speciality Hospital Saket, India

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 09:28

Heart failure patients might be at an increased risk for head and neck cancer

Presented By

Dr Mark Luedde, Christians-Albrechts-University of Kiel, Germany

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 09:21

The challenge of improving the quality of life of heart failure patients

Presented By

Prof. Ileana L. Piña, Central Michigan University, USA

Trial

DAPA-HF; PROVE-HF

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 09:20

Trastuzumab associated with cardiotoxicity in breast cancer

Presented By

Dr Ana Filipa Cardoso, Hospital Senhora da Oliveira-Guimarães, Portugal

Conference

HFA 2021

Type

Peer-reviewed article

19 August 2021 09:18

Effect of prasinezumab on motor features in early PD

Trial

Phase 2, PASADENA

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 11:36

Levodopa-carbidopa intestinal gel in patients with advanced PD

Presented By

Dr József Szász, University of Târgu Mures, Romania

Trial

COSMOS

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 11:32

Safinamide improves non-motor symptoms in PD

Trial

SAFINONMOTOR

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 11:31

Exploring the possibilities

Presented By

Prof. Andres Lozano; Prof. Jean-François Aubry; Prof. Roland Beisteiner

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 11:20

Factors associated with decreased migraine attack risk

Presented By

Prof. Christian Wöber, Medical University of Vienna, Austria

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:59

Eptinezumab shows acute benefits during migraine attack

Trial

Phase 3, RELIEF

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:58

Erenumab superior to topiramate for migraine treatment

Trial

Phase 4, HER-MES

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:57

Pregnant migraine patients at higher risk of complications

Presented By

Dr Nirit Lev, Rabin Medical Center, Israel

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:53

Occipital nerve stimulation in drug-resistant cluster headache

Presented By

Dr Javier Membrilla, University Hospital La Paz, Spain

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:51

Rhythmicity in primary headache disorders

Presented By

Dr Christoph Schankin, University Hospital of Bern, Switzerland

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:50

Typing behaviour to remotely monitor clinical MS status

Presented By

Dr Ka-Hoo Lam, Amsterdam UMC, the Netherlands

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:37

Machine-learning method accurately classifies patients with MS

Type

Peer-reviewed article

18 August 2021 10:36

Positive results from ublituximab versus teriflunomide

Trial

Phase 3, ULTIMATE I, ULTIMATE II

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:35

Alemtuzumab in treatment-naïve patients with aggressive MS

Presented By

Dr Lucia Moiola, IRCCS San Raffaele Hospital, Italy

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:33

No higher early MS relapse frequency after stopping ponesimod

Presented By

Prof. Ludwig Kappos, University of Basel, Switzerland

Trial

Phase 3, OPTIMUM

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:32

Satralizumab efficacious in AQP4-IgG-positive patients with NMOSD

Trial

Phase 3, SAkuraSky, SAkuraStar

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:30

Good long-term safety and efficacy of inebilizumab in NMOSD

Presented By

Prof. Bruce Cree, University of California San Francisco, CA, USA

Trial

Phase 3, N-MOmentum

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:28

Severe outcomes of COVID-19 in patients with dementia

Presented By

Dr Agathe Vrillon, Hôpital Lariboisière Fernand-Widal, France

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:27

First evidence of brainstem involvement in COVID-19

Presented By

Dr Tommaso Bocci, University of Milan, Italy

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:20

Minimally invasive device to detect focal seizure activity

Presented By

Prof. Mark Cook, University of Melbourne, Australia

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:18

Long-term effectiveness of ANT-DBS in epilepsy confirmed

Trial

MORE

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:16

Hypertension pathology visible in white matter lesion volume

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:15

Intracerebral haemorrhage only slightly increases mortality in COVID-19 patients

Presented By

Dr Davide Sangalli, Alessandro Manzoni Hospital, Italy

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:15

Cognitive/behavioural alterations persistent after COVID-19

Presented By

Prof. Federica Agosta, Vita-Salute San Raffaele University, Italy

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:10

Stroke with covert brain infarction indicates high vascular risk

Presented By

Dr Thomas Meinel, Bern University Hospital, Switzerland

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:10

Good safety and efficacy of cenobamate for focal seizures

Trial

C013, C017, C021

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:10

Promising diagnostic accuracy of plasma GFAP

Presented By

Dr Tandis Parvizi, Medical University of Vienna, Austria

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:10

24-month pooled FIREFISH data of risdiplam in SMA

Trial

Phase 3, FIREFISH

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:07

Inability to recognise disgust as first cognitive symptom of ALS

Presented By

Ms Veronica Castelnovo, Vita-Salute San Raffaele University, Italy

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:06

Sex modulates effect of cognitive reserve on subjective cognitive decline

Presented By

Dr Giulia Giacomucci, University of Florence, Italy

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:05

Expanding precision medicine to stroke care

Presented By

Dr Svetlana Lorenzano, Sapienza University of Rome, Italy

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:05

Prenatal valproate exposure increases risk of adverse neurodevelopmental outcome

Trial

SCAN-AED

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:05

Pathogenic T-cell signature identified in myasthenia gravis

Presented By

Dr Bettina Schreiner, University of Zürich, Switzerland

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:04

Neural base of persistent hyposmia after COVID-19

Presented By

Dr Matteo Pardini, University of Genoa, Italy

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:00

Hypersensitivity to uncertainty in subjective cognitive decline

Presented By

Dr Bahaaeddin Attaallah, University of Oxford, United Kingdom

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:00

‘Mozart effect’ in epilepsy: why Mozart tops Haydn

Presented By

Prof. Ivan Rektor, Masaryk University, Czech Republic

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:00

Dexamethasone not indicated for chronic subdural haematoma

Presented By

Dr Ishita Miah, Leiden University Medical Center, the Netherlands

Trial

Phase 4, DECSA

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:00

Neurological symptoms and complications of COVID-19 affect outcomes

Presented By

Dr Nina Kleineberg, University Hospital Cologne, Germany

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 09:50

Neoadjuvant nivolumab plus chemotherapy improves surgical outcomes in NSCLC

Presented By

Dr Jonathan Spicer, McGill University, Canada

Trial

Phase 3, CheckMate 816

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:59

PARP7 inhibitor shows promising results in first-in-human trial

Presented By

Dr Gerald Falchook , Sarah Cannon Research Institute at HealthONE, CO, USA

Trial

Phase 1

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:53

Molecular tumour profiling impacts the diagnosis and treatment of solid tumours

Presented By

Dr Alanna Church , Boston Children’s Hospital, MA, USA

Trial

GAIN/iCAT2

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:48

Excellent prognosis for breast cancer patients with ultra-low-risk gene signature

Presented By

Dr Josephine Lopes Cardozo, Netherlands Cancer Institute, the Netherlands

Trial

Phase 3, MINDACT

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:45

Pembrolizumab benefits survival in MSI-H/dMMR metastastic colorectal cancer

Presented By

Prof. Thierry André, Sorbonne University, France

Trial

Phase 3, KEYNOTE 177

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:32

Adjuvant chemotherapy does not improve outcome in patients with locally advanced cervical cancer

Presented By

Prof. Linda Mileshkin, Peter MacCallum Cancer Center, Australia

Trial

Phase 3, OUTBACK

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:24

Olutasidenib demonstrates efficacy in patients with relapsed/refractory IDH1 mutant AML

Presented By

Dr Stéphane de Botton , Institute Gustave Roussy, France

Trial

Phase 2, 2102M 101

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:20

VISION trial shows improved survival with 177Lu-PSMA-617 in mCRPC

Presented By

Dr Michael Morris, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, VISION

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:18

Long-term results from ground-breaking melanoma trials

Presented By

Dr Jedd Wolchok (Memorial Sloan Kettering Cancer Center, NY, USA). Prof. Reinhard Dummer (University Hospital Zürich, Switzerland) , Prof. Georgina Long (Melanoma Institute, Australia)

Trial

CheckMate 067, COLUMBUS, ABC

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:10

IACS-6274 is well tolerated and biologically active in selected advanced tumours

Presented By

Dr Timothy Yap, MD Anderson Cancer Center, TX, USA

Trial

Phase 1

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:55

Circulating tumour DNA to evaluate response in children with neuroblastoma

Presented By

Dr Kevin Campbell, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 2, NANT2011-01

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:50

Olaparib benefits early breast cancer patients with BRCA1/2 germline mutation

Presented By

Prof. Andrew Tutt , Institute of Cancer Research, UK

Trial

OlympiA

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:47

Novel drug combination for recurrent ovarian cancer

Presented By

Prof. David O’Malley, Ohio State University, OH, USA

Trial

Phase 1/2, FORWARD II

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:43

Panitumumab added to 5-FU/LV effective as maintenance therapy in patients with mCRC

Presented By

Prof. Dominik Modest, Charité Universitätsmedizin Berlin, Germany

Trial

Phase 3, PANAMA

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:34

Abiraterone added to ADT + docetaxel nearly doubles survival in de novo mCSPC

Presented By

Dr Karim Fizazi , Institut Gustav Roussy, France

Trial

Phase 3, PEACE-1

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:19

Novel dual checkpoint blockade improves progression-free survival in melanoma

Presented By

Dr Evan Lipson, Johns Hopkins University, MD, USA

Trial

Phase 3, RELATIVITY-047

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:14

Immune-related adverse events are associated with efficacy of atezolizumab in patients with advanced NSCLC

Presented By

Dr Mark Socinski, AdventHealth Cancer Institute, FL, USA

Trial

Phase 3, IMpower130, IMpower132, IMpower150

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:02

Sustained efficacy of nivolumab/ipilimumab plus 2 cycles of chemotherapy in NSCLC

Presented By

Prof. Martin Reck, Lung Clinic Grosshansdorf, Germany

Trial

Phase 3, CheckMate 9LA

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:00

Platinum-based adjuvant chemotherapy in TNBC is not superior or non-inferior to capecitabine

Presented By

Prof. Ingrid Mayer, Vanderbilt University School of Medicine, TN, USA

Trial

Phase 3, ECOG-ACRIN EA1131

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 21:50

Dual HER2-blockade shows anti-tumour activity in patients with uterine cancer

Presented By

Dr Eugene Ahn, Cancer Treatment Centers of America, IL, USA

Trial

Phase 2, TAPUR

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 21:45

Post-nephrectomy pembrolizumab improves disease-free survival

Presented By

Dr Toni Choueiri , Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, KEYNOTE 564

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 21:23

Trastuzumab-deruxtecan showed promising activity in patients with HER2-expressing mCRC

Presented By

Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan

Trial

Phase 2, DESTINY-CRC01

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 21:10

Dalpiciclib benefits patients with HR-positive, HER2-negative advanced breast cancer

Presented By

Prof. Binghe Xu, Chinese Academy of Medical Sciences and Peking Union Medical College, China

Trial

Phase 3, DAWNA-1

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 20:52

Glutaminase inhibitor telaglenastat does not improve survival mRCC

Presented By

Dr Nizar Tannir, Houston University, TX, USA

Trial

Phase 3, CANTATA

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 20:26

Benefit of both I-O/chemo combo and I-O/I-O combo over chemotherapy alone in oesophageal squamous cell cancer

Presented By

Dr Ian Chau, Royal Marsden Hospital, UK

Trial

Phase 3, CheckMate 648

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 20:12

Patritumab deruxtecan (HER3-DXd) in EGFR TKI-resistant NSCLC

Presented By

Dr Jänne Pasi, Dana Farber Cancer Institute, MA, USA

Trial

Phase 1

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 20:08

Trastuzumab-deruxtecan showed clinical activity in patients with brain metastases

Presented By

Prof. Guy Jerusalem , CHU Liège, Belgium

Trial

Phase 2, DESTINY-Breast01

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 19:54

Benefit of I-O/chemo combo over chemotherapy alone in advanced GC/GEJC/EAC

Presented By

Prof. Markus Moehler, Mainz University Clinic, Germany

Trial

Phase 3, CheckMate 649

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 19:15

CYT-0851 shows promising anti-tumour activity across different tumour types

Presented By

Dr Ryan Lynch, Fred Hutchinson Cancer Research Center, WA, USA

Trial

Phase 1/2

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 13:57

Acalabrutinib as effective but better tolerated than ibrutinib in CLL

Presented By

Prof. John Byrd, Ohio State University Comprehensive Cancer Center, OH, USA

Trial

Phase 3, ELEVATE-RR

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 13:22

Perioperative chemotherapy and neoadjuvant multimodality therapy appear equally effective

Presented By

Prof. John Reynolds, Trinity St James Cancer Institute, Ireland

Trial

Phase 3, Neo-AEGIS

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 13:18

Promising efficacy and safety of feladilimab in recurrent/metastatic urothelial carcinoma

Presented By

Dr Arjun Balar , Perlmutter Cancer Center, NY, USA

Trial

Phase 1, INDUCE-1

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 12:30

Neoadjuvant therapy with nivolumab plus relatlimab is safe and effective in patients with stage III melanoma

Presented By

Dr Rodabe Amaria , MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 12:16

Luspatercept improved anaemia in patients with non-transfusion-dependent β-thalassaemia

Presented By

Prof. Ali Taher, American University of Beirut Medical Center, Lebanon

Trial

Phase 2, BEYOND

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:43

Personalising treatment for sickle cell disease

Presented By

Dr Erfan Nur, Amsterdam University Medical Center, the Netherlands

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:38

Gene therapy: A promising approach for hereditary haemoglobinopathies

Presented By

Dr Haydar Frangoul, Sarah Cannon Research Institute, USA

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:32

Acquired TTP: new treatments and updated guidelines

Presented By

Dr María Mingot-Castellano, Hospital Universitario Virgen del Rocío, Spain

Trial

HERCULES; TITAN

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:25

Maternal screening to prevent foetal and neonatal alloimmune thrombocytopenia

Presented By

Prof. Dick Oepkes, Leiden University Medical Centre, the Netherlands

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:21

Fostamatinib effectively increased platelet counts in immune thrombocytopenic purpura

Presented By

Prof. Waleed Ghanima, University of Oslo, Norway

Trial

Phase 3, FIT-1,-2,-3

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:16

Physiopathology of coagulopathy in haematological malignancies and COVID-19

Presented By

Prof. Marcel Levi, Amsterdam University Medical Centre, the Netherlands

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:11

Haemostatic abnormalities are associated with mortality in COVID-19

Presented By

Dr Yu Hu, Wuhan Union Hospital, China

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:07

Mechanisms of COVID-19 vaccine-induced thrombotic thrombocytopenia

Presented By

Prof. Andreas Greinacher, Universitätsmedizin Greifswald, Germany

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 15:03

COVID-19 vaccine-induced immune thrombotic thrombocytopenia: discovery and diagnosis

Presented By

Prof. Sabine Eichinger, Medical University Hospital of Vienna, Austria

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:58

Novel targets in myelofibrosis: overview of emergent therapies

Presented By

Prof. Francesco Passamonti, University of Insubria, Italy

Trial

PERSIST; SIMPLIFY; BOREAS

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:54

Immune therapy of multiple myeloma

Presented By

Prof. Noopur Raje, Massachusetts General Cancer Center, USA

Trial

KarMMA; CARTITUDE-1; UNIVERSAL

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:49

MAIA results confirm superior efficacy of daratumumab with standard-of-care

Presented By

Prof. Thierry Facon, University of Lille, France

Trial

Phase 3, MAIA

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:46

ANDROMEDA: Addition of daratumumab showed superior efficacy in patients with AL amyloidosis

Presented By

Prof. Efstathios Kastritis, National and Kapodistrian University of Athens, Greece

Trial

Phase 3, ANDROMEDA

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:31

Sabatolimab achieved durable responses in patients with high-risk MDS and AML

Presented By

Prof. Andrew Wei, Alfred Hospital and Monash University, Australia

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:27

Final analysis of EURO-SKI: primary endpoints met in chronic myeloid leukaemia

Presented By

Prof. Susanne Saußele, Heidelberg University, Germany

Trial

EURO-SKI

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:13

Favourable outcomes with zanubrutinib versus ibrutinib in patients with r/r CLL

Presented By

Prof. Peter Hillmen, University of Leeds, UK

Trial

Phase 3, ALPINE

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 14:08

Oral azacitidine improves overall survival in patients with acute myeloid leukaemia

Presented By

Prof. Hartmut Döhner, Universitätsklinikum Ulm, Germany

Trial

Phase 2, QUAZAR AML-001

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 13:59

Reduced-intensity conditioning ASCT is effective in older patients with AML

Presented By

Prof. Nigel Russell, Guy's Hospital, UK

Trial

AML16; AML18

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 13:55

ELEVATE-TN: Acalabrutinib shows long-term efficacy in chronic lymphocytic leukaemia

Presented By

Dr Jeff Sharman, US Oncology Network, USA

Trial

Phase 3, ELEVATE-TN

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 13:50

ELEVATE-RR: Acalabrutinib demonstrates similar efficacy and better safety versus ibrutinib

Presented By

Prof. Peter Hillmen, St James’s University Hospital, UK

Trial

Phase 3, ELEVATE-RR

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 13:43

Fixed 12 cycles and MRD-guided venetoclax consolidation effective in CLL

Presented By

Dr Mark-David Levin, Albert Schweitzer Hospital, the Netherlands

Trial

Phase 2, HOVON 139/GiVe

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 13:38

GLOW: Ibrutinib + venetoclax showed superior PFS as first-line CLL treatment

Presented By

Prof. Arnon Kater, Amsterdam University Medical Centres, the Netherlands

Trial

Phase 2, GLOW

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 13:33

Immuno-oncology agents are effective in treating classic Hodgkin’s lymphoma

Presented By

Dr Marc André, Centre Hospitalier Universitaire UCL Namur, Belgium

Trial

CheckMate 205; KEYNOTE-087

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 12:26

MATRix with ASCT: best long-term survival for primary CNS lymphoma

Presented By

Dr Gerald Illerhaus, Klinikum der Landeshauptstadt Stuttgart, Germany

Trial

Phase 2, IELSG32

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 12:05

Naratuximab emtansine + rituximab safe and effective in diffuse large B-cell lymphoma

Presented By

Dr Moshe Yair Levy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, USA

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 11:55

The journey ahead for CAR T-cell therapy in r/r follicular lymphoma

Presented By

Dr Bastian von Tresckow, University Hospital Essen, Germany

Trial

ZUMA-5; ELARA

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 11:47

ZUMA-5 vs SCHOLAR-5: Axicabtagene ciloleucel significantly improves FL outcome

Presented By

Prof. John Gribben, Barts Cancer Institute, UK

Trial

ZUMA-5; SCHOLAR-5

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 11:18

Promising chemo-free treatment options in r/r DLBCL

Presented By

Prof. Marco Ladetto, University del Piemonte Orientale, Italy

Trial

LOTIS-2

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 11:17

JAK inhibitors and bDMARDs not associated with increased risk of serious infections in RA

Presented By

Dr Anja Strangfeld, German Rheumatism Research Centre Berlin, Germany

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 23:53

Rituximab or JAK inhibitors increase the risk of severe COVID-19

Presented By

Dr Jeffrey Sparks, Brigham and Women’s Hospital, MA, USA

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 23:36

Efficacy and safety of secukinumab in juvenile idiopathic arthritis

Presented By

Dr Nicola Ruperto, IRCCS Istituto G. Gaslini, Italy

Trial

Phase 3, JUNIPERA

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 23:33

Intensified treatment regimen of anifrolumab for lupus nephritis is promising

Presented By

Prof. David Jayne, University of Cambridge, UK

Trial

Phase 2, TULIP-LN

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 23:29

Gene-diet and gene-weight interactions associated with the risk of gout

Presented By

Dr Chio Yokose, Massachusetts General Hospital, USA

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 23:26

SELECT-AXIS: 64-week results of upadacitinib in active ankylosing spondylitis

Presented By

Dr Atul Deodhar, Oregon Health & Science University, OR, USA

Trial

SELECT-AXIS 1

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 23:25

Air pollution predicts decreased response to biological treatment in rheumatic diseases

Presented By

Dr Giovanni Adami, University of Verona, Italy

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 23:22

PET/CT is a reliable measure of disease activity in LVV, but does not predict future relapses

Presented By

Dr Elena Galli , University of Modena and Reggio Emilia, Italy

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 23:14

Remote management of RA is a feasible alternative for outpatient follow-up

Presented By

Dr Mwidimi Ndosi, University of the West of England, UK

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 22:57

Updates on COVID-19 vaccines in patients with rheumatic disease

Presented By

Dr Victoria Furer, Tel Aviv Sourasky Medical Center, Israel

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 22:44

Passive smoking associated with an increased risk of RA

Presented By

Dr Yann Nguyen, Université Paris-Saclay, France

Trial

Cohort study, E3N-EPIC

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 22:24

Ultrasound is useful for disease monitoring in giant cell arteritis

Presented By

Dr Cristina Ponte, Hospital de Santa Maria Lisbon, Portugal

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 22:19

Guselkumab efficacious in PsA patients with inadequate response to TNF inhibition

Presented By

Dr Laura Coates , University of Oxford, UK

Trial

Phase 3, COSMOS

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 22:06

Immunomodulatory therapies for severe COVID-19: literature update

Presented By

Dr Alessia Alunno, University of Perugia, Italy

Trial

RECOVERY, REMAP-CAP

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 21:50

Faecal microbiota transplantation not effective in active peripheral PsA

Presented By

Dr Maja Skov Kragsnaes , University of Southern Denmark, Denmark

Trial

FLORA

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 21:08

TOVERA: Ultrasound is a promising biomarker of early treatment response

Presented By

Dr Maria Stoenoiu, Cliniques Universitaires Saint-Luc, Belgium

Trial

Phase 3, TOVERA

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 21:00

Risankizumab meets primary and ranked secondary endpoints in PsA

Presented By

Prof. Andrew Östör, Monash University, Australia

Trial

Phase 3, KEEPsAKE 2

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 20:10

The risks of polypharmacy in RA

Presented By

Dr Soraya Benamar, University Hospital of Montpellier, France

Trial

Cohort study, ESPOIR

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 20:02

ABBV-3373: A potential new therapeutic agent for RA

Presented By

Dr Frank Buttgereit, Charité University Medicine, Germany

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 19:05

Emerging therapies and future treatment directions in osteoarthritis

Presented By

Prof. Xavier Chevalier, University Paris-Est Créteil, France

Trial

FORWARD, CANTOS

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 18:35

Systemic lupus erythematosus: increased risk of severe infection

Presented By

Mr Kai Zhao, Simon Fraser University, Canada

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 18:31

Prognostic factors for minimal disease activity in early psoriatic arthritis revealed

Presented By

Prof. Tatiana Korotaeva, Nasonova Research Institute of Rheumatology, Russia

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 18:13

JAK inhibitors and bDMARDs show comparable effectiveness

Presented By

Mr Andrei Barbulescu, Karolinska Institutet, Sweden

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 10:23

Dapagliflozin fails to show a significant protective effect in COVID-19

Presented By

Prof. Mikhail Kosiborod, Saint Luke’s Mid America Heart Institute, USA

Trial

DARE-19

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 23:46

Favourable outcomes with transcatheter atrial appendage occlusion

Presented By

Dr Matthew Price, Scripps Clinic, USA

Trial

PROTECT AF, PREVAIL

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 23:31

PARADISE-MI: Sacubitril/valsartan not superior to ramipril in reducing HF events

Presented By

Prof. Marc Pfeffer, Brigham and Women’s Hospital, USA

Trial

Phase 3, PARADISE-MI

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 23:29

STRENGTH trial fails to demonstrate cardioprotective effect of omega-3 fatty acids

Presented By

Dr Steven Nissen, Cleveland Clinic, USA

Trial

STRENGTH, REDUCE-IT

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 23:25

Men and women benefit equally from early aspirin withdrawal following PCI

Presented By

Dr Birgit Vogel, Icahn School of Medicine, USA

Trial

TWILIGHT

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 23:24

Apixaban outcomes similar to current standard of care following TAVR

Presented By

Prof. Jean-Philippe Collet, Sorbonne Université, France

Trial

ATLANTIS

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 23:14

No difference in ischaemic risk or bleeding with low vs high-dose aspirin for secondary prevention: Lessons and questions from the ADAPTABLE trial

Presented By

Prof. William Schuyler Jones , Duke Clinical Research Institute, USA

Trial

ADAPTABLE

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 23:03

Etripamil nasal spray significantly improves PSVT-related symptoms

Presented By

Dr Bruce Stambler, Piedmont Heart Institute, USA

Trial

Phase 3, NODE-301

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 22:38

Similar outcomes with fractional flow reserve and angiography-guided revascularisation

Presented By

Dr Etienne Puymirat, Hôpital Européen Georges-Pompidou

Trial

FLOWER-MI

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 22:30

Evinacumab lowers triglyceride levels in severe hypertriglyceridaemia

Presented By

Dr Robert Rosenson, Icahn School of Medicine at Mount Sinai, USA

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 22:29

Rivaroxaban reduces total ischaemic events after peripheral artery revascularisation

Presented By

Dr Rupert Bauersachs, Klinikum Darmstadt, Germany

Trial

VOYAGER PAD

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 22:13

Therapeutic anticoagulation not superior to prophylactic anticoagulation in COVID-19

Presented By

Prof. Renato Lopes, Duke University Medical Center, USA

Trial

Coalition ACTION

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 22:02

Older adults with heart failure benefit from rehabilitation programme

Presented By

Dr Dalane Kitzman , Wake Forest School of Medicine, NC, USA

Trial

REHAB-HF

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 21:42

Moderate hypothermia not superior to mild hypothermia following out-of-hospital cardiac arrest

Presented By

Dr Michel Le May , University of Ottawa, Canada

Trial

CAPITAL-CHILL

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 21:16

Quality improvement intervention fails to improve care for patients with heart failure

Presented By

Prof. Adam DeVore, Duke University School of Medicine, USA

Trial

CONNECT-HF

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 20:54

TALOS-AMI: Exploring outcomes after switching to clopidogrel versus ticagrelor at 1 month from MI

Presented By

Prof. Kiyuk Chang, Seoul St. Mary’s Hospital, South Korea

Trial

TALOS-AMI

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 20:46

Clopidogrel monotherapy associated with better net outcomes relative to aspirin monotherapy 6-18 months after PCI

Presented By

Prof. Hyo-Soo Kim, Seoul National University Hospital, South Korea

Trial

HOST-EXAM

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 19:52

Preliminary results encouraging for EVOQUE tricuspid valve replacement

Presented By

Dr Susheel Kodali , Columbia University Medical Center, USA

Trial

TRISCEND

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 18:18

Novel use of ivabradine in reversible cardiomyopathy

Presented By

Dr Eric Torkildsen, Lehigh Valley Health Network, USA

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 18:15

Atorvastatin does not reduce mortality in COVID-19

Presented By

Dr Behnood Bikdeli, Yale University School of Medicine, USA

Trial

INSPIRATION

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 18:08

Health equity and the role of the cardiologist: 7 priorities to consider

Presented By

Prof. Michelle Albert, University of California, USA

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 17:39

Ablation-based rhythm control as effective as rate control in AF and HF

Presented By

Prof. Anthony Tang, University of Ottawa, Canada

Trial

RAFT-AF

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 14:41

Finerenone reduces the risk of AF onset in patients with CKD and diabetes

Presented By

Prof. Gerasimos Filippatos, Attikon University Hospital, Greece

Trial

Phase 3, FIDELIO-DKD

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 13:46

Better outcomes with invasive strategy if anatomic complete revascularisation is possible

Presented By

Dr Gregg Stone, Mount Sinai Medical Centre, USA

Trial

ISCHEMIA

Conference

ACC 2021

Type

Peer-reviewed article

9 July 2021 10:20

Air pollution in winter linked to more hospital admissions in ILD patients

Presented By

Dr Marya Ghazipura, Marron Institute of Urban Management, NY, USA

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:56

Tobacco biomarkers do not improve prediction of lung cancer risk

Presented By

Dr Christine Lambert, University of Minnesota, USA

Trial

PLCO

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:56

Vaping identified as risk factor for asthma

Presented By

Prof. Theresa To, The Hospital for Sick Children, ON, Canada

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:56

Advanced cystic fibrosis – improved lung function with long-term triple therapy

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:56

IPF patients benefit from early antifibrotic therapy

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:55

Obesity: A risk factor for new-onset asthma and worse asthma control

Presented By

Prof. Fernando Holguin, University of Colorado Asthma Research and Education, CO, USA

Trial

Cohort study, CARDIA

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:52

Metabolic dysfunction and lung disease: children are no small adults

Presented By

Prof. Erick Forno, University of Pittsburgh, PA, USA

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:52

Possible aetiologies for COPD exacerbations – more evidence is needed

Presented By

Prof. Surya P. Bhatt, Birmingham School of Medicine, AL, USA

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:50

Does COPD plus COVID-19 equal higher mortality?

Presented By

Dr Jacob Schwartz, Lenox Hill Hospital, NY, USA

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:50

Biomarkers for acute exacerbations in COPD are required

Presented By

Prof. Don D. Sin, University of British Columbia, BC, Canada

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:50

Severe exacerbations: A key driver of all-cause mortality in COPD patients

Presented By

Prof. Manoj J. Mammen, Jacobs School of Medicine and Biomedical Sciences, NY, USA

Trial

Phase 3, IMPACT

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:50

Men and women with COPD differ in many ways

Presented By

Dr Franziska Trudzinski, University Hospital Centre Heidelberg, Germany

Trial

Cohort study, cosyconet

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:50

Younger adults with COPD at higher health risk than previously thought

Presented By

Dr Alina J. Blazer, University of Toronto, ON, Canada

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:50

OSA: A risk factor for earlier cognitive decline

Presented By

Prof. Andrew W. Varga, Mount Sinai Integrative Sleep Center, NY, USA

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:49

Subgroup of patients with high heart rate response and coronary artery disease benefit from CPAP

Presented By

Prof. Ali Azarbarzin, Harvard Medical School, MA, USA

Trial

Phase 4, RICCADSA

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:49

Association between positive airway pressure treatment adherence and COVID-19 infection rates

Presented By

Dr Dennis Hwang, Kaiser Permanente, CA, USA

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:49

“As-needed” inhaled corticosteroid therapy for mild asthma – what is the evidence?

Presented By

Prof. Kaharu Sumino, Prof. Anne Dixon

Trial

SYGMA 1 and 2, PRACTICAL, START

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:48

IL-4/13 blocker successful in treatment of paediatric moderate-to-severe asthma

Presented By

Prof. Leonhard B. Bacharier, Vanderbilt University Medical Center, TN, USA

Trial

VOYAGE

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:48

Benralizumab lives up to its phase 3 results in real-world findings

Presented By

Dr Donna Carstens, AstraZeneca, Wilmington, DE, USA

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:48

Tezepelumab – good success rates in various types of severe asthma

Presented By

Prof. Michael E. Wechsler, National Jewish Health, Denver, CO, USA

Trial

Phase 3, NAVIGATOR

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:48

Antibody treatment for COVID-19: a combination is successful

Presented By

Dr Julie V. Philley, University of Texas Health Science Center, USA

Trial

REGN-COV 2067

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:47

Air pollution: an underestimated negative prognostic factor for COVID-19

Presented By

Prof. Meredith McCormack, John Hopkins University, MD, USA

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:46

Healthcare workers vulnerable to SARS-CoV-2 infections

Presented By

Prof. Reynold A. Panettieri Jr, Rutgers Institute for Translational Medicine and Science, NJ, USA

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:46

Genetic risk variants responsible for COVID-19 predisposition

Presented By

Dr Ana Hernandez Cordero, Centre for Heart Lung Innovation, University of British Columbia, Canada

Conference

ATS 2021

Type

Peer-reviewed article

5 July 2021 13:46

Individualised approaches key to success in resynchronisation therapy non-responders

Presented By

Prof. Jagmeet Singh, Massachusetts General Hospital, USA

Conference

EHRA 2021

Type

Peer-reviewed article

16 June 2021 18:27

Antiarrhythmic drug treatment in children: evidence-based recommendations

Presented By

Dr Nico Blom, Leiden University Medical Center, the Netherlands

Conference

EHRA 2021

Type

Peer-reviewed article

16 June 2021 17:09

The importance of cardiac imaging in patients with congenital heart disease

Presented By

Dr Ivo Roca-Luque, Hospital Clinic de Barcelona, Spain

Conference

EHRA 2021

Type

Peer-reviewed article

16 June 2021 16:58

EHRA expert statement on pacemakers and intracardial devices: “watch out for the little old lady”

Presented By

Prof. Thomas Starck, German Heart Centre Berlin, Germany

Conference

EHRA 2021

Type

Peer-reviewed article

16 June 2021 16:27

5-Year efficacy of subcutaneous implantable cardioverter defibrillator

Presented By

Prof. Pier Lambiase, University College London, United Kingdom

Trial

EFFORTLESS S-ICD

Conference

EHRA 2021

Type

Peer-reviewed article

16 June 2021 16:18

EHRA Practical Guide on cardiac imaging in electrophysiology

Presented By

Prof. Thomas Deneke, Heart Centre Bad Neustadt, Germany

Conference

EHRA 2021

Type

Peer-reviewed article

16 June 2021 14:37

Novel diagnostic score accurately differentiates between athlete’s heart and ARVC

Presented By

Dr Valentina Rossi, University Hospital Zurich, Switzerland

Conference

EHRA 2021

Type

Peer-reviewed article

16 June 2021 14:28

The precordial R-prime wave: a discriminator between cardiac sarcoidosis and ARVC

Presented By

Dr Jarieke Hoogendoorn, Leiden University Medical Centre, the Netherlands

Conference

EHRA 2021

Type

Peer-reviewed article

16 June 2021 14:26

Limited added value of ECG-based mortality prediction in COVID-19 patients using machine learning

Presented By

Dr Hidde Bleijendaal, Amsterdam University Medical Center, the Netherlands

Conference

EHRA 2021

Type

Peer-reviewed article

16 June 2021 14:22

Early rhythm-control ablation: insight from the CHARISMA registry

Presented By

Dr Luca Segreti, Azienda Ospedaliero, Universitaria Pisana, Italy

Trial

CHARISMA

Conference

EHRA 2021

Type

Peer-reviewed article

16 June 2021 14:17

Personalised pulmonary vein isolation procedure feasible and effective

Presented By

Dr Cheryl Terés, Teknon Medical Centre, Spain

Trial

Ablate-by-LAW

Conference

EHRA 2021

Type

Peer-reviewed article

16 June 2021 14:11

Pulmonary vein isolation: cryoballoon non-inferior to radiofrequency ablation

Presented By

Dr Bastian Kaiser, Robert-Bosch-Hospital Bad Cannstatt, Germany

Conference

EHRA 2021

Type

Peer-reviewed article

16 June 2021 13:21

Pulmonary vein isolation lesions plus personalised methods shows promising results

Conference

EHRA 2021

Type

Peer-reviewed article

16 June 2021 13:18

Predictors of young-onset atrial fibrillation

Presented By

Dr Amitai Segev, Sheba Medical Centre, Israel

Conference

EHRA 2021

Type

Peer-reviewed article

16 June 2021 13:11

RACE 3 long-term results show fading benefit of targeted therapies in AF and HF

Presented By

Prof. Michiel Rienstra, University Medical Center Groningen, the Netherlands

Trial

RACE 3

Conference

EHRA 2021

Type

Peer-reviewed article

16 June 2021 13:07

Deep dive into EAST-AFNET 4 results on early rhythm-control in atrial fibrillation

Presented By

Dr Andreas Metzner, University Heart & Vascular Centre Hamburg, Germany

Trial

EAST-AFNET 4

Conference

EHA 2021

Type

Peer-reviewed article

16 June 2021 13:00

Cryo-FIRST study: improved AF and QoL outcomes with cryoballoon versus drug therapy

Presented By

Dr Nikola Pavlović, University Hospital Sestre Milosrdnice, Croatia

Trial

Phase 4, Cryo-FIRST

Conference

EHRA 2021

Type

Peer-reviewed article

16 June 2021 12:43

STROKESTOP: Benefits of systematic screening for atrial fibrillation

Presented By

Dr Emma Svennberg, Karolinska Institute, Denderyd Hospital, Sweden

Trial

STROKESTOP

Conference

EHRA 2021

Type

Peer-reviewed article

16 June 2021 12:38

Mast cell and neutrophil involvement in MS activity

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:52

Dysmetabolism may drive MS progression

Presented By

Dr Vijayshree Yadav, Oregon Health & Science University, USA

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:52

Serum NfL associated with clinical disability and brain atrophy

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:52

Plasma NfL and GFAP predict disability worsening in non-active secondary progressive MS

Trial

Phase 3, EXPAND

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:52

Serum NfL projects development of definite MS

Trial

Phase 3, REFLEX

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:52

Natalizumab versus fingolimod in subgroups of MS patients

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:51

Long-term safety of atogepant as migraine prophylaxis

Presented By

Prof. Messoud Ashina, University of Copenhagen, Denmark

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:51

Ublituximab versus teriflunomide in relapsing MS

Trial

Phase 2, ULTIMATE I, ULTIMATE II

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:50

Intranasal zavegepant effective treatment for acute migraine

Trial

Phase 3

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:50

The neurological impact of COVID-19

Presented By

Dr Anthony Fauci (National Institute of Allergy and Infectious Diseases, USA) & Dr Walter Koroshetz (National Institute of Neurological Disorders and Stroke, USA)

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:50

Tolebrutinib reduces brain lesions in very active MS

Trial

Phase 2

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:50

Ubrogepant for acute treatment of perimenstrual migraine

Trial

Phase 3

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:50

Chemosensory dysfunction often persistent after COVID-19

Presented By

Dr Nicolas Bussière, University of Quebec, Canada

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:50

Fenebrutinib at highest dose generally well tolerated

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:49

CGRP antagonists and complications in patients with Raynaud’s phenomenon

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:49

Obstructive sleep apnoea associated with lower cognition

Presented By

Dr David Colelli, University of Toronto, Canada

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:49

Pandemic results in decreased global stroke care

Presented By

Dr Thanh Nguyen, Boston University School of Medicine, MA, USA

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:49

Extraordinary transformation of epilepsy care in Ontario

Presented By

Dr O. Carter Snead III, University of Toronto, Canada

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:49

NfL is a better marker for neurodegeneration than T-tau

Presented By

Mr Jordan Marks, Mayo Clinic, MN, USA

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:49

Stroke uncommon in critically ill COVID-19 patients

Presented By

Dr Jonathon Fanning, University of Queensland, Australia

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:49

No neurodevelopmental effects of foetal antiseizure medication

Presented By

Dr Kimford Meador, Stanford University, CA, USA

Trial

MONEAD

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:44

Monoclonal antibody rapidly reduces brain amyloid

Presented By

Dr Chad Swanson, Neurology Business Group, Eisai Inc., NJ, USA

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:44

Neurologic symptoms in children with multisystem inflammatory syndrome

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:44

Durable seizure frequency reduction with cenobamate

Trial

Phase 3

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:43

Breast cancer treatment decreases risk of dementia

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:43

COVID-19 could cause novel seizures in patients without epilepsy

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:43

Predicting long-term prognosis in paediatric MS patients

Presented By

Dr Ermelinda De Meo, San Raffaele Hospital, Italy

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:42

Pimavanserin does not worsen motor function in patients with neurodegenerative disease

Trial

HARMONY, 019, 046, 032

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:42

MS therapies influence COVID-19 severity

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:42

Efficacy and safety of eptinezumab in acute migraine

Trial

Phase 3, RELIEF

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:41

Soticlestat in children with Dravet and Lennox-Gastaut

Trial

Phase 2, ELEKTRA

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:41

Functional and survival benefits of AMX0035 in ALS

Presented By

Dr Sabrina Paganoni, Massachusetts General Hospital, MA, USA

Trial

Phase 2, CENTAUR

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:39

Remission with rituximab in refractory generalised myasthenia gravis

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:39

Novel AAV-based gene therapy for Duchenne muscular dystrophy

Trial

Phase 2, SRP-9001-102

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:38

Autoimmune mechanisms implicated in Parkinson’s disease

Presented By

Dr Camille Michaud, University of Montreal Hospital Research Centre, Canada

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:36

Stable long-term effects of deep brain stimulation in Parkinson’s disease

Trial

CSP468 VA/NINDS, INTREPID

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:36

Novel non–D2-receptor-binding treatment for Parkinson’s disease psychosis

Presented By

Dr Stuart Isaacson, Parkinson's Disease and Movement Disorders Center of Boca Raton, FL, USA

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:35

Troriluzole for spinocerebellar ataxia

Presented By

Dr Melissa W. Beiner, Biohaven Pharmaceuticals, CT, USA

Trial

Phase 3, BHV4157-201

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:34

Lower-sodium oxybate for hypersomnia

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:34

Can linoleic acid help prevent stroke?

Presented By

Dr David Wu, University of Minnesota Medical School, MN, USA

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:34

No association between SSRIs and risk of ICH

Presented By

Dr Mithilesh Siddu, University of Miami, FL, USA

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:33

Gene therapy for Leber hereditary optic neuropathy

Trial

Phase 3, RESCUE, REVERSE

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:33

Patisiran for hATTR amyloidosis: 24-month efficacy and safety

Trial

APOLLO

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:32

Vutrisiran for hATTR amyloidosis with polyneuropathy

Presented By

Dr David Adams, Centre Hospitalier Universitaire Bicêtre, France

Trial

Phase 3, HELIOS-A

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:31

10 kHz spinal cord stimulation for painful diabetic neuropathy

Presented By

Prof. Erika Petersen, University of Arkansas, USA

Trial

SENZA-PDN

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:30

Effectiveness of public awareness campaigns on stroke signs

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:25

Blood pressure reduction after LVO potential target for intervention

Conference

AAN 2021

Type

Peer-reviewed article

16 June 2021 11:23

DOACs and bleeding: the role of antidotes

Presented By

Dr Kaveshree Govender, Milpark Hospital, South Africa

Trial

RE-VERSE AD

Conference

EHRA 2021

Type

Peer-reviewed article

16 June 2021 10:26

2021 EHRA practical guide: DOACs in pre-operative and bleeding patients

Presented By

Prof. Thomas Vanassche, University Hospitals Leuven, Belgium

Conference

EHRA 2021

Type

Peer-reviewed article

15 June 2021 15:37

Allergies: an underrated factor in alopecia pathogenesis

Presented By

Prof. Natasha Mesinkovska, UC Irvine School of Medicine, CA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:45

Psoriasis and hidradenitis suppurativa during COVID-19: keep calm and carry on

Presented By

Prof. April W. Armstrong, University of Southern California, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:32

Psoriasis: The treatment armamentarium continues to grow

Presented By

Prof. Bruce Strober, Yale University, CT, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:32

COVID-19 in children – cutaneous involvement is common

Presented By

Prof. Elena B. Hawryluk, Massachusetts General Hospital, MA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:31

Psoriasis management in times of COVID-19: the knowledge is growing steadily

Presented By

Prof. Joel Gelfand, University of Pennsylvania Perelman School of Medicine, PA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:31

Cutaneous reactions after COVID-19 vaccination: an update

Presented By

Prof. Esther Freeman, Harvard Medical School, MA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:30

Sunless tanning and other developments in sun protection

Presented By

Dr Henry Lim, Henry Ford Health System, MI, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:30

Comorbidity does not influence crisaborole efficacy in atopic dermatitis

Trial

Phase 3, CrisADe CORE 1 and 2

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:30

Comorbidity is common in adult and paediatric atopic dermatitis patients

Presented By

Prof. Jonathan Silverberg, George Washington University, WA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:30

Lower burden of high-risk atherosclerotic plaques in psoriasis patients treated with biologics

Presented By

Prof. Nehal N. Mehta, National Heart, Lung, and Blood Institute, MD, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:30

Botulinum toxin A: a contradictory role in hair loss

Presented By

Prof. Natasha Mesinkovska, UC Irvine School of Medicine, CA, USA

Conference

aad vmx 2021

Type

Peer-reviewed article

7 June 2021 13:21

New therapeutic options add value to current acne treatment

Presented By

Dr John Barbieri, Perelman School of Medicine, University of Pennsylvania, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:20

Significant improvements in the system armamentarium for AD treatment

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:20

Nicotinamide and probiotics can support acne therapy

Presented By

Prof. Juliana Choi, Penn Dermatology Perlman, PA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:15

Convincingly low levels of infections with long-term tildrakizumab

Trial

reSURFACE 1 and 2

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:15

No increased risk of infection with long-term dupilumab for atopic dermatitis

Trial

LIBERTY AD OLE

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:15

Topical pan-JAK inhibitor cream safe and efficacious in atopic dermatitis

Presented By

Prof. Jonathan Silverberg, George Washington University, WA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:10

Atopic dermatitis in children has a severe impact on their families

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:05

IL-17 inhibitor effective in axial manifestations of psoriatic arthritis

Trial

Phase 3, MAXIMISE

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:00

Platelet-rich plasma in androgenetic alopecia – hype or hope?

Presented By

Prof. Ronda S. Farah, University of Minnesota, MN, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:00

‘Maskne’ – How can it be managed?

Presented By

Prof. Juliana Choi, Penn Dermatology Perlman, PA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:00

Meaningful amelioration of quality of life in paediatric AD patients on dupilumab

Trial

Phase 3, LIBERTY AD PEDS

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 13:00

Small molecule effective in moderate-to-severe psoriasis

Presented By

Prof. April Armstrong, Keck School of Medicine at UCLA, CA, USA

Trial

Phase 3, POETYK PSO-1 and 2

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 10:50

Bruton’s tyrosine kinase inhibition promising for pemphigus vulgaris

Presented By

Prof. Dedee F. Murrell, St George Hospital, University of New South Wales, Australia

Trial

Phase 2, BELIEVE

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 10:48

Bimekizumab superior to secukinumab in psoriasis

Presented By

Prof. Kristian Reich, University Medical Center Hamburg-Eppendorf, Germany

Trial

Phase 3, BE RADIANT

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 10:47

Etrasimod – a new mode of action for treatment of atopic dermatitis

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 10:45

Women at higher risk for dermatologic side effects during immunotherapy

Presented By

Mr Jordan T. Said, Harvard School of Medicine, MA, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 10:44

Novel easy-to-use foam formulation clears scalp psoriasis in one-third of patients

Presented By

Prof. Leon Kircik, Icahn School of Medicine at Mount Sinai Medical Center, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 10:43

Anti-cholinergic gel demonstrates superior long-term tolerability and efficacy in axillary hyperhidrosis

Presented By

Dr Brandon M. Kirsch, Kirsch Dermatology, USA

Conference

AAD VMX 2021

Type

Peer-reviewed article

7 June 2021 10:42

Mavacamten significantly improves QoL of patients with hypertrophic cardiomyopathy

Presented By

Prof. John Spertus, Saint Luke’s Mid America Heart Institute, USA

Trial

Phase 3, EXPLORER-HCM

Conference

ACC 2021

Type

Peer-reviewed article

15 May 2021 22:34

Poorer outcomes in bladder cancer predicted by race/ethnicity and gender

Presented By

Dr Shaakir Hasan, New York Proton Centre, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 15:03

Enfortumab vedotin as a promising treatment option for bladder cancer: phase 3 results

Presented By

Dr Thomas Powles, Barts Cancer Centre, UK

Trial

Phase 3, EV-301

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 15:03

Enfortumab vedotin as a promising treatment option for bladder cancer: phase 2 results

Presented By

Dr Arjun Vasant Balar, NYU Langone Medical Oncology, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 15:02

New standard of care recommended for patients with upper tract urothelial cancer

Presented By

Dr Alison Birtle, Rosemere Cancer Centre, UK

Trial

Phase 3, POUT

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 15:02

Signature DNA alterations in subtypes of bladder cancer

Presented By

Dr Andrew Thomas Lenis, Memorial Sloan Kettering Cancer Centre, New York, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 15:02

ACE inhibitors associated with superior responses in bladder cancer

Presented By

Dr Jonathan Thomas, Beth Israel Deaconess Medical Centre, Massachusetts, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 15:02

New prediction model for brain metastasis in germ cell tumours

Presented By

Dr Ryan Ashkar, Indiana University Simon Comprehensive Cancer Centre, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:58

Reduction in radiation exposure is possible in testicular seminoma surveillance

Presented By

Prof. Robert Huddart, Royal Marsden Hospital and Institute of Cancer Research, UK

Trial

Phase 3, TRISST

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:58

New therapeutic option for early metastatic seminoma

Principal Investigator

Prof. Siamak Daneshmand, University of Southern California, USA

Trial

Phase 2, SEMS

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:57

Superior clinical outcomes and QoL with nivolumab plus cabozantinib in RCC

Presented By

Prof. David Cella, Robert H. Lurie Comprehensive Cancer Centre, Northwestern University, Illinois, USA

Trial

Phase 3, CheckMate 9ER

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:53

Lenvatinib plus pembrolizumab prolongs survival in renal cell carcinoma

Presented By

Dr Robert Motzer, Memorial Sloan Kettering Cancer Centre, New York, USA

Trial

Phase 3, CLEAR

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:53

Inflammatory markers may guide treatment decisions in metastatic renal cell cancer

Presented By

Ms Vishwani Chauhan, University of Edinburgh, UK

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:53

Clinical trial exclusion criteria may lead to lack of evidence in real-world patients: how do the excluded fare?

Presented By

Dr Diana Maslov, Ochsner Health System, Louisiana, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:53

Axitinib offers hope for improving renal cell cancer surgical outcomes

Presented By

Prof. Grant Stewart, University of Cambridge, UK

Trial

Phase 2, NAXIVA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:53

Cabozantinib as possible new first-line therapy in translocation renal cell carcinoma

Presented By

Dr Jonathan Thouvenin, Institut de Cancerologie Strasbourg Europe, France

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:52

Predictors of oral anti-cancer agent utilisation in renal cell carcinoma

Presented By

Prof. Stephanie Wheeler, University of North Carolina, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:52

Denosumab plus pembrolizumab in advanced clear cell renal cell carcinoma

Presented By

Dr Craig Gedye, Calvary Mater Newcastle, Australia

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:52

Prognosis of penile cancer associated with HPV status

Presented By

Dr Adithya Chennamadhavuni, University of Iowa, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:50

Lu177 as a promising new therapy for metastatic prostate cancer

Presented By

Dr Michael Hofman, Peter MacCallum Cancer Centre, Australia

Trial

Phase 2, TheraP

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:49

Role of prostate cancer genomics is evolving

Presented By

Dr Ashley Ross, Feinberg School of Medicine, Northwestern University, Chicago, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:49

Apalutamide prolongs progression-free survival in prostate cancer

Presented By

Dr Dana Rathkopf, Memorial Sloan Kettering Cancer Center, New York, USA

Trial

Phase 3, ACIS

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:49

Dose-intensified radiation therapy fails to provide better outcomes in prostate cancer

Presented By

Prof. Pirus Ghadjar, Charité Universitätsmedizin Berlin, Germany

Trial

Phase 3, SAKK 09/10

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:48

Intrinsic tumour biology may be predictive of treatment response in prostate cancer

Presented By

Prof. Felix Feng, University of California San Francisco, USA

Trial

Phase 3, SPARTAN

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:46

Final TITAN trial results favour use of apalutamide

Presented By

Dr Kim Chi, British Columbia Cancer and Vancouver Prostate Centre, Canada

Trial

Phase 3, TITAN

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:46

First-line pembrolizumab shows superior PFS in MSI-H/dMMR mCRC

Presented By

Dr Kai-Keen Shiu, University College London Hospitals NHS Foundation Trust, UK

Trial

Phase 3, KEYNOTE-177

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:52

Short-course radiotherapy with delayed surgery better for elderly rectal cancer patients

Presented By

Dr Eric Francois, Centre Antoine-Lacassagne, France

Trial

PRODIGE 42-GERICO 12 NACRE

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:50

Bemarituzumab response for gastric/GEJ cancers correlates with FGFR2b levels

Presented By

Prof. Zev Wainberg, UCLA, USA

Trial

Phase 2, FIGHT

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:50

Circulating tumour DNA predicts recurrence in colorectal cancer

Presented By

Tenna Henriksen, Aarhus University, Denmark

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:48

Gut microbiome DELIVERs nivolumab forecast in gastric cancer

Presented By

Prof. Yu Sunakawa, St Marianna University School of Medicine, Kanagawa, Japan

Trial

DELIVER

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:47

Ivosidenib in second-line improves OS in IDH1-mutant cholangiocarcinoma

Presented By

Dr Andrew Zhu, Harvard Medical School, USA

Trial

Phase 3, ClarIDHy

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:46

Neoadjuvant pembrolizumab in locally-advanced rectal cancer: primary results

Presented By

Dr Osama Rahma, Dana-Farber Cancer Institute, USA

Trial

Phase 2

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:46

OS benefit for trifluridine/tipiracil in advanced gastric cancer from third-line onward

Presented By

Prof. Josep Tabernero, Vall d'Hebron Institute of Oncology, Spain

Trial

TAGS

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:44

Prognostic value of tumour deposits in stage 3 colon cancer patients

Presented By

Dr Romain Cohen, Mayo Clinic, USA

Trial

Phase 3, CALGB/SWOG 80702

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:43

Final phase 2 results of second-line infigratinib for advanced cholangiocarcinoma

Presented By

Prof. Milind Javle, University of Texas MD Anderson Cancer Center, USA

Trial

Phase 2

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:42

Neoadjuvant chemotherapy does not increase perioperative complications in thoracic oesophageal cancer

Presented By

Prof. Kazuo Koyanagi, National Cancer Center, Japan

Trial

Phase 3, JCOG 1109

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:42

Ipilimumab/nivolumab plus panitumumab in patients with microsatellite-stable mCRC

Presented By

Dr Michael Lee, University of Texas MD Anderson Cancer Center, USA

Trial

Phase 2

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:41

Adjuvant nivolumab: good quality-of-life

Presented By

Prof. Eric Van Cutsem, University of Leuven, Belgium

Trial

Phase 3, CheckMate 577

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:40

Preliminary surgery salvage data after watch & wait policy from OPERA trial

Trial

Phase 3, OPERA

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:40

Landmark OS for HCC, updated IMbrave150 data

Presented By

Prof. Richard Finn, UCLA, USA

Trial

Phase 3, IMbrave150

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:39

Adding docetaxel to adjuvant S-1 reduces gastric cancer relapse

Presented By

Prof. Kazuhiro Yoshida, Gifu University, Japan

Trial

Phase 2, JACCRO GC-07

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:38

Second-line pembrolizumab after progression on sorafenib benefits OS/PFS in advanced HCC

Presented By

Prof. Philippe Merle, University Hospital Lyon, France

Trial

Phase 3, KEYNOTE-240

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:37

Predicting resistance to first-line FOLFOX plus bevacizumab in mCRC using circulating markers

Presented By

Prof. Thomas Seufferlein, University of Ulm, Germany

Trial

Phase 1/2, PERMAD

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:37

Phase 2 study supports first-line pembrolizumab in advanced HCC

Presented By

Dr Jean-Luc van Laethem, Hôpital Erasme–Université Libre de Bruxelles, Belgium

Trial

Phase 2, KEYNOTE-224

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:35

Final OS analyses comparing trifluridine/tipiracil + bevacizumab versus capecitabine + bevacizumab in first-line unresectable mCRC patients noneligible for intensive therapy

Presented By

Prof. Eric Van Cutsem, KU Leuven, Belgium

Trial

Phase 2, TASCO1

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:35

Yttrium-90 (Y-90) glass microspheres for HCC

Presented By

Prof. Robert Lewandowski, Northwestern University, Chicago, USA

Trial

LEGACY

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:33

Maintenance treatment with cetuximab versus observation in RAS wildtype mCRC

Presented By

Dr Valérie Boige, Institut Gustave Roussy, France

Trial

Phase 2, PRODIGE 28-time UNICANCER

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:33

Duloxetine ameliorates oxaliplatin-induced peripheral neuropathy

Presented By

Dr Jeffrey Chi, Northwell Health Cancer Institute, NY, USA

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:31

Sorafenib extends PFS, but not OS, for HCC transcatheter arterial chemoembolisation

Presented By

Prof. Masatoshi Kudo, Kindai University, Osaka, Japan

Trial

Phase 2, TACTICS

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:30

Zanidatamab provides ORR in HER2+ biliary tract cancer

Presented By

Prof. Funda Meric-Bernstam, University of Texas MD Anderson Cancer Center, USA

Trial

Phase 1

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:28

Borderline resectable pancreatic cancer: phase 2 results

Presented By

Prof. Matthew H. Katz, University of Texas MD Anderson Cancer Center, USA

Trial

Phase 2, Alliance A021501

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:12

No survival benefit for olaparib in BRCA-mutated metastatic pancreatic cancer

Presented By

Prof. Talia Golan, Sheba Medical Center, Israel

Trial

Phase 3, POLO

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:02

Metastatic pancreatic adenocarcinoma: second-line naI-IRI plus 5-FU/LV

Presented By

Prof. Kyunghye Bang, Asan Medical Center, Korea

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 10:59

COVID-19 impact on gastrointestinal cancer care

Presented By

Dr Nicholas Perkons, University of Pennsylvania, Philadelphia, USA)

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 10:59

Treatment delay for cholangiocarcinoma adjuvant therapy does not affect OS

Presented By

Dr Matthew Parsons, University of Utah, USA

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 10:58

No benefit of adding axitinib to ocreotide acetate in non-pancreatic neuroendocrine tumours

Presented By

Dr Rocio Garcia-Carbonero, Hospital Universitario 12 de Octubre, Spain

Trial

Phase 3, AXINET trial-GETNE-1107

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 10:44

Phase 2 abemaciclib trial in patients with advanced NETs

Presented By

Prof. Kaylyn Kit Man Wong, University of Washington, USA

Trial

Phase 2

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 10:39

PAD: Rivaroxaban reduces VTE risk after revascularisation

Presented By

Dr Connie Hess; Prof. Judith Hsia

Trial

VOYAGER PAD

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 11:45

Sotatercept: potential new treatment option for PAH

Presented By

Prof. Vallerie McLaughlin, University of Michigan, USA

Trial

Phase 2, PULSAR

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 11:37

Finerenone lowers CV events in diabetic CKD patients

Presented By

Prof. Gerasimos Filippatos, National and Kapodistrian University of Athens, Greece

Trial

Phase 3, FIDELIO-DKD

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 11:33

Mavacamten effective in obstructive hypertrophic cardiomyopathy

Presented By

Dr Sheila Hegde, Brigham and Women’s Hospital, USA

Trial

Phase 3, EXPLORER-HCM

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 11:28

Children exposed to tobacco smoke have worse heart function as adults

Presented By

Dr Chigozie Ezegbe, University of Tasmania, Australia

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 11:25

Transgender people have unaddressed heart disease risks

Presented By

Dr Kara Denby, Cleveland Clinic, USA

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 11:23

Rilonacept reduces risk of pericarditis recurrence

Presented By

Dr Alan Klein, Cleveland Clinic, USA

Trial

Phase 3, RHAPSODY

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 11:18

Intensive blood pressure lowering benefits older adults

Presented By

Prof. William Cushman, University of Tennessee Health Science, USA

Trial

SPRINT

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 11:13

Dobutamine versus milrinone in cardiogenic shock

Trial

Capital Do-Re-Mi

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 11:10

Longer chest compression pause worsens outcomes after paediatric IHCA

Presented By

Dr Kasper Glerup Lauridsen, Aarhus University, Denmark

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 11:06

AF monitoring following cardiovascular surgery

Presented By

Prof. Subodh Verma, University of Toronto, Canada)

Trial

SEARCH-AF

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 10:54

Extra imaging reveals cause of MINOCA in women

Presented By

Prof. Harmony Reynolds, New York University Grossman School of Medicine, USA

Trial

HARP-MINOCA

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 10:50

Ticagrelor not superior to clopidogrel after elective PCI

Presented By

Prof. Johanne Silvain, Sorbonne University, France

Trial

Phase 3, ALPHEUS

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 10:43

Validation of MY-RADS response assessment category criteria

Presented By

Dr Angelo Belotti, ASST Spedali Civili di Brescia, Italy

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:43

High symptom burden in transplant-ineligible patients with newly diagnosed MM

Presented By

Dr Hira Mian, McMaster University, Canada

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:42

Added value of ixazomib to lenalidomide plus dexamethasone in transplant-ineligible newly diagnosed MM

Presented By

Prof. Thierry Facon, University Hospital Lille, France

Trial

Phase 3, TOURMALINE-MM2

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:37

Survival of transplant-eligible newly diagnosed MM in FORTE trial

Presented By

Dr Francesca Gay, GIMEMA, European Myeloma Network, Italy

Trial

Phase 2, FORTE

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:35

No benefit from omega-3 fatty acids after recent MI

Presented By

Dr Are Kalstad, Oslo University Hospital, Norway

Trial

OMEMI

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 10:34

PIONEER III trial: Drug-eluting stents comparable

Presented By

Prof. Alexandra Lansky, Yale School of Medicine, USA

Trial

PIONEER III

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 10:30

Better survival with upfront autoSCT versus bortezomib-based intensification

Presented By

Prof. Michele Cavo, University of Bologna, Italy

Trial

Phase 3, EMN02/HO95

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:29

Subcutaneous daratumumab plus pomalidomide and dexamethasone in R/R MM

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, APOLLO

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:26

Omecamtiv mecarbil improves outcomes in HFrEF-patients

Presented By

Prof. John Teerlink, University of California, San Francisco, USA

Trial

GALACTIC-HF

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 10:25

Melflufen well tolerated with encouraging activity in heavily pretreated R/R MM

Presented By

Dr Enrique Ocio, University Hospital Marqués de Valdecilla, Spain

Trial

Phase 1/2, ANCHOR (OP-104)

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:22

IV iron reduces HF hospitalisation

Presented By

Prof. Piotr Ponikowski, Wroclaw Medical University, Poland

Trial

AFFIRM-AHF

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 10:22

Initial data of FcRH5/CD3 T-cell-engaging bispecific antibody

Presented By

Dr Adam Cohen, University of Pennsylvania, Philadelphia, USA

Trial

Phase 1, GO39775

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:20

Dapagliflozin reduces renal risk independent of CV disease status

Presented By

Prof. John McMurray, University of Glasgow, Scotland

Trial

DAPA-CKD

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 10:18

Deep and durable responses with ide-cel in RRMM

Presented By

Dr Yi Lin, Mayo Clinic, Minnesota, USA

Trial

Phase 1, CRB-401

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:17

CD58 aberrations limit durable responses to CD19 CAR T-cell therapy

Presented By

Dr Robbie Majzner, Stanford University, California, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:15

“Strongly consider an SGLT2-inhibitor in most T2DM patients”

Presented By

Prof. Deepak Bhatt, Brigham and Women’s Hospital, USA

Trial

Phase 3, SOLOIST-WHF; SCORED

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 10:14

Anti-CD19 CAR T-cell therapy in relapsed/refractory indolent NHL

Presented By

Dr Caron Jacobson, Dana Farber Cancer Institute, Massachusetts, USA

Trial

Phase 2, ZUMA-5

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:12

Additional HFrEF education and patient-engagement tools

Presented By

Prof. Larry Allen, University of Colorado School of Medicine, USA

Trial

EPIC-HF

Conference

AHA 2020

Type

Peer-reviewed article

18 February 2021 10:09

MPN disease burden, quality of life, and treatment patterns

Presented By

Dr Rami S. Komrokji (H. Lee Moffitt Cancer Center and Research Institute, Florida, USA) & Dr Michael R. Grunwald (Levine Cancer Institute, North Carolina, USA)

Trial

MOST

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:08

Interventions in JAK/STAT signalling pathway

Presented By

Dr Srdan Verstovsek, MD Anderson Cancer Center, Texas, USA

Trial

SIMPLIFY

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:05

Novel, orally available inhibitor of BCL-XL/BCL-2

Presented By

Dr Naveen Pemmaraju, MD Anderson Cancer Center, Texas, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:59

New insights into genetics of MPN

Presented By

Dr Jyoti Nangalia, University of Cambridge, United Kingdom

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:53

Mycophenolate efficacious and tolerable, even in elderly patients

Presented By

Dr Charlotte Bradbury, University of Bristol, United Kingdom

Trial

FLIGHT

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:50

BTK inhibition provides clinically active and durable platelet response

Presented By

Dr David J. Kuter, Massachusetts General Hospital & Harvard Medical School, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:42

More complicated course of COVID-19 in leukaemia patients

Presented By

Dr Susanne Ghandili, University Medical Center Hamburg-Eppendorf, Germany

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:34

Older age and imatinib treatment associated with COVID-19 mortality in CML

Presented By

Dr Delphine Rea, Université de Paris, France

Trial

CANDID

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:32

Allogeneic SARS-CoV-2-specific T cells to treat COVID-19

Presented By

Dr Spyridoula Vasileiou, Baylor College of Medicine, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:30

More severe COVID-19 outcomes for patients with haematologic malignancies

Presented By

Prof. William A. Wood, University of North Carolina, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:28

Improved outcomes, but still substantial part experiences relapses

Presented By

Dr Danielle Fredman, Sheba Medical Center, Israel

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:26

Strong correlation between peripheral blood and bone marrow NGS MRD

Presented By

Dr Lori Muffly, Stanford University, California, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:24

Encouraging outcomes after autoHCT in patients with ALL

Presented By

Prof. Sebastian Giebel, Maria Skłodowska-Curie National Research Institute of Oncology, Poland

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:23

Prognostic validity of AML composite model in predicting mortality

Presented By

Dr Shannon Murphy, Dalhousie University, Canada

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:21

Venetoclax plus hypomethylating agents in favourable-risk AML

Presented By

Dr Shukaib Arslan, City Of Hope Helford Clinical Research Hospital, California, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:19

Encouraging clinical activity of decitabine plus ipilimumab in R/R or secondary MDS/AML

Presented By

Ms Jacqueline S. Garcia, Dana-Farber Institute, Massachusetts, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:18

Bosutinib effective and well tolerated in newly diagnosed CP-CML

Presented By

Prof. Tim Brümmendorf, RWTH Aachen University, Germany

Trial

Phase 3, BFORE

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:17

AML patients with specific mutations are unlikely to achieve MRD

Presented By

Dr Maximilian Stahl, Memorial Sloan Kettering Cancer Center, New York, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:15

Comparable outcomes with gilteritinib or quizartinib in R/R AML

Presented By

Dr Alexander Perl, University of Pennsylvania, USA

Trial

Phase 3, QuANTUM-R

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:14

First-in-class macrophage immune checkpoint inhibitor in AML

Presented By

Dr David Sallman, H. Lee Moffitt Cancer Center and Research Institute, Florida, USA

Trial

Phase 1

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:11

Bispecific DART® as salvage therapy for primary induction failure and early relapse

Presented By

Dr Ibrahim Aldoss, City of Hope Medical Center, California, USA

Trial

Phase 1/2

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:09

Efficacy and safety of ponatinib in patients with CP-CML who failed second-generation TKIs

Presented By

Dr Hagop Kantarjian, MD Anderson Cancer Center, Texas, USA

Trial

OPTIC, PACE

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:08

Gilteritinib in R/R AML patients priorly treated with midostaurin or sorafenib

Presented By

Dr Alexander Perl, University of Pennsylvania, USA

Trial

CHRYSALIS, ADMIRAL

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:07

Addition of venetoclax provides an effective, lower-intensity regimen

Presented By

Dr Tapan Kadia, MD Anderson Cancer Center, Texas, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:05

First-in-class STAMP inhibitor versus bosutinib in resistant or intolerant CML

Presented By

Dr Andreas Hochhaus, Universitätsklinikum Jena, Germany

Trial

Phase 3, ASCEMBL

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 08:58

PFS and ORR benefits of first-line ibrutinib-based treatment in CLL

Presented By

Prof. Jan Burger, MD Anderson Cancer Center, Texas, USA

Trial

Phase 3, RESONATE-2, iLLUMINATE

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 08:54

First results from gene therapy trial in haemophilia B

Presented By

Prof. Steven Pipe, University of Michigan, USA

Trial

Phase 3, HOPE-B

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 08:25

Impact of haemophilia on children and their caregivers

Presented By

Dr Kate Khair, Great Ormond Street Hospital for Children, UK

Trial

CHESS Paediatrics

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 08:22

Promising CRISPR gene editing results in β-thalassaemia and sickle cell disease

Presented By

Dr Haydar Frangoul, Sarah Cannon Research Institute, USA

Trial

CLIMB THAL-111 & CLIMB SCD-121

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 08:18

Erythroid maturation agent in patients with β-thalassaemia requiring regular RBC transfusions

Presented By

Prof. Olivier Hermine, Université de Paris, France

Trial

Phase 3, BELIEVE

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 08:12

Clever trial design gets patients back on statins: the SAMSON trial

Presented By

Dr James Howard, Imperial College London, UK

Trial

SAMSON

Conference

AHA 2020

Type

Peer-reviewed article

17 February 2021 15:10

Polypill plus aspirin reduces cardiovascular events

Presented By

Prof. Salim Yusuf, Population Health Research Institute, Canada

Trial

TIPS-3

Conference

AHA 2020

Type

Peer-reviewed article

17 February 2021 14:58

Lowering LDL cholesterol in older patients is beneficial

Presented By

Dr Baris Gencer, Brigham and Women’s Hospital, USA

Conference

AHA 2020

Type

Peer-reviewed article

17 February 2021 14:54

No CV benefit from omega 3 in high-risk patients

Presented By

Prof. Michael Lincoff, Cleveland Clinic, USA

Trial

STRENGTH

Conference

AHA 2020

Type

Peer-reviewed article

17 February 2021 14:44

Safety and efficacy of inclisiran for hypercholesterolemia

Presented By

Prof. R. Scott Wright, Mayo Clinic, USA

Trial

Phase 3, ORION

Conference

AHA 2020

Type

Peer-reviewed article

17 February 2021 14:37

Remote risk management programme effective and efficient

Presented By

Prof. Benjamin Scirica, Brigham and Women’s Hospital, USA

Conference

AHA 2020

Type

Peer-reviewed article

17 February 2021 14:31

Healthy lifestyle lowers mortality irrespective of medication burden

Presented By

Dr Neil Kelly, Weill Cornell University, USA

Trial

REGARDS

Conference

AHA 2020

Type

Peer-reviewed article

17 February 2021 14:24

Vitamin D or omega 3 fatty acids do not prevent AF

Presented By

Prof. Christine Albert, Cedars-Sinai Medical Center, USA

Trial

VITAL Rhythm

Conference

AHA 2020

Type

Peer-reviewed article

17 February 2021 14:19

Active screening for AF improves clinical outcomes

Presented By

Dr Steven Steinhubl, Scripps Research Translational Institute, USA

Trial

mSToPS

Conference

AHA 2020

Type

Peer-reviewed article

17 February 2021 14:16

AF screening in older adults at primary care visits

Presented By

Dr Steven Lubitz, Massachusetts General Hospital, USA

Trial

VITAL-AF

Conference

AHA 2020

Type

Peer-reviewed article

17 February 2021 14:06

Fewer CV complications than expected in AHA COVID-19 Registry

Presented By

Prof. James de Lemos, University of Texas Southwestern Medical Center, USA

Trial

AHA COVID-19 CVD Registry

Conference

AHA 2020

Type

Peer-reviewed article

17 February 2021 13:39

Worse COVID-19 outcomes in younger obese patients

Presented By

Dr Nicholas Hendren, University of Texas Southwestern, USA

Trial

AHA COVID-19 CVD Registry

Conference

AHA 2020

Type

Peer-reviewed article

17 February 2021 13:28

Effects of CVD in hospitalised COVID-19 patients

Presented By

Prof. Ann Marie Navar, University of Texas Southwestern, USA

Conference

AHA 2020

Type

Peer-reviewed article

17 February 2021 13:22

Meta-analyses: ACEI/ARB and COVID-19

Presented By

Dr Yujiro Yokoyama, St. Luke's University Hospital

Conference

AHA 2020

Type

Peer-reviewed article

17 February 2021 13:18

Unfavourable outcomes for COVID-19 patients with AF and atrial flutter

Presented By

Dr Zaniar Ghazizadeh, Brigham and Women’s Hospital, USA

Trial

Yale Cardiovascular COVID Registry

Conference

AHA 2020

Type

Peer-reviewed article

17 February 2021 12:08

High-dose influenza vaccine in patients with CVD

Presented By

Prof. Orly Vardeny, University of Minnesota Medical School, USA

Trial

Phase 4, INVESTED

Conference

AHA 2020

Type

Peer-reviewed article

17 February 2021 10:36

Gout treatment with febuxostat: no higher cardiovascular mortality

Presented By

Prof. Thomas MacDonald, University of Dundee, UK

Trial

CARES, FAST

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 11:03

New agent with great potential for the treatment of giant cell arteritis in the pipeline

Presented By

Dr Maria Cinta Cid, Hospital Clínic of Barcelona, Spain

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 11:02

Autotaxin inhibitor successful in the first trial in diffuse cutaneous systemic sclerosis

Presented By

Prof. Dinesh Khanna, University of Michigan Scleroderma Program, USA

Trial

Phase 2, NOVESA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 11:02

JAK inhibition as a treatment option for ankylosing spondylitis

Presented By

Prof. Atul Deodhar, Oregon Health & Science University, USA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 11:02

Persuasive long-term results for JAK inhibition in rheumatoid arthritis

Presented By

Prof. Josef Smolen, Medical University of Vienna, Austria

Trial

Phase 3, SELECT-MONOTHERAPY

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 11:00

Rheumatoid arthritis: new EULAR treatment guidelines

Presented By

Prof. Daniel Aletaha, Medical University Vienna, Austria

Trial

IDEA, NORD-STAR

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 11:00

Rheumatoid arthritis and interstitial lung disease: a deadly combination

Presented By

Prof. Joan Bathon, Columbia University, USA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:59

COVID-19 in patients with rheumatic disease: most report mild disease

Presented By

Dr Akhil Sood, University of Texas Medical Branch, USA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:57

Poor disease control: a risk factor for severe COVID-19

Presented By

Prof. Rebecca Grainger, University of Otago, New Zealand

Trial

COVID-19 Global Rheumatology Alliance Registry

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:57

No heightened outcome risk for rheumatic patients with COVID-19

Presented By

Dr Naomi Serling-Boyd, Massachusetts General Hospital, USA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:56

Lupus nephritis biomarkers: moving toward an omic-driven approach

Presented By

Prof. Chaim Putterman, Albert Einstein College of Medicine, USA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:54

Lupus nephritis: new therapies on the horizon in 2020

Presented By

Prof. Joan T. Merrill, Oklahoma Medical Research Foundation, USA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:54

Signs of benefit for T2T in axial spondyloarthritis

Trial

Cohort study, TICOSPA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:53

Artificial intelligence can help in the diagnosis of axSPA

Presented By

Prof. Denis Poddubnyy, Charité Universitätsmedizin Berlin, Germany

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:53

Promising novel treatment option for psoriatic arthritis

Presented By

Prof. Philip J. Mease, University of Washington, USA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:51

How to choose imaging modalities in large vessel vasculitis

Presented By

Dr Anisha Dua, Northwestern Medical Group, USA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:50

Diagnosis of large vessel vasculitis with imaging

Presented By

Dr Peter Grayson, National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, USA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:50

Knee osteoarthritis patients with indicators of inflammation could profit from methotrexate

Presented By

Prof. Biswadip Ghosh, Institute of Post Graduate Medical Education and Research, India

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:48

Anticoagulation with vitamin K antagonist is associated with risk of knee and hip replacement

Presented By

Dr Priyanka Ballal, Boston University Medical Center, USA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:48

Bisphosphonate use: Asian American women have a smaller treatment benefit

Presented By

Prof. Jinoos Yazdany, University of California San Francisco, USA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:47

Inflammatory disease as a risk factor for fractures

Presented By

Dr Giovanni Adami, University of Verona, Italy

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:45

No progression of osteoarthritis with corticosteroid injections

Presented By

Dr Justin J. Bucci, Boston University School of Medicine, USA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:43

No elevated risk for influenza AE in tofacitinib-treated RA patients

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:42

Hydroxychloroquine use: no indication for arrhythmias in RA and SLE patients

Presented By

Dr Elizabeth Park, Columbia University Irving Medical Center, USA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:41

Children with rheumatic disease have no greater risk of a COVID-19 infection

Presented By

Dr Jonathan S. Hausmann, Harvard Medical School and Boston Children’s Hospital, USA

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:40

Insufficient antimalarial supply for rheumatic disease treatment in the early COVID-19 pandemic

Presented By

Ms Emily Sirotich, COVID‐19 Global Rheumatology Alliance Steering Committee and McMaster University, Canada

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:38

Risky sexual behaviour and STIs on the rise despite the pandemic

Presented By

Dr Marco Cusini

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:36

Real-world data on brodalumab affirms efficacy and fast onset of action

Presented By

Dr Ralph Von Kiedrowski

Trial

LIBERO

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:35

Bimekizumab in psoriasis: Up-and-coming

Presented By

Prof. Bruce Strober, Yale University, USA

Trial

Phase 3, BE VIVID

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:34

Heightened risk for psychiatric comorbidities in hidradenitis suppurativa patients

Presented By

Dr Kevin Phan, Liverpool Hospital, Australia

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:34

Meaningful sleep improvement with IL-13 inhibition

Presented By

Prof. Jonathan Silverberg, George Washington University, USA

Trial

Phase 3, ECZTRA

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:33

Preventing foot odour with zinc oxide coated socks

Presented By

Dr Punyawee Ongsri, Mahidol University, Thailand

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:32

Baricitinib in AD: Efficacy paired with consistent long-term results

Presented By

Prof. Jonathan Silverberg , George Washington University, USA

Trial

Phase 3, BREEZE-AD3

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:31

Bacterial resistance in skin infections – a challenging threat

Presented By

Prof. Domenico Bonamonte, Bari University, Italy

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:30

Borreliosis: A multifaceted disease

Presented By

Dr Markus Starink, Amsterdam University Medical Centre, the Netherlands

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:28

JAK inhibitors in AA: re-establishing the immune privilege of hair follicles

Presented By

Prof. Taisuke Ito, Hamamatsu University School of Medicine, Japan

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:27

Chronic spontaneous urticaria: hives, wheals & biomarkers

Presented By

Prof. Ana Giménez-Arnau, Autonomous University of Barcelona, Spain

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:27

Scabies – A global health challenge

Presented By

Prof. Olivier Chosidow, Henri Mondor University Hospital, France

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:27

Ligelizumab for chronic spontaneous urticaria: a new star on the horizon

Presented By

Prof. Marcus Maurer, Charité Universitätsmedizin Berlin, Germany

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:26

JAK inhibitors in vitiligo

Presented By

Dr Mehdi Rashighi, Massachusetts Medical School, USA

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:26

JAK1 inhibition successful in hidradenitis suppurativa

Presented By

Dr Afsaneh Alavi , Mayo Clinic, USA

Trial

Phase 2

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:25

Topical JAK inhibition: a novel treatment option for patients with mild-to-moderate AD

Presented By

Prof. Megan Landis, University of Louisville School of Medicine, USA

Trial

Phase 2

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:22

Biologic psoriasis treatment and COVID-19 risk: Contradictory results

Presented By

Dr Anne-Claire Fougerousse; Dr Giovanni Damiani

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:12

Much to be learned about COVID-19 and the skin

Presented By

Prof. Esther Freeman, Director of the COVID-19 Dermatology Registry

Trial

COVID-19 Dermatology Registry

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 14:00

Selective IL-23 blocker shows potential in psoriasis treatment

Presented By

Dr Kim Papp, Probity Medical Research, Canada

Trial

Phase 3, OASIS-2

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 13:44

Promising results with nanobody treatment in psoriasis

Presented By

Dr Kim A. Papp, Probity Medical Research, Canada

Trial

Phase 2

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 13:40

Light at the end of the tunnel for chronic hand eczema

Presented By

Prof. Margitta Worm, Prof. Howard Sofen

Trial

Phase 2

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 13:37

Epidermolysis bullosa: Novel wound treatment on the horizon

Presented By

Prof. Dedee F. Murrell, St George Hospital, University of New South Wales, Australia

Trial

Phase 3

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 13:32

Efficacious non-steroidal topical for psoriasis

Presented By

Prof. Mark Lebwohl, Icahn School of Medicine at Mount Sinai, USA

Trial

Phase 3, PSOARING

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 13:28

Oral JAK 1 inhibitor leads to fast itch relieve and remarkable skin clearance in AD

Presented By

Prof. Emma Guttman-Yassky, Icahn School of Medicine at Mount Sinai, USA

Trial

Phase 3, Measure Up

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 13:24

Effects IL-13 blocker improves with longer treatment duration

Presented By

Prof. Eric Simpson, Oregon Health & Science University, USA

Trial

Phase 3, ECZTRA

Conference

EADV 2020

Type

Peer-reviewed article

17 December 2020 12:37

Risk of COVID-19 not increased in MS patients

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:10

Age and EDSS are risk factors for severe COVID-19

Trial

Cohort study, COVISEP

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:09

Anti-CD20 DMTs associated with worse COVID-19 outcomes

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:09

Black MS patients have poorer COVID-19 outcomes

Trial

COViMS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:08

Gut bacteria associated with relapse in paediatric-onset MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:08

Predictive value of CSF Aβ and tau proteins in MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:08

Serum NfL as biomarker for suboptimal treatment response

Trial

Cohort study, Swiss MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:07

Interrupting DMT due to pregnancy increases NfL levels

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:06

Predicting autoimmunity in patients treated with alemtuzumab

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:06

Serum glial fibrillary acidic protein predicts relapses in NMOSD

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:06

Assessing demyelination using myelin water imaging

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:06

Grey matter network measures predict disability and cognition

Trial

Phase 3, ASCEND

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:05

Lesion-specific perfusion levels affect myelin loss and repair

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:05

Management of progressive MS with approved DMT

Presented By

Prof. Xavier Montalban, Vall d'Hebron University Hospital, Spain

Trial

ASCEND, MS-SMART

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:01

Outcomes in patients on alemtuzumab with thyroid adverse events

Trial

CARE-MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:01

Safety and efficacy of dimethyl fumarate: 13 years of follow-up

Trial

ENDORSE, DEFINE, CONFIRM

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:00

Update on estimated PML risk related to fingolimod

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:00

Less thalamic atrophy in patients initiating ocrelizumab earlier

Conference

MS Virtual

Type

Peer-reviewed article

25 November 2020 16:59

No new safety signals in ofatumumab open-label data

Trial

ALITHIOS, ASCLEPIOS I, ASCLEPIOS II, APLIOS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:57

Long-term safety and efficacy of ozanimod in RMS

Trial

Phase 3, DAYBREAK

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:57

Low-dose rituximab as effective as high-dose, but safer

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:57

TERIKIDS trial extension of teriflunomide in paediatric MS

Trial

Phase 3, TERIKIDS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:56

Teriflunomide improves satisfaction versus prior DMT regardless of age

Trial

Phase 4, Teri-PRO

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:55

Safety and efficacy of cladribine, glatiramer acetate, and more

Trial

CLASSIC-MS, OPTIMUM

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:55

Functional potential of gut microbiome in paediatric MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:49

Modulating BTK-dependent inflammatory signalling in microglia

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:49

Therapeutic potential of anti-MOSPD2 monoclonal antibodies

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:49

Masitinib: a first-in-class TKI as treatment of progressive MS

Trial

AB07002

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:49

Gold nanocrystals may improve brain metabolic profile

Trial

REPAIR-MS, REPAIR-PD, VISIONARY-MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:48

Retinoid-X receptor agonist promotes remyelination

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:48

Gut dysbiosis in NMOSD promotes CNS autoimmunity

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:46

NG-specific biomarkers differentiate NMOSD from MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:46

Eculizumab reduces long-term relapse risk in AQP4-positive NMOSD

Trial

Phase 3, PREVENT

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:45

Satralizumab lowers risk of severe relapse in NMOSD patients

Trial

SAkuraSky, SAkuraStar

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:45

Clinical features of a recently identified disease: GFAP autoimmunity

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:45

Gender-based approach to MS therapeutics: a missed opportunity

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:43

Disease activity during pregnancy in a modern MS cohort

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:27

Cardiovascular risk factors may contribute to brain atrophy in MS patients

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:26

Amantadine, modafinil, and methylphenidate for MS-related fatigue

Trial

Phase 3, TRIUMPHANT-MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:23

COVID-19 and Cancer

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 16:22

CDK4/6 inhibition in high-risk early breast cancer

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 16:20

Neoadjuvant treatment in patients with high-risk early breast cancer

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 16:19

Prognostic value of tumour infiltrating lymphocytes in young TNBC patients

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 16:16

Contradicting results for chemoimmunotherapy in metastatic TNBC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 16:01

Second-line sacituzumab govitecan improves survival in metastatic TNBC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:14

Rechallenge of RAS/BRAF wildtype CRC with avelumab plus cetuximab

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:13

Surveillance after curative treatment for CRC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:11

Adjuvant chemotherapy less effective in elderly CRC patients

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:10

Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer?

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:08

Preoperative immunotherapy in early stage NSCLC safe and feasible

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:07

No advantage of post-operative radiotherapy in patients with stage IIIA N2 NSCLC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:06

Adjuvant osimertinib in NSCLC reduces risk of CNS recurrence

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:05

Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:02

First-line immune checkpoint inhibition in metastatic NSCLC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:00

PD-L1 density, a new predictive biomarker in NSCLC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:59

Atezolizumab/bevacizumab for non-squamous NSCLC with high PD-L1 expression

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:58

Consolidation ipilimumab and nivolumab in limited stage SCLC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:56

Adjuvant immune checkpoint inhibition after complete resection

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:55

Immuno-combination therapy in metastatic melanoma

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:52

Abiraterone in M1 hormone-naïve prostate cancer

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:51

New treatment option for patients with mCRPC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:50

First-line treatment of advanced/metastatic RCC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:44

First-line immune-combination therapies in mUC

Trial

Phase 3, KEYNOTE-361

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:43

Second- and third-line treatment options in mUC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:41

Treatment of newly diagnosed ovarian cancer

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:39

Treatment of recurrent ovarian cancer

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:35

Palbociclib effective in ER-positive endometrial cancer

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:23

Bispecific antibodies targeting PD-1 and CTLA-4: new kids on the block(ade)

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 12:45

PD-(L)1, LAG-3, and TIM blockade

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 12:43

CRC disseminates using collective migration

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 12:30

2020 Atrial Fibrillation Guidelines

Presented By

Prof. Gerhard Hindricks, Heart Centre Leipzig, Germany

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 14:05

2020 Non-ST-Segment Elevation Acute Coronary Syndromes Guidelines

Presented By

Prof. Jean-Phillippe Collet, Pitié-Salpêtrière Hospital, France

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:58

2020 Sports Cardiology and Exercise in Cardiovascular Patients Guidelines

Presented By

Prof. Antonio Pelliccia, Institute of Sports Medicine and Science, Italy

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:53

2020 Adult Congenital Heart Disease Guidelines

Presented By

Prof. Helmut Baumgartner, University Hospital Münster, Germany

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:46

SGLT2 inhibitor improves cardiovascular outcomes in heart failure patients

Presented By

Dr Milton Packer, Baylor University Medical Center, USA

Trial

Phase 3, EMPEROR-Reduced trial

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:40

First-in-class cardiac myosin inhibitor effective in obstructive hypertrophic cardiomyopathy

Presented By

Prof. Iacopo Olivotto, Azienda Ospedaliera Universitaria Careggi, Italy

Trial

Phase 3, EXPLORER-­HCM trial

Type

Peer-reviewed article

5 November 2020 13:37

Reduced cardiovascular outcomes with early rhythm control

Presented By

Prof. Paulus Kirchhof, University Heart & Vascular Center Hamburg, Germany

Trial

EAST-AFNET 4

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:35

Trimetazidine after successful PCI not associated with fewer cardiac events

Presented By

Prof. Roberto Ferrari, University of Ferrara, Italy

Trial

ATPCI trial

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:30

POPular TAVI: Aspirin-only antiplatelet strategy?

Presented By

Dr Jorn Brouwer, St Antonius Hospital, the Netherlands

Trial

POPular TAVI trial

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:28

Reduced NT-proBNP in HFpEF with sacubitril/valsartan

Presented By

Prof. Burkert Pieske, Charité University Medicine Berlin, Germany

Trial

Phase 3, PARALLAX study

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:26

DAPA-CKD: Dapagliflozin improves CKD survival ± diabetes

Presented By

Prof. Hiddo Heerspink, University of Groningen, the Netherlands

Trial

DAPA-CKD trial

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:23

Low-dose colchicine reduces CV death and ischaemic events in coronary disease

Presented By

Dr Stefan Nidorf, Heart Care Western Australia, Australia

Trial

LoDoCo2 trial

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:19

Similar outcomes sPESI and HESTIA for pulmonary embolism triage

Presented By

Prof. Pierre-Marie Roy, University Hospital of Angers, France

Trial

HOME-PE trial

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:16

Antihypertensives also reduce CV risk in people with normal blood pressure

Presented By

Prof. Kazem Rahimi, University of Oxford, UK

Trial

BPLTTC study

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:14

COVID-19: Continuing versus suspending ACE inhibitors and ARBs

Presented By

Prof. Renato Lopes, Duke University, USA

Trial

Phase 4, BRACE CORONA trial

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:10

Drug initiation strategy not associated with increased use of oral anticoagulants

Presented By

Prof. Sean Pokorney , Duke University, USA

Trial

IMPACT-AFib trial

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:07

Restrictive blood transfusion non-inferior and cost-effective strategy

Presented By

Prof. Philippe Gabriel Steg, University of Paris, Frane

Trial

REALITY trial

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:05

Increased mortality with colchicine in patients with ACS

Presented By

Prof. Jamie Layland , Monash University, Australia

Trial

COPS trial

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 13:00

Rivaroxaban protects limbs and ischaemic events in CAD-PAD patients

Presented By

Prof. William Hiatt, University of Colorado, USA

Trial

VOYAGER PAD trial

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 12:57

Antisense APOC3 oligonucleotide lowers triglyceride and atherogenic lipoproteins

Presented By

Prof. Jean-Claude Tardif, University of Montréal, Canada

Trial

Phase 2, AKCEA-APOCIII-LRx study

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 12:54

Antisense ANGPTL3 lowers triglycerides

Presented By

Prof. Daniel Gaudet, University of Montréal, Canada

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 12:50

Reduced progression of coronary atherosclerosis with icosapent ethyl

Presented By

Prof. Matthew Budoff, Harbor-UCLA Medical Center, USA

Trial

EVAPORATE trial

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 12:48

Digoxin improves symptoms in stable patients with permanent AF

Presented By

Prof. Dipak Kotecha, University of Birmingham, UK

Trial

Phase 4, RATE-AF trial

Conference

ERS 2020

Type

Peer-reviewed article

5 November 2020 12:45

SGLT2 inhibitor ertugliflozin shows similar mortality but fewer HF hospitalisations

Presented By

Prof. Francesco Cosentino, Karolinska University Hospital, Sweden

Trial

VERTIS CV

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 12:39

Risk factors for thromboembolism and bleeding in COVID-19: lessons from Wuhan

Presented By

Prof. Yutao Guo , Chinese PLA General Hospital, China

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 12:27

The Yale COVID-19 Cardiovascular Registry

Presented By

Dr Manan Pareek, Yale University School of Medicine, USA

Trial

Yale COVID-19 Cardiovascular Registry

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 12:24

COVID-19 treatments and the importance of randomised trials

Presented By

Prof. Martin Landray, University of Oxford, UK

Trial

RECOVERY

Conference

ESC 2020

Type

Peer-reviewed article

5 November 2020 11:49

Prognostic tools in the management of clinical high risk for psychosis

Presented By

Prof. Celso Arango & Dr Carrie Bearden

Trial

PSYSCAN, PRONIA, NAPLS

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 17:09

Reduced auditory cortex activation during speech perception in patients with schizophrenia

Presented By

Mr J. Soler-Vidal, University of Barcelona, Spain

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 17:01

Predicting MCI and dementia by assessing worrying about memory

Presented By

Prof. Frank Jessen, University Hospital of Cologne, Germany

Trial

Cohort study, AgeCoDe

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 16:49

Genomics of vascular dementia and stroke

Presented By

Prof. Elisabeth Tournier-Lasserve, Saint Louis Hospital, France

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 16:45

Social media and bipolar disorder: a risky combination

Presented By

Ms Klara Rydahl, Aarhus University Hospital, Denmark

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 16:39

How to prevent the onset and first relapse of bipolar disorders?

Presented By

Prof. Lars Vedel Kessing, Copenhagen Affective Disorder Research Center, Denmark

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 16:38

Seasonal pattern and bipolar disorder

Presented By

Dr Giovanna Fico, Hospital Clínic de Barcelona, Spain

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 16:34

rTMS is not effective in OCD

Presented By

Dr Alper Zıblak, Pamukkale University, Turkey

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 16:29

Personalised medicine in depression: a realistic way forward?

Presented By

Prof. Brenda Penninx, Amsterdam UMC, the Netherlands

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 16:25

Heart rate could be a potential biomarker for depression

Presented By

Dr Carmen Schiweck, Goethe University, Frankfurt

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 16:19

Mental health during the COVID-19 pandemic

Presented By

Prof. Emily Holmes, Karolinska Institutet, Sweden

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 16:02

Microdosing psychedelics offers perspective but needs further evaluation

Presented By

Dr Kim Kuypers, Maastricht University, the Netherlands

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 15:59

The PRISM project: focusing on biological parameters across neuropsychiatric disorders

Presented By

Dr Hugh Marston, Eli Lilly and Company Ltd, Germany

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 15:56

Smartphone can support personalised medicine in psychiatry

Presented By

Prof. Inez Myin-Germeys, Center for Contextual Psychiatry, Belgium

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 15:55

Baby’s heart rate shows stress if their mother is depressed or anxious

Presented By

Mr Fabio Blanco-Dormond, University of Heidelberg, Germany

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 15:53

Movement computing promising in analysing motor impairment in children with autism spectrum disorder

Presented By

Mr Thomas Gargot, Hôpital La Pitié Salpêtrière, France

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 15:52

Screening with ADHD Self-Report accurate in girls

Presented By

Dr Águeda Fernández-Quintana, University of Uppsala, Sweden

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 15:50

No altered fractional anisotropy in ADHD

Presented By

Ms Christienne Damatac, Donders Institute for Brain- Cognition and Behaviour, the Netherlands

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 15:46

The gut-brain axis and obesity

Presented By

Dr Harriët Schellekens, University of Cork, Ireland

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 15:44

Micronutrient supplementation as treatment for psychiatric symptoms

Presented By

Dr Alexander Häge, ZI Mannheim, Germany

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 15:42

Altered gene expression of endogenous opioid system after alcohol exposure in adolescent rodents

Presented By

Mr Fabio Bellia, University of Teramo, Italy

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 15:39

Subgroups in alcohol use disorder based on externalising symptoms

Principal Investigator

Dr Bernadett Gál, University of Szeged, Hungary

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 15:38

New drugs for alcohol use disorder to focus on combination therapy

Presented By

Dr Hamid Noori, Max Planck Institute for Biological Cybernetics, Germany

Conference

ECNP 2020

Type

Peer-reviewed article

2 November 2020 15:34

COVID-19 infections: Bronchoscopy provides additional diagnostic certainty

Presented By

Dr Thomas Malfait, Ghent University Hospital, Belgium

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 20:11

COVID-19 vaccines: An ongoing race

Presented By

Prof. George Karakiulakis, Aristotle University of Thessaloniki, Greece

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 20:08

COVID-19: What is the risk of reinfection?

Presented By

Prof. Peter Openshaw, Imperial College of London, UK

Trial

ISARIC-4C

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 20:01

COVID-19 App: The Dutch experience

Presented By

Prof. Niels Chavannes, Leiden University, the Netherlands

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 19:57

Smartphone-based cough detection helpful in predicting asthma deterioration

Presented By

Dr Frank Rassouli, Cantonal Hospital St. Gallen, Switzerland

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 19:53

Reduced lung function associated with cognitive decline in the elderly

Presented By

Dr Yutong Cai, University of Oxford, UK

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 19:49

Longer hospital stay and fewer transplants for frail ILD patients

Presented By

Dr Karan Chohan, University of Toronto, Canada

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 19:46

Lung cancer screening: Most patients not eligible 1-2 years prior to diagnosis

Presented By

Dr Kiran Desai, Barking, Havering and Redbridge University Hospitals, UK

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 19:43

Biomarkers: a novel tool to improve lung nodule classification

Presented By

Dr Michael Pritchett

Trial

PANOPTIC, ORACLE

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 19:40

Distinct changes in lung microbiome precede clinical diagnosis of lung cancer

Presented By

Ms Erin Marshall, University of British Columbia, Canada

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 19:30

LEAD study shows multiple phenotypes in many chronic cough patients

Presented By

Dr Hazim Abozid, Otto Wagner Hospital, Austria

Trial

Cohort study, LEAD

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 19:26

Poly-use of nicotine products and cannabis: a deadly combination

Presented By

Prof. Charlotta Pisinger, University of Copenhagen & Danish Heart Foundation, Denmark

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 19:11

E-cigarettes: A source of chronic lung inflammation

Presented By

Prof. Shama Ahmad, University of Alabama at Birmingham, USA

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 19:08

Social smoking: Do not underestimate the risks

Presented By

Dr Pallavi Balte, Columbia University, USA

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 19:04

CPAP withdrawal has negative consequences for sleep apnoea patients

Presented By

Prof. David Kim, Johns Hopkins University, USA

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 18:59

Physical activity improves AHI in sleep apnoea patients

Presented By

Prof. Monique Mendelson, University of Grenoble, France

Trial

Cohort study, EPISONO

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 18:33

The role of chronic symptoms as early biomarkers of COPD development

Presented By

Dr James Allinson, Imperial College London, UK

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 18:29

Urgent call for studies in COPD patients aged 40-60 years

Presented By

Prof. Wisia Wedzicha , Imperial College London, UK

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 18:25

Nasal high-flow therapy: a novel treatment option for hypercapnic COPD patients

Presented By

Dr Jens Bräunlich, Kliniken Aurich-Emden-Norden, Germany

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 18:10

Exacerbation history is a reliable predictor of future exacerbations

Presented By

Prof. Claus Vogelmeier, Philipps University of Marburg, Germany

Trial

Cohort study, AvoidEx

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 18:07

Singing training effective as physical rehabilitation in COPD

Presented By

Prof. Uffe Bødtger, Nætved Hospital, Denmark

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 18:02

Mild asthma: A fundamental change in management

Presented By

Prof. Roland Buhl, Johannes Gutenberg University of Mainz, Germany

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 17:55

Dupilumab shows long-term efficacy in asthma patients

Presented By

Dr Michael Wechsler, Prof. Chris Brightling

Trial

LIBERTY ASTHMA TRAVERSE, LUSTER

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 17:47

Severe asthma: Oral corticosteroids maintenance therapy associated with toxicity

Presented By

Prof. Njira Lugogo, University of Michigan, USA

Trial

CHRONICLE

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 17:42

First-in-class tyrosine kinase inhibitor shows promise in severe asthma

Presented By

Prof. Pascal Chanez, Aix-Marseille Université, France

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 17:39

Predicting individual effectiveness of biologics in severe asthma

Presented By

Prof. Celeste Porsbjerg, Bispebjerg-Frederiksberg University Hospital, Denmark

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 17:34

Current prediction tools underestimate exacerbation risk of severe COPD patients

Presented By

Mr Spencer Keene, Maastricht University, the Netherlands

Trial

ECLIPSE

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 16:57

First-in-class P2X3 receptor antagonist shows promise for chronic cough treatment

Presented By

Prof. Lorcan McGarvey , Queen's University Belfast

Trial

Phase 3, COUGH-1, COUGH-2

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 16:52

Secondary pulmonary fibrosis: a possible long-term effect of severe COVID-19

Presented By

Prof. Francesco Blasi , University of Milan, Italy

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 16:48

IL-5 antagonist showed efficacy in chronic rhinosinusitis with nasal polyps

Presented By

Dr Claire Hopkins, Guy’s and St Thomas Hospital and King’s College London, UK

Trial

Phase 3, SYNAPSE

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 16:42

COVID-19 survivors benefit from structured follow-up

Presented By

Dr Sabina Sahanic, Medical University of Innsbruck, Austria

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 16:35

Treatment according to genotype: The future of asthma therapy?

Presented By

Dr Tom Ruffles, Brighton & Sussex Medical School, UK

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 15:49

Early pulmonary rehabilitation post-COVID-19 aids recovery

Presented By

Ms Yara Al Chikhanie, Grenoble Alps University, France

Conference

ERS 2020

Type

Peer-reviewed article

29 October 2020 15:29

Listening to Mozart has a beneficial effect on epilepsy

Presented By

Dr Gianluca Sesso, University of Pisa, Italy

Conference

ECNP 2020

Type

Peer-reviewed article

29 October 2020 15:27

REGOMUNE: a phase 2 study combining regorafenib and avelumab

Expert

Dr Sophie Cousin, Institut Bergonié, France

Trial

Phase 1/2, REGOMUNE

Conference

ASCO 2020

Type

Peer-reviewed article

17 September 2020 14:52

Cardiotoxicity: consider switching to S-1

Expert

Prof. Pia Österlund, Tampere University Hospital, Finland

Conference

ASCO 2020

Type

Peer-reviewed article

17 September 2020 14:49

Perioperative chemotherapy for resectable pancreatic ductal adenocarcinoma

Expert

Prof. Davendra Sohal, University of Cincinnati, OH, USA

Trial

Phase 2, SWOG S1505

Conference

ASCO 2020

Type

Peer-reviewed article

17 September 2020 14:47

Real-world data of sequential sorafenib followed by regorafenib in unresectable HCC

Expert

Dr Philippe Merle, Groupement Hospitalier Lyon Nord, France

Trial

REFINE

Conference

ASCO 2020

Type

Peer-reviewed article

17 September 2020 14:45

ARAMIS final OS and nmCRPC safety outcomes

Expert

Prof. Karim Fizazi, Institut Gustave Roussy, France

Trial

Phase 3, ARAMIS

Conference

ASCO 2020

Type

Peer-reviewed article

17 September 2020 14:11

Novel drug for kidney cancers/VHL patients

Expert

Prof. Eric Jonasch, University of Texas MD Anderson Cancer Center, USA

Trial

Phase 2

Conference

ASCO 2020

Type

Peer-reviewed article

17 September 2020 13:59

Primary analysis from IMvigor010, adjuvant atezolizumab in high risk muscle-invasive urothelial carcinoma

Expert

Dr Maya H.A. Hussain, Northwestern University in Chicago, IL, USA

Trial

Phase 3, IMvigor010

Conference

ASCO 2020

Type

Peer-reviewed article

17 September 2020 13:57

First randomised trial of Lu-PSMA in mCRPC progressing after docetaxel

Expert

Prof. Michael S. Hofman, Peter MacCallum Cancer Centre, Australia

Trial

TheraP

Conference

ASCO 2020

Type

Peer-reviewed article

17 September 2020 13:54

Biomarkers predicting motor function in SMA

Presented By

Prof. Valeria Sansone, University of Milano, Italy

Trial

Phase 2, NURTURE

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 14:53

Sustained benefits of avalglucosidase alfa in late-onset Pompe disease

Presented By

Dr Benedikt Schoser, Ludwig-Maximilians-University of Munich, Germany

Trial

NEO1; NEO-EXT

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 14:37

Efficacy and safety of rituximab in refractory MG corroborated

Presented By

Dr A Dos Santos, University Hospital of Nantes, France

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 14:24

Genetic association studies in NMOSD needed

Presented By

Dr Viktoria Papp, Aarhus University Hospital, Denmark

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 14:08

Eculizumab in NMOSD: the PREVENT study

Presented By

Dr Celia Oreja-Guevara, Hospital Clínico San Carlos, Spain

Trial

Phase 3, PREVENT

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 14:03

Long-term safety of satralizumab consistent with double-blind periods

Presented By

Prof. Benjamin Greenberg, University of Texas Southwestern Medical Center, USA

Trial

Phase 3, SAkuraSky; SAkuraStar

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 13:58

Imaging to evaluate remyelination and neuroprotection

Presented By

Dr Benedetta Bodini, Sorbonne University, France

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 13:41

MRI-based clustering of MS patients

Presented By

Dr Raffaello Bonacchi, IRCCS San Raffaele, Italy

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 13:29

Serum NfL predicts long-term clinical outcomes in MS

Presented By

Dr Simon Thebault, Ottawa Hospital Research Institute, Canada

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 12:39

Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS

Principal Investigator

Prof. Amit Bar-Or, University of Pennsylvania, PA, USA

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 12:30

High NEDA rates after 2 years of ocrelizumab

Presented By

Prof. Patrick Vermersch, University of Lille, France

Trial

Phase 3, CASTING

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 12:25

Two trials comparing relapsing MS treatments

Presented By

Dr L. Kappos & Dr T. Sprenger

Trial

Phase 3, OPTIMUM, ASCLEPIOS

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 12:21

Switching from natalizumab to moderate- versus high-efficacy DMT

Presented By

Dr Carrie M. Hersh, Cleveland Clinic Lerner College of Medicine, OH, USA

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 12:17

Results of compounds in late stages of development

Presented By

Dr B.A.C. Cree, Dr D.S. Reich, Dr E. Jasińska

Trial

Phase 3, EVOLVE-MS-1, SPI2

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 12:10

Alemtuzumab efficacy and safety data of over 9 years

Presented By

Dr T. Ziemssen, Dr J. Jones, Prof. P. Vermersch

Trial

Phase 3, CARE-MS

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 12:07

Fampridine treatment results in routine clinical practice

Presented By

Dr Giovanni Castelnovo, Centre Hospitalier Régional Universitaire de Nîmes, France

Trial

LIBERATE

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 12:05

Air pollution is a possible risk factor for MS

Presented By

Prof. Roberto G.E. Bergamasch, IRCCS Mondino Foundation, Italy

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 11:31

Small fibre pathology as biomarker for fibromyalgia

Presented By

Dr Dimitar Evdokimov, University of Würzburg, Germany

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 11:10

Migraine as a cyclical functional disorder

Presented By

Mr Daniele Martinelli, University of Pavia, Italy

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 11:07